ffirs.fm Page i Wednesday, October 19, 2005 9:13 AM
Bipolar Psychopharmacotherapy
Bipolar Psychopharmacotherapy: Caring for the Patient Edited by Hagop S. Akiskal and Mauricio Tohen # 2006 John Wiley & Sons, Ltd ISBN: 0-470-85607-6
c19.fm Page 367 Wednesday, October 19, 2005 9:59 AM
ffirs.fm Page iii Wednesday, October 19, 2005 9:13 AM
Bipolar Psychopharmacotherapy Caring for the Patient Editors
Hagop S. Akiskal International Mood Center, University of California at San Diego, La Jolla, CA, USA
and
Mauricio Tohen Lilly Research Laboratories, Indianapolis, IN and McLean Hospital, Harvard Medical School, Belmont, MA, USA
ffirs.fm Page iv Wednesday, October 19, 2005 9:13 AM
Copyright © 2006
John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex PO19 8SQ, England Telephone (+44) 1243 779777
Email (for orders and customer service enquiries):
[email protected] Visit our Home Page on www.wiley.com All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, scanning or otherwise, except under the terms of the Copyright, Designs and Patents Act 1988 or under the terms of a licence issued by the Copyright Licensing Agency Ltd, 90 Tottenham Court Road, London W1T 4LP, UK, without the permission in writing of the Publisher. Requests to the Publisher should be addressed to the Permissions Department, John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex PO19 8SQ, England, or emailed to
[email protected], or faxed to (+44) 1243 770620. Designations used by companies to distinguish their products are often claimed as trademarks. All brand names and product names used in this book are trade names, service marks, trademarks or registered trademarks of their respective owners. The Publisher is not associated with any product or vendor mentioned in this book. This publication is designed to provide accurate and authoritative information in regard to the subject matter covered. It is sold on the understanding that the Publisher is not engaged in rendering professional services. If professional advice or other expert assistance is required, the services of a competent professional should be sought. Other Wiley Editorial Offices John Wiley & Sons Inc., 111 River Street, Hoboken, NJ 07030, USA Jossey-Bass, 989 Market Street, San Francisco, CA 94103–1741, USA Wiley-VCH Verlag GmbH, Boschstr. 12, D-69469 Weinheim, Germany John Wiley & Sons Australia Ltd, 33 Park Road, Milton, Queensland 4064, Australia John Wiley & Sons (Asia) Pte Ltd, 2 Clementi Loop #02–01, Jin Xing Distripark, Singapore 129809 John Wiley & Sons Canada Ltd, 22 Worcester Road, Etobicoke, Ontario, Canada M9W 1L1 Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic books. Library of Congress Cataloging in Publication Data Bipolar psychopharmacotherapy : caring for the patient / editors, Hagop S. Akiskal and Mauricio Tohen. p. cm. Includes bibliographical references and index. ISBN-13 978-0-470-85607-9 (cloth : alk. paper) ISBN-10 0-470-85607-6 (cloth : alk. paper) 1. Manic-depressive illness—Chemotherapy. 2. Lithium—Therapeutic use. 3. Antipsychotic drugs. 4. Psychopharmacology. [DNLM: 1. Bipolar Disorder—drug therapy. 2. Anticonvulsants—therapeutic use. 3. Antimanic Agents—therapeutic use. 4. Antipsychotic Agents—therapeutic use. 5. Bipolar Disorder—prevention & control. WM 207 B6176 2006] I. Akiskal, Hagop S. II. Tohen, Mauricio. RC516.B529 2006 616.89′5061—dc22 2005013978 British Library Cataloguing in Publication Data A catalogue record for this book is available from the British Library ISBN-13 978-0-470-85607-9 (HB) ISBN-10 0-470-85607-6 (HB) Typeset in 11/13pt Times by Integra Software Services Pvt. Ltd, Pondicherry, India Printed and bound in Great Britain by Antony Rowe Ltd, Chippenham, Wiltshire This book is printed on acid-free paper responsibly manufactured from sustainable forestry in which at least two trees are planted for each one used for paper production.
ffirs.fm Page v Wednesday, October 19, 2005 9:13 AM
Dedication This book is dedicated to bipolar patients and their families, for the privilege of caring for them.
c19.fm Page 367 Wednesday, October 19, 2005 9:59 AM
ftoc.fm Page vii Wednesday, October 19, 2005 9:13 AM
Contents
List of Contributors Preface Chapter 1
ix xiii
The Scope of Bipolar Disorders Hagop S. Akiskal
Chapter 2 Lithium Treatment: Focus on Long-Term Prophylaxis Mogens Schou and Paul Grof Chapter 3 Valproate: Clinical Pharmacological Profile Charles L. Bowden and Vivek Singh
1
9
27
Chapter 4 Pharmacological Profile and Clinical Utility of Lamotrigine in Bipolar Disorders David J. Muzina, Joseph R. Calabrese
43
Chapter 5 Carbamazepine, Other Anticonvulsants and Augmenting Agents Heinz Grunze
63
Chapter 6 Olanzapine in Treatment for Bipolar Disorder Mauricio Tohen, Giedra Campbell, and Daniel Lin Chapter 7 Haloperidol and Risperidone in Mania John Cookson Chapter 8 A Comparison of “Second Generation Antipsychotics” in the Treatment for Bipolar Disorder: Focus on Clozapine, Quetiapine, Ziprasidone and Aripiprazole Paul E. Keck, Jr. and Susan L. McElroy
85
105
125
ftoc.fm Page viii Wednesday, October 19, 2005 9:13 AM
viii Chapter 9
Contents Complex Combination Therapy: The Evolution Toward Rational Polypharmacy in Lithium-Resistant Bipolar Illness Robert M. Post, Andrew M. Speer and Gabriele S. Leverich
Chapter 10 The Primacy of Mania Athanasios Koukopoulos Chapter 11 Diagnostic and Clinical Management Approaches to Bipolar Depression, Bipolar II and Their Comorbidities Giulio Perugi, S. Nassir Ghaemi and Hagop S. Akiskal Chapter 12 Bipolarity in Women: Therapeutic Issues Susan L. McElroy, Lesley M. Arnold and Lori L. Altshuler Chapter 13 Pediatric Bipolar Disorder: The Promise of Psychopharmacotherapy Joseph Biederman Chapter 14 Treatment for Bipolar Disorder in Older Adults Kenneth I. Shulman
135
169
193
235
279
301
Chapter 15 Psychosocial Interventions in Bipolar Disorders: Rationale and Effectiveness David J. Miklowitz
313
Chapter 16 The Pivotal Role of Psychoeducation in the Long-Term Treatment of Bipolar Disorder Francesc Colom and Eduard Vieta
333
Chapter 17 The Role of Treatment Setting in the Pharmacotherapy of Bipolar Disorder Jean-Michel Azorin
347
Chapter 18 Suicide Prevention Zoltán Rihmer
353
Chapter 19 Principles of Caring for Bipolar Patients Hagop S. Akiskal and Kareen K. Akiskal
367
Index
389
fbetw.fm Page ix Wednesday, October 19, 2005 9:13 AM
List of Contributors
Hagop S. Akiskal, International Mood Center, Department of Psychiatry at the University of San Diego and Veterans Administration Medical Center, 3350 La Jolla Village Dr. (116-A), San Diego, CA 92161, USA Kareen K. Akiskal, International Mood Center, University of California at San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0603, USA Lori L. Altshuler, UCLA Mood Disorders Research Program, UCLA, USA Lesley M. Arnold, Women’s Health Research Program, University of Cincinnati College of Medicine, 231 Albert Sabin Way, Cincinnati, OH 45267, USA Jean-Michel Azorin, Department of Psychiatry, Ste Marguerite Hospital, 13274 Marseille Cedex 9, France Joseph Biederman, Pediatric Psychopharmacology Unit (ACC 725), Massachusetts General Hospital, 15 Parkman Street, Boston, MA 02114-3139, USA Charles L. Bowden, Department of Psychiatry, Mail Code 7792, University of Texas Health Science Center, 7703 Floyd Curl Drive, San Antonio TX 78229-3900, USA Joseph R. Calabrese, Case Western Reserve University, School of Medicine, Cleveland, Ohio 44106, USA Giedra Campbell Lilly, Research Laboratories, Eli Lilly & Co, 525 S. Meridian Street, Indianapolis, IN 46225, USA Francesc Colom, Bipolar Disorders Program, Stanley Research Center, IDIBAPS, Hospital Clínic, University of Barcelona, 08036 Barcelona, Spain John Cookson, Royal London Hospital, St Clement’s, 2A Bow Road, London E3 4LL, UK
fbetw.fm Page x Wednesday, October 19, 2005 9:13 AM
x
List of Contributors
S. Nassir Ghaemi, Bipolar Disorder Research Program, Cambridge Hospital, Department of Psychiatry and Harvard University, Cambridge, MA 02139, USA Paul Grof, Deparmtent of Psychiatry, University of Ottawa, Royal Ottawa Hospital, 1145 Carling Avenue, Ottawa, Ontario K2E 7L2, Canada Heinz Grunze, Psychiatrische Klinik und Poliklinik LMU München, Ludwig Maximilians Universität München, Nussbaumstrasse 7, D-80336 Munich, Germany Paul E. Keck, University of Cincinnati College of Medicine, Department of Psychiatry, 231 Albert Sabin Way, ML 559, Cincinnati, OH 45267-0559, USA Athanasios Koukopoulos, Centro Lucio Bini, Via Crescenzio 42, 00193 Rome, Italy Gabriele S. Leverich, Biological Psychiatry Branch, National Institute of Mental Health, Bldg. 10, 10 Center Drive MSC 1272, Bethesda, MD 20892-1272, USA Daniel Lin Lilly, Research Laboratories, Eli Lilly & Co, 525 S. Meridian Street, Indianapolis, IN 46225, USA Susan L. McElroy, Psychopharmacology Research Program, Department of Psychiatry, University of Cincinnati College of Medicine, 231 Albert Sabin Way, Cincinnati, OH 45267, USA David J. Miklowitz, Department of Psychology, Davie Hall CB#3270, University of North Carolina, Chapel Hill, NC 27599-3270, USA David Muzina, Department of Psychiatry and Psychology, Desk P-57, 9500 Euclid Avenue, Cleveland, Ohio 44195, USA Giulio Perugi, Institute of Psychiatry, Via Roma 67, 56100 Pisa, Italy Robert M. Post, Biological Psychiatry Branch, National Institute of Mental Health, Bldg. 10, Rm. 3s239, 10 Center Drive MSC 1272, Bethesda, MD 20892-1272, USA Zoltán Rihmer, National Institute for Psychiatry and Neurology, Budapest 27, POB 1, 1281 Hungary Mogens Schou, The Psychiatric Hospital, Skovagervej 2, DK-8240 Risskov, Denmark
fbetw.fm Page xi Wednesday, October 19, 2005 9:13 AM
List of Contributors
xi
Kenneth I. Shulman, Department of Psychiatry, Sunnybrook & Women’s College Health Sciences Center, University of Toronto, 2075 Bayview Avenue, Toronto, ON M4N 3M5, Canada Vivek Singh, Department of Psychiatry, University of Texas Health Science Center, 7703 Floyd Curl Drive, San Antonio TX 78229-3900, USA Andrew Speer, Biological Psychiatry Branch, National Institute of Mental Health, Bldg. 10, 10 Center Drive MSC 1272, Bethesda, MD 20892-1272, USA Mauricio Tohen, McLean Hospital, Harvard Medical School, Belmont, MA and Lilly Research Laboratories, Eli Lilly & Co, 525 S. Meridian Street, Indianapolis, IN 46225, USA Eduardo Vieta, Clinical Institute of Psychiatry and Psychology, Hospital Clinic, University of Barcelona, Villarroel 170, 08036 Barcelona, Spain
c19.fm Page 367 Wednesday, October 19, 2005 9:59 AM
fpref.fm Page xiii Wednesday, October 19, 2005 9:13 AM
Preface Bipolar disorder has emerged as a major public health problem. Its prevalence, phenomenology, subtypes, treatment and outcome are all under reevaluation. A burgeoning research-based literature has appeared and continues to grow. New therapeutic modalities, both psychopharmacologic and psychosocial, have been introduced. The clinical and scientific challenges presented by this condition have created the psychiatric subspecialty for bipolar disorders. One of the major challenges for this subspecialty is to integrate the emerging clinical science of bipolar treatments. The idea for this book was born in October 1998 at the ECNP Congress in Paris. One of the topics discussed at that meeting was the fact that clinicians in both Europe and the United States used antipsychotics in bipolar disorder, yet US guidelines gave priority to lithium or anticonvulsants. The two editors decided to hold an international conference in Paris, France, on bipolar disorder at the 50th anniversary of the introduction of chlorpromazine in the same city in 1952. It would be recalled that the first patients treated with this agent suffered from bipolar mania. For a variety of logistic reasons, the conference was held in Monte Carlo instead of Paris in February 2002. Presided by the present editors and supported by an unrestricted educational grant from Eli Lilly, the conference covered the clinical psychopharmacology and related topics dealing with all agents available at that time for the treatment of bipolar disorder. With a roster of 24 of the top experts in the field and over 500 opinion leaders and researchers from all over the world in attendance, to the best of our knowledge, it was the largest freestanding conference on bipolar disorder. As we were editing the book on the material presented at the Monte Carlo conference, the field of bipolar psychopharmacology virtually exploded into a revolution. With so many new agents approved for bipolar disorder between 2002 and 2005, we had to revise the plans for this book in a radical way. The 19 chapters of the present book now overlap no more than 20% with the original conference in Monte Carlo. All chapters have been independently peer reviewed and updated through April 2005. We have endeavored – and we believe we have succeeded – in recruiting contributors who are the pioneers in bipolar psychopharmacotherapy and its clinical applications in children, the elderly and women. Special attention
fpref.fm Page xiv Wednesday, October 19, 2005 9:13 AM
xiv
Preface
is also given to bipolar depression, which has emerged as a major clinical and therapeutic challenge. The book goes beyond pharmacotherapy to cover innovative psychoeducational and psychosocial interventions, managing the patients in the hospital and subsequent long-term care in the community. Questions about the health care climate, advocacy organizations for bipolar disorder and social parameters impacting it are also addressed. Finally, suicide prevention is given special consideration. This book, then, provides a broad integrative philosophy of caring for bipolar patients and their families. Hagop S. Akiskal and Mauricio Tohen
c01.fm Page 1 Wednesday, October 19, 2005 9:13 AM
CHAPTER
1 The Scope of Bipolar Disorders Hagop S. Akiskal International Mood Center University of California at San Diego, USA
DIAGNOSTIC AND PUBLIC HEALTH ASPECTS Recent advances in the epidemiology, psychopathology and pharmacotherapy of bipolar disorders have led to a greater recognition of this illness in all of its varieties (Akiskal et al., 2000). The lifetime risk for bipolar conditions is about 1% for the core (bipolar I) phenotype, making it at least equal in prevalence to schizophrenia. A higher percentage of acute psychiatric hospital admissions is now being assigned to the category of mania, and the recognition of clinically attenuated outpatient forms of the illness (soft bipolar spectrum) is increasing. The latter (bipolar II and beyond) is now estimated to be at least 4–5 times more prevalent than bipolar I (Angst et al., 2003; Hirschfeld et al., 2003; Judd and Akiskal, 2003). Reasons for the current focus on the entire diagnosable range of bipolar conditions are several. Predominant among these is the tendency of diagnostic practice to follow the availability of effective treatment modalities (Lehmann, 1969). After the discovery of chlorpromazine, North American psychiatrists were tacitly encouraged to elicit subtle degrees of formal thought disorder from their patients so as to bring them the benefits of this new class of drugs. By the early 1970s, schizophrenia had become more or less synonymous with psychosis. With the advent of lithium carbonate treatment and its well-documented efficacy for bipolar disorders, this trend became reversed in favor of bipolar disorders. Beginning with DSM-III (American Psychiatric Association, 1980), the concept of schizophrenia has been largely restricted to a core group of deteriorating psychotic disorders, while mood disorders have been broadened to include even those with mood-incongruent psychotic features that may or may not coincide with affective episodes. This diagnostic approach reflects more than just therapeutic fashion; it is supported by familial aggregation, course and outcome (Akiskal, 2002). Available evidence indicates that mood disorders are often recurrent and, especially in bipolar conditions, Bipolar Psychopharmacotherapy: Caring for the Patient Edited by Hagop S. Akiskal and Mauricio Tohen # 2006 John Wiley & Sons, Ltd ISBN: 0-470-85607-6
c01.fm Page 2 Wednesday, October 19, 2005 9:13 AM
2
Bipolar Psychopharmacotherapy
can lead to considerable impairment in developmental, conjugal and social spheres. The public health significance of bipolar disorder is summarized in Table 1.1. The most important of these is suicide, seen in as many as 20% of those who receive inadequate or no treatment, and must be considered a preventable complication (Khuri and Akiskal, 1983). It now appears that bipolar II may account for a disproportionately large portion of suicidal morbidity and mortality among all the affectively ill (Rihmer and Pestality, 1999), emphasizing the importance of early and accurate diagnosis. At the “softest” end of the spectrum, milder degrees of bipolar disorder – subsumed under the rubrics of cyclothymic disorder (Akiskal etal., 1977) and bipolar disorder not otherwise specified (bipolar NOS) – are now categorized as mood disorders rather than being grouped with neurotic or personality disorders. Although these seemingly attenuated and “atypical” variants may not be easily distinguishable from nonaffective personality disorders, the clinician is advised to err on the side of affective diagnosis because of treatment implications. External validating strategies – such as family history, course and inter-episodic temperamental features – are often necessary to confirm the diagnosis of the bipolar spectrum (Akiskal, 2003). The most established of bipolarity beyond classic mania and bipolar I is the bipolar II type, so-named originally by Dunner, Gershon and Goodwin (1976). Like diabetes type II, its onset is often insidious, but its ravages no less devastating than that of the psychotic forms of the illness. This is particularly true for cyclothymic depression, a variant of bipolar II we have termed “bipolar II-½” (Akiskal and Pinto, 1999). Arising from a cyclothymic temperament, it pursues an unstable course and is likely to be misdiagnosed as axis II cluster B. These patients represent the “dark side” of bipolarity (Akiskal, Hantouche and Allilaire, 2003; Hantouche, Angst and Akiskal, 2003). The American Psychiatric Association (2000) Diagnostic Manual of Mental Disorders, even in its last edition (DSM-IV), does not recognize hypomanic or Table 1.1: Public health aspects of bipolar disorder • • • • • • • • • • • • •
Lifelong cyclical illness 1–5% of population Peak onset 15–30 years 5–10-year delay in correct diagnosis Frequent hospitalization Repeated hospitalization Repeated conjugal disruption: promiscuity Repeated job change/loss Financial disasters Alcohol/substance abuse 50% nonadherence to medication Increased cardiovascular mortality Suicide (highest within 10 years of illness onset)
c01.fm Page 3 Wednesday, October 19, 2005 9:13 AM
The Scope of Bipolar Disorders
3
manic switches occurring during pharmacotherapy, electroconvulsive therapy, phototherapy and sleep deprivation as indicators of bipolar disorder. These patients are obviously not unipolar major depressive disorder (MDD), nor are they classified under bipolar not-otherwise specified (NOS). Therefore, this common clinical phenomenon is voted by the DSM Committee out of existence! Since at least 1983, there has been good evidence that such switching on antidepressants requires bipolar family history (Akiskal et al., 1983, 2000, 2003). They are best regarded as less penetrant forms of bipolar disorder (bipolar III). Diagnostic status of depressive states with mood swings in the setting of multiple drug abuse, particularly that of stimulants, is controversial, but we contend that many of these individuals belong to a provisional bipolar type III-½ (Akiskal and Pinto, 1999; Maremmani et al., 2003; Camacho and Akiskal, 2005). This is relevant in a book on advances in bipolar disorder, because many of these patients respond favorably to anticonvulsant mood stabilizers. Finally, I would like to mention bipolar type IV, which refers to individuals who develop depression later in life from a lifelong background of hyperthymic temperament (hypomanic traits without clear-cut episodes); their bipolar status might be inferred from familial bipolarity (Cassano et al., 1992). In a French national study (Table 1.2), 65% of all major depressions belonged to the bipolar spectrum, of which the most prevalent were the bipolar II and II-½ phenotypes (Akiskal et al., 2005b). These considerations are important because nearly all pharmacologic treatments covered in this book – certainly those approved by regulatory bodies – pertain to bipolar I. Thus, there is a wide gap between the psychopharmacology of bipolar disorder and the public health significance of the phenotypes observed in the community and the clinic. Lithium was the first specific agent for bipolar disorder approved for clinical use. This was 35 years ago. Many other agents have been approved since then, almost all of them in the last decade. They are all covered in this book. Lithium medicalized psychiatry in bringing significant attention to the course of bipolar disorder. Its importance should not be overshadowed by these new developments. Many patients, Table 1.2: Bipolar spectrum subtypes (n=316) in the French EPIDEP study of major depression (n=493): validation by bipolar family history* N
%
Bipolar I Bipolar II Bipolar II-½ Bipolar III Bipolar IV
41 61 164 28 22
8.4 12.4 33.5 5.7 4.5
Total
316
64.5
* Akiskal et al. (2005b)
c01.fm Page 4 Wednesday, October 19, 2005 9:13 AM
4
Bipolar Psychopharmacotherapy
especially those in the “core” classic form of the illness, do respond to lithium. Its judicious use, often in combination with other agents in rational polypharmacy, requires intimate knowledge of its physiological and medical characteristics. Regrettably, young psychiatrists are not having adequate experience with this agent. A summary of the medical workup of patients in preparation of lithium use (Akiskal, 1999) is given in this chapter’s appendix.
PSYCHOLOGICAL AND SOCIAL ASPECTS The long-term, essentially life-long, nature of bipolar disorder and its vicissitudes dictate continuity of treatment and long-term caring. To solve practical problems in the patients’ lives requires caring that goes beyond medications and psychotherapy, to include the family, significant others and the community. Bipolar disorder continues to be poorly understood by both the public and doctors. More often than not, a bipolar child is classified as having conduct disorder or Attention Deficit Hyperactivity Disorder (ADHD) (Dilsaver, Henderson-Fuller and Akiskal, 2003). A teenager’s suicide attempt is misattributed to problems of the heart, adolescent crisis or substance abuse; promiscuous behavior is blamed on childhood “sexual abuse.” Bipolar patients from time to time describe their parents as “monsters” or “emotionally abusive,” which some psychotherapists accept on blind faith without ever talking to the parents. Bipolar II patients are often diagnosed as unipolar and/or borderline personality (Akiskal, 2004), treated with antidepressants without mood stabilizers, resulting in tragic aggravation of the course of the illness (Akiskal and Mallya, 1987; Akiskal et al., 2005a). Excessive spending, squandering, of one’s economic resources and pathological generosity may lead to financial ruin before bipolarity is considered. Polls of members of the Depressive and Manic-Depressive Association in the U.S. have shown a latency of 10 years from the onset of symptoms until the correct diagnosis of bipolar disorder (Hirschfeld et al., 2003). Early diagnosis is critical because suicide in bipolar patients often occurs within this early period. The comfort, support, destigmatization, information and advocacy provided by such a conglomeration of patients, families and community leaders (many of whom are themselves bipolar) represents a novel approach in the rehabilitation of the bipolar patient into society. This is a humane and just cause. Given that about 10% of patients with bipolar illness have creative and leadership achievements (Akiskal and Akiskal, 1988), sophisticated clinical management of bipolar illness can potentially safeguard the adaptive capacity and contributions that gifted bipolar people provide to society. Although psychotically ill (bipolar) patients are represented in the media as being creative, this is a destigmatization campaign at best and glamorizing madness at worst. Achievement and creativity are largely attributes of the softer spectrum represented in the attenuated temperamental expressions of bipolarity involving bipolar II (Akiskal and Akiskal, 1988, 2005).
c01.fm Page 5 Wednesday, October 19, 2005 9:13 AM
The Scope of Bipolar Disorders
5
Spanning from temperament to psychosis, bipolarity is a fascinating yet tragic human condition. Mental health professionals who treat these individuals must use pharmacotherapy and psychosocial interventions compassionately, judiciously and rigorously – only rarely “aggressively.” Severe bipolar illness is not just an ordinary illness to be medicated to “mediocrity.” The temperament of these individuals deserves all our consideration and respect. While most psychotic bipolar patients are neither leaders nor creators, they are the reservoir of the genes, which in dilute form, might serve as the seeds of genius (Akiskal, 2000).
APPENDIX: LABORATORY CONSIDERATIONS IN THE CLINICAL USE OF LITHIUM More than any other development, the introduction of lithium has emphasized the role of physicianship in psychiatry. The scientific literature and clinical wisdom on the therapeutic aspects of this salt have been well summarized in a monograph by Jefferson et al. (1983). The success of lithium treatment is dependent on the thoroughness of the initial workup, on dosage titration procedures and on appropriate monitoring throughout therapy. The type of workup depends on the age of the patient and concurrent medical conditions (Table 1.3). In young (less than 40 years), physically healthy subjects, preparation for lithium therapy should include medical history (especially focused on neurologic, renal, cardiac, gastrointestinal, endocrine and cutaneous systems), physical examination and laboratory evaluation focusing on electrolytes and thyroid. In older patients or those with a history of cardiac disease, a baseline electrocardiogram (EKG) should be obtained, and an electroencephalogram (EEG) performed if epilepsy is suspected; if there is a history of renal disease, thorough evaluation of baseline kidney function is mandatory. Given rigorous indications for lithium, major medical illness and abnormalities in laboratory indices do not necessarily contraindicate its use; they do dictate, however, greater medical vigilance, including frequent determination of blood levels and use of lower doses. Table 1.3: Recommended laboratory workup of patients considered for lithium therapy Healthy <40 years
All others: consider
Weight CBC T4/TSH FBS/serum electrolytes Urinalysis BUN/creatinine
EKG EEG TRH test 24-hour urine volume Urine concentration test Creatinine clearance
c01.fm Page 6 Wednesday, October 19, 2005 9:13 AM
6
Bipolar Psychopharmacotherapy
A short-term lithium trial in the controlled environment of a hospital is relatively easy to administer and is recommended for acutely manic, medically ill or elderly subjects. In outpatient practice, the physician must make sure that the patient and significant others understand the importance of adherence with periodic laboratory procedures and monitoring of side effects. Lithium is rapidly and completely absorbed from the gastrointestinal tract and peaks in the serum in about 1.5–2.0 (standard preparation) or 4.0–4.5 hours (slow release preparation), depending on age. Its half-life varies from 24–36 hours; steady state is reached in about four days. Lithium is not protein bound and is excreted unchanged almost entirely through the kidneys. It can be safely combined with most classes of drugs except diuretics and nonsteroidal anti-inflammatory agents (other than aspirin), which tend to increase the serum lithium level. Acutely manic and possibly bipolar depressive patients have a high tolerance for lithium and preferentially retain it during the first 10 days while excreting sodium; a regular diet is recommended. Postpubertal bipolar patients, who typically have excellent glomerular function, require higher doses to achieve the same level of equilibrium in the serum. The reverse is true in the geriatric age group. Elderly subjects with adequate glomerular function can benefit considerably from judicious lithium use. However, greater medical vigilance is required for this group; initial doses should be low (150–300 mg/day), with frequent clinical and laboratory monitoring to maintain blood levels in the lower range (0.3–0.8 mEq/L). Special attention must be paid to signs of sinus node dysfunction (bradycardia) or neurotoxicity; the latter is particularly likely in patients with concurrent neurologic disease or sedative and alcohol abuse. In healthy subjects who achieve good episode prevention, quarterly serum levels (12 hours after the last dose) and serum creatinine are generally sufficient; thyroid indices must be obtained at least once a year. For elderly or medically compromised patients, laboratory tests should be repeated as dictated by the medical condition, with frequent serum lithium levels; the dosage should be kept at the lowest possible level compatible with prophylaxis.
REFERENCES Akiskal HS. Mood (Affective) Disorders, in Berkhow R (ed.). Merck Manual of Diagnosis and Therapy, 17th ed. Rathaway, NJ, Merck Sharp and Dohme, 1999, pp. 1525–44. Akiskal HS. Dysthymia, cyclothymia and related chronic subthreshold mood disorders. In Gelder M, Lopez-Ibor J, Andreasen N (eds). New Oxford Textbook of Psychiatry. London, Oxford University Press, 2000, pp. 736–749. Akiskal HS. Classification, Diagnosis and boundaries of bipolar disorders. In Maj M, Akiskal HS, Lopez-Ibor JJ, Sartorius N (eds). Bipolar Disorder. London, John Wiley & Sons, 2002, pp. 1–52. Akiskal HS. Validating “hard” and “soft” phenotypes within the bipolar spectrum: Continuity or discontinuity? J. Affect. Disord. 2003; 73: 1–5.
c01.fm Page 7 Wednesday, October 19, 2005 9:13 AM
The Scope of Bipolar Disorders
7
Akiskal HS. Demystifying borderline personality: Critique of the concept and unorthodox reflections on its natural kinship with the bipolar spectrum. Acta Psychiatr. Scand. 2004; 110: 401–407. Akiskal HS, Akiskal KK. Re-assessing the prevalence of bipolar disorders: Clinical significance and artistic creativity. Psychiatrie et Psychobiologie. 1988; 3: 29s–36s. Akiskal KK, Akiskal HS. The theoretical underpinnings of affective temperaments: Implications for evolutionary foundations of bipolarity and human nature. J. Affect. Disord. 2005; 85: 231–239. Akiskal HS, Mallya G. Criteria for the “soft” bipolar spectrum: Treatment implications. Psychopharmacol. Bull. 1987; 23: 68–73. Akiskal HS, Pinto O. The evolving bipolar spectrum: Prototypes I, II, III, IV. Psychiatr. Clin. North Am. 1999; 22: 517–534. Akiskal HS, Hantouche EG, Allilaire J-F. Bipolar II with and without cyclothymic temperament: “dark” and “sunny” expressions of soft bipolarity. J. Affect. Disord. 2003; 73: 49–57. Akiskal HS, Djenderedjian AH, Rosenthal RH, Khani MK. Cyclothymic disorder: Validating criteria for inclusion in the bipolar affective group. Am. J. Psychiatry. 1977; 134: 1227–1233. Akiskal HS, Walker PW, Puzantian VR, King D, Rosenthal TL, Dranon M. Bipolar outcome in the course of depressive illness: Phenomenologic, familial, and pharmacologic predictors. J. Affect. Disord. 1983; 5: 115–128. Akiskal HS, Bourgeois ML, Angst J, Post R, Moller HJ, Hirschfeld RMA. Re-evaluating the prevalence of and diagnostic composition within the broad clinical spectrum of bipolar disorders. J. Affect. Disord. 2000; 59 (Suppl 1): 5s–30s. Akiskal HS, Hantouche EG, Allilaire JF, Sechter D, Bourgeois M, Azorin JM, ChatenêtDuchêne L, Lancrenon S. Validating antidepressant-associated hypomania (bipolar III): A systematic comparison with spontaneous hypomania (bipolar II). J. Affect. Disord. 2003; 73: 65–74. Akiskal HS, Benazzi F, Perugi G, Rihmer Z. Agitated “unipolar” depression re-conceptualized as a depressive mixed state: Implications for the antidepressant-suicide controversy. J. Affect. Disord. 2005a; 85: 245–58. Akiskal HS, Hantouche EG, Allilaire JF, Akiskal KK. Validating the bipolar spectrum: Overview of the phenomenology and relative prevalence of clinical subtypes in the French national EPIDEP study. J. Affect. Disord. 2005b, in press. American Psychiatric Association. DSM-III. Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: American Psychiatric Press, 1980. American Psychiatric Association. DSM-IV. Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: American Psychiatric Press, 2000. Angst J, Gamma A, Benazzi F, Ajdacic V, Eich D, Rossler W. Toward a re-definition of subthreshold bipolarity: Epidemiology and proposed criteria for bipolar-II, minor bipolar disorders and hypomania. J. Affect. Disord. 2003; 73: 133–146. Camacho A, Akiskal HS. Proposal for a bipolar-stimulant spectrum: Temperament, diagnostic validation and therapeutic outcomes with mood stabilizers. J. Affect. Disord. 2005; 85: 217–230. Cassano GB, Akiskal HS, Savino M, Musetti L, Perugi G, Soriani A. Proposed subtypes of bipolar II and related disorders: With hypomanic episodes (or cyclothymia) and with hyperthymic temperament. J. Affect. Disord. 1992; 26: 127–140. Dilsaver SC, Henderson-Fuller S, Akiskal HS. Occult mood disorders in 104 consecutively presenting children referred for the treatment of attention-deficit/hyperactivity
c01.fm Page 8 Wednesday, October 19, 2005 9:13 AM
8
Bipolar Psychopharmacotherapy
disorder in a community mental health clinic. J. Clin. Psychiatry 2003; 64: 1170–1176. Dunner DL, Gershon ES, Goodwin FK. Heritable factors in the severity of affective illness. Biol. Psychiatry 1976; 11: 31–42. Hantouche EG, Angst J, Akiskal HS. Factor Structure of hypomania: Interrelationships with cyclothymia and the soft bipolar spectrum. J. Affect. Disord. 2003; 73: 39–47. Hirschfeld RM, Lewis L, Vornik LA. Perceptions and impact of bipolar disorder: How far have we really come? Results of the national depressive and manic-depressive association 2000 survey of individuals with bipolar disorder. J. Clin. Psychiatry 2003; 64: 161–74. Hirschfeld RM, Holzer C, Calabrese JR, Weissman M, Reed M, Davies M, Frye MA, Keck P, McElroy S, Lewis L, Tierce J, Wagner KD, Hazard E. Validity of the mood disorder questionnaire: A general population study. Am. J. Psychiatry 2003; 160: 178–180. Jefferson J, Greist JH, Ackerman DL, Carroll JA. Lithium Encyclopedia. Washington, DC: American Psychiatric Press, 1983. Judd LL, Akiskal HS. The prevalence and disability of bipolar spectrum disorders in the U.S. population: Re-analysis of the ECA database taking into account subthreshold cases. J. Affect. Disord. 2003; 73: 123–131. Khuri R, Akiskal HS. Suicide prevention: The necessity of treating contributory psychiatric disorders. Psychiatr. Clin. North Am. 1983; 6: 193–207. Lehmann HE. The impact of the therapeutic revolution on nosology. In Doucet P, Laurin C (eds). Problematique de la psychose. New York, Excerpta Medica Foundation, 1969, pp. 136–153. Maremmani I, Pacini M, Lubrano S, Lovrecic M, Perugi G. Dual diagnosis heroin addicts. The clinical and therapeutic aspects. Heroin Addict. Relat. Clin. Probl. 2003; 5: 7–98. Rihmer Z, Pestality P. Bipolar II disorder and suicidal behavior. Psychiatr. Clin. North Am. 1999; 22: 667–73.
c02.fm Page 9 Wednesday, October 19, 2005 9:14 AM
CHAPTER
2 Lithium Treatment: Focus on Long-Term Prophylaxis Mogens Schou1 and Paul Grof2 1
2
Syrenvej 4, Risskov, DK-8240, Denmark Mood Disorders Center of Ottawa, Suite 301, 1929 Russell RD, Ottawa, Ontario, Canada.
INTRODUCTION It is difficult to tell the exact age of lithium treatment for mood disorders. In the 1880s lithium was used for the treatment and prevention of recurrent depressions (Lange, 1886; Schioldann, 2001), but statistics and controlled trials were not known at that time, and the observations remained clinical impressions. In the 1950s lithium treatment for mania became evidence based (Schou etal., 1954), and in 1967–1970, prophylactic lithium treatment did the same (Baastrup and Schou, 1967; Baastrup et al., 1970). There is nevertheless good reason to count the age of lithium treatment from 1949, when Cade (1949) published his paper “Lithium salts in the treatment of psychotic excitement”, for lithium has remained in psychiatric use since then. Why is lithium treatment still being used after half a century? This chapter does not aim at giving a systematic chronological exposition of the history of lithium treatment in psychiatry. This has been done in other publications to which the reader is referred, e.g. Johnson (1984), Schou (1992), and Healy (1997). An attempt will be made to answer the question by recounting briefly and commenting in detail on selected events. Methodological problems are given more attention than presentation of data. There have been many misunderstandings about lithium. Some of them will be addressed in this chapter, but it has not been possible to deal with them all.
The original version of this paper was published in the Journal of Affective, Disorders in 2001: Mogens Schou: Lithium treatment at 52. J Affect Disord 2001; 67: 21–32. The journal kindly permitted an updating by Schou and Grof in 2003. This chapter has not been updated since 2003. The authors.
Bipolar Psychopharmacotherapy: Caring for the Patient Edited by Hagop S. Akiskal and Mauricio Tohen # 2006 John Wiley & Sons, Ltd ISBN: 0-470-85607-6
c02.fm Page 10 Wednesday, October 19, 2005 9:14 AM
10
Bipolar Psychopharmacotherapy
Since lithium is used primarily for the prevention of recurrences, this review – based on previous work by Schou (1993b, 1998c, 2001) – deals primarily with prophylactic treatment and disregards treatment for individual episodes. In collaboration with Grof (2003), this chapter has been thoroughly updated from previous contributions to address contemporaneous challenges in the long-term treatment for what the authors term “typical” bipolar disorders.
CADE’S PIONEERING STUDY It has often been claimed that the so-called “psychopharmacological era” started with the introduction of chlorpromazine in 1952. The era actually started when Cade introduced lithium as an antimanic drug in 1949. When the word “serendipity” was used about Cade’s discovery, he became annoyed and pointed out that it was based on a specific hypothesis and experimental observations. The hypothesis was that mental illnesses are caused by intoxication with an unknown compound, and that this toxic agent can be found in the patients’ urine. His hypothesis led him to inject lithium urate, the only soluble salt of uric acid, into guinea pigs, and when he saw that they became docile and lethargic, he started treating psychiatric patients with lithium carbonate after having tried it on himself without ill effects. Whereas schizophrenic and depressed patients did not show essential changes, all ten manic patients showed abatement or cessation of their symptoms. Later attempts to induce lethargy in guinea pigs with lithium showed, however, that this was possible only with high doses. Cade’s animals were presumably intoxicated rather than merely lethargic. To make therapeutic discoveries on the basis of misinterpreted experiments requires curiosity, daring, luck and compassion for patients!
DISCOVERY OF THE PROPHYLACTIC ACTION OF LITHIUM By 1964 Schou (1956), Hartigan (1963) and Baastrup (1964) had independently made observations on small groups of patients that seemed to indicate that prolonged treatment with lithium might ameliorate or prevent not only manic but also depressive recurrences. This was a new and unexpected observation, and it called for closer examination.
NON-BLIND MIRROR TRIAL A confirmation of the original observations came from a large, open study. A non-blind trial lasting six years and involving eighty-eight bipolar and unipolar patients who had suffered at least two episodes within two years provided the first systematically collected evidence of a prophylactic action of lithium against both manic and depressive episodes of manic-depressive illness (Baastrup and Schou, 1967). The average number of episodes per year decreased by 87% from the time before lithium
c02.fm Page 11 Wednesday, October 19, 2005 9:14 AM
Lithium Treatment
11
treatment to the time during lithium treatment (p < 0.001). The decreases were equally large in the two groups. A Swiss–Czech–Danish collaborative trial confirmed the findings (Angst et al., 1970). Psychiatrists in other countries then initiated lithium treatment. They also observed depressive as well as manic recurrences diminish in intensity and frequency, and they were gratified by lithium’s prophylactic action. However, Blackwell and Shepherd (1968) expressed sharp skepticism. This was not based on a failure to confirm the Danish findings for they never tried treating patients with lithium; their skepticism was purely speculative. Blackwell and Shepherd contested the validity of the evidence. They felt that bias and the suggestive power of the psychiatrists accounted for the observations, and that patients selected because they had suffered frequent episodes during recent years could be expected to have fewer episodes during the following years. In their reply Baastrup and Schou (1968) pointed out that most of the patients were discharged soon after starting lithium treatment. General practitioners, who were unaware of the ongoing trial and therefore unbiased, determined when a recurrence had taken place. Moreover, rather than decrease, the frequency of episodes must be expected to increase in the way that is characteristic of recurrent affective disorders (Angst and Weis, 1969; Grof et al., 1970a). Blackwell and Shepherd were apparently not familiar with these findings, or they chose to overlook them. The discussions between Blackwell and Shepherd, and Baastrup and Schou went on for some time and created uncertainty among British and American psychiatrists, who hesitated to start prophylactic lithium treatment. Baastrup and Schou felt that no useful purpose was served by continuing a potentially interminable discussion and that double-blind observations were required.
DOUBLE-BLIND DISCONTINUATION TRIAL Baastrup, Schou and their associates therefore carried out a double-blind discontinuation trial (1970). Bipolar and unipolar patients who had been given lithium for at least a year were allocated randomly to either placebo or continued lithium treatment. Within six months the difference between the groups had reached a pre-determined significance level (p < 0.01), and sequential analysis terminated the trial. While 21 of 39 placebo-treated patients had relapsed, none of 45 lithiumtreated patients had done so. The final analysis revealed a statistical difference of p < 0.001. Later randomized, placebo-controlled trials of both discontinuation design and prospective design confirmed the findings, e.g. Melia (1970), Coppen et al. (1971), Cundall, Brooks and Murray (1972), Hullin, McDonald and Allsopp (1972), Prien, Caffey and Klett (1973) and Stallone et al. (1973). The evidence was now so strong that lithium became approved for prophylactic treatment by regulatory agencies in many countries. In 1974 the FDA approved its long-term use in bipolar disorder.
c02.fm Page 12 Wednesday, October 19, 2005 9:14 AM
12
Bipolar Psychopharmacotherapy
OBSERVER BIAS, DISEASE COURSE Schou, Thomson and Baastrup (1970) tested the assumptions on which Blackwell and Shepherd had based their criticism. The effect of observer bias and psychological factors on the recording of recurrences was investigated by comparing the disease course of a group of patients in whom lithium treatment was switched double-blind to placebo, and another group who stopped taking lithium on their own initiative. When lithium is discontinued during a double-blind study, observer bias and suggestion continue to work at full force; when lithium is discontinued openly, their psychological effect ends. The percentage of patients who suffered relapse each month was the same in the two groups. The trial showed that in manic-depressive patients neither observer bias nor placebo effects were strong enough to exert significant influence on the recorded recurrence rate. In the same study a survival analysis revealed that before lithium treatment 14% of the patients relapsed each month. While the patients were in lithium treatment, the proportion of patients who relapsed was 1.5%. When lithium was discontinued, 16% of the patients relapsed each month. The low frequency of episodes during lithium treatment was accordingly not a result of ‘regression toward the mean’ as Blackwell and Shepherd had suggested.
FURTHER DOUBTS ABOUT THE EFFICACY OF LITHIUM TREATMENT Lithium prophylaxis became widely used during the following years, but occasionally doubts about its efficacy were still expressed. Dickson and Kendell (1986) found that even though long-term lithium treatment was being increasingly administered in Edinburgh during the period 1970–1981, admission rates for mania and depression were on the rise; the authors felt that this cast doubts on the efficacy of lithium treatment. Schou (1986) pointed out that drawing conclusions about the efficacy of a treatment administered to a limited number of patients from the admission rates of a much larger number is a dubious procedure. Prophylactic lithium treatment is given only to manic-depressive patients with frequent recurrences, so even if lithium treatment were 100% effective, it could only be expected to prevent a small fraction of re-admissions. Grof (1987) drew attention to the many other factors that could have led to a rise in the number of admissions, for example a shift in diagnostic practice. In other hospitals rises in admissions for comparable reasons were observed. In 1995 Moncrieff claimed that a prophylactic action of lithium treatment was never satisfactorily demonstrated. She found it likely that development of side effects had compromised the blindness of the prophylactic lithium trials, but she presented no evidence in support of that notion. The evidence available shows that the blindness had not been invalidated (Schou, 1998a).
c02.fm Page 13 Wednesday, October 19, 2005 9:14 AM
Lithium Treatment
13
Basing her arguments purely on speculation Moncrieff claimed that discontinuation studies are invalid because abrupt discontinuation of lithium treatment provokes manic recurrences. This is strange logic. Even if a discontinuation design with rebound manias might inflate the size of lithium’s effect, this in itself shows that lithium is not without effect (Goodwin, 1995). Moncrieff insisted that the rise in frequency of recurrences after discontinuation of lithium was not caused by the removal of an active prophylactic drug. The cause was instead, she claimed, rebound recurrences precipitated by withdrawal of lithium. She referred to a study by Suppes etal. (1993) that reported rapid development of predominantly manic recurrences after abrupt discontinuation of lithium. These observations are impressive, but they were made in patients who differed diagnostically from those in whom lithium was originally shown prophylactically effective in 1967–1970. During the last decades the increasing use of standardized cross-sectional diagnoses (DSM) has led to a widening of the indications for lithium use (Grof, 1998). Patients with, for example, excessive motor activity have been classified as bipolar manic and given lithium, and many of them benefitted somewhat from the anti-aggressive and anti-psychotic effects lithium also has in bipolar patients (Kingsbury and Garver, 1988). In the early prophylactic trials the patients were diagnosed according to ICD criteria and had classical manic-depressive illness, and in these patients discontinuation of lithium led to re-emergence of recurrences at a rate that did not exceed their experiences before they started lithium treatment (Grof, Cakuls and Dostal, 1970b; Schou, Thomsen and Baastrup, 1970; Rifkin, Quitkin and Howard, 1975; Fyrö and Petterson, 1977; Sashidharan and McGuire, 1983; Mendlewicz, 1984; Berghöfer, Kossman and Müller-Oerlinghausen, 1996). Moncrieff had extrapolated from one group of patients to another group that was diagnosed differently. The principal argument in Moncrieff’s “case” against prophylactic lithium treatment failed.
DEBATE There are few psychiatric treatments that have been debated as hotly as prophylactic treatment with lithium. The reasons for this are difficult to understand. Perhaps the treatment was so effective that psychiatrists who had not themselves used it for their patients found the observations utterly unlikely and refused to believe the evidence.
METHODOLOGICAL ISSUES The debate raised by Blackwell and Shepherd revealed two different attitudes toward clinical trials. Shepherd himself had worked with randomized, placebo-controlled trials and was convinced that valid evidence could be obtained only with this procedure;
c02.fm Page 14 Wednesday, October 19, 2005 9:14 AM
14
Bipolar Psychopharmacotherapy
any other evidence had to be rejected. The 1967 trial by Baastrup and Schou was not randomized and placebo controlled, the reason being that it had started more or less on an exploratory basis and then had gradually grown. The authors felt, however, that data collected in an open prophylactic study of mirror-design need not necessarily be disregarded. The marked and long-lasting change produced by lithium in the course of the disease of patients having had a median of nine episodes prior to lithium treatment coincided with the start of that treatment and was unlikely to be fortuitous.
PERSONAL ISSUES Perhaps it may at this point be appropriate to correct an error that started with Shepherd’s description of Schou as an “enthusiastic advocate”. This is an ambiguous compliment. The term “enthusiast” might refer to someone who is strongly engaged in their work, but in the given context the term “advocate” can hardly have been meant as a compliment. In British English an advocate is someone who gathers evidence exclusively for or exclusively against a particular case or person. A clinical scientist, on the other hand, is someone who gathers all relevant evidence and then weighs it carefully before drawing a conclusion. The latter is usually in the form of a hypothesis that may later be rejected, by the scientist himself or by others. A conversation between Healy and Schou (Healy, 1997) revealed that Shepherd used his epithet with a more special meaning. Healy: “I happen to know that there are people at the Maudsley who explain your position by hinting that you yourself had manic-depression and are on lithium and that therefore you have a vested interest in seeing things one way . . . Did you know that?” Schou: “This is entirely new to me. Perhaps it explains why Shepherd always referred to me as an enthusiast, clearly meaning an uncritical person whose opinions couldn’t be trusted. Well, I am not manic and never was in lithium treatment. But what difference does it make? Baastrup’s and my data, arguments and conclusions are there for anyone to assess. Should data, arguments and conclusions presented by insane persons be disregarded rather than judged on their merits?” This may appear to be a personal grudge without wider implications. It involves, however, an important question of principles. A reader may pay attention to the author’s assumed motives and his mental state. But should this, apart from perhaps sharpening the reader’s critical sense, lead him to reject totally the data, arguments and conclusions of a person whose motives the reader does not find sufficiently noble or whose mental state he does not deem sufficiently sane? If that were so, science and the patients might be deprived of potentially valuable information.
c02.fm Page 15 Wednesday, October 19, 2005 9:14 AM
Lithium Treatment
15
CONCERNS ABOUT SIDE EFFECTS AND RISKS Pharmaceutical companies have regarded lithium as a competitor with their own products, and claims about lithium’s many and severe side effects have been repeated again and again. Lithium does have side effects, and sometimes they are so troublesome that treatment must be discontinued. However, if lithium treatment is carried out competently, most of the side effects are mild and a small price to pay for the emotional stability obtained.
EFFECT OF THE SERUM LITHIUM CONCENTRATION The frequency and severity of side effects depends primarily on the serum lithium concentration being kept low and competently tailored to each patient. At the psychiatric hospital in Risskov, Denmark, the range of serum lithium concentrations was lowered from 0.8–1.0 mmol/L to 0.5–0.8 mmol/L (Schou, 1988; Vestergaard and Schou, 1988; Schou and Vestergaard, 1988; Vestergaard, Poulstrup and Schou, 1988). The average serum lithium concentration decreased by about 30%, and the proportion of patients not having side effects rose from 10 to 40%. Lithium-induced tremor and diarrhea were markedly less pronounced during treatment with low serum concentrations than with high; so were lithium-induced increase of urine volume and reduction of renal concentrating ability. It is worth noting that the claims of many and severe side effects of lithium are made primarily in the United States. In 1989 a group from Boston (Gelenberg etal., 1989) compared doses leading to what they called “standard” serum lithium levels, 0.8–1.0 mmol/L, with doses leading to low levels, 0.4–0.6mmol/L. The trial showed that the higher levels were not only more effective but also associated with a higher incidence of side effects than the lower. There was more non-compliance in the highlevel group; the authors nevertheless chose to recommend the high levels. They did not examine effects and side effects of the levels in between 0.6 and 0.8 mmol/L. In Europe the recommended serum lithium range has for several years been 0.4–0.8 mmol/L, to be exceeded at each end in particularly sensitive and particularly resistant patients respectively (Birch etal., 1993). A single American author has recommended serum lithium concentrations between 0.3 and 0.8mmol/L (Akiskal, 1999).
LITHIUM EFFECTS ON THE KIDNEYS Owing to its important clinical implications this issue has been investigated systematically in thousands of patients. Critical data come from studies testing the kidney function of patients both before and during lithium treatment. Long-lasting lithium treatment does not lead to a gradual deterioration of the kidney function. The urine volume and the renal concentrating ability do not change over treatment
c02.fm Page 16 Wednesday, October 19, 2005 9:14 AM
16
Bipolar Psychopharmacotherapy
periods from 1 to 30 years. In investigations by European authors (Povlsen et al., 1992; Kallner and Petterson, 1995; Bendz, Sjödin and Aurell, 1996) the glomerular filtration rate of patients maintained at serum lithium concentrations between 0.3 and 0.9 mmol/L decreased only corresponding to the patients’ increasing age. In an American study (Gitlin, 1993) 3 out of 82 patients showed gradual rises of the serum creatinine concentration. Gitlin’s patients were maintained at serum lithium concentrations between 0.6 and 1.2 mmol/L.
PREVENTION OF LITHIUM INTOXICATION Patients undergoing lithium treatment rarely commit suicide by taking overdoses of lithium but lithium intoxications can develop under various unfortunate circumstances. Intoxication does not develop randomly. Lithium is eliminated through the kidneys, and the mechanisms governing the excretion have by now been unraveled through animal experiments and clinical experiences over many years. This knowledge has led to precautionary guidelines (Thomsen and Schou, 1999). Situations to be avoided during lithium treatment include overdose, kidney disease, dehydration, sodium deficiency and interaction with various drugs. It is useful for physicians and patients to keep such conditions in mind.
USE DURING PREGNANCY AND LACTATION Early experiments on primitive aquatic animals had shown that exposure to high concentrations of lithium in the surrounding fluid led to malformations of the offspring. After lithium came into use for the treatment of manic-depressive patients in 1949, a “Register of Lithium Babies” was established (Schou, 1969) in order to reveal whether malformed children would be born to mothers having been in lithium treatment during pregnancy. The register was based on voluntary reports, and it indicated an increased frequency of congenital malformations of the heart. However, these findings exaggerated the risk because congenitally malformed babies were more likely to be reported than normal babies, and the retrospective register was closed in 1990 (Schou, 1990). When the lithium baby register was started, psychiatrists were not used to thinking along teratogenic lines, and the register’s estimate of maximum teratogenic risk was taken as a measure of the true teratogenic effect of lithium. That gave lithium a “bad press”. Later investigations without the bias of the register have given reassuring results and found no relationship between malformations and lithium given during pregnancy. Lithium can be given safely during the last six months of the pregnancy, and if the risk of recurrence is high, it can also be given during the first three months. The risk of fetal changes is minimal (Jacobson et al., 1992; Schou, 1998b).
c02.fm Page 17 Wednesday, October 19, 2005 9:14 AM
Lithium Treatment
17
BREASTFEEDING DURING LITHIUM TREATMENT Small amounts of lithium pass from the mother’s blood to her milk and hence to the nursing child. However, breastfeeding plays an important role for both mother and child, physically and psychologically, and it is today doubtful whether it is advisable to abstain from breastfeeding during lithium treatment. One can today measure the lithium concentration in the mothers’ milk, and it is still lower than in the blood of the fetus.
‘NATURALISTIC’ TRIALS In some ‘naturalistic’ or ‘outpatient’ or ‘clinical practice’ trials the prophylactic effectiveness of lithium has been found to be lower than it was in the early trials. The explanation of this discrepancy is hardly that lithium has changed its properties. What may have changed is treatment adherence and patient selection. In these trials the patients may have been supervised insufficiently to keep non-compliance under control (Schou, 1993a). Poor compliance is the major cause of the difference between efficacy, the potential of a treatment, and effectiveness, the result obtained under clinical conditions (Guscott and Taylor, 1994), and efforts should be made to improve compliance and increase effectiveness also when lithium treatment is given under naturalistic or outpatient or clinical practice conditions (Schou, 1997). In some of the ‘naturalistic’ trials lithium treatment was given to patients with atypical features and co-morbid psychopathology and to patients who previously had been found refractory to lithium (Schou, 1998a). The indications for lithium treatment had been influenced by the introduction of new diagnostic criteria (Gershon and Soares, 1997; Gitlin and Altshuler, 1997). The effectiveness of lithium prophylaxis is a question of carefully monitored lithium treatment given on indications where it has been shown efficacious. Optimum results of lithium treatment are obtained only when well-informed and conscientious physicians administer it to well-informed and conscientious patients.
ARE NEW AND BETTER PROPHYLACTIC AGENTS ABOUT TO OUST LITHIUM? Lithium treatment has side effects, and it would be welcome if something better were forthcoming and its advantages convincingly demonstrated (Schou, 1998a). However, the search for other prophylactic drugs has faced certain obstacles. Since lithium prophylaxis is so effective (Goodwin and Jamison, 1990), it might be difficult to obtain permission from ethical committees and informed consent from patients to compare new drugs of unproved prophylactic efficacy with placebo or
c02.fm Page 18 Wednesday, October 19, 2005 9:14 AM
18
Bipolar Psychopharmacotherapy
with lithium. The investigators have employed two approaches to be able to use drugs other than lithium. The first was to emphasize the shortcomings of lithium treatment, real or alleged. The second was to treat patients who were refractory to lithium treatment or had troublesome side effects.
CRITICISMS OF LITHIUM The claim that lithium has many and severe side effects, notably on the kidneys, was discussed in an earlier section. It has also been claimed that lithium is not effective in rapid cycling and mixed states. That is only partly true. Lithium can be efficacious in some of these disorders (Baastrup and Schou, 1967; Hanna et al., 1972), but it is often ineffective, and it would be welcome if other drugs could be proved better.
THE DRUG A/DRUG B FALLACY It is sound and responsible practice to switch to another drug when lithium is not effective or not tolerated. One must, however, realize that observations made under these circumstances are biased in favor of the new drug; the trial cannot show whether the new drug is prophylactically efficacious also when given as first treatment, let alone more efficacious than lithium. When a patient is switched from drug A to drug B because the former was ineffective or not tolerated, then drug B must necessarily come out as good as or better than drug A, for it cannot come out worse. Since many studies have had this design, the evidence of a prophylactic effect of new drugs must be assessed with caution.
ANTICONVULSANTS In bipolar disorder it is primarily the anticonvulsant drugs carbamazepine, valproate and lamotrigine for which a prophylactic action has been claimed. When these and similar drugs are compared with lithium, experience from recent decennia has shown it important to distinguish between typical and atypical bipolar disorder (Schou, 1998a). Patients with typical, classical bipolar disorder have an episodic course, mood-congruent symptoms and often present with full manias (bipolar I). Patients with atypical bipolar disorder have an incompletely remitting, non-episodic course and often include mood-incongruent symptoms, rapid cycling, dysphoric mania and comorbidity. In two prospective randomized double-blind studies (Placidi et al., 1986; Greil et al., 1997, 1998; Greil and Kleindienst, 1999) the prophylactic efficacies of lithium and carbamazepine were compared. Whereas lithium was consistently superior to carbamazepine in patients with typical bipolar disorder, carbamazepine
c02.fm Page 19 Wednesday, October 19, 2005 9:14 AM
Lithium Treatment
19
had the same efficacy as lithium or showed an edge to be better in patients with atypical bipolar disorder. Valproate is used extensively as a mood stabilizer. However, in a prophylactic study by Bowden et al. (2000) only mildly ill patients were treated, and neither valproate nor lithium differed significantly from placebo. The trial was accordingly invalid. Lamotrigine has been tested extensively and been shown to be an efficacious treatment for preventing bipolar episodes, particularly bipolar depression and rapid cycling (Calabrese et al., 2000; Bowden et al., 2003).1 Studies by Canadian researchers from Halifax and Ottawa compared lamotrigine and lithium and were primarily patient oriented rather than drug oriented. Passmore et al. (2003) studied 164 subjects from 21 families of bipolar probands, 14 responders to lithium and 7 responders to lamotrigine. There were differences between the drugs with respect to clinical course (episodic in the lithium group, rapid cycling in the lamotrigine group) and comorbidity (panic attacks and substance abuse in the lamotrigine group). The relatives of lithium responders had significantly higher risk of bipolar disorder, and the relatives of lamotrigine responders had higher prevalence of schizoaffective disorder, major depression and panic attacks. Replication of the Canadian study would be of great clinical and public health relevance. Grof (2003) discussed more broadly the principle and the execution of longterm monotherapy in bipolar patients. A current and quite widespread practice is to add further mood stabilizers already when the first mood stabilizer has been given for only a short time. It has, however, been found by the Canadian researchers that many patients can be successfully stabilized on monotherapy if the drug is initially selected according to the patients’ clinical characteristics. Likely to respond well to lithium are patients with typical bipolar disorder, an episodic and fully remitting disease course and a family history of remitting bipolar disorder with an episodic course and usually the absence of comorbidity. Likely to respond to lamotrigine and olanzapine are patients with atypical symptoms, a non-episodic course with residual symptoms, comorbidity and a family history of other psychiatric disorders and substance addiction.2
PROPHYLAXIS IN RECURRENT DEPRESSIVE DISORDER Long-term lithium treatment exerts a recurrence-preventive action not only in bipolar disorder but also in depressive disorder (Baastrup and Schou, 1967; Angst et al., 1970; Baastrup et al., 1970). This observation did not then have, and has not later had, any noticeable effect on the prophylactic treatment for depressive disorder. 1
This topic is further discussed in Chapter 4. As discussed throughout this book, these “atypical” patients are prevalent in clinical practice, and their clinical management represents a formidable challenge.
2
c02.fm Page 20 Wednesday, October 19, 2005 9:14 AM
20
Bipolar Psychopharmacotherapy
The antidepressant drugs had been introduced in the late 1950s, and they have later dominated both the acute and the prophylactic treatments for this disorder. It should, however, be noted that many patients are treated with antidepressants who according to present-day international classifications have, or must be suspected of having, bipolar disorder. They are patients with bipolarity in the family, patients whose depressive disorder started in childhood or puberty, patients about whom there is information about at least one episode with hypomanic symptoms and patients with antidepressant-induced hypomania (Akiskal etal., 2003; Chun and Dunner, 2004). Such patients may with advantage be treated with lithium instead of with antidepressants. These observations are in good agreement with the conclusion of recent extensive epidemiological studies suggesting that many depressive patients may in fact have bipolar propensity (Angst et al., 2003; Judd and Akiskal, 2003).3
COMBINATION TREATMENT There is mounting clinical evidence that in patients who do not tolerate lithium or in patients who are refractory to long-term lithium, the addition of an antiepileptic or of atypical neuroleptics may in some cases be of use (Grof, 2003; Yatham, Calabrese and Kusumakar, 2003). There has, however, until now been a relative scarcity of controlled trials demonstrating superiority of the combination over either drug given alone. Such studies are described elsewhere in this book. It is noteworthy that in nearly all of them lithium is considered the gold standard to be augmented. While giving two drugs together might achieve better results by reaching two subgroups of bipolar patients in a heterogeneous population, the real question that needs to be answered is whether such a side effect-prone combination works better than the tailoring of each drug to appropriately selected patients. During unsatisfactory maintenance treatment for recurrent major depressions with antidepressant drugs, augmentation with lithium is frequently useful. In patients who respond to antidepressants plus augmentation with lithium it may be worth trying to discontinue the antidepressant after some time. The patients may then remain stabilized on long-term lithium alone.
THE EFFECT OF LITHIUM ON THE PATIENTS’ SUICIDAL BEHAVIOR In the 1980s it was noted that among about 9000 lithium-treated patients in three major mood disorder clinics in the United States the frequency of suicides was conspicuously low (Jamison, 1986). In the 1990s systematic investigations on very large groups of patients revealed that the frequencies of suicides and of 3
Such data have been published from clinical settings (See review by Akiskal et al., 2000; Akiskal, 2003).
c02.fm Page 21 Wednesday, October 19, 2005 9:14 AM
Lithium Treatment
21
suicide attempts were about 10–15 times lower in patients given prophylactic lithium treatment than in patients not given such treatment (Coppen et al., 1991; Müller-Oerlinghausen et al., 1992; Tondo et al., 1997; Kallner et al., 2000; Schou, 2000; Baldessarini, Tondo and Hennen, 2001; Goodwin et al., 2003). It would, however, be wrong to claim that an antisuicidal effect of lithium has been definitively proved. Such proof is in principle not possible for any kind of antisuicidal intervention because there is no matching patient group to compare with. One cannot, after all, keep suicide-threatened patients on placebo or deprived of psychological and social support merely to observe if and when they will commit suicide. Nor can one determine by throwing a die when and in whom an ongoing and possibly effective intervention should be discontinued. But the studies reviewed are not incompatible with the assumption that lithium has a striking antisuicidal effect. As scientists we must concede that the investigations merely indicate such a possibility. As responsible clinicians we owe it to patients and relatives alike not to disregard that possibility. No other prophylactic agent in mood disorders has shown a similar evidence of antisuidal action.
BENEFITS OF PROPHYLACTIC LITHIUM TREATMENT The discovery and implementation of prophylactic lithium treatment have had far-reaching results. (1) The efficacy of lithium therapy and prophylaxis has established that recurrent mood disorders are treatable conditions and psychiatry is a medical discipline. (2) Lithium was the first psychotropic drug for which a recurrence-preventive action in mood disorders was demonstrated. This paved the way for other medications to be studied on this indication. Lithium prevents recurrences not only in bipolar disorder but also in recurrent unipolar depressions. Such a double action has not been seen with other drugs. (3) During the last fifty years lithium has stimulated research in numerous fields – clinical, pharmacological, physiological, biochemical, genetic, etc. (4) Mood disorders place a heavy burden on the economy of individuals, the health system and society at large (Wyatt and Henter, 1995). Since lithium treatment is effective and inexpensive, its widespread use has reduced such costs substantially (Reifman and Wyatt, 1980). (5) Last but not least, prophylactic lithium treatment has changed the lives of millions of people for the better. After years in the shadow of fear it may be difficult to hope again, but gradually patients and their families experience how the course of the disease has been altered, and how fear loses its grip. Patients feel that life once more becomes safe and predictable, and that normal friendships can be established or re-established. Prophylactic lithium treatment can
c02.fm Page 22 Wednesday, October 19, 2005 9:14 AM
22
Bipolar Psychopharmacotherapy improve the quality of life significantly for patients whose existence was dominated by frequent and severe recurrences.
CONCLUSION Prophylactic lithium treatment for mood disorders was introduced more than thirty years ago, and in spite of being an inexpensive drug, unsupported by powerful pharmaceutical industries, lithium is still used all over the world. Lithium is, with the exception of the USA where valproate has overtaken it, the prophylactic agent most widely used in bipolar disorder. Lithium unquestionably produces the most dramatic benefits of any medication used in psychiatry if it is used correctly. It is clearly the treatment of choice for many patients who suffer from “classic” bipolar disorder, effectively preventing both the manic and the depressed phases of the disorder. This has happened in spite of the fact that few psychiatric treatments have been debated so hotly. Trial strategies, the selection of patients and diagnostic criteria for giving lithium to patients have been commented upon. Misunderstandings and misstatements about lithium have abounded, and this chapter attempts to rectify the most common ones. Competition from pharmaceutical companies trying to replace lithium with new prophylactic medications has been fierce. All this might have meant a short life for lithium. But prophylactic lithium treatment is still widely in use, waiting for something indisputably better to replace it.
REFERENCES Akiskal, H.S. (1999) Affective disorders. In: Berkow, R. (ed.), Merck Manual of Diagnosis and Therapy. 14th edn Rathaway, NJ., Merck, Sharp and Dohme Research Laboratories, pp. 1525–1544. Akiskal, H.S., Bourgeois, M.L., Angst, J., Post, R., Moller, H.J., Hirschfeld, R.M.A. (2000) Reevaluating the prevalence of and diagnostic composition within the broad clinical spectrum of bipolar disorders. J. Affect. Disord. 59 (Suppl. 1): 5s–30s. Akiskal, H.S., Hantouche, E.G., Allilaire, J.F., Sechter, D., Bourgeois, M.L., Azorin, J.M., Chatenet-Duchene, L., Lancrenon, S. (2003) Validating antidepressant-associated hypomania (bipolar III): A systematic comparison with spontaneous hypomania (bipolar II). J. Affect. Disord. 73: 65–74. Angst, J., Weis, P. (1969) Zum Verlauf depressiver Psychosen. In: Schulte, W., Mende, W. (eds), Melancholie in Forschung, Klinik und Behandlung. Stuttgart, Thieme. pp. 2–9. Angst, J., Weis, P., Grof, P., Baastrup, P.C., Schou, M. (1970) Lithium prophylaxis in recurrent affective disorders. Brit. J. Psychiatry 116: 604–614. Angst, J., Gamma, A., Benazzi, F., Ajdacic, V., Eich, D., Rössler, W. (2003) Toward a re-definition of subthreshold bipolarity: Epidemiology and proposed criteria for bipolar-II, minor bipolar disorders and hypomania. J. Affect. Disord. 23: 133–146. Baastrup. P.C. (1964) The use of lithium in manic-depressive psychosis. Compr. Psychiatry 5: 396–408.
c02.fm Page 23 Wednesday, October 19, 2005 9:14 AM
Lithium Treatment
23
Baastrup, P.C., Schou, M. (1967) Lithium as a prophylactic agent: Its effect against recurrent depressions and manic-depressive psychosis. Arch. Gen. Psychiatry 16: 162–172. Baastrup, P.C., Schou, M. (1968) Prophylactic lithium. Lancet I: 1419–1422. Baastrup, P.C., Poulsen, J.C., Schou, M., Thomsen, K., Amdisen, A. (1970) Prophylactic lithium: Double-blind discontinuation in manic-depressive disorders. Lancet II: 326–330. Baldessarini, R.J., Tondo, L., Hennen, J. (2001) Treating the suicidal patient with bipolar disorder. Reducing suicide risk with lithium. Ann. N.Y. Acad. Sci. 932: 24–38. Bendz, H., Sjödin, I., Aurell, M. (1996) Renal function on and off lithium in patients treated with lithium for 15 years or more: A controlled, prospective lithium withdrawal study. Nephrol. Dial. Transplant. 11: 457–460. Berghöfer, A., Kossman, A.B., Müller-Oerlinghausen, B. (1996) Course of illness and pattern of recurrences in patients with affective disorders during long-term lithium prophylaxis: A retrospective analysis over 15 years. Acta Psychiatr. Scand. 93: 349–354. Birch, N.J., Grof, P., Hullin, R.P., Kehoe, R.F., Schou, M., Srinivasan, D.P. (1993) Lithium prophylaxis: Proposed guidelines for good clinical practice. Lithium 4: 225–230. Blackwell, B., Shepherd, M. (1968) Prophylactic lithium: Another therapeutic myth? An examination of the evidence to date. Lancet I: 968–971. Bowden, C.L., Calabrese, J.R., McElroy, S.L., Gyulai, L., Wassef, A., Petty, F., Pope, A.C. Jr., Chou, J.C., Keck, P.E., Rhodes, L.J., Swann, A.C., Hirschfeld, R.M., Wosniack, P.J. (2000) A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Arch. Gen. Psychiatry 57: 481–489. Bowden, C.L., Calabrese, J.R., Sachs, G., Yatham, L.N., Asghar, S.A., Hompland, M., Montegomery, P., Earl, N., Smoot, T.M., DeVeaugh-Geiss, J. (2003) A placebocontrolled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch. Gen. Psychiatry 60: 392–400. Cade, J.F.J. (1949) Lithium salts in the treatment of psychotic excitement. Med. J. Aust. 36: 349–352. Calabrese, J.F., Suppes, T., Bowden, C.L., Sachs, G.S., Swann, A.C., McElroy,S.L., Kusumakar, V., Ascher, J.A., Earl, N.L., Green, P.L., Monaghan, E.T. (2000) A double-blind, placebo-controlled prophylactic study of lamotrigine in rapid-cycling bipolar disorder. Lamotrigine 614 Study Group. J. Clin. Psychiatry 61: 841–850. Coppen, A., Noguera, R., Bailey, J., Burns, B.H., Swani, M.S., Hare, E.H., Gardner, R., Maggs, R. (1971) Prophylactic lithium in affective disorders: Controlled trial. Lancet II: 275–279. Coppen, A., Standish-Barry, H., Bailey, J., Houston, G., Silcocks, P., Hermon, C. (1991) Does lithium reduce the mortality of recurrent mood disorders? J. Affect. Disord. 23: 1–7. Cuhn. B.J. D.H., Dunner, L.D. (2004) A review of antidepressant-induced hypomania in major depression: Suggestions for DSM-V. Bipolar Disord. 6: 32–42. Cundall, R.L., Brooks, P.W., Murray, L.G. (1972) A controlled evaluation of lithium prophylaxis in affective disorders. Psychol. Med. 2: 308–311. Dickson, W.E., Kendell, R.E. (1986) Does maintenance lithium therapy prevent recurrences of mania under ordinary clinical conditions? Psychol. Med. 16: 521–530. Fyrö, B., Petterson, U. (1977) A double blind study of the prophylactic effect of lithium in manic-depressive illness. Acta Psychiatr. Scand. 269 (Suppl.): 17–22. Gelenberg, A.J., Kane, J.M., Keller, M.B., Lavori, P., Rosenbaum, J.F., Cole, K., Lavalle, J. (1989) Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder. New Engl. J. Med. 321: 1489–1493.
c02.fm Page 24 Wednesday, October 19, 2005 9:14 AM
24
Bipolar Psychopharmacotherapy
Gershon, S., Soares, J.C. (1997) Current therapeutic profile of lithium. Arch. Gen. Psychiatry 54: 16–20. Gitlin, M.J. (1993) Lithium-induced renal insufficiency. J. Clin. Psychopharmacol. 13: 276–279. Gitlin, M.J., Altshuler, L.L. (1997) Unanswered questions, unknown future for one of our oldest medications. Arch. Gen. Psychiatry 54: 21–23. Goodwin, G.M. (1995) Lithum revisited. A reply. Brit. J. Psychiatry 167: 573–574. Goodwin, F.K., Jamison, K.R. (1990) Manic-Depressive Illness. Oxford University Press, New York. Goodwin, F.K., Fireman, B., Simon, G.E., Hunkeler, E.M., Lee, J., Revicki, D. (2003) Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA 290: 1467–1473. Greil, W., Kleindienst, N. (1999) Lithium versus carbamazepine in the maintenance treatment of bipolar II disorder and bipolar disorder not otherwise specified. Int. Clin. Psychopharmacol. 14: 283–285. Greil, W., Ludwig-Mayerhofer, W., Erazo, N., Engel, R.R., Czernik, A., Giedke, H., MüllerOerlinghausen, B., Osterheider, M., Rudolf, G.A., Sauer, H., Tegeler, J., Wetterling, T. (1997) Lithium vs carbamazepine in the maintenance treatment of schizoaffective disorder: A randomised study. Eur. Arch. Psychiatry Clin. Neurosci. 247: 42–50. Greil, W., Kleindienst, N., Erazo, N., Müller-Oerlinghausen, B. (1998) Differential response to lithium and carbamazepine in the prophylaxis of bipolar disorder. J. Clin. Psychopharmacol. 18: 455–460. Grof, P. (1987) Admission rates and lithium therapy. Brit. J. Psychiatry 150: 264–265. Grof, P. (1998) Has the effectiveness of lithium changed? Impact of the variety of lithium’s effects. Neuropsychopharmacol. 19: 183–188. Grof, P. (2003) Selecting effective long-term treatment for bipolar patients: Monotherapy and combination therapy. J. Clin. Psychiatry 64 (Suppl.5): 53–61. Grof, P., Schou, M., Angst, J., Baastrup. P.C., Weis, P. (1970a) Methodological problems of prophylactic trials in recurrent affective disorders. Brit. J. Psychiatry 116: 599–603. Grof, P., Cakuls, P., Dostal, T. (1970b) Lithium drop-outs: A follow-up study of patients who discontinued prophylactic treatment. Int. Pharmacopsychiatry 5: 162–169. Guscott, R., Taylor, L. (1994) Lithium prophylaxis in recurrent affective illness: Efficacy, effectiveness and efficiency. Brit. J. Psychiatry 164: 741–764. Hanna, S., Jenner, A., Pearson, I., Thompson, E. (1972) The effect therapeutic effect of lithium carbonate on a patient with a forty-eight hour periodic psychosis. Brit. J. Psychiatry 121: 271–280. Hartigan, G.P. (1963) The use of lithium salts in affective disorders. Brit. J. Psychiatry 109: 810–814. Healy, D. (ed.) (1997) Lithium. Interview with Mogens Schou. In The Psychopharmacologists II. Chapman & Hall, London. pp. 259–284. Hullin, R.P., McDonald, R., Allsopp, M.N.E. (1972) Prophylactic lithium in recurrent affective disorders. Lancet I: 1044–1046. Jacobson, S.J., Jones, K., Johnson, K., Ceolin, L., Kaur, P., Sahn, D., Donnenfeld, A.E., Rieder, M., Santelli, R., Smythe, J., Einarson, T. Koren,G. (1992) Prospective multicentre study of pregnancy outcome after lithium exposure during first trimester. Lancet 339: 530–533. Jamison, K.R. (1986) Suicide and bipolar disorders. Ann. N.Y. Acad. Sci. 487: 301–315. Johnson, F.N. (1984) The History of Lithium Treatment. Mcmillan, London.
c02.fm Page 25 Wednesday, October 19, 2005 9:14 AM
Lithium Treatment
25
Judd, L.L., Akiskal, H.S. (2003) The prevalence and disability of bipolar spectrum disorders in the US population: re-analysis of the ECA database taking into account subthreshold cases. J. Affect. Disord. 73: 123–31. Kallner, G., Petterson, U. (1995) Renal, thyroid and parathyroid function during lithium treatment: laboratory tests in 207 people treated for 1–30 years. Acta Psychiatr. Scand. 91: 48–51. Kallner, G., Lindelius, R., Petterson, U., Stockman, O., Tham, A. (2000) Mortality in 497 patients with affective disorders attending a lithium clinic or after having left it. Pharmacopsychiatry 33, 8–13. Kingsbury, S.J., Garver, D.L. (1988) Lithium and psychosis revisited. Prog. Neuropharmacol. Biol. Psychiatry 22: 249–263. Lange, C. (1886). Bidrag til Urinsyrediatesens Klinik. Hospitalstidende 5, 1–15, 21–38, 45–63, 69–83. Melia, P.I. (1970) Prophylactic lithium: A double-blind trial in recurrent affective illness. Brit. J. Psychiatry 116: 621–624. Mendlewicz, J. (1984) Lithium discontinuation in bipolar illness: A double-blind prospective controlled study. In Corsini, G.U. (ed.), Current Trends in Lithium and Rubidium Therapy. Stuttgart, MTP Press. pp. 125–141. Moncrieff, J. (1995) Lithium revisited: A re-examination of the placebo-controlled trials of lithium prophylaxis in manic-depressive disorder. Brit. J. Psychiatry 167: 569–574. Müller-Oerlinghausen, B., Ahrens, B., Grof, E., Grof, P., Lenz. G., Schou, M., Simhandl, C., Thau, K., Volk, J., Wolf, R., Wolf, T. (1992) The effect of long-term lithium treatment on the mortality of patients with manic-depressive or schizo-affective illness. Acta Psychiatr. Scand. 86: 218–222. Passmore, M.J., Garnham, J., Duffy, A., MacDougall, M., Munro, A., Slaney, C., Teehan, A., Alda, M. (2003) Penotypic spectra of bipolar disorder in responders to lithium versus lamotrigine. Bipolar Disord. 5: 110–114. Placidi, G.F., Lenzi, A., Lazzerini, F., Cassano, G.B., Akiskal, H.S. (1986) The comparative efficacy and safety of carbamazepine versus lithium: A randomized, double-blind, 3-year trial in 83 patients. J. Clin. Psychiatry 47: 490–494, 1986. Povlsen, U.J., Hetmar, O., Ladefoged, J., Bolwig, T.B. (1992) Kidney functioning during lithium treatment: A prospective study of patients treated with lithium for up to ten years. Acta Psychiatr. Scand. 85: 56–60. Prien, R.F., Caffey, E.M., Klett, C.J. (1973) Prophylactic efficacy of lithium carbonate in manic-depressive illness. Arch. Gen. Psychiatry 28: 337–341. Reifman, A., Wyatt, R.J. (1980) Lithium: A brake in the rising cost of mental illness. Arch. Gen. Psychiatry 37: 355–388. Rifkin, A.F., Quitkin, F., Howard, A. (1975) A study of abrupt lithium withdrawal. Psychopharmacol 44: 157–158. Sashidharan, S.P., McGuire, R.J. (1983) Recurrence of affective illness after withdrawal of long-term lithium treatment. Acta Psychiatr. Scand. 68: 126–133. Schioldann, J. (2001) In commemoration of the century of the death of Carl Lange. The Lange theory of ‘Periodical Depressions’. A landmark in the history of lithium therapy. Adelaide Academic Press. Schou, M. (1956) Lithiumterapi ved mani: Praktiske retningslinier. Nord. Med. 55: 790–794. Schou, M. (1969) The ‘Scandinavian Register of Lithium Babies’. In: Diding, N., Ottosson, J.O., Schou, M. (eds), Lithium in Psychiatry. Acta Psychiatr. Scand. Suppl. 207: 97. Schou, M. (1986) Admission rates and lithium therapy. Brit. J. Psychiatry 149: 798–799. Schou, M. (1988) Effects of long-term lithium treatment on kidney function: An overview. J. Psychiatr. Res. 22: 287–296.
c02.fm Page 26 Wednesday, October 19, 2005 9:14 AM
26
Bipolar Psychopharmacotherapy
Schou, M., Vestergaard, P. (1988) Prospective studies on a lithium cohort. 2. Renal function. Water and electrolyte metabolism. Acta Psychiatr. Scand. 78: 427–433. Schou, M. (1990) Lithium treatment during pregnancy, delivery, and lactation. An update. J. Clin. Psychiatry 51: 410–413. Schou, M. (1992) Phases in the development of lithium treatment in psychiatry. In: Samson, F. and Adelman, G. (eds), The Neurosciences: Paths of Discovery II. Birkhäuser, Boston. pp. 147–166. Schou, M. (1993a) Lithium prophylaxis: About ‘naturalistic’ or ‘clinical practice’ studies. Lithium 4: 77–81. Schou, M. (1993b) Lithium Treatment of Manic-Depressive Illness: A Practical Guide, 5th edn, Karger, Freiburg, London, New York. Schou, M. (1997) The combat of non-compliance during prophylactic lithium treatment. Acta Psychiatr. Scand. 95: 361–363. Schou, M. (1998a) Has the time come to abandon prophylactic lithium treatment? A review for clinicians. Pharmacopsychiatry 31: 210–215. Schou, M. (1998b) Treating recurrent affective disorders during and after pregnancy: What can be taken safely? Drug. Saf. 18: 143–152. Schou, M. (1998c) The effect of prophylactic lithium treatment on mortality and suicidal behavior: A review for clinicians. J. Affect. Disord. 50: 253–259. Schou M. (2000) Suicidal behavior and prophylactic lithium treatment of major mood disorders: A review for clinicians. Suicide and Life-Threatening Behavior 30: 289–293. Schou, M. (2001) Lithium treatment at 52. J. Affect. Disord. 67: 21–23. Schou, M., Thomsen, K., Baastrup, P.C. (1970) Studies on the course of recurrent endogenous affective disorders. Int. Pharmacopsychiatry 5: 100–106. Schou, M., Juel-Nielsen, N., Strömgren, E., Voldby, H. (1954) The treatment of manic psychoses by the administration of lithium salts. J. Neurol. Neurosurg. Psychiatry 17: 250–260. Stallone, F., Shelley, E., Mendlewicz, J., Fieve, R.R. (1973) The use of lithium in affective disorders, III. A double-blind study of prophylaxis in bipolar illness. Am. J. Psychiatry 130: 1006–1010. Suppes, T., Baldessarini, R.J., Faedda, G.I., Tondo, L., Tohen, M. (1993) Discontinuation of maintenance treatment of bipolar disorder: Risks and implications. Harv. Rev. Psychiatry 1: 131–144. Thomsen, K., Schou, M. (1999) Avoidance of lithium intoxications: Advice based on knowledge about the renal lithium clearance under various circumstances. Pharmacopsychiatry 32: 83–86. Tondo, L., Jamison, K.R., Baldessarini, R.J. (1997) Effect of lithium maintenance on suicidal behavior in major mood disorders. Ann. N.Y. Acad. Sci. 836: 339–351. Vestergaard, P., Poulstrup, I., Schou, M. (1988) Prospective studies on a lithium cohort. 3. Tremor, weight gain, diarrhea, psychological complaints. Acta Psychiatr. Scand. 78: 343–441. Vestergaard, P., Schou, M. (1988) Prospective studies on a lithium cohort. 1. General features. Acta Psychiatr. Scand. 78: 434–441. Wyatt, R.J., Henter, I. (1995) An economic evaluation of manic-depressive illness. Soc. Psychiatry Psychiatr. Epidemiol. 30: 213–219. Yatham, L.N., Calabrese, J.R., Kusumakar, V. (2003) Bipolar depression: Criteria for treatment selection, definition of refractoriness, and treatment options. Bipolar Disord. 5: 85–97.
c03.fm Page 27 Wednesday, October 19, 2005 9:51 AM
CHAPTER
3 Valproate: Clinical Pharmacological Profile Charles L. Bowden and Vivek Singh Department of Psychiatry, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA
Valproate has a unique history, current importance, mechanism and profile of action in bipolar disorder, and several other conditions in psychiatry and other areas of medicine. We review the development of this information for bipolar disorders, the current guidelines for effective clinical use of valproate, and provide a commentary on possible future developments with this molecule. Valproic acid was developed as an organic solvent in 1881 (Burton, 1881), recognized serendipitously as an anticonvulsant in the 1960s, then in its French formulation (valpromide) found to have behavioral benefits in bipolar patients (Lambert et al., 1966; Puzynski and Klosiewicz, 1984). Two pivotal studies, the first a small single center trial in treatment of refractory patients (Pope Jr. et al., 1991), the other a large multicenter study published in 1994 (Bowden et al., 1994), led to regulatory approval in the U.S. (in its divalproex formulation) for treatment of mania in 1995, and at the present throughout most of the world. Valproate has had a large and continually evolving impact on the treatment for bipolar disorders, and circa 2005 is the most widely prescribed treatment for the disorder in the United States. This article focuses on the main dimensions of valproate’s development over the past decade, and their implications for current treatments in bipolar disorder.
MANIA Valproate was significantly superior to lithium in the subset of patients with mixed mania (Bowden, 1995) and among patients with more than 2 lifetime episodes of depression (Swann et al., 1990). In a double-blind randomized study versus carbamazepine, valproate yielded significantly greater improvement in
Bipolar Psychopharmacotherapy: Caring for the Patient Edited by Hagop S. Akiskal and Mauricio Tohen # 2006 John Wiley & Sons, Ltd ISBN: 0-470-85607-6
c03.fm Page 28 Wednesday, October 19, 2005 9:51 AM
28
Bipolar Psychopharmacotherapy
manic symptomatology, earlier improvement, significantly greater for elevated mood, irritability, speech and thought disturbance, required less use of rescue medications, and was associated with fewer adverse effects (17% vs 67%). Valproate was similarly effective to haloperidol in patients with psychotic mania (McElroy et al., 1996) and in two studies compared with olanzapine, although dosing differences in the comparisons with olanzapine limit interpretation of results (Tohen et al., 1994; Zajecka and Weisler, 2000); divalproex was associated with fewer adverse effects than olanzapine, specifically weight gain, sedation, changes in low density lipoproteins and cholesterol (Zajecka etal., 2002). Intravenous valproate infused as 600 mg over 20 minutes yielded rapid improvement in 4 of 5 manic patients (Grunze et al., 1999). In an open randomized study of adolescents experiencing mania, divalproex yielded non-significantly higher rates of response than did lithium or carbamazepine (Kowatch et al., 2002). These studies of the past decade extend the evidence of the efficacy of valproate as equivalent or superior to other approved treatments for mania in bipolar disorder, and the breadth of circumstances in which it can be effectively employed. No methodologically adequate studies have been conducted in patients with hypomania or cyclothymic disorder, though open clinical case material showing utility on clinical grounds has been published (Jacobsen, 1993; Deltito etal., 1994). The same considerations apply to the open data in rapid cycling patients (Calabrese etal., 1992).
COMBINATION TREATMENT Several studies indicate that valproate is effective when combined with other drugs used in the treatment for mania. Each of the studies reviewed below has utilized a randomized, double-blind, placebo-controlled design. Three of the reports studied addition of an antipsychotic drug to either valproate or lithium, and reported results combining patients who received either mood stabilizer. The reports suggest that similar results occurred with the subsets of patients treated with valproate and with lithium. The studies consistently showed that when combined with antipsychotic drugs, lower doses of the antipsychotic drug are needed than when an antipsychotic drug is used as monotherapy for the same type manic condition (Sachs et al., 2002; Tohen et al., 2002; Yatham et al., 2003). Addition of valproate to haloperidol resulted in significantly greater improvement than did haloperidol alone, and in lower dosage of haloperidol than in patients treated with haloperidol alone (Muller-Oerlinghausen et al., 2000). Addition of risperidone (Yatham, 2000; Sachs et al., 2002) or olanzapine (Tohen et al., 2002) to valproate or lithium resulted in a greater response rate than did continuation of the mood stabilizers as monotherapy. The Sachs et al. study allowed patients to enroll who had received treatment with either valproate or lithium at an adequate dose for two weeks or longer and were still manic, or patients who were manic
c03.fm Page 29 Wednesday, October 19, 2005 9:51 AM
Valproate
29
without treatment, in which case both risperidone and either lithium or valproate were started concurrently. No advantage for the combination treatment occurred in the cotherapy group, whereas the subset of patients who had demonstrated unresponsiveness to valproate or lithium showed the advantage of the add-on therapy. Each of the other studies required some degree of failure on the first treatment. Therefore, the studies indicate that in most circumstances combination therapy should be limited to patients who fail to respond to a relatively short period of adequate treatment with a first drug before adding a second. One maintenance study with similar enrollment of manic patients who continued to have manic symptoms despite valproate or lithium treatment has been completed. Among the subset of patients who achieved remission of mania with olanzapine plus valproate or lithium, those then randomized to combination treatment had longer time to manic relapse, but not depressive relapse, than did those treated with valproate or lithium as monotherapy. Rates of earlier discontinuation and weight gain were higher in the combination group (Tohen etal., 2004).
FACTORS ASSOCIATED WITH ACUTE RESPONSE TO VALPROATE Mania with depressive features has been associated with greater responsiveness to divalproex than lithium in manic patients (Freeman et al., 1992; Bowden, 1995). In contrast, patients with mania without any depressive features had equivalent acute responses to divalproex and lithium. Irritability in manic patients has been associated with greater likelihood of response to divalproex than to lithium (Swann etal., 2002), and even versus carbamazepine (Vasudev etal., 2000). Irritability has been the most consistently differentiating symptom favoring divalproex benefit in patients with disorders other than bipolar disorder (Hollander etal., 2001; Frankenburg and Zanarini, 2002; Casey etal., 2003). The first of the latter studies was among schizophrenic patients; the latter two studies included bipolar patients “comorbid” with borderline personality disorder. In one double-blind study, manic patients with a history of prior poor response to lithium had superior responses to divalproex than to lithium (Bowden, 1994). Manic patients with a higher number of lifetime episodes of mania or depression (≥8) and, especially, with more than two lifetime depressive episodes were more likely to respond to divalproex than to lithium (Swann et al., 1999). Open studies have suggested that patients with atypical manic states, e.g., associated with other neurological conditions, substance abuse, later age at onset were generally more likely to respond to valproate than to lithium (Kahn, Stevenson and Douglas, 1988). No randomized, double-blind data have been presented on these points. One study of behavioral components in manic patients found that patients with “hyperactivity” as a predominant feature of mania were equally responsive to divalproex and lithium, with both superior to placebo (Swann et al., 2002). The
c03.fm Page 30 Wednesday, October 19, 2005 9:51 AM
30
Bipolar Psychopharmacotherapy
same study also found that for patients whose manic episodes were marked by psychosis or by core depressive features neither divalproex nor lithium was more efficacious than placebo over a three-week period. The foregoing analyses of symptom and illness course features consistently suggest that divalproex’s efficacy is broader, particularly in more severe and complicated presentations of mania, than is the efficacy for lithium or, although less extensively studied, carbamazepine. There are insufficient controlled comparisons with other antimanic drugs to draw conclusions about response patterns.
DEPRESSION One small-blinded randomized study showed divalproex and paroxetine added to lithium to be equivalently efficacious in patients with bipolar depression, with fewer patients treated with paroxetine plus lithium requiring early discontinuation than those treated with VPA plus lithium (Young et al., 2000). Two small studies reported trends for superiority of valproate compared with placebo in treatment for bipolar depression (Winsberg etal., 2001; Petty etal., 2002; Davis etal., 2004). These studies suggest that acute effectiveness of valproate in depression is modest.
MAINTENANCE TREATMENT FOR BIPOLAR DISORDER One large, double-blind, placebo monotherapy study has been published (Bowden et al., 2000). Patients who met the recovery criteria within 3 months of the onset of an index manic episode (n = 372) were randomized to one year of maintenance treatment with divalproex, lithium or placebo. Psychotropic medications were discontinued before randomization, except for open-label divalproex or lithium, which were gradually tapered over the first 2 weeks of maintenance treatment. The primary outcome measure was time to recurrence of any full mood episode. Secondary measures were time to a manic episode, time to a depressive episode, average change from baseline in Schedule for Affective Disorders and Schizophrenia-Change Version subscale scores for depression and mania, and Global Assessment of Function scores. The divalproex group did not differ significantly from the placebo group in time to any mood episode, in part because substantially lower rates of relapse into mania occurred with placebo than had occurred in early lithium studies, thereby reducing study power from 0.8 to under 0.3. On other planned analyses which were not affected by the lower rate of relapse into mania, which was in part consequent to tapering of lithium at the time of randomization, rather than abruptly discontinuing lithium as had occurred in early lithium maintenance studies, divalproex was significantly more efficacious than placebo. Divalproex was superior to placebo in terms of lower rates of early discontinuation for either a recurrent mood episode or depressive episode or drop out for any reason (Bowden, 2003). Divalproex was superior to lithium in longer
c03.fm Page 31 Wednesday, October 19, 2005 9:51 AM
Valproate
31
duration of successful prophylaxis in the study, and displayed less deterioration in depressive symptoms and Global Assessment Scale scores. A post hoc relative risk analysis (Macritchie et al., 2000) of the study reported that patients treated with divalproex were significantly less likely than those treated with placebo to have prematurely left the study for a mood episode (R2 = 0.63, 95% CI 0.44–0.90).
FACTORS ASSOCIATED WITH RESPONSE IN MAINTENANCE TREATMENT In this section, a series of findings uniquely related to maintenance and prophylactic treatment effectiveness with valproate (and in some cases the comparator treatment regimen studied) are summarized. Almost all studies regarding predictors of response other than the ones reviewed here for valproate, as well as other mood stabilizing drugs, have been on acute treatment effects. However, although the earlier section on predictors of response in mania is important, one should not extrapolate findings in that section to maintenance treatment decisions. Several of the subjects covered here can only apply in maintenance, e.g. whether a drug’s acute efficacy is predictive of its maintenance efficacy or whether an acute symptom presentation is predictive of maintenance responsiveness. In the authors’ view, these considerations will prove to be the most important set of predictors in the care of bipolar patients.
CONTINUATION OF ACUTE TREATMENT INTO MAINTENANCE During the open phase of the large divalproex, lithium, placebo maintenance study, approximately half of the patients were treated by psychiatrist choice with divalproex and the other half with lithium to bring their manic symptoms under control. A small number of patients received no mood stabilizer treatment during the open phase, as either their required manic episode had resolved without intervention, or the drug treatment had been discontinued. Among the patients initially treated with divalproex, those then randomized to divalproex had wider advantages compared to placebo for time to mania or depression (p = .05), time to depression (p = 0.03) and the proportion of patients who completed the trial and did not have either a manic or depressive episode (Div = 41%, Pla = 13%, Li = 27%, Div > Pla, p = 0.002) (Bowden et al., 2000). The divalproex to divalproex group continued in the maintenance phase for a significantly longer period of time (mean = 208.9 days) compared to subjects treated initially with lithium and randomized to lithium (mean = 130.3 days; p = 0.019), while subjects treated acutely with no mood stabilizer and randomized to placebo demonstrated an intermediate response (mean = 175.9 days). Among patients who were treated in the open phase with lithium, there was no significant advantage on any of the analyses for those subsequently randomized to lithium compared to those randomized to
c03.fm Page 32 Wednesday, October 19, 2005 9:51 AM
32
Bipolar Psychopharmacotherapy
placebo or divalproex. This is the only study published to date that has allowed a statistical test of the relationship between acute episode response and maintenance treatment outcomes (Bowden, 2004). The results are particularly informative, as the patients prescribed open divalproex treatment were generally experiencing a more severe form of bipolar illness than those selected for open lithium treatment. For example, the duration of the open phase was significantly shorter for the no mood stabilizer group (16.0 days) than the lithium group (35.3 days; p<0.001) and the divalproex group (48.2 days; p<0.001), and for the lithium group compared to the divalproex group (p<0.001). Similarly, the time from the start of the index episode to randomization was also significantly shorter for the no mood stabilizer group (59.5 days) compared to the lithium group (74.1 days; p<0.001) and the divalproex group (81.7 days; p <0.001), than for the lithium group. The mean age of the first manic episode was significantly younger in the divalproex group (23.3 years) compared to the lithium group (25.7 years; p= 0.04), and the mean number of days since the last manic episode was longer for the lithium group (447.2 days) compared to either the no mood stabilizer (334.4 days; p =0.007) or divalproex (343.6 days; p=0.01) group.
DYSPHORIC VS EUPHORIC MANIA In contrast to evidence in acute mania, patients whose acute manic episode included significant dysphoric symptoms (dysphoric mania, n = 249) had equivalent maintenance outcomes with divalproex or lithium treatment, with overall outcomes equivalent for patients with dysphoric and euphoric features, e.g. the likelihood of premature discontinuation from maintenance therapy among patients with initial dysphoric mania and euphoric mania was similar: 63.4% vs 71.1%; p = 0.154. Unexpectedly, the rate of discontinuation for intolerance during maintenance treatment was higher for initially dysphoric manic patients than euphoric patients (15.7% vs 7.3% respectively; p = 0.032), whether treated with lithium (23.2%) or valproate (17.1%). These findings indicate that some component of the more complex symptomatology of dysphoric mania increases subjective distress from adverse effects independent of treatment, and has implications for dosing and treatment selection in long-term care of mixed or dysphoric mania (Bowden et al., 2005). Conversely, among initially euphoric manic patients, randomized treatment with divalproex was associated with significantly less discontinuation due to intolerance than treatment with lithium (7.1% vs 18.2%; p = 0.03). The rate of discontinuation due to intolerance in euphoric manic patients was similar for divalproex and placebo. Additionally, treatment with divalproex was significantly (p = 0.05) more effective than lithium in delaying time to a depressive episode in the initially euphoric manic patients. Additionally, among euphoric manic patients, mean depressive symptomatology during maintenance treatment increased significantly more with lithium than with either divalproex or placebo. Also, GAS scores among euphoric manic patients worsened significantly more with lithium
c03.fm Page 33 Wednesday, October 19, 2005 9:51 AM
Valproate
33
treatment than with either divalproex or placebo. Whether for overall efficacy, prophylaxis of depression or tolerability among initially euphoric manic patients, those randomized to lithium treatment fared less well than did those randomized to divalproex. Thus, where divalproex works acutely, it seems to outperform lithium in the long term.
SERUM-LEVEL RELATIONSHIPS TO MAINTENANCE OUTCOMES Whereas both for valproate and lithium, serum level-response relationships are well established for treatment of mania, minimal systematic study has been conducted regarding optimally effective maintenance serum levels. In this study, the daily dose was adjusted upward from the starting dose to maintain target serum through drug concentrations of 71–125μg/mL for valproate or 0.8–1.2mmol/L for lithium, as tolerated. In a post hoc analysis, four ranges of serum levels were defined for both divalproex and lithium (Keck et al., 2005). For divalproex, the valproate serum level ranges used to define these categories were: nontherapeutic, <49.9 μg/mL; low therapeutic, 50.0–74.9 μg/mL; medium therapeutic, 75.0–99.9 μg/mL; and high therapeutic, >100.0 μg/mL. For lithium, the corresponding serum level ranges were: nontherapeutic, <0.49 mmol/L; low therapeutic, 0.50–0.79 mmol/L; medium therapeutic, 0.80–1.00 mmol/L; high therapeutic, >1.00 mmol/L. Significant differences between divalproex at the medium range (75–99.9 μg/mL) and placebo were demonstrated in Kaplan-Meier survival results for discontinuation for any reason (median survival time: divalproex, 8 months; placebo, 4 months; p < 0.05) (Figure 3.1) and for discontinuation for a manic or depressive episode (median survival time: divalproex, 8 months; placebo, 3 months, p=0.003). No lithium serum level range differed significantly from another, nor from placebo. A smaller sample of patients were treated with lithium in the study, therefore the results for lithium should be seen as suggestive, not definitive (Table 3.1). 100% 80% Survival
Placebo Nontherapeutic
60%
Low therapeutic 40%
Medium therapeutic High therapeutic
20% 0% 0
1
2
3
4
5
6
7
8
9
10 11 12
Months of Study
Figure 3.1: Survival analysis: Discontinuation for any reason divalproex-treated patients
c03.fm Page 34 Wednesday, October 19, 2005 9:51 AM
34
Bipolar Psychopharmacotherapy Table 3.1: Median survival time: Discontinuation for protocol-defined mania or depression Treatment Group (N) Placebo (88) Lithium Nontherapeutic (5) Low Therapeutic (16) Medium Therapeutic (37) High Therapeutic (16) Divalproex Nontherapeutic (11) Low Therapeutic (45) Medium Therapeutic (85) High Therapeutic (28)
Median Survival Time, months (95% Confidence Limit) 3.5 (2, 5) 1 (1, 3) 4 (2, 10) 4 (2, 9) 3 (1, 5) 5 (1, NC) 5 (4, 10) 8 (5, 12) 2 (1, 3)
NC = not calculable
TOLERABILITY Overall, tremor and reported weight gain were the only symptoms more commonly seen with divalproex than placebo (Bowden et al., 2000). Patients treated acutely with divalproex had significantly fewer premature discontinuations due to intolerance when randomized to maintenance treatment with divalproex (7.1%) than did patients randomized to lithium. The results from this large, randomized, blinded study are re-enforced by similar results regarding overall effectiveness of valpromide versus lithium in an earlier, randomized open study conducted by Lambert and Venaud (1992). A retrospective analysis of 38 patients with bipolar disorder treated with lithium or divalproex in a university outpatient psychiatry clinic sample for over one year adds perspective to the above studies. Mean duration of follow-up was 90 weeks. Lithium and divalproex were equally effective and tolerated in the total sample. Divalproex monotherapy (24%) was more common than lithium monotherapy (7%, p = 0.07) and was significantly more effective in treating depressive symptoms, with improvement on the HDRS (14.8 ± 9.2 vs 7.6 ± 7.8, p = 0.003) (Ghaemi and Goodwin, 2001). It is clinically noteworthy that cognitive dulling may be reversed by switching patients to divalproex (Stoll et al., 1996). The side-effect profile of valproate is generally well characterized, including from studies conducted in epileptic and migraine patients. Several recent randomized studies with placebo or active treatment comparator groups add relevant new information, and are reviewed here.
c03.fm Page 35 Wednesday, October 19, 2005 9:51 AM
Valproate
35
None of the studies of the past decade has indicated evidence of hepatic dysfunction, or significant worsening of hepatic indices, as compared with results seen in placebo- or comparator-treated patients (Bowden etal., 2000). This finding suggests that some of the earlier evidence was associated with dosing factors, or patient selection, that are not relevant in current practice. High serum levels, particularly above 125 μg/ml, are associated with reductions in platelet count and WBC, increased appetite and sedation (Bowden et al., 2000). Studies in migraine employing doses of 500–1000 mg/day have reported no adverse effects compared with placebo, including for weight gain, indicating that patients who are able to achieve benefits from relatively lower doses are likely to be free of even the more common side effects associated with valproate. Immediate release formulations are more likely to cause these adverse events when compared to the extended or enteric coated formulations (Zarate et al., 2000). Extended release formulations (DepakoteER, Depakine Chrono, Orfiril Long) have much flatter peak to trough relationships, and thereby lessen the frequency of adverse effects that are associated with high serum levels (Wilder et al., 1983; Zarate et al., 2000). Recent studies have shown that valproate reduces cholesterol and LDL levels, may increase HDL levels, and protects against effects of some antipsychotic drugs to worsen lipid function (Zajecka et al., 2002). In schizophrenic patients treated for 12 weeks, adjunctive valproate significantly reduced cholesterol increases observed among patients receiving only olanzapine or risperidone (Casey et al., 2003). PCOS has been associated with valproate taken in combination with other drugs in retrospective analyses of epileptic and bipolar patients (Rasgon, 2004). PCOS did not occur across a sectional study of bipolar patients treated with valproate, although menstrual irregularities were seen in a large proportion of the patients (Rasgon et al., 2000). A study evaluating four groups of women with epilepsy: an untreated group, a carbamazepine-treated group, a valproate-treated group and a group receiving more than one antiepileptic, found no evidence of a causative role for valproate in the development of PCOS. Valproate did not alter endocrine measures indicative of PCOS in a 12–15-month study in rhesus monkeys. Studies suggest that obesity may be a mechanistic pathway whereby valproate, and potentially other drugs, increase androgenic compounds. It therefore seems advisable to treat weight gain as a risk factor for possible development of PCOS and intervene as needed to avoid clinically significant weight gain.
EFFECTS ON SUICIDALITY A retrospective study of patients with bipolar disorder who had at least one filled prescription for lithium, divalproex or carbamazepine found a higher risk of
c03.fm Page 36 Wednesday, October 19, 2005 9:51 AM
36
Bipolar Psychopharmacotherapy
suicide attempts and death with divalproex than with lithium treatment (Goodwin et al., 2003). A second retrospective study found no difference in suicide attempt rates among lithium-, valproate- or carbamazepine-treated patients (Yerevanian, Koek and Mintz, 2003). Rates of suicidal behavior in bipolar disorder were reduced significantly by treatment with lithium, valproate or carbamazepine, compared to patients in treatment, but not taking a mood stabilizer, with no differences among the three drugs. The study suggests that treatment with a mood stabilizer, which likely reduced illness symptomatology, may be more important than the specific mood stabilizer in reducing suicidal risk in bipolar disorders (11.6 vs 22.9 events/100 patient years).
MECHANISMS OF ACTION Recent studies indicate substantially overlapping, but also distinct mechanisms on signal transduction for valproate and for lithium, nearly always at tissue concentrations that are achieved with therapeutic doses of either valproate or lithium. In general, when other psychotropic drugs have been studied in these paradigms, no comparable results have emerged.
INHIBITION OF GSK-3 Both valproate and lithium inhibit glycogen synthase kinase 3 (GSK-3) at concentrations obtained therapeutically, whereas carbamazepine had no effects (Gould, Chen and Manji, 2004). The effect of valproate in reduction of GSK-3 activity may be indirect, linked to its capability to up-regulate gene expression through inhibition of histone deacetylase (Harwood and Agam, 2003). Histone deacetylase is a target of valproate that results in gradual increases in the phosphorylation of Akt and GSK-3 beta. Although chronic lithium treatment increased the Ser-9 phosphorylation of GSK-3 beta, it did not alter the phosphorylation of Akt. Although valproate and lithium each increased inhibitory phosphorylation of Ser-9-GSK-3 beta, this appears to be directly by phosphorylation following lithium administration, in contrast to the effects of valproate which are mediated by inhibition of histone deacetylase (DeSarno, Li and Jope, 2002). GSK-3 is associated with functional roles in neuroprotection and circadian rhythms. Bipolar patients have altered circadian rhythm activity in relationship to motor activity, interests and sleep, therefore this action constitutes a possible functional pathway by which valproate and lithium control manic systems (Gray et al., 2003). GSK-3 beta is a key enzyme of the Wnt signaling pathway, which is critical for proper embryonic development. One may speculate that inhibition of GSK-3 could contribute to the mechanisms by which valproate and lithium can cause fetal abnormalities (Gould and Manji, 2002).
c03.fm Page 37 Wednesday, October 19, 2005 9:51 AM
Valproate
37
ACTIVATION OF ERK KINASE Both valproate and lithium also stimulated the extracellular signal-regulated kinase (ERK) pathway in the rat hippocampus and frontal cortex (Einat et al., 2003). An ERK kinase inhibitor, SL327, induced qualitatively similar effects to amphetamine, which can cause relapse in remitted manic patients and mood elevation in normal subjects. The results suggest that the ERK pathway may mediate the antimanic effects of mood stabilizers (Gould and Manji, 2002).
INCREASE OF BCL-2 EXPRESSION Lithium and valproate increase the expression of the cytoprotective protein B-cell lymphoma/leukemia-2 gene (bcl-2) in the CNS in vivo and in cells of human neuronal origin (Gray et al., 2003). VPA concurrently increased the expression of genes regulated by the ERK pathway, including growth cone-associated protein 43 and bcl-2 promoted neurite growth and cell survival, and enhanced norepinephrine uptake and release. These data link VPA activation of the ERK pathway with production of neurotrophic effects (Yuan et al., 2001).
INHIBITION OF PKC Chronic administration of lithium and valproate results in reduction in protein kinase C (PKC) isozymes in rat frontal cortex and hippocampus. Although VPA reduces the activity of PKC and reduces the protein levels of different PKC isoforms, the effect of VPA appears to be largely independent of myoinositol (Brunello and Tascedda, 2003). Lithium and VPA increase the DNA binding of the activator protein 1 (AP-1) family of transcription factors for PKC in cultured cells in vitro, and in rat brain ex vivo and increase (Chen, Masana and Manji, 2000). Additionally, both omega 3 fatty acids DHA and EPA, as well as the combination of DHA and EPA, inhibited PKC activity at concentrations as low as 10 μmol, suggesting that this group of compounds that has been putatively suggested to have mood stabilizing properties share a similar mechanism with valproate (Seung Kim et al., 2001). Valproate is incorporated into neuronal membranes in an active, saturable process at concentrations found clinically, and appears to substitute for naturally occurring phospholipids involved in neuronal membrane and ion channel integrity (Siafaka-Kapadai et al., 1998).
ACTIVATION OF MARCKS PROTEIN Two prominent substrates for PKC in the brain, MARCKS and GAP-43, which have been implicated in actin-membrane plasticity and neurite outgrowth during neuronal differentiation respectively, and are essential to normal brain development,
c03.fm Page 38 Wednesday, October 19, 2005 9:51 AM
38
Bipolar Psychopharmacotherapy
are activated by valproate within as little as one day at therapeutically relevant concentrations. Valproate reduced MARCKS protein expression and demonstrated increased GAP-43 protein expression, with concomitant alterations in cellular morphology, including an increase in the number and length of neurites and accompanied by a reduction in cell growth rate. The reduction in MARCKS protein expression and increased GAP-43 protein expression were associated with concomitant alterations in cellular morphology, including an increase in the number and length of neurites and a reduction in cell growth rate.
ATTENUATION OF CRF Valproate reduced CRF mRNA expression and reduced CRF1 receptor binding, suggesting that one of valproate’s effects in brain is to dampen tone in this pathway that is associated with stress linked psychopathology, including mixed mania (Watterson et al., 2002). Some neurochemical actions of valproate are not shared with lithium. Valproate, but not lithium or carbamazepine, dose-dependently inhibited substance P (SP)-induced IL-6 synthesis (seen with pre-incubation periods of 30 minutes, 3, 7 and 14 days). The inhibitory effect of valproate was not mediated by inhibition of the stress-regulated kinases p38 and p42/44 (Erk1/2) but by inhibition of PKC epsilon activation. Furthermore, valproate down-regulated the expression of the substance P receptor (neurokinin(NK)-1) (Lieb et al., 2003).
SUMMARY The central role of valproate in the treatment for bipolar disorders is accounted for by the large effect sizes of its benefits in mania and maintenance treatment. It benefits relatively severe bipolar disorders and behavioral components, particularly irritability, in ways that appear to differentiate it from other currently available treatments for bipolar disorders. Studies of the last decade provide more practical guidelines for selection of valproate as monotherapy, or as a component of combination treatment. Serum level monitoring is a helpful guide to efficacious use and dosing to avoid adverse effects in both acute and maintenance treatment. Valproate has some adverse risks that warrant its discontinuation on occurrence, e.g. pancreatitis; or risks for offspring, e.g. neural tube defects in the first trimester of pregnancy. Patients sometimes wish to discontinue it when they experience severe hair loss. Expanding knowledge of its molecular mechanisms may lead to a role for valproate in other disease states, new specific treatments for bipolar disorders, and productive studies on the neurobiological bases of bipolar disorders.
c03.fm Page 39 Wednesday, October 19, 2005 9:51 AM
Valproate
39
REFERENCES Bowden CL. Efficacy of Divalproex vs. Lithium and Placebo in Mania. JAMA. 1994; 272: 1005–1006. Bowden CL. Valproate. Bipolar Disord. 2003; 5: 189–202. Bowden CL. Predictors of response to divalproex and lithium. J. Clin. Psychiatry. 1995; 56: 25–30. Bowden CL. Relationship of acute mania symptomatology to maintenance treatment response. Curr. Psychiatry Rep. 2004; Dec. 6(6): 473–477. Bowden CL, Brugger AM, Swann AC, Calabrese JR, Janicak PG, Petty F, Dilsaver SC, Davis JM, Rush AJ, Small JG, Garza-Trevino ES, Risch SC, Goodnick PJ, Morris DD. Efficacy of divalproex vs lithium and placebo in the treatment of mania. JAMA. 1994; 271: 918–924. Bowden CL, Calabrese JR, McElroy SL, Gyulai L, Wassef A, Petty F, Pope HG, Jr., Chou JC-Y, Keck PE, Jr., Rhodes LJ, Swann AC, Hirschfeld RMA, Wozniak PJ. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Arch. Gen. Psychiatry. 2000; 57: 481–489. Bowden CL, Collins MA, McElroy SL, Calabrese JR, Swann AC, Weisler RH, Wozniak PJ. Relationship of Mania Symptomatology to maintenance treatment response with divalproex lithium or Placebo. Neuropsychopharmacology. 2005; June 8. (online pub: 3 May 2005 at http://www.acnp.org/citations/NPP050305040404/default.pdf). Brunello N, Tascedda F. Cellular mechanisms and second messengers: relevance to the psychopharmacology of bipolar disorders. Int. J. Neuropsychopharmacol. 2003; 6: 181–189. Burton BS. On the propyl derivatives and decomposition products of ethyl acetoacetate. Am. Chem. J. 1881; 3: 385–395. Calabrese JR, Markovitz PJ, Kimmel SE, Wagner SC. Spectrum of efficacy of valproate in 78 rapid-cycling bipolar patients. J. Clin. Psychopharmacol. 1992; 12: 53S-56S. Casey DE, Daniel DG, Wassef AA, Tracy KA, Wozniak P, Sommerville KW. Effect of divalproex combined wth olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Neuropsychopharmacology. 2003; 28: 182–192. Chen G, Masana MI, Manji HK. Lithium regulates PKC-mediated intracellular cross-talk and gene expression in the CNS in vivo. Bipolar Disord. 2000; 2: 217–236. Davis LL, Kabel D, Patel D, Choate AD, Foslien-Nash C, Gurguis GN, Kramer GL, Petty F. Valproate as an antidepressant in major depressive disorder. Psychopharmacol. Bull. 2004; 32: 647–652. Deltito J, Martin L, Riefkohl J, Austria B, Kissilenko A, Corless P, Morse C. Do patients with borderline personality disorder belong to the bipolar spectrum ? J. Affect. Disord. 2001; 67: 221–228. DeSarno P, Li X, Jope RS. Regulation of Akt and glycogen synthas kinase-3 beta phosphorylation by sodium valproate and lithium. Neuropharmacology. 2002; 43: 1158–1164. Einat H, Yuan P, Gould TD, Li J, Du J, Zhang L, Manji HK, Chen G. The role of the extracellular signal-regulated kinase signaling pathway in mood modulation. J. Neurosci. 2003; 23: 7311–7316. Frankenburg FR, Zanarini MC. Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: A double-blind placebo-controlled pilot study. J. Clin. Psychiatry. 2002; 63: 442–446. Freeman TW, Clothier JL, Pazzaglia P, Lesem MD, Swann AC. A double-blind comparison of valproate and lithium in the treatment of acute mania. Am. J. Psychiatry. 1992; 149: 108–111. Ghaemi SN, Goodwin FK. Long-term naturalistic treatment of depressive symptoms in bipolar illness with divalproex, vs lithium in the setting of minimal antidepressant use. J. Affect. Disord. 2001; 65: 281–287.
c03.fm Page 40 Wednesday, October 19, 2005 9:51 AM
40
Bipolar Psychopharmacotherapy
Goodwin FK, Fireman B, Simon GE, Hunkeler EM, Lee J, Rivicki D. Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA. 2003; 290: 1467–1473. Gould TD, Manji HK. The Wnt signaling pathway in bipolar disorder. Neuroscientist. 2002; 8: 497–511. Gould TD, Chen G, Manji HK. In vivo evidence in the brain for lithium inhibition of glycogen synthase kinase-3. Neuropsychopharmacology. 2004; 29: 32–38. Gray NA, Zhou R, Du J, Moore GJ, Manji HK. The use of mood stabilizers as plasticity enhancers in the treatment of neuropsychiatric disorders. J. Clin. Psychiatry. 2003; 64(S): 3–17. Grunze H, Erfurth A, Amann B, Giupponi G, Kammerer C, Walden J. Intravenous valproate loading in acutely manic and depressed bipolar I patients. J. Clin. Psychopharmacol. 1999; 19: 303–309. Harwood AJ, Agam G. Search for a common mechanism of mood stabilizers. Biochem. Pharmacol. 2003; 66: 179–189. Hollander E, Lopez AA, Bienstock CA, Grossman R, Siever LJ, Merkatz L, Stein DJ (2001), A preliminary double-blind, placebo controlled trial of divalproex sodium in borderline personality disorder. J. Clin. Psychiatry. 62: 199–203. Jacobsen FM. Low dose valproate: A new treatment for cyclothymia, mild rapid cycling disorders, and premenstrual syndrome. J. Clin. Psychiatry. 1993; 54: 229–234. Kahn D, Stevenson E, Douglas CJ. Effect of sodium valproate in three patients with organic brain syndromes. Am. J. Psychiatry. 1988; 145: 1010–1011. Keck PE, Meinhold JM, Prihoda TJ, Baker JD, Wozniak PJ, Bowden CL. Relation of serum valproate and lithium concentrations to efficacy and tolerability in maintenance therapy for bipolar disorder. Accepted for publication by “Psychiatry in Clinical Practice”, 2005. Kowatch RA, Suppes T, Carmody TJ, Bucci JP, Hume JH, Kromelis MR, Emslie GJ, Weinberg WA, Rush AJ. Effect size of lithium, divalproex sodium, and carbamazepine in children and adolescents with bipolar disorder. J. Am. Acad. Child Adolesc. Psychiatry. 2002; 39: 713–720. Lambert PA, Cavaz G, Borselli S, Carrel S. Action neuropsychotrope d’un nouvel anti-epileplique: Le Depamide. Ann. Med. Psychol. 1966; 1: 707–710. Lambert PA, Venaud G. A comparative study of valpromide versus lithium in the prophylaxis of thymic disorders. J. Psychiatry, Published by Maxmed. 1992; 5(2): 57–65. Lieb K, Treffurth Y, Hamke M, Akundi RS, von Kleinsorgen M, Fiebich BL. Valproic acid inhibits substance P-induced activation of proten in kinase C epsilon and expression of the substance P receptor. J. Neurochem. 2003; 86: 69–76. Macritchie KA, Geddes JR, Scott J, Haslam DR, Goodwin GM. Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder. Psychiatr. Serv. 2000; 51: 1179–1181. McElroy SL, Keck PE, Stanton SP, Tugrul KC, Bennett JA, Strakowski SM. A randomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania. J. Clin. Psychiatry. 1996; 57: 142–146. Muller-Oerlinghausen B, Retzow A, Henn FA, Giedke H, Walden J. Valproate as an adjunct to neuroleptic medication for the treatment of acute episodes of mania: A prospective, randomized, double-blind, placebo-controlled, multicenter study. J. Clin. Psychopharmacol. 2000; 20: 195–203. Petty F, Davis LL, Nugent AL, Kramer GL, Teten A, Schmitt A, Stone RC. Valproate therapy for chronic, combat-induced postraumatic stress disorder. J. Clin. Psychopharmacol. 2002; 22: 100–101. Pope HG, Jr., McElroy SL, Keck PE, Jr., Hudson JI. Valproate in the treatment of acute mania: A placebo-controlled study. Arch. Gen. Psychiatry. 1991; 48: 62–68.
c03.fm Page 41 Wednesday, October 19, 2005 9:51 AM
Valproate
41
Puzynski S, Klosiewicz L. Valproic acid amide in the treatment of affective and schizoaffective disorders. J. Affect. Disord. 1984; 6: 115–121. Rasgon N. The relationship between polysystic ovary syndrome and antiepileptic drugs: A review of the evidence. J. Clin. Psychopharmacol. 2004; 24: 322–334. Rasgon NL, Altshuler LL, Gudeman D, Burt VK, Tanavoli S, Hendrick V, Korenman S. Medication status and polycystic ovary syndrome in women with bipolar disorder: A preliminary report. J. Clin. Psychiatry. 2000; 61: 173–178. Sachs G, Grossman F, Okamoto A, Ghaemi SN, Bowden CL. Risperidone plus mood stabilizer versus placebo plus mood stabilizer for acute mania of bipolar disorder: A double-blind comparison of efficacy and safety. Am. J. Psychiatry. 2002; 159: 1146–1154. Seung Kim HF, Weeber EJ, Sweatt JD, Stoll AL, Marangell LB. Inhibitory effects of omega-3 fatty acids on protein kinase C activity in vitro. Mol. Psychiatry. 2001; 6: 246–248. Siafaka-Kapadai A, Patiris M, Bowden C, Javors M. Incorporation of [3H]-Valproic Acid into Lipids in GT1–7 Neurons. Biochem. Pharmacol. 1998; 56: 207–212. Stoll AL, Locke CA, Vuckovic A, Mayer PV. Lithium-associated cognitive and functional deficits reduced by a switch to divalproex sodium: A case series. J. Clin. Psychiatry. 1996; 57: 356–359. Swann AC, Bowden CL, Calabrese JR, Dilsaver SC, Morris DD. Differential effect of number of previous episodes of affective disorder on response to lithium or divalproex in acute mania. Am. J. Psychiatry. 1999; 156: 1264–1266. Swann AC, Bowden CL, Calabrese JR, Dilsaver SC, Morris DD. Pattern of response to divalproex, lithium, or placebo in four naturalistic subtypes of mania. Neuropsychopharmacology. 2002; 26: 530–536. Swann AC, Secunda SK, Stokes PE, Croughan J, Davis JM, Koslow SH, Maas JW. Stress, depression, and mania: Relationship between perceived role of stressful events and clinical and biochemical characteristics. Acta Psychiatr. Scand. 1990; 81: 389–397. Tohen M, Chengappa KN, Suppes T, Baker RW, Zarate CA, Bowden CL, Sachs GS, Kupfer JD, Ghaemi SN, Feldman PD, Risser RC, Evans AR, Calabrese JR. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br. J. Psychiatry. 2004; Apr. 184: 337–345. Tohen M, Chengappa KNR, Suppes T, Zarate CA JR, Calabrese JR, Bowden CL, Sachs GS, Kupfer DJ, Baker RW, Risser RC, Keeter EL, Feldman PD, Tollefson GD, Breier A. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch. Gen. Psychiatry. 2002; 59: 62–69. Tohen M, Castillo-Ruiz J, Pope HG Jr., Herbstein J. Concomitant use of valproate and carbamazepine in bipolar and schizoaffective disorders. J. Clin. Psychopharmacol. 1994; 14: 67–70. Vasudev K, Goswami U, Kohli K. Carbamazepine and valproate monotherapy: Feasibility, relative safety and efficacy, and therapeutic drug monitoring in manic disorder. Psychopharmacology. 2000; 150: 15–23. Watterson JM, Watson DG, Meyer EM, Lenox RH. A role for protein kinase C and its substrates in the action of valproic acid in the brain: Implications for neural plasticity. Brain Res. 2002; 934: 69–80. Wilder BJ, Karas BJ, Penry JK, Asconape J. Gastrointestinal tolerance of divalproex sodium. Neurology. 1983; 33: 808–811. Winsberg ME, DeGolia SG, Strong CM, Ketter TA. Divalproex therapy in medication-naïve and mood stabilizer-naïve bipolar II depression. J. Affect. Disord. 2001; 67: 207–212.
c03.fm Page 42 Wednesday, October 19, 2005 9:51 AM
42
Bipolar Psychopharmacotherapy
Yatham L. Safety and efficacy of risperidone as combination therapy for the manic phase of bipolar disorder: Preliminary findings of a randomized, double-blind study (Abstract). Presented at the 13th European College of Neuropsychopharmacology Congress, Munich, Germany, 2000. Yatham LN, Grossman F, Augustyns I, Vieta E, Ravindran A. Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial. Br. J. Psychiatry. 2003; 182: 141–147. Yerevanian BI, Koek RJ, Mintz J. Lithium, anticonvulsants and suicidal behavior in bipolar disorder. J. Affect. Disord. 2003; 73: 223–228. Young LT, Joffe RT, Robb JC, MacQueen GM, Marriott M, Patelis-Siotis I. Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression. Am. J. Psychiatry. 2000; 157: 124–126. Yuan PX, Huang LD, Jiang YM, Gutkind JS, Manji HK, Chen G. The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth. J. Biol. Chem. 2001; 276: 31674–83. Zajecka J, Weisler RSKW. Divalproex Sodium Vs. Olanzapine for the Treatment of Mania in Bipolar Disorder. Presented at the 39th Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 2000. Zajecka J, Weisler R, Sachs G, Swann AC, Wozniak P, Sommerville KW. A comparison of the efficacy, safety and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. J. Clin. Psychiatry. 2002; 63: 1148–1155. Zarate CA Jr., Tohen M, Narendran R, Tomassini EC, McDonald J, Sederer M, Madrid AR. The adverse effect profile and efficacy of divalproex sodium compared with valproic acid: A pharmacoepidemiology study. J. Clin. Psychiatry. 2000; 60: 232–236.
c04.fm Page 43 Wednesday, October 19, 2005 9:14 AM
CHAPTER
4 Pharmacological Profile and Clinical Utility of Lamotrigine in Bipolar Disorders David J. Muzina1, Joseph R. Calabrese2 1
Department of Psychiatry and Psychology, Cleveland Clinic Foundation, Cleveland, Ohio, USA 2 Case Western Reserve University School of Medicine, University Hospitals of Cleveland, Cleveland, Ohio, USA
INTRODUCTION There remains a pressing need for additional treatment options for affective illnesses, particularly those refractory or difficult to treat mood disorders such as bipolar disorder. Estimates of the prevalence of bipolar I disorder across diverse cultures and ethnic groups are consistent, ranging between 0.4 and 1.6% in adults (Weissman et al., 1996). Recent estimates of the overall prevalence of bipolar disorder (types I and II) in the general Unites States population suggest that 4–6% of American adults may suffer from this debilitating mental disorder (Hirschfeld et al., 2003; Judd and Akiskal, 2003). Bipolar disorder carries a high burden, negatively affecting lives in many areas, most notably the performance of work-related, leisure and interpersonal activities (Calabrese et al., 2003b). The greatest need exists in the treatment for depressive episodes associated with bipolar disorder as symptoms of depression are much more commonly experienced and more difficult to treat than manic symptoms (Judd et al., 2002; Post et al., 2002). Reports of lamotrigine’s beneficial effects on mood in epilepsy patients led to its use and study in affective disorders. Studies involving bipolar patients suggested that lamotrigine possessed a broad spectrum of therapeutic activity in bipolar disorder, with later descriptions of greater efficacy for depressive than for manic symptoms. Given the significant burden, prevalence and recurrent nature of bipolar disorder – especially bipolar depression – lamotrigine Bipolar Psychopharmacotherapy: Caring for the Patient Edited by Hagop S. Akiskal and Mauricio Tohen # 2006 John Wiley & Sons, Ltd ISBN: 0-470-85607-6
c04.fm Page 44 Wednesday, October 19, 2005 9:14 AM
44
Bipolar Psychopharmacotherapy
appears to begin to address an area of serious unmet public health need (Calabrese et al., 2003b). We will review the pharmacological profile of this structurally unique anticonvulsant that has become a critical component in the treatment for bipolar disorder. The clinical applications for lamotrigine in mood disorders will be discussed by initially reviewing research evidence supporting its use and then outlining particular clinical scenarios in which lamotrigine can be best utilized as an effective mood stabilizer in acute and chronic therapy. Issues surrounding dosing, drug interactions, rash and use in women of child-bearing age with bipolar disorder will also be discussed. Although the most robust data for lamotrigine is in its prophylactic activity in bipolar I depression, extrapolation of its use for bipolar II (via secondary analyses) will also be undertaken.
CLINICAL PHARMACOLOGY OF LAMOTRIGINE PHARMACODYNAMICS Lamotrigine is an antiepileptic drug of the phenyltriazine class that has demonstrated efficacy as add-on treatment for partial seizures (Matsuo et al., 1993; Mikati et al., 1989) and as maintenance treatment for bipolar I disorder to delay the time of occurrence of mood episodes (Bowden et al., 2003; Calabrese et al., 2003a). Although its mechanism of therapeutic action in humans is not definitively understood, lamotrigine is thought to possess modulatory and protective effects on neurotransmission and intracellular signal transduction processes. Structurally distinct from other antiepileptic drugs, lamotrigine interacts preferentially on the slow inactivated state of presynaptic neuronal sodium and calcium channels to prolong inactivation of the neuron and promote stabilization of the neuronal membrane (Xie and Hagan 1998). This effect is augmented by a use-dependent action in which further inhibition by the drug develops during rapid, repetitive stimulation (i.e. epileptiform bursts). Consequently, the release of the excitatory amino acid glutamate is antagonized (Fitton and Goa, 1995; Li, Ketter and Frye, 2002). Lamotrigine has also been observed to inhibit cortical and amygdaloid kindling (Leach, Marden and Miller, 1986; Gilman, 1995; Xie et al., 1995). Lamotrigine has no substantial in vitro affinity for adenosine, adrenergic, dopaminergic, muscarinic and opioid receptors at clinically applicable concentrations and binds only weakly to inhibit serotonin 5HT3 receptors (Leach, Baxter and Critchley, 1991). Lamotrigine lacks clinically meaningful activity at the 5HT1A receptor, where changes in 5HT1A receptor-mediated cyclic adenosine monophosphate pathway have been implicated in affective disorders (Shiah et al., 1998; Vinod and Subhash, 2002). In early epilepsy studies with lamotrigine it was noted that many patients reported improvement in mood and psychological well-being independent from
c04.fm Page 45 Wednesday, October 19, 2005 9:14 AM
Lamotrigine
45
reduction in seizure frequency, which led to its investigation for use in affective disorders (Smith et al., 1993a,b; Jacoby et al., 1996). Significantly, lamotrigine has minimal negative effects on cognitive, memory or psychomotor function and is not associated with sedative effects or weight gain (Cohen et al., 1985; Goa, Ross and Chrisp, 1993; Ginsberg, Sachs and Ketter, 2003).
PHARMACOKINETICS Lamotrigine is extensively absorbed demonstrating linear kinetics, resulting in 98% bioavailability (Garnett, 1997). Peak plasma concentrations are attained after 1–3 hours with mean plasma protein binding of 55–68% (Cohen et al., 1987; Ramsay et al., 1991; Rambeck and Wolf, 1993). Lamotrigine readily crosses the placental barrier causing fetal blood concentrations similar to maternal levels and passes into breast milk reaching 40–80% of the maternal lamotrigine concentration (Ohman, Vitols and Tomson, 2000; Pennell, 2003). The rate-limiting step in the elimination of lamotrigine is N-glucoronidation by the liver with a plasma elimination half-life of 25 + 10 hours (Cohen et al., 1987). Autoinduction of its own metabolism does not occur and there are no active metabolites. Pregnancy increases lamotrigine clearance by more than 50% early during pregnancy and reverts quickly after delivery (Tran et al., 2002). Clearance may be reduced in the elderly and in patients with moderate to severe hepatic dysfunction.
DRUG INTERACTIONS Lamotrigine administration does not affect the serum concentrations of other drugs. However, enzyme-inhibiting drugs such as divalproex sodium increase lamotrigine concentrations by significantly competing for metabolism through glucoronidation effectively increasing the mean half-life of lamotrigine to about 70 hours (Yuen et al., 1992; Anderson et al., 1996). Enzyme-inducing drugs, such as phenytoin, carbamazepine and phenobarbital, reduce lamotrigine’s mean elimination half-life to about 12 hours and decrease lamotrigine concentrations (Hachad et al., 2002). A recently completed but unpublished study shows that there is no clinically significant drug–drug interaction between oxcarbazepine and lamotrigine, and although there is a need for lamotrigine dosage adjustment when co-prescribed with carbamazepine, this is not necessary for oxcarbazepine (data on file, GlaxoSmithKline 2003). Lamotrigine does not significantly affect the pharmacokinetics of lithium (Chen, Veronese and Yin 2000). Table 4.1 summarizes lamotrigine drug interaction information.
c04.fm Page 46 Wednesday, October 19, 2005 9:14 AM
46
Bipolar Psychopharmacotherapy
Table 4.1: Lamotrigine drug interactions Lamotrigine has no known effects on levels of: Increased levels of lamotrigine caused by: (estimated % increase LTG) Decreased levels of lamotrigine caused by: (estimated % decrease LTG)
Lithium Carbamazepine Divalproex
Phenytoin Phenobarbital Mesuximide
Antidepressants Benzodiazepines Antipsychotics
Divalproex/Valproate (−100%) Carbamazepine (40%) Phenytoin (50%)
Phenobarbital (40%) *Oxcarbazepine <30%
Bold indicates interaction with clinically significant importance. * No dosage adjustment appears necessary for lamotrigine with oxcarbazepine
LAMOTRIGINE AND AFFECTIVE DISORDERS The observations of Smith and colleagues (1993a,b) that patients treated with add-on lamotrigine for partial seizures experienced improved mood apart from effects on epilepsy stimulated investigations of lamotrigine’s efficacy to treat mood disorders. Early case reports involving bipolar patients suggested that lamotrigine possessed a broad spectrum of therapeutic activity in bipolar disorder, including rapid cycling and mixed states (Weisler et al., 1994; Calabrese, Fatemi and Woyshville, 1996; Walden et al., 1996). A subsequent open-label study provided preliminary data that lamotrigine was effective for patients with refractory bipolar disorder, with 68% of depressed patients and 84% of manic/ hypomanic/mixed patients showing moderate to marked response (Calabrese et al., 1999a). Lamotrigine was used as an add-on therapy in 60 of these patients and as monotherapy in 15. Later studies focused on the ability of lamotrigine to prevent mood episodes associated with bipolar I disorder, for which it received a US-FDA approved indication in 2003.
ACUTE MOOD DISTURBANCES: DEPRESSION An open naturalistic study of 22 depressed bipolar patients who were refractory to treatment with a combination of divalproex sodium and another mood stabilizer or divalproex sodium and an antidepressant for 6 weeks were treated with add-on lamotrigine. By the end of week 4, 16 out of 22 (72%) responded, suggesting that lamotrigine may be useful in bipolar depression (Kusumakar and Yatham, 1997). In a double-blind placebo-controlled study of lamotrigine monotherapy in outpatients
c04.fm Page 47 Wednesday, October 19, 2005 9:14 AM
Lamotrigine
47
with non–rapid-cycling bipolar I depression, treatment with lamotrigine over 7 weeks (50 or 200 mg/day) resulted in significant improvements from baseline depression scores (HAM-D, HAM-D Item 1, MADRS), particularly in the 200mg group, compared with placebo (Calabrese etal., 1999b). Improvements were observed as early as week 3. Figure 4.1 demonstrates the percentage of patients showing a response to treatment at endpoint. Thirty-one patients with refractory bipolar and unipolar mood disorders participated in a double-blind, randomized, crossover study of three 6-week monotherapy evaluations including lamotrigine, gabapentin and placebo. Using the Clinical Global Impressions (CGI) Scale for Bipolar Illness as the primary outcome variable, this study reported a 52% response rate (CGI-I as much or very much improved) for lamotrigine, compared to 26% for gabapentin and 23% for placebo-treated patients (Frye et al., 2000). A placebo-controlled, double-blind study of lamotrigine as adjunct to paroxetine in acute depression did not find a significant difference in HAM-D total score at the endpoint of the study for the paroxetine plus lamotrigine group when compared with paroxetine alone (Normann et al., 2002). However, lamotrigine appeared to accelerate the onset of action of the antidepressant and improved core depressive symptoms as reflected by HAM-D items 1 (depressed mood), 2 (guilt feelings) and 7 (work and interest) and the CGI-Severity of Illness scale (p < 0.0001). Lamotrigine-treated patients had fewer days on treatment with benzodiazepines and fewer withdrawals for treatment failure. A recently completed double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with HAM-D-17
MADRS
CGI-I
60% 54%*
51%
50%
51%*
48%*
45%
x Responders
41%** 40%
37% 29%
30%
26%
20% 10% 0% HAM-D-17
MADRS
CGI-I
Figure 4.1: Lamotrigine vs placebo in bipolar I depression. Reprinted by permission from J Clin Psychiatry (Calabrese et al., 1999b) * p < 0.05 vs. placebo ** p < 0.1 vs. placebo
c04.fm Page 48 Wednesday, October 19, 2005 9:14 AM
48
Bipolar Psychopharmacotherapy
fluoxetine for resistant major depressive episodes produced mixed results concerning lamotrigine’s antidepressant efficacy (Barbosa, Berk and Vorster, 2003). Twenty-three patients with a resistant major depressive episode (unipolar N = 15, bipolar II N = 8) were treated with fluoxetine 20 mg/day and concomitantly randomly assigned to receive either lamotrigine (N = 13) or placebo (N = 10) over 6 weeks. Lamotrigine was initiated at 25 mg/day and titrated to 100 mg/day. Although lamotrigine was statistically superior to placebo on the CGI scale at endpoint (absolute score and responder analysis) for both unipolar and bipolar II patients, it failed to separate statistically from placebo on the Hamilton Rating Scale for Depression and Montgomery-Asberg Depression Rating Scale. The authors suggested that this negative study may have been the result of artifact from the small sample size used and the limited power of the study. The brief duration of the study (6 weeks), the need to titrate lamotrigine slowly to minimize rash risk, and the use of relatively low dose lamotrigine (maximum of 100 mg/ day) also contributed to the observed findings. Two unpublished studies (data on file, GlaxoSmithKline, 2003) of patients with bipolar I depression (study GW40910) or bipolar I or II depression (study GW603) reportedly found no significant differences between lamotrigine and placebo treatments over the 8–10 weeks study duration on primary endpoints of the MADRS and 17-item Ham-D scores (Goldsmith et al., 2003). The longer duration of these studies, higher dosing for lamotrigine used (200 mg/day in GW40910 and 100–400 mg/day in GW603) and larger numbers of subjects studied (458 total) raises doubts about the acute antidepressant effects of lamotrigine monotherapy in bipolar disorder. Reviews of recent placebo-controlled acute trials in bipolar depression and the use of antiepileptic drugs in psychiatry confirm that the greatest unmet need in bipolar disorder is depression (Muzina, El-Sayegh and Calabrese, 2002; Muzina and Calabrese, 2003).
ACUTE MOOD DISTURBANCES: MANIA/MIXED STATES The 1999 open-label study by Calabrese and colleagues observed a robust response to lamotrigine (primarily as add-on therapy) in 84% of manic/ hypomanic/mixed patients (Calabrese et al., 1999a). In the first double-blind, randomized, controlled study of lamotrigine in acute mania lamotrigine titrated to 100 mg/day over three weeks was as effective as lithium 800 mg/ day (mean blood level 0.77 mmol/L) in reducing manic symptoms (Ichim, Berk and Brook, 2000). However, lamotrigine has not shown anti-manic activity in placebo-controlled studies (Bowden, 2003). Unpublished studies (data on file, GlaxoSmithKline, 2003) in patients with acute manic or mixed exacerbations of bipolar I disorder have found no significant difference from baseline in the 11-item Mania Rating Scale (MRS) between lamotrigine and placebo (Goldsmith et al., 2003).
c04.fm Page 49 Wednesday, October 19, 2005 9:14 AM
Lamotrigine
49
PREVENTION OF MOOD DISTURBANCES: MAINTENANCE THERAPY The initial lamotrigine maintenance study was a double-blind, placebo-controlled study in rapid cycling bipolar disorder (Calabrese etal., 2000). Open label lamotrigine added to the treatment regimens of 324 patients meeting DSM-IV criteria for rapid cycling bipolar disorder resulted in 182 stabilized patients stabilized who were then randomly assigned to the double-blind maintenance phase after being stratified for bipolar I or II disorder. Other psychotropic agents were tapered and patients randomly assigned to either lamotrigine monotherapy or placebo in a 1:1 ratio for the six-month maintenance phase. Overall 49 placebo-treated patients (56%) and 45 lamotriginetreated patients (50%) required treatment for an emerging mood episode with additional pharmacotherapy. Although there was no statistical significance between these two treatment groups on the primary outcome measure of time to additional pharmacotherapy (median of 12 weeks for placebo versus 18 weeks for lamotrigine), lamotrigine was significantly more effective than placebo in the survival in study analysis (median of 8 weeks for placebo versus 14 weeks for lamotrigine). In the subanalysis according to disease type, lamotrigine was significantly more effective than placebo in delaying time to additional pharmacotherapy for bipolar II patients than bipolar I patients. Forty-six percent of bipolar II patients on lamotrigine monotherapy were stable without relapse after 6 months compared to only 18% of placebo-treated bipolar II patients. Figure 4.2 depicts survival curves indicating length of study participation for
Survival Estimate
Bipolar I 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0
Bipolar II
A. Additional Pharmacotherapy
C. Additional Pharmacotherapy
p = 0.073
p = 0.738 B. Survival in Study
PBO LTG
D. Survival in Study
p = 0.426
p = 0.015
0 2 4 6 8 10 12 14 16 18 20 22 24 26 0
2
4
6
8 10 12 14 16 18 20 22 24 26
Week Calabrese et al., 2000
Figure 4.2: Lamotrigine in rapid cycling bipolar I and II disorders. Reprinted by permission from J Clin Psychiatry (Calabrese et al., 2000)
c04.fm Page 50 Wednesday, October 19, 2005 9:14 AM
50
Bipolar Psychopharmacotherapy
bipolar I versus bipolar II subtypes treated with lamotrigine compared with placebo (Calabrese etal., 2000). In an unpublished study (data on file, GlaxoSmithKline, 2003), these findings were not replicated. However, significantly fewer lamotriginetreated rapid cyclers required intervention for a depressive episode. Collectively, these results suggest that lamotrigine may be a useful treatment for rapid cycling bipolar patients, especially for type II and for the prevention of depressive relapses. Two 18-month maintenance studies (Bowden et al., 2003; Calabrese et al., 2003) comparing lamotrigine, lithium and placebo provided further support for the use of lamotrigine as a mood stabilizer and led to its approval by the US FDA in June 2003 as a maintenance treatment for bipolar I disorder. These complementary studies enrolled patients in a double-blind phase of maintenance therapy after a recent depressed, hypomanic or manic episode remitted (CGI-S score of <3 for 4 consecutive weeks) during open-label stabilization during which lamotrigine was initiated as adjunctive or monotherapy and other psychotropics discontinued. In both studies, 50% of patients achieved stabilization criteria allowing for progression into double-blinded maintenance therapy with lamotrigine (50–400 mg/day), lithium (0.8–1.1 mEq/L) or placebo. The primary efficacy endpoint used was time to intervention for any mood episode. In both of these studies, lamotrigine and lithium demonstrated effective prophylaxis against any emerging mood episode compared with placebo. There were statistically fewer relapsing mood episodes and longer median survival in lamotrigine- and lithium-treated patients compared with placebo. Median survival before intervention for any mood episode for lamotrigine-treated patients ranged from 118 to 256 days, significantly better than placebo (85–93 days). Lithium also outperformed placebo with a median survival of 170–292 days. However, there were important differences in the spectra of maintenance efficacy. In both studies, lithium, but not lamotrigine was superior to placebo at delaying the time to intervention for a manic or hypomanic episode. In total for both studies 123 manic/hypomanic events emerged during maintenance, with 25% of placebotreated patients experiencing a manic hypomanic/mixed episode (47 of 188); 21% of the lamotrigine group relapsed (58 of 273), but only 11% of patients in the lithium-treatment arm had breakthrough mania or hypomania (18 of 164). Lithium was clearly more effective than placebo and lamotrigine in preventing manic and hypomanic relapse in recently symptomatic bipolar I patients. In contrast, lamotrigine appears to be more effective than lithium in the prevention of depressive relapse in bipolar I patients. In both studies, lamotrigine but not lithium, was significantly better than placebo at prolonging time to intervention for a depressive mood episode. There were 209 depressive relapses in the patients observed in the two studies, with a higher rate of relapse in the placebo (68 of 188, or 36%) and lithium treatment groups (56 of 164, or 34%); lamotrigine was better at preventing recurrence of depression with a 31% rate of depressive relapse and a longer median survival before treatment of depression was necessary. The difference
c04.fm Page 51 Wednesday, October 19, 2005 9:14 AM
Lamotrigine
51
was particularly evident in the treatment of recently manic or hypomanic patients in whom only 14% of those receiving lamotrigine (8 of 58) needed intervention for emergent depression compared with 23% of patients receiving lithium (10 of 44) and 30% receiving placebo (21 of 69). A combined analysis of these two pivotal maintenance studies confirms that lamotrigine delays time to intervention of mood episodes in recently stabilized bipolar I patients. Figure 4.3 shows that the percentage of lamotrigine-treated patients that remained free from the need for intervention for any mood episode was significantly greater than placebo (37% vs 22%). Figures 4.4 and 4.5 demonstrate lamotrigine’s bimodal preventative efficacy over 18 months of treatment. Lamotrigine was effective at delaying depressive episodes compared with placebo, with a 39% increase in the percent of patients who remained intervention-free for depression (Figure 4.4). Lamotrigine was also superior to placebo at prolonging the time to intervention for mania, with a 22% increase in the percent of patients who remained intervention-free at 18 months (Figure 4.5) Goodwin et al., 2004.
RASH Rashes requiring hospitalization and discontinuation of treatment have been reported with lamotrigine. A German registry that documents the incidences of serious rash has been in place since 1990 and ascertains hospitalized cases of
Estimated % of pts intervention-free
100
Lamotrigine 100– 400 mg (n = 223) Placebo (n = 188)
90 80 70 60 50 40 30 20
LTG vs PBO, p < 0.001
10 0 1 2 3
4
5 6 7
8 9 10 11 12 13 14 15 16 17 18 Month
Figure 4.3: Time to intervention for any mood episode combined analysis*. Adapted by permission from J Clin Psychiatry (Goodwin et al., 2004) * Bowden et al., 2003, Calabrese et al., 2003 and Goodwin et al., 2004
c04.fm Page 52 Wednesday, October 19, 2005 9:14 AM
Bipolar Psychopharmacotherapy Estimated % of pts intervention-free
52 100
Lamotrigine 100– 400 mg (n = 233) Placebo (n = 188)
90 80 70 60 50 40 30 20
LTG vs PBO, p = 0.009
10 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 Month
Figure 4.4: Time to intervention for a depressive episode combined analysis*. Adapted by permission from J Clin Psychiatry (Goodwin et al., 2004) * Bowden et al., 2003, Calabrese et al., 2003 and Goodwin et al., 2004
Estimated % of pts intervention -free*
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) related to antiepileptic drug use (Rzany et al., 1996). Reported cases are confirmed by a registry physician and reviewed by a dermatological expert committee ensuring high diagnostic accuracy. The incidence of serious rash rising to the level of SJS/TEN diagnosis in the German registry was 0.02% from 1993 to 2001 (Messenheimer, 2002).
100 Lamotrigine 100– 400 mg (n = 223) Placebo (n = 188)
90 80 70 60 50 40 30 20
LTG vs PBO, p = 0.034
10 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 Month
Figure 4.5: Time to intervention for a manic episode combined analysis*. Adapted by permission from J Clin Psychiatry (Goodwin et al., 2004) * Bowden et al., 2003, Calabrese et al., 2003 and Goodwin et al., 2004
c04.fm Page 53 Wednesday, October 19, 2005 9:14 AM
Lamotrigine
53
The rate of lamotrigine-associated rash in patients with mood disorders has been reported in a retrospective analysis conducted of rates of lamotrigine-related rash in 12 multicenter studies of lamotrigine for mood disorders (n=955) (Calabrese et al., 2002). These studies included 1 open study, 7 randomized controlled acute trials and 4 randomized controlled maintenance trials from 1996 to 2001. Overall, benign rash was observed in 8.3% of patients receiving lamotrigine compared with 6.4% receiving placebo. Serious rash rate was 0.1% in lamotrigine-treated patients (one in 1000) across all controlled and open-label trials. There were no observed cases of serious rash observed with lamotrigine during the controlled phases of these trials, including the three maintenance studies with duration up to 76 weeks. Risk of rash is noted to be higher in pediatric patients, and is increased by coadministration of divalproex sodium or exceeding the recommended initial dose or dose escalation schedule for lamotrigine. Dose escalation of lamotrigine when co-administered with divalproex should be at 50% of the recommended rate, and the same is true for the target dose. Women may be at increased risk for rash compared with men, with a relative risk of 1.8 (Wong, Mawer and Sander, 1999). The clinical management of rash begins initially with the prescription of clear instructions to the patient to follow the recommended dosing schedule to minimize the risk of rash occurring. Rash occurring during the first 5 days of initial lamotrigine therapy is probably non-drug related, however patients should be monitored closely by holding lamotrigine and observing the course of rash. A benign rash typically peaks within days and is spotty, not confluent and non-tender; no systemic features are present and the rash does not involve any mucosal surfaces. In these cases, lamotrigine dosage should be lowered and the titration slowed with a warning to the patient to discontinue the medication if the rash worsens or systemic signs arise (headache, fever, malaise, pharyngitis). Serious rashes tend to be confluent and widespread, cause tenderness and appear hemorrhagic. Systemic signs of illness are often present and careful assessment of internal organ functioning must be performed promptly to exclude hepatic, renal or hematologic system involvement. Patients may require hospitalization and discontinuation of other medications that may contribute to rash progression, such as other anticonvulsants, sulfonamides and penicillins. Progression of erythematous rash with fever and mucosal involvement, or SJS, may be halted by early discontinuation of the causative agent. Patients with a history of serious rash should not be rechallenged with lamotrigine (Calabrese et al., 2002).
OTHER SIDE-EFFECTS AND TOLERABILITY Lamotrigine is known to be generally well tolerated in the treatment for epilepsy (Choi and Morrell, 2003). A great deal of data generated by the 18-month lamotrigine maintenance trials (Bowden et al., 2003; Calabrese et al., 2003) confirm clinical experience and epilepsy management reports of lamotrigine’s favorable side-effect
c04.fm Page 54 Wednesday, October 19, 2005 9:14 AM
54
Bipolar Psychopharmacotherapy Table 4.2: Adverse events observed during randomized phase of lamotrigine maintenance studies (in %)*. Reprinted by permission from J Clin Psychiatry (Goodwin et al., 2004) Event Nausea Insomnia Somnolence Back pain Fatigue Rhinitis Benin rash Abdominal pain Dry mouth Constipation Vomiting Cough exacerbation Pharyngitis
Lamotrigine n = 227
Placebo n = 190
14 10 9 8 8 7 7 6 6 5 5 5 5
11 6 7 6 5 4 5 3 4 2 2 3 4
* Adverse events listed had incidence >5% and were numerically greater than placebo. (Bowden et al., 2003; Calabrese et al., 2003a; Goodwin et al., 2004)
profile in the treatment of bipolar patients. In 280 patients on maintenance lamotrigine during double-blinded treatment in both trials combined, only 23 (8.2%) discontinued study participation prematurely due to an adverse event; 7.9% of placebo-treated patients experienced adverse events that led to end of study (15 of 191). Over the 18 months randomized phase, lamotrigine treated patients exhibited a 4.9 pound mean decrease in body weight, compared to a 2.6 pound mean weight gain in the placebo group. In a combined analysis of both studies, the incidence of manic/hypomanic/ mixed episodes reported as adverse events was 5% for patients treated with lamotrigine, 4% for patients treated with lithium and 7% for patients treated with placebo. In general, lamotrigine exhibits placebo level rates of treatment-emergent adverse events and is better tolerated than lithium (Calabrese, Vieta and Shelton, 2003). Table 4.2 lists treatment-emergent adverse events for the combined maintenance studies during randomized phase.
CLINICAL APPLICATIONS FOR LAMOTRIGINE IN MOOD DISORDERS ACUTE MOOD DISTURBANCES: DEPRESSION With the wealth of available pharmacotherapies for the treatment of unipolar major depressive disorder and the relative paucity of data to support its use for acute depression, lamotrigine remains a distant option in any medication algorhythm
c04.fm Page 55 Wednesday, October 19, 2005 9:14 AM
Lamotrigine
55
to manage unipolar illness. However, there is sufficient available literature and clinical experience to suggest a possible adjunctive role for lamotrigine in some patients only partially responsive to traditional antidepressants or suffering with treatment refractory depression. Based on preliminary evidence (Barbosa Berk and Vorster, 2003; Normann et al., 2002), patients experiencing ongoing depressive symptoms despite adequate antidepressant medication dosing may benefit from augmentation with lamotrigine titrated to 100–200 mg/day. A minimum of 6–9 weeks of adjunctive lamotrigine should be considered an adequate trial when used as an off-label add-on therapy in these cases. For the management of acute bipolar depression, APA Practice Guidelines recommend lamotrigine as a first-line option with moderate clinical confidence (Hirschfeld etal., 2003). Only lithium carries a higher degree of confidence in these guidelines for the initial treatment of acute bipolar depression. In patients experiencing persistent bipolar depression despite adequate lithium or other first-line treatment, lamotrigine can be recommended as add-on therapy with clinical confidence. However, these 2002 APA Practice Guidelines were created and published prior to the completion of the two pivotal lamotrigine maintenance studies (Bowden etal., 2003; Calabrese et al., 2003). As of November 2003, lamotrigine has been approved for long-term use in bipolar disorder in 25 countries worldwide. In the authors’ clinical experiences (Calabrese and Muzina, 2004), acute bipolar II depression can be treated initially with lamotrigine monotherapy. Dosing should follow published titration schedules to minimize the risk of rash, with a minimum dose of 50 mg/day and a target dose of 200 mg/day for most patients (Table 4.3). In bipolar II patients experiencing a breakthrough depression or rapid cycling on other pharmacotherapy, lamotrigine may be considered for augmentation, keeping in mind potential drug interactions that may affect dosing. In type I bipolar depression, lamotrigine should not be used as monotherapy due to a relatively modest efficacy against potential manic relapse. British guidelines suggest lamotrigine be used for acute bipolar depression as a monotherapy only “where depressive symptoms are less severe” (Goodwin, 2003). We suggest
Table 4.3: Recommended lamotrigine dosing schedule Concomitant medication? Week 1&2 Week 3&4 Week 5 Not on divalproex or carbamazepine On divalproex On carbamazepine or phenytoin
Week 6
Week 7
25 mg qd
50 mg qd
100 mg qd 200 mg qd 200 mg qd
25 mg qd 50 mg qd
25 mg qd 100 mg qd
50 mg qd 100 mg qd 100 mg qd 200 mg qd 300 mg qd 300 mg qd
c04.fm Page 56 Wednesday, October 19, 2005 9:14 AM
56
Bipolar Psychopharmacotherapy
initial lithium monotherapy or lithium–lamotrigine combination for bipolar I depression to improve acute antidepressant activity and to provide greater bimodal prophylactic efficacy in the long-term management of the disorder. Severe acute bipolar I depression can be treated with a combination of lithium and lamotrigine, although combination with other mood stabilizers, atypical antipsychotics or traditional antidepressants may be necessary. Comorbid catatonic or psychotic features should merit consideration of ECT. Patients with a history of rapid cycling or activation on antidepressants should be prescribed traditional antidepressants only after other options have failed and only carefully in combination with known mood stabilizers to minimize the risk of manic switch or cycling. Rapid cycling bipolar I patients most certainly will require combination therapy and may benefit from lamotrigine in tandem with other mood stabilizers, particularly to address below baseline mood disturbances.
ACUTE MOOD DISTURBANCES: MANIA/MIXED STATES Lamotrigine monotherapy is not recommended for the acute management of mania or mixed states associated with bipolar I disorder. Despite limited case reports and early data suggesting that lamotrigine may possess anti-manic properties, further study has led to the conclusion that lamotrigine has only mild to moderate efficacy in mania and should not be reliably used as monotherapy in these urgent above baseline mood disturbances. The addition of lamotrigine to other first-line antimanic agents, such as lithium, divalproex, olanzapine or quetiapine, may hasten or complete recovery from acute manic or mixed states. Lamotrigine should definitely be considered as an initial adjunctive treatment for these bipolar I patients to address the need to prevent future mood episodes after recovery from the current manic or mixed episode. Again, dosing guidelines should be followed as indicated previously and in the package insert to avoid increased risk of rash. In bipolar II patients experiencing hypomanic relapse with disruptive irritability, lamotrigine can be used as a monotherapy or, preferably, in conjunction with another mood stabilizer such as lithium. Another useful strategy is the prescription of lamotrigine plus a short-term atypical antipsychotic. This combination rapidly provides relief of such hypomanic symptoms as irritability, lack of sleep, racing thoughts (we submit via the atypical antipsychotic acutely and longer-term prophylaxis of future mood disruptions via lamotrigine). This is critical given the known predominance of the depressive state in bipolar II disorder, to which lamotrigine’s therapeutic profile best lends itself as an effective mood stabilizer. Lamotrigine is particularly effective in the management of rapid cycling bipolar II disorder, although these patients often require the addition of a second or even third medication.
c04.fm Page 57 Wednesday, October 19, 2005 9:14 AM
Lamotrigine
57
PREVENTION OF MOOD DISTURBANCES: MAINTENANCE THERAPY Lamotrigine is indicated by the US FDA for the maintenance treatment of bipolar I disorder to delay the time to occurrence of mood episodes. It should therefore be considered in the treatment of all bipolar patients due to the inherent natural tendency for the illness to be chronic and recurrent. Maintenance monotherapy with lamotrigine can be considered on clinical grounds in those individuals with non-bipolar I illness, “milder” forms of bipolar II disorder with predominant depressive course, and in other bipolar spectrum disorders such as cyclothymic disorder with disruptive effects on the patients’ social and occupational life. In theory, lamotrigine monotherapy could also be considered as a maintenance therapy after successful ECT for either unipolar or bipolar depression and there are early studies in the planning stages to investigate lamotrigine’s potential in these clinical situations. In most patients, lamotrigine should be part of a combined pharmacological strategy to prevent relapse. Although lamotrigine has been demonstrated an effective maintenance treatment for bipolar I disorder, its ability to prevent manic episodes was considerably less robust than its antidepressant ability. A comprehensive bipolar maintenance medication treatment plan must address prevention of depressive and manic phases, and lamotrigine is only moderately effective in the delay of manic episodes necessitating use of other mood stabilizers with a complementary efficacy profile, such as lithium or divalproex. To date there are still no known pharmacologic agents with true and complete “bimodal” efficacy able to deal with the acute and chronic manifestations of this serious mental illness.
USE IN WOMEN AND THE RISK OF MALFORMATIONS IN PREGNANCY There have been reports of lamotrigine serum concentrations decreasing in women after starting oral contraceptives and increasing after oral contraceptives were discontinued. Dosage adjustments may have to be made in women taking lamotrigine during times of oral contraceptive initiation or termination, although no known link existence between blood levels and therapeutic effects for affective disorders. Lamotrigine carries a Category C FDA warning for use during pregnancy. Pregnant women maintained on lamotrigine during pregnancy should have blood levels of lamotrigine checked monthly as its clearance increases significantly as pregnancy progresses. A preconception determination of lamotrigine blood level in a stable bipolar woman may provide a target dose range to maintain during pregnancy. Clearance of lamotrigine drops quickly after delivery, requiring dosage reduction in most postpartum patients. Breast-feeding is not recommended to nursing mothers on lamotrigine since significant levels of lamotrigine are present in breast milk and long-term effects of exposure to neonates is unknown.
c04.fm Page 58 Wednesday, October 19, 2005 9:14 AM
58
Bipolar Psychopharmacotherapy
While there are no lamotrigine interactions with progesterone-only oral contraceptives (Crawford 2002), Sabers and colleagues (2001) have reported have reported decreased plasma lamotrigine levels (mean 49%, range 41–64%) in seven patients taking oral contraceptives containing ethinylestradiol. More recently, these findings have been replicated in an open-label, non-randomized, non-placebo-controlled, single sequence design conducted in 22 healthy women (see GSK Revisions to Prescribing Information 2005). An ethinylestradiol-containing oral contraceptive administered in combination with lamotrigine significantly decreased levels of lamotrigine (on average, 52% decrease in AUC and 39% decrease in Cmax. Based on these new data, when lamotrigine is started in a woman currently taking an estrogen-containing oral contraceptive, the titration schedule remains unchanged whereas the maintenance dose may need to be increased as much as twofold in women starting or currently taking oral contraceptives. Conversely, the maintenance dose of lamotrigine may need to be decreased by as much as 50% below the maintenance dose if oral contraceptives are stopped. According to the most recent interim report of the Lamotrigine Pregnancy Registry issued July 2003, during the period September 1, 1992 through March 31, 2003, 593 pregnancies with lamotrigine exposure were reported in 29 countries (USA 193). In the prospective reports with lamotrigine monotherapy exposure during first trimester in 302 outcomes, there were 9 major birth defects (3% rate). In lamotrigine exposure, 7 of 67 outcomes (10.4%) with polytherapy including valproate had major birth defects, while only five major malformations were observed in 148 outcomes when lamotrigine was part of a polytherapy not including valproate (3.4%). There appears to be a higher frequency of major birth defects when lamotrigine and valproate are used together during first trimester pregnancy (data on file, GlaxoSmithKline, 2003). More recently, Cunnington and colleagues (2005) have reported on the frequency of major congenital malformations (MCM) in lamotrigine-exposed pregnancies from September 1, 1992 through March 21, 2004, in the International Lamotrigine Pregnancy Registry. Healthcare professional throughout the world voluntarily enrolled lamotrigine-exposed pregnancies in this observational study of women with epilepsy. Among 414 first-trimester exposures to lamotrigine monotherapy, 12 outcomes with MCM were reported (2.9%; 95% CI 1.6% to 5.1%). Among 88 first-trimester exposures to lamotrigine polytherapy including valproate, 11 outcomes with MCM were report (12.5%; 95% CI 6.7% to 21.7%). Among 182 first-trimester exposures to lamotrigine polytherapy excluding valproate, 5 outcomes with MCM were reported (2.7%; 95% CI 1.0% to 6.6%). No distinctive pattern of MCMs was apparent among the offspring exposed to lamotrigine monotherapy or polytherapy. At the time of the analysis, the Registry had the power to detect a 1.79 to 2.00-fold increase in the risk of MCM, assuming a baseline rate of 2 to 3%. The authors concluded that the risk of all MCM after first-trimester exposure to lamotrigine montotherapy (2.9%) was similar to that in the general population and in other registries enrolling women exposed to antiepileptic monotherapy (3.3% to 4.5%).
c04.fm Page 59 Wednesday, October 19, 2005 9:14 AM
Lamotrigine
59
SUMMARY The discovery of lamotrigine’s positive effects on mood in epilepsy patients led to its investigations in and eventual approval for treating bipolar affective disorder. Although the exact mood stabilizing mechanism of action for this novel anticonvulsant is unknown, it is thought to work by inhibiting voltage-sensitive sodium currents, in this manner stabilizing neuronal membranes and as a result modulating the presynaptic transmitter release of excitatory amino acids such as glutamate. Although there is some suggestion that lamotrigine may have some beneficial effect in the treatment for unipolar depression, available evidence points to a primary role as a mood stabilizer in bipolar disorders that has moderate to marked acute and prophylactic antidepressant efficacy, only modest antimanic prophylaxis and no acute antimanic efficacy. Lamotrigine is very well tolerated, requires careful dose monitoring in certain clinical situations and offers significant potential benefit as monotherapy or in combination with other mood stabilizers in the acute and long-term management of bipolar disorder. Current data are strongest for bipolar I disorder. Its role in bipolar II is in need of further systematic studies. Our discussion was meant to enrich rational clinical considerations.
REFERENCES Anderson, G. D., Yau, M. K., Gidal, B. E., Harris, S. J., Levy, R. H., Lai, A. A., Wolf, K. B., Wargin, W. A. and Dren, A. T. (1996). Bidirectional interaction of valproate and lamotrigine in healthy subjects, Clin Pharmacol Ther, 60, 145–56. Barbosa, L., Berk, M. and Vorster, M. (2003). A double-blind, randomized, placebocontrolled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes, J Clin Psychiatry, 64, 403–407. Bowden, C. L. (2003). Acute and maintenance treatment with mood stabilizers, Int J Neuropsychopharmacol, 6, 269–75. Bowden, C. L., Calabrese, J. R., Sachs, G., Yatham, L. N., Asghar, S. A., Hompland, M., Montgomery, P., Earl, N., Smoot, T. M. and DeVeaugh-Geiss, J. (2003). A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder, Arch Gen Psychiatry, 60, 392–400. Calabrese J. R., Muzina D. J. How to treat bipolar II depression and bipolar II mixed depression? A reply to Benazzi, Int J Neuropsychopharmacol, Mar. 7 (1–2), 2004. Calabrese, J. R., Fatemi, S. H. and Woyshville, M. J. (1996). Antidepressant effects of lamotrigine in rapid cycling bipolar disorder, Am J Psychiatry, 153, 1236. Calabrese, J. R., Vieta, E. and Shelton, M. D. (2003). Latest maintenance data on lamotrigine in bipolar disorder, Eur Neuropsychopharmacol, 13, Suppl. 2, S57–66. Calabrese, J. R., Bowden, C. L., McElroy, S. L., Cookson, J., Andersen, J., Keck, P. E., Jr., Rhodes, L., Bolden-Watson, C., Zhou, J. and Ascher, J. A. (1999a). Spectrum of activity of lamotrigine in treatment-refractory bipolar disorder, Am J Psychiatry, 156, 1019–23. Calabrese, J. R., Bowden, C. L., Sachs, G. S., Ascher, J. A., Monaghan, E. and Rudd, G. D. (1999b). A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group, J Clin Psychiatry, 60, 79–88.
c04.fm Page 60 Wednesday, October 19, 2005 9:14 AM
60
Bipolar Psychopharmacotherapy
Calabrese, J. R., Suppes, T., Bowden, C. L., Sachs, G. S., Swann, A. C., McElroy, S. L., Kusumakar, V., Ascher, J. A., Earl, N. L., Greene, P. L. and Monaghan, E. T. (2000). A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group, J Clin Psychiatry, 61, 841–50. Calabrese, J. R., Bowden, C. L., Sachs, G., Yatham, L. N., Behnke, K., Mehtonen, O.P., Montgomery, P., Ascher, J., Paska, W., Earl, N. and DeVeaugh-Geiss, J. (2003a). A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder, J Clin Psychiatry, 64, 1013–24. Calabrese, J. R., Hirschfeld, R. M., Reed, M., Davies, M. A., Frye, M. A., Keck, P. E., Lewis, L., McElroy, S. L., McNulty, J. P. and Wagner, K. D. (2003b). Impact of bipolar disorder on a U.S. community sample, J Clin Psychiatry, 64, 425–32. Calabrese, J. R., Sullivan, J. R., Bowden, C. L., Suppes, T., Goldberg, J. F., Sachs, G. S., Shelton, M. D., Goodwin, F. K., Frye, M. A. and Kusumakar, V. (2002). Rash in multicenter trials of lamotrigine in mood disorders: clinical relevance and management, J Clin Psychiatry, 63, 1012–19. Chen, C., Veronese, L. and Yin, Y. (2000). The effects of lamotrigine on the pharmacokinetics of lithium, Br J Clin Pharmacol, 50, 193–5. Choi, H. and Morrell, M. J. (2003). Review of lamotrigine and its clinical applications in epilepsy, Expert Opin Pharmacother, 4, 243–51. Cohen, A. F., Ashby, L., Crowley, D., Land, G., Peck, A. W. and Miller, A. A. (1985). Lamotrigine (BW430C), a potential anticonvulsant. Effects on the central nervous system in comparison with phenytoin and diazepam, Br J Clin Pharmacol, 20, 619–29. Cohen, A. F., Land, G. S., Breimer, D. D., Yuen, W. C., Winton, C. and Peck, A. W. (1987). Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans, Clin Pharmacol Ther, 42, 535–41. Crawford, P. (2002). Interactions between antiepileptic drugs and hormonal contraception, CNS Drugs, 16(4), 263–272. Cunnington, M., Tennis, P. and the International Lamotrigine Pregnancy Registry Scientific Advisory Committee. (2005). Neurology, 64, 955–960. Fitton, A. and Goa, K. L. (1995). Lamotrigine. An update of its pharmacology and therapeutic use in epilepsy, Drugs, 50, 691–713. Frye, M. A., Ketter, T. A., Kimbrell, T. A., Dunn, R. T., Speer, A. M., Osuch, E. A., Luckenbaugh, D. A., Cora-Ocatelli, G., Leverich, G. S. and Post, R. M. (2000). A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders, J Clin Psychopharmacol, 20, 607–14. Garnett, W. R. (1997). Lamotrigine: Pharmacokinetics, J Child Neurol, 12, Suppl. 1, S10–15. Gilman, J. T. (1995). Lamotrigine: An antiepileptic agent for the treatment of partial seizures, Ann Pharmacother, 29, 144–51. Ginsberg, L., Sachs, G. and Ketter, T. (2003). In American Psychiatric Association 2003 Annual Meeting, San Francisco, CA, pp. 173–4. Goa, K. L., Ross, S. R. and Chrisp, P. (1993). Lamotrigine. A review of its pharmacological properties and clinical efficacy in epilepsy, Drugs, 46, 152–76. Goldsmith, D. R., Wagstaff, A. J., Ibbotson, T. and Perry, C. M. (2003). Lamotrigine: A review of its use in bipolar disorder, Drugs, 63, 2029–50. Goodwin, G. M. (2003). Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology, J Psychopharmacol, 17, 149–73; discussion 147. Goodwin, G. M., Bowden, C. L., Calabrese, J. R., Grunze, H., Kasper, S., White, R., Greene, P. and Leadbetter, R. (2004). A pooled analysis of two placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry, 65(3), 432–41.
c04.fm Page 61 Wednesday, October 19, 2005 9:14 AM
Lamotrigine
61
Hachad, H., Ragueneau-Majlessi, I. and Levy, R. H. (2002). New antiepileptic drugs: review on drug interactions, Ther Drug Monit, 24, 91–103. Hirschfeld, R. M., Calabrese, J. R., Weissman, M. M., Reed, M., Davies, M. A., Frye, M.A., Keck, P. E., Jr., Lewis, L., McElroy, S. L., McNulty, J. P. and Wagner, K. D. (2003). Screening for bipolar disorder in the community, J Clin Psychiatry, 64, 53–9. Ichim, L., Berk, M. and Brook, S. (2000). Lamotrigine compared with lithium in mania: a double-blind randomized controlled trial, Ann Clin Psychiatry, 12, 5–10. Jacoby, A., Baker, G. A., Steen, N., Potts, P. and Chadwick, D. W. (1996). The clinical course of epilepsy and its psychosocial correlates: Findings from a U.K. community study, Epilepsia, 37(2), 148–161. Judd, L. L. and Akiskal, H. S. (2003). The prevalence and disability of bipolar spectrum disorders in the U.S. population: Re-analysis of the ECA database taking into account subthreshold cases. J Affect Disord, 73, 123–131. Judd, L. L., Akiskal, H. S., Schettler, P. J., Endicott, J., Maser, J., Solomon, D. A., Leon, A. C., Rice, J. A. and Keller, M. B. (2002). The long-term natural history of the weekly symptomatic status of bipolar I disorder, Arch Gen Psychiatry, 59, 530–7. Kusumakar, V. and Yatham, L. N. (1997). An open study of lamotrigine in refractory bipolar depression, Psychiatry Res, 72, 145–8. Leach, M. J., Marden, C. M. and Miller, A. A. (1986). Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II. Neurochemical studies on the mechanism of action, Epilepsia, 27, 490–7. Leach, M. J., Baxter, M. G. and Critchley, M. A. (1991). Neurochemical and behavioral aspects of lamotrigine, Epilepsia, 32, Suppl. 2, S4–8. Li, X., Ketter, T. A. and Frye, M. A. (2002). Synaptic, intracellular, and neuroprotective mechanisms of anticonvulsants: are they relevant for the treatment and course of bipolar disorders?, J Affect Disord, 69, 1–14. Matsuo, F., Bergen, D., Faught, E., Messenheimer, J. A., Dren, A. T., Rudd, G. D. and Lineberry, C. G. (1993). Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. U.S. Lamotrigine Protocol 0.5 Clinical Trial Group, Neurology, 43, 2284–91. Messenheimer, J. A. (2002). In: American Academy of Neurology Annual Meeting, Denver, CO. Mikati, M. A., Schachter, S. C., Schomer, D. L., Keally, M., Osborne-Shafer, P., Seaman, C. A., Sheridan, P. H., Ashworth, M., Kupferberg, H., Valakas, A., etal. (1989). Long-term tolerability, pharmacokinetic and preliminary efficacy study of lamotrigine in patients with resistant partial seizures, Clin Neuropharmacol, 12, 312–21. Muzina, D. J. and Calabrese, J. R. (2003). Recent placebo-controlled acute trials in bipolar depression: focus on methodology, Int J Neuropsychopharmacol, 6, 285–91. Muzina, D. J., El-Sayegh, S. and Calabrese, J. R. (2002). Antiepileptic drugs in psychiatry-focus on randomized controlled trial, Epilepsy Res, 50, 195–202. Normann, C., Hummel, B., Scharer, L. O., Horn, M., Grunze, H. and Walden, J. (2002). Lamotrigine as adjunct to paroxetine in acute depression: a placebo-controlled, doubleblind study, J Clin Psychiatry, 63, 337–44. Ohman, I., Vitols, S. and Tomson, T. (2000). Lamotrigine in pregnancy: pharmacokinetics during delivery, in the neonate, and during lactation, Epilepsia, 41, 709–13. Pennell, P. B. (2003). Antiepileptic drug pharmacokinetics during pregnancy and lactation, Neurology, 61, S35–42. Post, R. M., Denicoff, K. D., Leverich, G. S. Altshuler, L. L., Frye, M. A., Suppes, T. M., Keck, P. E., McElroy, S. L., Kupka, R., Nolen, W. A., Grunze, H. and Walden, J. (2002). Presentations of depression in bipolar illness, Clin Neurosci Res, 2, 142–57.
c04.fm Page 62 Wednesday, October 19, 2005 9:14 AM
62
Bipolar Psychopharmacotherapy
Rambeck, B. and Wolf, P. (1993). Lamotrigine clinical pharmacokinetics, Clin Pharmacokinet, 25, 433–43. Ramsay, R. E., Pellock, J. M., Garnett, W. R., Sanchez, R. M., Valakas, A. M., Wargin, W. A., Lai, A. A., Hubbell, J., Chern, W. H., Allsup, T. et al. (1991). Pharmacokinetics and safety of lamotrigine (Lamictal) in patients with epilepsy, Epilepsy Res, 10, 191–200. Rzany, B., Mockenhaupt, M., Baur, S., Schroder, W., Stocker, U., Mueller, J., Hollander, N., Bruppacher, R. and Schopf, E. (1996). Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990–1992): Structure and results of a population-based registry, J Clin Epidemiol, 49, 769–73. Sabers, A., Buchholt, J., Uldall, P. and Hansen, E. (2001). Lamotrigine plasma levels reduced by oral contraceptives, Epilepsy Res, 47, 151–4. Shiah, I. S., Yatham, L. N., Lam, R. W. and Zis, A. P. (1998). Effects of lamotrigine on the 5-HT1A receptor function in healthy human males, J Affect Disord, 49, 157–62. Smith, D., Baker, G., Davies, G., Dewey, M. and Chadwick, D. W. (1993a). Outcomes of add-on treatment with lamotrigine in partial epilepsy, Epilepsia, 34, 312–22. Smith, D., Chadwick, D., Baker, G., Davis, G. and Dewey, M. (1993b). Seizure severity and the quality of life, Epilepsia, 34, Suppl. 5, S31–5. Tran, T. A., Leppik, I. E., Blesi, K., Sathanandan, S. T. and Remmel, R. (2002). Lamotrigine clearance during pregnancy, Neurology, 59, 251–5. Vinod, K. Y. and Subhash, M. N. (2002). Lamotrigine induced selective changes in 5-HT(1A) receptor mediated response in rat brain, Neurochem Int, 40, 315–9. Walden, J., Hesslinger, B., van Calker, D. and Berger, M. (1996). Addition of lamotrigine to valproate may enhance efficacy in the treatment of bipolar affective disorder, Pharmacopsychiatry, 29, 193–5. Weisler, R., Risner, M., Ascher, J. and Houser, T. (1994). In: American Psychiatric Association 1994 Annual Meeting, Philadelphia, PA. Weissman, M. M., Bland, R. C., Canino, G. J., Faravelli, C., Greenwald, S., Hwu, H. G., Joyce, P. R., Karam, E. G., Lee, C. K., Lellouch, J., Lepine, J. P., Newman, S. C., Rubio-Stipec, M., Wells, J. E., Wickramaratne, P. J., Wittchen, H. and Yeh, E. K. (1996). Cross-national epidemiology of major depression and bipolar disorder, JAMA, 276, 293–9. Wong, I. C., Mawer, G. E. and Sander, J. W. (1999). Factors influencing the incidence of lamotrigine-related skin rash, Ann Pharmacother, 33, 1037–42. Xie, X. and Hagan, R. M. (1998). Cellular and molecular actions of lamotrigine: Possible mechanisms of efficacy in bipolar disorder, Neuropsychobiology, 38, 119–30. Xie, X., Lancaster, B., Peakman, T. and Garthwaite, J. (1995). Interaction of the antiepileptic drug lamotrigine with recombinant rat brain type IIA Na + channels and with native Na + channels in rat hippocampal neurones, Pflugers Arch, 430, 437–46. Yuen, A. W., Land, G., Weatherley, B. C. and Peck, A. W. (1992). Sodium valproate acutely inhibits lamotrigine metabolism, Br J Clin Pharmacol, 33, 511–3.
c05.fm Page 63 Wednesday, October 19, 2005 9:14 AM
CHAPTER
5 Carbamazepine, Other Anticonvulsants and Augmenting Agents Heinz Grunze Department of Psychiatry, LMU Munich, Germany
INTRODUCTION Despite the fact that a multitude of well established and extensively studied medications for bipolar disorder is nowadays available, a fair proportion of patients need treatment with additional drugs. This includes very often older anticonvulsants, e.g. carbamazepine or its off-spring, oxcarbazepine, other older agents with so far limited scientific evidence or which only became available recently, and drugs which appear useful only for one pole of the illness, e.g. antidepressants. However, as described in greater detail in Chapter 9, a concomitant use of these agents is rather the rule than the exception. This chapter will focus on three different classes of medication: 1. Anticonvulsants (other than valproate and lamotrigine, already covered in Chapters 3 and 4) 2. Antidepressants 3. Nutritional supplements and thyroid hormone.
ANTICONVULSANTS CARBAMAZEPINE Starting with the first studies of Okuma etal. (1973) the efficacy of carbamazepine for the acute treatment of mania has been demonstrated in several, mostly small studies, both by the group of Okuma and by others investigators (e.g. Ballenger and Post, 1980; Müller and Stoll, 1984; Emrich, Dose and von Zerssen, 1985; Post etal., 1987). Comparative studies have been conducted as well with conventional antipsychotics as with lithium (Okuma et al., 1979, 1990; Klein et al., 1984; Stoll et al., 1986; Bipolar Psychopharmacotherapy: Caring for the Patient Edited by Hagop S. Akiskal and Mauricio Tohen # 2006 John Wiley & Sons, Ltd ISBN: 0-470-85607-6
c05.fm Page 64 Wednesday, October 19, 2005 9:14 AM
64
Bipolar Psychopharmacotherapy
Lerer et al., 1987; Brown, Silverstone and Cookson, 1989). The impression of these studies was that carbamazepine was overall equally effective as the comparators, with a probably slightly slower onset of response compared to antipsychotics, but still slightly faster acting than lithium (Small et al., 1996). In a recent comparative trial with valproate (Vasudev, Goswami and Kohli, 2000) both carbamazepine and valproate were found to be efficacious as first-line antimanic agents. However, advantages for valproate were observed both for time to onset of action and tolerability. Summarizing these trials, antimanic efficacy of carbamazepine appears apparent despite the relative absence of methodological unambiguous controlled studies. Looking into specific sub-groups of patients carbamazepine may be especially helpful in patients with incomplete response to lithium in acute mania, rapid cycling (Denicoff et al., 1997; Greil et al., 1998), patients with co-morbid organic (neurological) disorders (Schneck, 2002) and schizoaffective patients (Elphick, 1985; Goncalves and Stoll, 1985; Greil et al., 1997a). For the depressed phase of bipolar disorder, unequivocal evidence for the usefulness of carbamazepine is missing. Small, mainly open, studies (reviewed by Brambilla, Barale and Soares, 2001) suggest that carbamazepine may be useful in the treatment of both unipolar and bipolar depression. But again, in the absence of randomized placebo-controlled studies, this statement remains questionable. There have been two new trials of carbamazepine in acute mania which addresses the foregoing methodological problems. These are a large multicenter randomized double-blind placebo-controlled trial of an extended release formulation of carbamazepine (ERC-CBZ) for monotherapy for bipolar, manic and mixed patients (Weisler et al. 2004, 2005). They included 204 and 239 patients, respectively, with acute manic or mixed states. Both studies initiated treatment at 400 mg/day and increased as necessary and tolerated up to 1600mg/day. In the first study, ERC-CBZ started showing significantly greater improvement than placebo as of week two, and in the second already as of week one. The main side effects in both studies that were higher than placebo were dizziness, nausea and somnolence. These studies finally provided clear and unambiguous evidence for the efficacy of carbamazepine in acute mania. A main disadvantage of carbamazepine is the induction of different members of the cytochrome P 450 family. This may cause an increased metabolism of different antidepressants leading to reduced effectiveness. Thus, carbamazepine has not been recommended as a first-line treatment for bipolar depression. First evidence for a prophylactic efficacy of carbamazepine in bipolar disorder was established by five randomized controlled trials in the 1980s and early 1990s. Four of these studies compared carbamazepine with lithium (Placidi et al., 1986; Watkins et al., 1987; Lusznat, Murphy and Nunn, 1988; Coxhead, Silverstone and Cookson, 1992), and one with placebo (Okuma et al., 1981). A meta-analysis of the four lithium trials concluded that carbamazepine’s efficacy as a prophylactic
c05.fm Page 65 Wednesday, October 19, 2005 9:14 AM
Carbamazepine and Augmenting Agents
65
agent could not be established on a basis of these trials because of the heterogeneity in design, differences in statistical power and sensitivity of outcome measures (Dardennes et al., 1995). More convincing evidence for prophylactic efficacy of carbamazepine is now available with three new maintenance studies. Denicoff et al. compared carbamazepine, lithium and the combination of both in 52 bipolar I patients. Patients were randomized either to carbamazepine or lithium treatment for the first year, then switched over to the alternative treatment for the second year and finally to combination treatment for the third year. Whereas the prophylactic efficacy of both monotherapies was disappointing, combination treatment with both lithium and carbamazepine was clearly superior to each monotherapy. Greil et al. (1997b) and Greil and Kleindienst (1999) compared carbamazepine and lithium in an open-label, but randomized parallel group study, lasting for 2.5 years and involving 144 patients with bipolar I, II and not otherwise specified bipolar disorders. No significant difference was observed between both treatments based on survival analysis with time to hospitalization or episode recurrence. However, when combining different outcome-measures (recurrence and need for additional medication and/or adverse events) lithium was significantly better than carbamazepine. Additionally, less suicide attempts and completed suicides were observed in the lithium group (Thies-Flechtner et al., 1996); this finding is also supported by a recent chart analysis by Yerevanian, Koek and Mintz (2003) showing a trend toward better antisuicidal properties for both lithium and valproate compared to carbamazepine. The impression that lithium may be overall more efficacious than carbamazepine in the prophylactic treatment for bipolar disorders is also backed up by a recent study of Hartong et al. (2003) comparing 94 patients in a randomized, two-year double-blind study. Out of 44 patients on lithium, 12 patients developed a new episode compared with 21/50 on carbamazepine treatment. Significant superiority for lithium was shown in those patients who were not previously treated with any other mood stabilizer. Interestingly, relapse with lithium occurred almost exclusively within the first three months of the trial while carbamazepine patients carried a constant risk of an episode of about 40% per study year. This may hint to different intracellular effects and modes of action of these two drugs. In conclusion, carbamazepine appears to be an effective drug in bipolar disorder, especially in the treatment for acute mania, but not of special utility. There is no strong evidence for an antidepressant efficacy, and in long-term treatment the general impression is that it is less efficacious than lithium and lacks special antisuicidal properties. Additionally, in combination treatment, induction of the cytochrome P 450 metabolism complicates combination treatments both with other mood stabilizers and with several antipsychotics and antidepressants.
c05.fm Page 66 Wednesday, October 19, 2005 9:14 AM
66
Bipolar Psychopharmacotherapy
OXCARBAZEPINE Oxcarbazepine is the 10-keto-analog of carbamazepine and uses a different pathway of metabolism. It avoids the formation of the 10,11-epoxide metabolite of carbamazepine which is thought to be responsible for the majority of neurological side effects. Instead, oxcarbazepine is reduced by a cytosolic reductase to its 10-mono-hydroxy derivative (MHD). Avoiding the metabolism by cytochrome P 450 3A4, oxcarbazepine does not induce its own metabolism and has only a few clinically significant drug interactions. As a drawback, the scientific evidence for efficacy in bipolar disorder is considerably less than for carbamazepine. Most of the work on oxcarbazepine in bipolar disorder, especially in acute mania, was performed by Emrich et al. in the early 1980s (Emrich, Dose and von Zerssen, 1984; Emrich, 1994). The antimanic effect of oxcarbazepine appeared comparable to the one of valproate in these early studies. In a double-blind comparative trial with haloperidol by Müller and Stoll (1984) no difference in efficacy was observed between oxcarbazepine and haloperidol. This impression was also supported by another study by Emrich (1990). With similar efficacy, the tolerability of oxcarbazepine was significantly better, with the incidence of side effects 3.5 times higher in the haloperidol group compared to the oxcarbazepine group. These studies are also comprehensively reviewed by Dietrich, Kropp and Emrich (2001). More recently, a study by Hummel et al. (2002) supplied further supporting evidence for antimanic efficacy of oxcarbazepine, using an on–off–on design. Oxcarbazepine monotherapy was effective in patients with mild to moderate mania (Young Mania Rating Score <25) but not in severely manic patients. So far, no controlled studies are available for oxcarbazepine in bipolar depression. A retrospective chart review by Ghaemi, Ko and Katzow (2002) suggests that oxcarbazepine may possess mild to moderate efficacy in bipolar depressed patients. However, this impression has not been verified by controlled studies so far. Considering prophylactic treatment we also have to refer to case series and open studies. Munoz (2002) investigated the mood stabilizing effect of oxcarbazepine as adjunctive treatment over 12 weeks. Improvement according to pre-defined criteria was observed after 3 weeks in 71% of patients entering this study manic and all patients entering this study depressed, with 60% of the responders of the manic group remaining euthymic through the remaining 9 weeks of the study, and all of the responders in the depressed group remaining stable for the remainder of this study. Nasr and Casper (2002) conducted a further open, but prospective review in 87 patients with mood disorders including 28 patients with bipolar disorder. With the addition of oxcarbazepine, a significant improvement in the CGI severity of illness score was observed in all patients. The greatest improvement was seen in bipolar II patients with predominant hostility. In the study of Reinstein (2001) 42 patients with bipolar or schizoaffective disorder were stabilized with valproate. Half of them were switched to oxcarbazepine after 10 weeks
c05.fm Page 67 Wednesday, October 19, 2005 9:14 AM
Carbamazepine and Augmenting Agents
67
of treatment and followed up for another 10 weeks. Compared to patients remaining on valproate, mood stability was maintained to a similar degree. As a secondary outcome, it was noted that 47% of patients on valproate gained weight compared to only 26% of patients on oxcarbazepine and a substantial proportion (70%) of patients lost weight after being switched from valproate to oxcarbazepine. In conclusion, there is some evidence for acute antimanic effects of oxcarbazepine, at least in mild to moderate manic patients, but probably not in severely ill patients. Data on the treatment for bipolar depression and prophylactic efficacy are sparse (for further review: Grunze and Walden, 2002; Hellewell, 2002). However, oxcarbazepine may be a potential candidate drug for patients who previously responded well to carbamazepine, but had problems with tolerability or drug interactions in combination treatment.
PHENYTOIN Although phenytoin has been a first choice treatment for epilepsies since the 1940s, it has never been studied in a thorough way in bipolar disorder until recently. Mishory et al. (2000) were the first who published a placebo-controlled add-on trial with phenytoin in acute mania. Patients entering the study were started on haloperidol in a dose of the physician’s discretion and then randomly assigned to receive either phenytoin or placebo as an add-on treatment. The improvement for the phenytoin group was significantly better starting from week 3 until the end of the study (week 5). In general, phenytoin was well tolerated, except for one patient developing tachycardia at 500 mg/day at week 4 and another patient developing dizziness at study initiation which responded to reduction of the dose. The same group also investigated the acute antimanic effect of fosphenytoin in a small open trial, observing no antimanic effects after one hour despite using doses which are effective in status epilepticus (Applebaum, Levine and Belmaker, 2003). In a recent study the same group looked into prophylactic efficacy of phenytoin (Mishory, Winokur and Bersudsky, 2003) Phenytoin or placebo were randomly added to ongoing and not changed prophylactic treatment in stabilized bipolar patients. After six months patients who had not relapsed were crossed over to the other drug without breaking the blind. There were only three patients (21.4%) who had a relapse on phenytoin, nine (56.3%) relapsed on placebo. This effect was significantly in favor of phenytoin. However, with the small size of the study, further conclusive trials have to be awaited before a more extensive use of phenytoin in bipolar disorder can be recommended.
CLONAZEPAM AND LORAZEPAM These two benzodiazepam derivatives are quite frequently used in bipolar disorder. However, they are generally not considered as primarily mood stabilizing
c05.fm Page 68 Wednesday, October 19, 2005 9:14 AM
68
Bipolar Psychopharmacotherapy
agents, but are used as add-on treatment to calm down the patient and relieve anxiety. This is especially true for lorazepam. Nevertheless, there are some studies supporting mood stabilizing effects of these two drugs. Clonazepam is a high-potency 1,4-benzodiazepine derivative. Besides acting on the GABA A receptor (Haefely, 1983) clonazepam may also modulate the central serotonergic metabolism (Lima, 1991). Several open trials and case series support antimanic efficacy (Chouinard, Young and Annable, 1983; Chouinard, 1985; Adler, 1986; Pande, 1988; Chouinard etal., 1993; Bottai etal., 1995; Morishita and Aoki, 1999). For treating the depressed phase of the illness, evidence for efficacy of clonazepam appears less convincing. In a study of Kishimoto etal. (1988) 27 patients with major depression, among them 9 with bipolar depression, were treated openly with clonazepam. The authors report marked or moderate improvement to be obtained in 84% of the patients with a rapid onset of the antidepressive effect of clonazepam. For maintenance treatment diverging results have been reported. Sachs et al. (Sachs, Rosenbaum and Jones, 1990a; Sachs, Weilburg and Rosenbaum, 1990b; Sachs, 1990) describe positive effects of add-on clonazepam for maintenance treatment. This is also in line with previous results of the study of Chouinard (Chouinard, 1987) where clonazepam was administered as an adjunct to lithium or combined lithium/tryptophane treatment. However, the most recent study of Winkler et al. (2003) could not establish prophylactic efficacy for clonazepam in bipolar patients. Interestingly, they saw a prophylactic efficacy of clonazepam in recurrent unipolar depression. Summarizing these results most evidence points toward antimanic efficacy of clonazepam whereas data for the treatment of bipolar depression and maintenance treatment are either missing or ambiguous. As for lorazepam, it is often used as a standard rescue medication in controlled mania studies, but it may by itself influence the outcome of the trial when not applied in a controlled and restricted manner. Several studies point toward an antimanic efficacy of lorazepam which may even be comparable to the one of haloperidol (Lenox et al., 1992). Used as an add-on medication to haloperidol, lorazepam was less efficacious than lithium add-on treatment (Chou et al., 1999). In a double-blind randomized comparison with clonazepam, however, lorazepam appeared more efficacious for treating acute mania (Bradwejn et al., 1990). Recently, parenteral administration of lorazepam was also studied in comparison to olanzapine and placebo in 201 acutely manic patients. At endpoint after 24 hours, lorazepam injections were significantly superior to placebo in several outcome parameters measuring agitated behavior, although the study was not powered to show differences between lorazepam and placebo (Meehan et al., 2001). Due to the imminent danger of dependency, long-term use of lorazepam cannot be recommended. Thus, prophylactic efficacy has not been studied in a controlled manner so far.
c05.fm Page 69 Wednesday, October 19, 2005 9:14 AM
Carbamazepine and Augmenting Agents
69
LEVETIRACETAM Levetiracetam is a pyrrolidine derivative which has been approved for add-on treatment of refractory partial epilepsy in adults. Its mechanisms of action appear different from those known from other classic antiepileptic drugs (Hovinga, 2001). In an animal model of mania, levetiracetam appeared efficacious (Lamberty, Margineanu and Klitgaard, 2001). A first case report (Goldberg and Burdick, 2002) and an open add-on study applying an on–off–on design (Grunze et al., 2003) are supportive of antimanic efficacy in men, but double-blind randomized controlled trials for mania have still to be conducted. A case report suggests also efficacy in long-term mood stabilization in rapid cycling patients (Bräunig and Krüger, 2003). Further data on long-term maintenance treatment or on the treatment for bipolar depression are currently not available.
ZONISAMIDE Zonisamide has recently been approved in several countries for the adjunctive treatment of refractory epilepsies. With classical antiepileptic drugs it shares several mechanisms of actions, such as sodium and T-type calcium channel blocker properties. Additionally, zonisamide also exerts effects on serotonine and dopamine turnover (Okada etal., 1995, 1999; Oommen and Mathews, 1999). Zonisamide also binds to the GABA A receptor and inhibits carbonic anhydrase which, in turn, effects both extra- and intracellular pH-dependent neurotransmitter systems. In 1994, Kanba et al. presented evidence of antimanic effects of zonisamide in an open study with a responder rate of 80%. These findings were recently followed up in a study of the Stanley Foundation Bipolar Network where 63 bipolar outpatients received zonisamide adjunctive open treatment in mania, bipolar depression or continuous cycling. In all phases of the illness, the addition of zonisamide appeared helpful (Leverich et al., 2003). In addition, zonisamide seems to have a potentially beneficial side-effect profile in terms of weight loss. With currently more controlled data lacking zonisamide may be a future choice as add-on treatment in patients who are not sufficiently responsive to standard therapy, especially, if weight gain constitutes an additional problem.
TOPIRAMATE Several open studies favored topiramate as a potential antimanic agent (Marcotte, 1998; McElroy, Kmetz and Keck, 1998; Normann etal., 1999; Calabrese etal., 2001; Grunze et al., 2001) reporting also about the beneficial weight loss properties in some patients. However, this positive first impression could not hold true in rigorous randomized, placebo-controlled trials (which to the best of our knowledge
c05.fm Page 70 Wednesday, October 19, 2005 9:14 AM
70
Bipolar Psychopharmacotherapy
remain unpublished). For the depressed phase of the illness, an open trial with adjunctive topiramate by McElroy et al. (2000) showed no improvement. However, McIntyre et al. (2002) found in an eight week, single-blind, randomized comparator trial with bupropione similar efficacy of topiramate in patients with bipolar I or II depression. Clearly, more controlled data are needed, not only for bipolar depressed patients but also for long-term treatment in order to give any advice on topiramate’s use in bipolar disorder.
GABAPENTIN Although several open trials have favored gabapentin treatment in acute mania, the two double-blind controlled studies of Pande et al. (2000a) and Frye et al. (2000) could not prove antimanic efficacy of this drug. Controlled data for bipolar depression are missing. As gabapentin appears to have also mild anxioloytic properties (Pande et al., 1999, 2000b) it may still be helpful in selected bipolar patients with anxiety comorbidity or mixed depression and anxiety (Carta et al., 2003). In line with these findings, an open systematic prospective study demonstrated that the utility of this agent in refractory bipolar disorder was accounted for by its anxiolytic effects in patients with comorbid alcohol problems.
TIAGABINE Only open studies exist so far for tiagabine in bipolar disorder. No antimanic effect was observed in an open study by Grunze et al. (1999). Convincing effects were also not seen in a case series of Suppes et al. (2002). In the studies of both Grunze and Suppes significant adverse events (provocation of seizures) were observed. The clinical utility of tiagabine, however, may be different when used in low doses for long-term treatment. Case reports of Schaffer and Schaffer (1999) showed some degree of stabilization in outpatients previously not responding satisfactorily to standard medication. With the severe side effects which may be provoked by tiagabine, however, it appears unlikely that further controlled studies will be conducted in bipolar disorder.
ANTIDEPRESSANTS IN BIPOLAR DISORDER Antidepressants in the bipolar context can be viewed as augmenting agents on ongoing mood stabilizers, or vice versa (when a patient on antidepressants has failed to respond and is deemed bipolar or otherwise worthy of a trial with a mood stabilizer). The discussion in this section pertains to their use as augmenting agents in a patient protected against mania by a mood stabilizer.
c05.fm Page 71 Wednesday, October 19, 2005 9:14 AM
Carbamazepine and Augmenting Agents
71
During recent years, one of the main points of discrepancy between treatment recommendations was the role of antidepressants in bipolar disorder (Möller and Grunze, 2000). In the absence of large, rigorously controlled trials, the role of antidepressants was interpreted very differently, depending whether someone considered bipolar depression as a unique pathophysiology very different from unipolar depression, or a more syndrome and symptom orientated view was applied. The pros and cons for antidepressants have been discussed in a reasonable number of recent review papers (Montgomery et al., 2000; Thase and Sachs, 2000; Grunze and Möller, 2002; Keck and McElroy 2003; Thase, Bhargava and Sachs, 2003). Despite having different opinions about treatment, all experts agree that bipolar depression is the greater challenge compared to mania. As pointed out by recent articles by the San Diego group (Judd et al., 2002, 2003), Bipolar I patients suffer three times as many days per years from depression than from mania; in Bipolar II patients, the relation is even thirty-seven to one comparing the number of depressed and hypomanic days. Besides the longer illness duration, bipolar depression constitutes also a high risk factor for suicide, exceeding even the risk in unipolar depression (Bottlender et al., 2000). Thus, a most efficacious treatment is demanded, but keeping in mind that the patient should not be exposed unnecessarily to the risk of a switch into mania or cycle acceleration. For the effectiveness of antidepressants in bipolar depression, the best evidence so far is the large cohort study by Möller et al. (2001) in 2032 hospitalized depressed patients. Comparing unipolar and bipolar depressed patients no difference was observed between these two groups looking at treatment success, captured by CGI ratings, and the duration of hospitalization. At the time of data collection, bipolar depressed patients of this cohort were almost exclusively treated with antidepressants only and mood stabilizers were added after stabilization was achieved. Most of these patients received tricyclic antidepressants, and only a minority were treated with selective serotonin reuptake inhibitors. Secondary analysis revealed a significant difference in switch rates between these different antidepressants which is in line with several other studies (e.g. Peet, 1994; Boerlin et al., 1998; Calabrese et al., 1999). For most antidepressants, proof of placebo-controlled efficacy or superiority compared to other antidepressants is still sparse. A study by Cohn etal. (1989) compared fluoxetine to imipramine and placebo in 89 patients with bipolar depression. Fluoxetine appeared superior to both placebo and imipramine. Retrospective analysis of one of the few large-scale placebo-controlled phase III studies, allowing also bipolar II patients to be recruited, also favored fluoxetine over placebo (Amsterdam et al., 1998). Subgroup analysis also showed that response in bipolar II patients was not different from matched unipolar patients. Similar to a subgroup analysis of the study of Möller (Bottlender et al., 2002), this is supportive of the argument that antidepressants do not treat specific disease entities but just a syndrome. Similar efficacy to fluoxetine has also been reported for tianeptine, a new antidepressant
c05.fm Page 72 Wednesday, October 19, 2005 9:14 AM
72
Bipolar Psychopharmacotherapy
which increases both serotonin and dopamine uptake in the brain (Loo etal., 1999). Similar to SSRIs, tianeptine showed also a low switch rate in this study. Two studies including also bipolar patients have been reported for venlafaxine. In a retrospective analysis of a randomized study, venlafaxine was similarly effective for both unipolar and bipolar II depression (Amsterdam, 1998; Amsterdam and Garcia-Espana, 2000). However, conclusions from these studies are limited by their retrospective nature and the small sample size. A further randomized trial compared venlafaxine and paroxetine showing a trend toward a better response for venlafaxine but also a clearly higher switch rate (Vieta et al., 2002). Nevertheless, at least in severely ill bipolar patients the efficacy of modern antidepressants alone seems to be not satisfactory. In a double-blind randomized trial of the Stanley Foundation Bipolar Network, three modern antidepressants (bupropion, sertraline, venlafaxine) were administered as add-on treatment to ongoing mood stabilizer in bipolar depression. In a blinded intermediate analysis of 175 patients an overall response rate of 49.7% was observed after 10 weeks of treatment (Post et al., 2002). Thus, bipolar depression is not only a very prominent but also difficult-to-treat phase of the illness. Several open and small double-blind trials also exist for bupropion, monoamine oxidase inhibitors (MAOI) and, of course, tricyclic antidepressants. Due to the small number of patients all trials appear not very conclusive. Some studies show that the MAOI tranylcypromine, compared with the tricyclic imipramine, is less likely to be associated with disruptive hypomanic switches; this is a distinct clinical advantage. Likewise, Bupropion appears to be less prone to induce a switch into mania than tricyclic antidepressants, and thus should be preferred. In any case, treatment with antidepressants in bipolar patients should always be accompanied by a mood stabilizer, not only to minimize the switch risk but also to maintain continuous control of the long-term course of illness (Grunze et al., 2002). Another point of controversy is the duration of antidepressant treatment. Most recommendations today emphasize, if at all, only the intermittent use of antidepressants instead of continuous treatment (Nolen and Bloemkolk, 2000; Sachs et al., 2000; el Mallakh and Karippot, 2002). Analysis of seven small controlled trials could not supply sufficient information to support the long-term use of antidepressants in bipolar patients (Ghaemi, Lenox and Baldessarini, 2001). However, a recent analysis comparing patients in the Stanley Foundation Bipolar Network who decided (on their own wish) to discontinue antidepressants after relief of depressed symptoms with those who continued on the antidepressants showed a statistically significant advantage for treatment continuation (Altshuler et al., 2003). Patients continuing were less likely to suffer from a depressive relapse within one year (41% compared to 71%, median time to relapse 532 and 159 days respectively). Even more surprisingly, at one year post-treatment 29% of the medication discontinuer group compared to 13% of the medication continuer group had a relapse into mania. Thus, the general rule to discontinue
c05.fm Page 73 Wednesday, October 19, 2005 9:14 AM
Carbamazepine and Augmenting Agents
73
antidepressants as early as possible may not hold true in a significant minority of bipolar patients; subgroup analysis is still pending to find out which patients have the most profit of continuation of antidepressants, and which patients are exposed to additional risks by not stopping antidepressant treatment. There remains, nonetheless, a subgroup of bipolar patients, possibly those with cyclothymic temperament who appear at risk for switching and cycle acceleration. These are the patients where antidepressants are likely to be problematic, even when covered with mood stabilizers. Without confirmation from double-blind randomized studies, all the foregoing considerations are tentative. The exception is a doubleblind randomized study by Tohen et al. (2003), which demonstrated that fluoxetine added to olanzapine was more effective than olanzapine alone, both of which were significantly better than placebo in bipolar I depression. In conclusion, antidepressants will remain part of the treatment portfolio of bipolar disorder especially as long as the evidence for antidepressant properties of both lithium (Grunze, 2003) and anticonvulsants (Ernst and Goldberg, 2003) is not convincing, with the exception of lamotrigine (covered in Chapter 4). Considering the potential suicide risk of bipolar depression, an optimized and sometimes maximized treatment is mandatory. Nevertheless, there is clearly a demand for more controlled data to inform current clinical practice.1
OTHER POTENTIALLY USEFUL AGENTS IN BIPOLAR DISORDER OMEGA 3 FATTY ACIDS Omega 3 fatty acids are essential polyunsaturated fatty acids. The general interest of psychiatry stems from the fact that supplementing animal diets with omega 3 fatty acids leads to significant changes in the content of major brain neurotransmitters (Chalon et al., 1998). In addition, omega 3 fatty acids are able to modulate brain gene expression (Kitajka et al., 2002) and possess neuroprotective properties (Lauritzen et al., 2000). The special interest for affective disorders originates in the concept that omega 3 fatty acid deficiency may be one of the yet unrecognized risk factors (Coryell et al., 1999) that predispose patients to both affective disorders and cardiovascular disease (Hibbeln, 1998). In a first double-blind, placebo-controlled trial of omega 3 fatty acids, prophylactic antidepressive and mood stabilizing properties were observed in thirty patients with unstable bipolar disorder (Stoll et al., 1999). These findings were also confirmed in a twelve week, randomized, double-blind placebo-controlled study comparing one or two grams ethyl-EPA to placebo in addition to standard treatments in 75 patients with acute depression (Frangou and Lewis, 2002). Opposite to these findings, a large randomized and 1
Further discussion of suicidal patients is covered in Chapter 18.
c05.fm Page 74 Wednesday, October 19, 2005 9:14 AM
74
Bipolar Psychopharmacotherapy
placebo-controlled study of the Stanley Foundation (Keck et al., manuscript in preparation) could not find any difference between omega 3 fatty acids (preparation containing 6 gram ethyl-EPA) and placebo in bipolar depressed or cycling patients. The assumption had been made that a bell-shaped curve of efficacy may be the underlying reason for these different findings, but clearly further controlled studies are needed to establish omega 3 as an effective treatment in bipolar disorder.
CHROMIUM Chromium picolinate was effective in a small open trial in eight patients with refractory depression (McLeod and Golden, 2000). These preliminary findings were also supported by a small placebo-controlled study in atypical depression (Davidson et al., 2003). Studies in bipolar depression are currently ongoing but first case reports suggest that chromium may be a helpful add-on treatment in instable and cycling patients (Amann et al., 2002).
CALCIUM ANTAGONISTS Calcium fluxes across the membrane and altered intracellular calcium levels may play a role not only in epilepsies but also in the pathophysiology of affective disorders (Dubovsky and Franks, 1983). Different calcium antagonists like verapamil and diltiazem were found to be effective in manic patients in open and small controlled clinical studies; however, they may exert intolerable orthostatic side effects in higher dosages. The dihydropyridine L-type calcium channel blocker nimodipine is highly lipid soluble and penetrates the blood–brain barrier already in concentrations where peripheral side effects are negligible. Nimodipine showed efficacy in open trials in both acute mania (Brunet et al., 1990; Grunze et al., 1996) and depression (Walden et al., 1995) and treatment refractory rapid cycling disorder (Pazzaglia et al., 1993, 1998). However, its use appears not very practical due to its short half life time and the consequent need of multiple dosing. Nevertheless, it may be still an alternative in patients unsatisfactorily responsive to standard treatment.
THYROID HORMONES As many patients do not respond adequately to standard medications alone, augmentation strategies have been developed. The interest in using thyroid hormones to treat affective disorders originates from the observed association between psychiatric symptoms and thyroid disease states (Whybrow, Prange and Treadway, 1969). Since then, a series of open and controlled clinical trials have been conducted on the therapeutic use of thyroid hormones in mood disorders (Bauer and Whybrow, 2001). Whereas tri-iodothyronin (T3) has been investigated
c05.fm Page 75 Wednesday, October 19, 2005 9:14 AM
Carbamazepine and Augmenting Agents
75
in earlier years, Levothyroxin (T4) became increasingly the drug of interest due to a better tolerability, especially in high, supra-physiological doses. Several open studies in both bipolar depression and rapid cycling patients suggest efficacy of T4 (for an overview, see Bauer et al., 2003). Randomized, double-blind studies are currently under way. Thus, T4 may become an additional option for augmentative treatment in refractory bipolar patients.
CONCLUDING REMARKS In this chapter, the author has attempted to provide a comprehensive review about additional pharmacological treatment options in bipolar disorder. Treatment options not covered in this chapter (e.g. magnesium, mexiletine, clonidine, pramipexol, etc.) have only been evaluated in small case series or open studies. Others, like tamoxifen, with an interesting mechanism of protein kinase inhibition, have even been evaluated in double-blind controlled studies showing positive effects in acute mania, but due to tolerability problems and toxicity are unlikely to become an acceptable treatment in bipolar patients. With the increasing portfolio of treatment options in bipolar disorder, every review is incomplete, leaving out some treatment options that other authors would consider as promising. Thus, in a subsequent edition of this book some years from now, this chapter is likely to be substantially revised.
REFERENCES Adler LW (1986). Mixed bipolar disorder responsive to lithium and clonazepam. J. Clin. Psychiatry, 47, 49–50. Altshuler L, Suppes T, Black D, Nolen WA, Keck PE, Jr., Frye MA, McElroy S, Kupka R, Grunze H, Walden J, Leverich G, Denicoff K, Luckenbaugh D, and Post R (2003). Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at 1-year follow-up. Am. J. Psychiatry, 160, 1252–1262. Amann B, Forsthoff A, Matzner N, Dargl S, and Grunze H (2002). Chromium as antidepressant and mood stabilizer in refractory cycling patients: A case report. Bipolar Disord., 4, 123. Amsterdam J (1998). Efficacy and safety of venlafaxine in the treatment of bipolar II major depressive episode. J. Clin. Psychopharmacol., 18, 414–417. Amsterdam JD and Garcia-Espana F (2000). Venlafaxine monotherapy in women with bipolar II and unipolar major depression. J. Affect. Disord., 59, 225–229. Amsterdam JD, Garcia-Espana F, Fawcett J, Quitkin FM, Reimherr FW, Rosenbaum JF, Schweizer E, and Beasley C (1998). Efficacy and safety of fluoxetine in treating bipolar II major depressive episode. J. Clin. Psychopharmacol., 18, 435–440. Applebaum J, Levine J, and Belmaker RH (2003). Intravenous fosphenytoin in acute mania. J. Clin. Psychiatry, 64, 408–409. Ballenger JC and Post RM (1980). Carbamazepine in manic-depressive illness: A new treatment. Am. J. Psychiatry, 137, 782–790.
c05.fm Page 76 Wednesday, October 19, 2005 9:14 AM
76
Bipolar Psychopharmacotherapy
Bauer M, Adli M, Bschor T, Heinz A, Rasgon N, Frye M, Grunze H, Kupka R, and Whybrow PC (2003). Clinical Applications of Levothyroxine in Refractory Mood Disorders. Clin. Approach. Bipolar Disord., 2, 49–56. Bauer M and Whybrow PC (2001). Thyroid hormone, neural tissue and mood modulation. World J. Biol. Psychiatry, 2, 59–69. Boerlin HL, Gitlin MJ, Zoellner LA, and Hammen CL (1998). Bipolar depression and antidepressant-induced mania: A naturalistic study. J. Clin. Psychiatry, 59, 374–379. Bottai T, Hue B, Hillaire-Buys D, Barbe A, Alric R, Pouget R, and Petit P (1995). Clonazepam in acute mania: Time-blind evaluation of clinical response and concentrations in plasma. J. Affect. Disord., 36, 21–27. Bottlender R, Jager M, Strauss A, and Möller H-J (2000). Suicidality in bipolar compared to unipolar depressed inpatients. Eur. Arch. Psychiatry Clin. Neurosci., 250, 257–261. Bottlender R, Rudolf D, Jager M, Strauss A, and Moller H (2002). Are bipolar I depressive patients less responsive to treatment with antidepressants than unipolar depressive patients? Results from a case control study. Eur. Psychiatry, 17, 200–205. Bradwejn J, Shriqui C, Koszycki D, and Meterissian G (1990). Double-blind comparison of the effects of clonazepam and lorazepam in acute mania. J. Clin. Psychopharmacol., 10, 403–408. Brambilla P, Barale F, and Soares JC (2001). Perspectives on the use of anticonvulsants in the treatment of bipolar disorder. Int. J. Neuropsychopharmacol., 4, 421–446. Bräunig P and Krüger S (2003). Levetiracetam in the treatment of rapid cycling bipolar disorder. J. Psychopharmacol., 17, 239–241. Brown D, Silverstone T, and Cookson J (1989). Carbamazepine compared to haloperidol in acute mania. Int. Clin. Psychopharmacol., 4, 229–238. Brunet G, Cerlich B, Robert P, Dumas S, Souetre E, and Darcourt G (1990). Open trial of a calcium antagonist, nimodipine, in acute mania. Clin. Neuropharmacol., 13, 224–228. Calabrese JR, Keck PE, Jr., McElroy SL, and Shelton MD (2001). A pilot study of topiramate as monotherapy in the treatment of acute mania. J. Clin. Psychopharmacol., 21, 340–342. Calabrese JR, Rapport DJ, Kimmel SE, and Shelton MD (1999). Controlled trials in bipolar I depression: Focus on switch rates and efficacy. Eur. Neuropsychopharmacol., 9 Suppl. 4, 109–112. Carta MG, Hardoy MC, Hardoy MJ, Grunze H, and Carpiniello B (2003). The clinical use of gabapentin in bipolar spectrum disorders. J. Affect. Disord., 75, 83–91. Chalon SA, Delion-Vancassel S, Belzungl C, Guilloteau D, Leguisquet AM, and Besnard JC (1998). Dietary fish oil affects monoaminergic neurotransmission and behavior in rats. J. Nutr., 128, 2512–2519. Chou JC, Czobor P, Charles O, Tuma I, Winsberg B, Allen MH, Trujillo M, and Volavka J (1999). Acute mania: Haloperidol dose and augmentation with lithium or lorazepam. J. Clin. Psychopharmacol., 19, 500–505. Chouinard G (1985). Antimanic effects of clonazepam. Psychosomatics, 26 Suppl. 12, 7–12. Chouinard G (1987). Clonazepam in acute and maintenance treatment of bipolar affective disorder. J. Clin. Psychiatry, 48 Suppl., 29–37. Chouinard G, Young SN, and Annable L (1983). Antimanic effect of clonazepam. Biol. Psychiatry, 18, 451–466. Chouinard G, Annable L, Turnier L, Holobow N, and Szkrumelak N (1993). A double-blind randomized clinical trial of rapid tranquilization with I.M. clonazepam and I.M.
c05.fm Page 77 Wednesday, October 19, 2005 9:14 AM
Carbamazepine and Augmenting Agents
77
haloperidol in agitated psychotic patients with manic symptoms. Can. J. Psychiatry, 38 Suppl. 4, 114–121. Cohn JB, Collins G, Ashbrook E, and Wernicke JF (1989). A comparison of fluoxetine imipramine and placebo in patients with bipolar depressive disorder. Int. Clin. Psychopharmacol., 4, 313–322. Coryell W, Turvey C, Leon A, Maser JD, Solomon D, and Endicott J (1999). Persistence of depressive symptoms and cardiovascular death among patients with affective disorder. Psychosom. Med., 61, 755–761. Coxhead N, Silverstone T, and Cookson J (1992). Carbamazepine versus lithium in the prophylaxis of bipolar affective disorder. Acta Psychiatr. Scand., 85, 114–118. Dardennes R, Even C, Bange F, and Heim A (1995). Comparison of carbamazepine and lithium in the prophylaxis of bipolar disorders. A meta-analysis. Br. J. Psychiatry, 166, 378–381. Davidson JR, Abraham K, Connor KM, and McLeod MN (2003). Effectiveness of chromium in atypical depression: A placebo-controlled trial. Biol. Psychiatry, 53, 261–264. Denicoff KD, Smith-Jackson EE, Disney ER, Ali SO, Leverich GS, and Post RM (1997). Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. J. Clin. Psychiatry, 58, 470–478. Dietrich DE, Kropp S, and Emrich HM (2001). Oxcarbazepine in affective and schizoaffective disorders. Pharmacopsychiatry, 34, 242–250. Dubovsky SL and Franks RD (1983). Intracellular calcium ions in affective disorders: A review and an hypothesis. Biol. Psychiatry, 18, 781–797. el Mallakh RS and Karippot A (2002). Use of antidepressants to treat depression in bipolar disorder. Psychiatr. Serv., 53, 580–584. Elphick M (1985). An open clinical trial of carbamazepine in treatment-resistant bipolar and schizo-affective psychotics. Br. J. Psychiatry, 147, 198–200. Emrich HM (1990). Studies with Oxcarbazepine (Trileptal) in acute mania. Int. Clin. Psychopharmacol, 5 Suppl. 1, 83–88. Emrich HM (1994). In Experiences with oxcarbazepine in acute mania. Modigh K, Robak OH, and Vestergaard P (eds), Wrightson Biomedical Publishing Ltd., Petersfield, pp. 23–35. Emrich HM, Dose M, and von Zerssen D (1984). In Action of Sodium-Valproate and of Oxcarbazepine in Patients with Affective Disorders. Emrich HM, Okuma T, and Muller AA (eds), Excerpta Medica, Amsterdam, pp. 45–55. Emrich HM, Dose M, and von Zerssen D (1985). The use of sodium valproate, carbamazepine and oxcarbazepine in patients with affective disorders. J. Affect. Disord., 8, 243–250. Ernst CL and Goldberg JF (2003). Antidepressant properties of anticonvulsant drugs for bipolar disorder. J. Clin. Psychopharmacol., 23, 182–192. Frangou S and Lewis M (2002). The Maudsley Bipolar Disorder Project: A double-blind, randomized, placebo-controlled trial of Ethyl-EPA as an adjunct treatment of depression in bipolar disorder. Bipolar Disord., 4, Suppl. 1, 123. Frye M, Ketter T, Kimbrell TA, Dunn R, Speer A, Osuch E, Luckenbaugh D, Cora-Locatelli G, Leverich G, and Post R (2000). A placebo controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J. Clin. Psychopharmacol., 20, 607–614. Ghaemi NS, Ko JY, and Katzow JJ (2002). Oxcarbazepine treatment of refractory bipolar disorder: A retrospective chart review. Bipolar Disord., 4, 70–74. Ghaemi SN, Lenox MS, and Baldessarini RJ (2001). Effectiveness and safety of long-term antidepressant treatment in bipolar disorder. J. Clin. Psychiatry, 62, 565–569.
c05.fm Page 78 Wednesday, October 19, 2005 9:14 AM
78
Bipolar Psychopharmacotherapy
Goldberg JF and Burdick KE (2002). Levetiracetam for acute mania. Am. J. Psychiatry, 159, 148. Goncalves N and Stoll K-D (1985). Carbamazepin bei manischen Syndromen. Eine kontrollierte Doppelblind-Studie. Nervenarzt, 56, 43–47. Greil W and Kleindienst N (1999). Lithium versus carbamazepine in the maintenance treatment of bipolar II disorder and bipolar disorder not otherwise specified. Int. Clin. Psychopharmacol., 14, 283–285. Greil W, Kleindienst N, Erazo N, and Müller-Oerlinghausen B (1998). Differential response to lithium and carbamazepine in the prophylaxis of bipolar disorder. J. Clin. Psychopharmacol., 18, 455–460. Greil W, Ludwig-Mayerhofer W, Erazo N, Engel RR, Czernik A, Giedke H, Müller-Oerlinghausen B, Osterheider M, Rudolf GA, Sauer H, Tegeler J, and Wetterling T (1997a). Lithium vs carbamazepine in the maintenance treatment of schizoaffective disorder: A randomised study. Eur. Arch. Psychiatry Clin. Neurosci., 247, 42–50. Greil W, Ludwig-Mayerhofer W, Erazo N, Schöchlin C, Schmidt S, Engel RR, Czernik A, Giedke H, Müller-Oerlinghausen B, Osterheider M, Rudolf GA, Sauer H, Tegeler J, and Wetterling T (1997b). Lithium versus carbamazepine in the maintenance treatment of bipolar disorders—a randomised study. J. Affect. Disord., 43, 151–161. Grunze H (2003). Lithium in the acute treatment of bipolar disorders-a stocktaking. Eur. Arch. Psychiatry Clin. Neurosci., 253, 115–119. Grunze H, Erfurth A, Marcuse A, Amann B, Normann C, and Walden J (1999). Tiagabine appears not to be efficacious in the treatment of acute mania. J. Clin. Psychiatry, 60, 759–762. Grunze H, Kasper S, Goodwin G, Bowden CL, Baldwin D, Licht RW, Vieta E, Möller H-J, and WFSBP Task Force on Treatment Guidelines for Bipolar Disorders (2002). The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders. Part I: Treatment of Bipolar Depression. World J. Biol. Psychiatry, 3, 115–124. Grunze H and Möller H-J (2002). The place of antidepressants in the acute treatment of bipolar disorder. Clin. Approach. Bipolar Disord., 1, 40–46. Grunze H and Walden J (2002). Relevance of new and newly rediscovered anticonvulsants for atypical forms of bipolar disorder. J. Affect. Disord., 72, Suppl. 1, 15–21. Grunze H, Walden J, Wolf R, and Berger M (1996). Combined treatment with lithium and nimodipine in a bipolar I manic syndrome. Prog. Neuropsychopharmacol. Biol. Psychiatry, 20, 419–426. Grunze HC, Normann C, Langosch J, Schaefer M, Amann B, Sterr A, Schloesser S, Kleindienst N, and Walden J (2001). Antimanic efficacy of topiramate in 11 patients in an open trial with an on-off-on design. J. Clin. Psychiatry, 62, 464–468. Grunze H, Langosch J, Born C, Schaub G, and Walden J (2003). Levetiracetam in the treatment of acute mania: An open add-on study with an on-off-on design. J. Clin. Psychiatry, 64, 781–784. Haefely W (1983). The biological basis of benzodizepine actions. J. Psychoact. Drugs, 15, 19–39. Hartong EG, Moleman P, Hoogduin CA, Broekman TG, and Nolen WA (2003). Prophylactic efficacy of lithium versus carbamazepine in treatment-naive bipolar patients. J. Clin. Psychiatry, 64, 144–151. Hellewell JS (2002). Oxcarbazepine (Trileptal) in the treatment of bipolar disorders: A review of efficacy and tolerability. J. Affect. Disord., 72, Suppl. 1, 23–34. Hibbeln JR (1998). Fish consumption and major depression. Lancet, 351, 1213.
c05.fm Page 79 Wednesday, October 19, 2005 9:14 AM
Carbamazepine and Augmenting Agents
79
Hovinga CA (2001). Levetiracetam: A novel antiepileptic drug. Pharmacotherapy, 21, 1375–1388. Hummel B, Walden J, Stampfer R, Schlösser S, Amann B, Sterr A, Schäfer M, Frye M, and Grunze H (2002). Acute antimanic Efficacy and Safety of Oxcarbazepine in an Open Trial with an On-Off-On Design. Bipolar Disord., 4, 412–417. Judd LL, Akiskal HS, Schettler PJ, Coryell W, Endicott J, Maser JD, Solomon DA, Leon AC, and Keller MB (2003). A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch. Gen. Psychiatry, 60, 261–269. Judd LL, Akiskal HS, Schettler PJ, Endicott J, Maser J, Solomon DA, Leon AC, Rice JA, and Keller MB (2002). The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch. Gen. Psychiatry, 59, 530–537. Kanba S, Yagi G, Kamijima K, Suzuki T, Tajima O, Otaki J, Arata E, Koshikawa H, Nibuya M, and Kinoshita N (1994). The first open study of zonisamide, a novel anticonvulsant, shows efficacy in mania. Prog. Neuropsychopharmacol. Biol. Psychiatry, 18, 707–715. Keck PE and McElroy SL (2003). New approaches in managing bipolar depression. J. Clin. Psychiatry, 64, Suppl. 1, 13–18. Kishimoto A, Kamata K, Sugihara T, Ishiguro S, Hazama H, Mizukawa R, and Kunimoto N (1988). Treatment of depression with clonazepam. Acta Psychiatr. Scand., 77, 81–86. Kitajka K, Puskas LG, Zvara A, Hackler L, Barcelo-Coblijn G, and Yeo YK (2002). The role of n-3 polyunsaturated fatty acids in brain: Modulation of rat brain gene expression by dietary n-3 fatty acid. Proc. Natl. Acad. Sci. U.S.A., 99, 2619–2624. Klein E, Bental E, Lerer B, and Belmaker RH (1984). Carbamazepine and haloperidol v placebo and haloperidol in excited psychoses. A controlled study. Arch. Gen. Psychiatry, 41, 165–170. Lamberty Y, Margineanu DG, and Klitgaard H (2001). Effect of the New Antiepileptic Drug Levetiracetam in an Animal Model of Mania. Epilepsy Behav., 2, 454–459. Lauritzen I, Blondeau N, Heurteaux C, Widmann C, Romey G, and Lazdunski M (2000). Polyunsaturated fatty acids are potent neuroprotectors. EMBO J., 19, 1784–1793. Lerer B, Moore N, Meyendorff E, Cho SR, and Gershon S (1987). Carbamazepine versus lithium in mania: A double-blind study. J. Clin. Psychiatry, 48, 89–93. Lenox RH, Newhouse PA, Creelman WL, and Whitaker TM (1992). Adjunctive treatment of manic agitation with lorazepam versus haloperidol: A double-blind study. J. Clin. Psychiatry, 53, 47–52. Leverich G, McElroy S, Altshuler L, Frye M, Grunze H, Keck PE, Kupka R, Nolen W, Suppes T, Walden J, and Post R (2003). The anticonvulsant zonisamide in bipolar illness: Clinical response and weight loss. Proceedings of the 3rd AIP at Elmau. Lima L (1991). Region-selective reduction of brain serotonin turnover rate and serotonin agonist- induced behavior in mice treated with clonazepam. Pharmacol. Biochem. Behav., 39, 671–676. Loo H, Saiz-Ruiz J, Costa e Silva JACE, Ansseau M, Herrington R, Vaz-Serra A, Dilling H, and de Risio S (1999). Efficacy and safety of tianeptine in the treatment of depressive disorders in comparison with fluoxetine. J. Affect. Disord., 56, 109–118. Lusznat RM, Murphy DP, and Nunn CM (1988). Carbamazepine vs lithium in the treatment and prophylaxis of mania. Br. J. Psychiatry, 153, 198–204. McElroy SL, Kmetz GF, and Keck PE (1998). A pilot trial of adjunctive topiramate in the treatment of bipolar disorder. Abstr. XXIst CINP Congress, 281. McElroy SL, Suppes T, Keck PE, Frye MA, Denicoff KD, Altshuler LL, Brown ES, Nolen WA, Kupka RW, Rochussen J, Leverich GS, and Post RM (2000). Open-label adjunctive topiramate in the treatment of bipolar disorders. Biol. Psychiatry, 47, 1025–1033.
c05.fm Page 80 Wednesday, October 19, 2005 9:14 AM
80
Bipolar Psychopharmacotherapy
McIntyre JS, Mancini DA, McCann S, Stinivasan J, Sagman D, and Kennedy SH (2002). Topiramate versus Bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: A preliminary single-blind study. Bipolar Disord., 4, 207–213. McLeod MN and Golden RN (2000). Chromium treatment of depression. Int. J. Neuropsychopharmacol., 3, 311–314. Marcotte D (1998). Use of topiramate, a new anti-epileptic as a mood stabilizer. J. Affect. Disord., 50, 245–251. Meehan K, Zhang F, David S, Tohen M, Janicak P, Small J, Koch M, Rizk R, Walker D, Tran P, and Breier A (2001). A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J. Clin. Psychopharmacol., 21, 389–397. Mishory A, Winokur M, and Bersudsky Y (2003). Prophylactic effect of phenytoin in bipolar disorder: A controlled study. Bipolar Disord., 5, 464–467. Mishory A, Yaroslavsky Y, Bersudsky Y, and Belmaker RH (2000). Phenytoin as an antimanic anticonvulsant: A controlled study. Am. J. Psychiatry, 157, 463–465. Möller HJ, Bottlender R, Grunze H, Strauss A, and Wittmann J (2001). Are antidepressants less effective in the acute treatment of bipolar I compared to unipolar depression? J. Affect. Disord., 67, 141–146. Möller H-J and Grunze H (2000). Have some guidelines for the treatment of acute bipolar depression gone too far in the restriction of antidepressants? Eur. Arch. Psychiatry Clin. Neurosci., 250, 57–68. Montgomery SA, Schatzberg AF, Guelfi JD, Kasper S, Nemeroff C, Swann A, and Zajecka J (2000). Pharmacotherapy of depression and mixed states in bipolar disorder. J. Affect. Disord., 59, Suppl., 39–56. Morishita S and Aoki S (1999). [A trial of clonazepam treatment for manic-depressive psychoses]. Nihon Shinkei Seishin Yakurigaku Zasshi, 19, 127–132. Müller AA and Stoll K-D (1984). In Carbamazepine and oxcarbamazepine in the treatment of manic syndromes: Studies in Germany. Emrich HM, Okuma T, and Muller AA (eds), Amsterdam, pp. 139–147. Munoz RA (2002). Oxcarbazepine (Trileptal) for the treatment of bipolar disorder. Proc. APA Annual Meeting. Nasr SJ and Casper ML (2002). Oxcarbazepine (Trileptal) use in the treatment of mood disorders. Proc. APA Annual Meeting. Nolen W and Bloemkolk D (2000). Treatment of bipolar depression, a review of the literature and a suggestion for an algorithm. Neuropsychobiology, 42, Suppl. 1, 11–17. Normann C, Langosch J, Schaerer LO, Grunze H, and Walden J (1999). Treatment of acute mania with topiramate. Am. J. Psychiatry, 156, 2014 Okada M, Hirano T, Kawata Y, Murakami T, Wada K, Mizuno K, Kondo T, and Kaneko S (1999). Biphasic effects of zonisamide on serotonergic system in rat hippocampus. Epilepsy Res., 34, 187–197. Okada M, Kaneko S, Hirano T, Mizuno K, Kondo T, Otani K, and Fukushima Y (1995). Effects of zonisamide on dopaminergic system. Epilepsy Res., 22, 193–205. Okuma T, Inanaga K, Otsuki S, Sarai K, Takahashi R, Hazama H, Mori A, and Watanabe M (1979). Comparison of the antimanic efficacy of carbamazepine and chlorpromazine: a double-blind controlled study. Psychopharmacology, 66, 211–217. Okuma T, Inanaga K, Otsuki S, Sarai K, Takahashi R, Hazama H, Mori A, and Watanabe S (1981). A preliminary double-blind study on the efficacy of carbamazepine in prophylaxis of manic-depressive illness. Psychopharmacology Berl., 73, 95–96.
c05.fm Page 81 Wednesday, October 19, 2005 9:14 AM
Carbamazepine and Augmenting Agents
81
Okuma T, Kishimoto A, Inoue K, Matsumoto H, and Ogura A (1973). Anti-manic and prophylactic effects of carbamazepine (Tegretol) on manic depressive psychosis. A preliminary report. Folia Psychiatr. Neurol. Jpn., 27, 283–297. Okuma T, Yamashita I, Takahashi R, Itoh H, Otsuki S, Watanabe S, Sarai K, Hazama H, and Inanaga K (1990). Comparison of the antimanic efficacy of carbamazepine and lithium carbonate by double-blind controlled study. Pharmacopsychiatry, 23, 143–150. Oommen KJ and Mathews S (1999). Zonisamide: A new antiepileptic drug. Clin. Neuropharmacol., 22, 192–200. Pande AC (1988). Clonazepam treatment of atypical bipolar disorder. Psychosomatics, 29, 333–335. Pande AC, Crockatt JG, Janney CA, Werth JL, and Tsaroucha G (2000a). Gabapentin in bipolar disorder: A placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group. Bipolar Disord., 2, 249–255. Pande AC, Davidson JR, Jefferson JW, Janney CA, Katzelnick DJ, Weisler RH, Greist JH, and Sutherland SM (1999). Treatment of social phobia with gabapentin: A placebocontrolled study. J. Clin. Psychopharmacol., 19, 341–348. Pande AC, Pollack MH, Crockatt J, Greiner M, Chouinard G, Lydiard RB, Taylor CB, Dager SR, and Shiovitz T (2000b). Placebo-controlled study of gabapentin treatment of panic disorder. J. Clin. Psychopharmacol., 20, 467–471. Pazzaglia P, Post RM, Ketter TA, Callahan AM, Marangell LB, Frye MA, George MS, Kimbrell TA, Leverich GS, Cora-Locatelli G, and Luckenbaugh DA (1998). Nimodipine monotherapy and carbamazepine augmentation in patients with refractory recurrent affective illness. J. Clin. Psychopharmacol., 18, 404–413. Pazzaglia PJ, Post RM, Ketter TA, George MS, and Marangell LB (1993). Preliminary controlled trial of nimodipine in ultra-rapid cycling affective dysregulation. Psychiatry Res., 49, 257–272. Peet M (1994). Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants. Br. J. Psychiatry, 164, 549–550. Placidi GF, Lenzi A, Lazzerini F, Cassano GB, and Akiskal HS (1986). The comparative efficacy and safety of carbamazepine versus lithium: A randomized, double-blind 3-year trial in 83 patients. J. Clin. Psychiatry, 47, 490–494. Post R, Leverich G, Nolen W, Kupka R, Altshuler L, Frye M, Suppes T, McElroy SL, Keck PE, Grunze H, and Walden J (2002). A re-evaluation of the role of antidepressants in the treatment of bipolar depression: Data from the Stanley Bipolar Treatment Network. Bipolar Disord., 5, 396–406. Post RM, Uhde TW, Roy-Byrne PP, and Joffe RT (1987). Correlates of antimanic response to carbamazepine. Psychiatry Res., 21, 71–83. Reinstein MJ (2001). Prospective open label comparison of oxcarbazepine and valproate. Proc. APA Annual Meeting. Sachs GS (1990). Use of clonazepam for bipolar affective disorder. J. Clin. Psychiatry, 51, Suppl., 31–34. Sachs GS, Printz DJ, Kahn DA, Carpenter D, and Docherty JP (2000). The Expert Consensus Guideline Series: Medication Treatment of Bipolar Disorder 2000. Postgrad. Med. Spec. Report, 1–104. Sachs GS, Rosenbaum JF, and Jones L (1990a). Adjunctive clonazepam for maintenance treatment of bipolar affective disorder. J. Clin. Psychopharmacol., 10, 42–47. Sachs GS, Weilburg JB, and Rosenbaum JF (1990b). Clonazepam vs. neuroleptics as adjuncts to lithium maintenance. Psychopharmacol. Bull., 26, 137–143.
c05.fm Page 82 Wednesday, October 19, 2005 9:14 AM
82
Bipolar Psychopharmacotherapy
Schaffer LC and Schaffer CB (1999). Tiagabine and the treatment of refractory bipolar disorder. Am. J. Psychiatry, 156, 2014–2015. Schneck CD (2002). Bipolar Disorder in Neurologic Illness. Curr. Treat. Options Neurol., 4, 477–486. Small JG, Klapper MH, Milstein V, Marhenke JD, and Small IF (1996). Comparison of therapeutic modalities for mania. Psychopharmacol. Bull., 32, 623–627. Stoll AL, Severus WE, Freeman MP, Rueter S, Zboyan HA, Diamond E, Cress KK, and Marangell LB (1999). Omega 3 fatty acids in bipolar disorder: A preliminary doubleblind, placebo-controlled trial. Arch. Gen. Psychiatry, 56, 407–412. Stoll KD, Bisson HE, Fischer E, Gammel G, Goncalves N, Kröber HL, Mülder H, Nadler A, and Troyke P (1986). In Carbamazepine versus haloperidol in manic syndromes. Shagass C, Josiassen RC, Bridger WH, Weiss KJ, Stoff D, and Simpson GM (eds), Elsevier, New York, pp. 332–334. Suppes T, Chisholm K, Dhavale D, Frye M, Altshuler L, McElroy SL, Keck PE, Nolen W, Kupka R, Denicoff K, Leverich G, Rush AJ, and Post R (2002). Tiagabine in treatment refractory bipolar disorder: A clinical case series. Bipolar Disord., 4, 283–289. Thase ME and Sachs GS (2000). Bipolar depression: Pharmacotherapy and related therapeutic strategies. Biol. Psychiatry, 48, 558–572. Thase ME, Bhargava M, and Sachs GS (2003). Treatment of bipolar depression: Current status, continued challenges, and the STEP-BD approach. Psychiatr. Clin. North Am., 26, 495–518. Thies-Flechtner K, Müller-Oerlinghausen B, Seibert W, Walther A, and Greil W (1996). Effect of prophylactic treatment on suicide risk in patients with major affective disorders. Data from a randomized prospective trial. Pharmacopsychiatry, 29, 103–107. Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, Mitchell PB, Centorrino F, Risser R, Baker RW, Evans AR, Beymer K, Dube S, Tollefson GD, and Berier A (2003). Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch. Gen. Psychiatry, 60, 1079–1088. Vasudev K, Goswami U, and Kohli K (2000). Carbamazepine and valproate monotherapy: Feasibility, relative safety and efficacy, and therapeutic drug monitoring in manic disorder. Psychopharmacol. Berl., 150, 15–23. Vieta E, Martinez-Aran A, Goikolea JM, Torrent C, Colom F, Benabarre A, and Reinares M (2002). A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. J. Clin. Psychiatry, 63, 508–512. Walden J, Fritze J, van Calker D, Berger M, and Grunze H (1995). A calcium antagonist for the treatment of depressive episodes: single case reports. J. Psychiatr. Res., 29, 71–76. Watkins SE, Callender K, Thomas DR, Tidmarsh SF, and Shaw DM (1987). The effect of carbamazepine and lithium on remission from affective illness. Br. J. Psychiatry, 150, 180–182. Weisler RH, Kalali AH, and Ketter TA (2004). A multicenter, randomized, double-blind, placebo-controlled trial of extended-release carbamazepine capsules as monotherapy for bipolar disorder patients with manic or mixed episodes. J. Clin. Psychiatry, 65, 478–484. Weisler RH, Keck PE, Jr., Swann AC, Cutler AJ, Ketter TA, and Kalali AH (2005). Extended-release carbamazepine capsules as monotherapy for acute mania in bipolar disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry, 66, 323–330.
c05.fm Page 83 Wednesday, October 19, 2005 9:14 AM
Carbamazepine and Augmenting Agents
83
Whybrow PC, Prange AJ, Jr., and Treadway CR (1969). Mental changes accompanying thyroid gland dysfunction. A reappraisal using objective psychological measurement. Arch. Gen. Psychiatry, 20, 48–63. Winkler D, Willeit M, Wolf R, Stamenkovic M, Tauscher J, Pjrek E, Konstantinidis A, Schindler S, Barnas C, and Kasper S (2003). Clonazepam in the long-term treatment of patients with unipolar depression, bipolar and schizoaffective disorder. Eur. Neuropsychopharmacol., 13, 129–134. Yerevanian BI, Koek RJ, and Mintz J (2003). Lithium, anticonvulsants and suicidal behavior in bipolar disorder. J. Affect. Disord., 73, 223–228.
c19.fm Page 367 Wednesday, October 19, 2005 9:59 AM
c06.fm Page 85 Wednesday, October 19, 2005 9:14 AM
CHAPTER
6 Olanzapine in Treatment for Bipolar Disorder Mauricio Tohen1,2, Giedra Campbell1, and Daniel Lin1 1
2
Lilly Research Laboratories, Indianapolis, IN, USA McLean Hospital, Harvard Medical School, Belmont, MA, USA
Over the past several decades, significant advances have been made in the pharmacological treatment for bipolar disorder. Yet a significant proportion of patients with this condition are not responsive or only partially responsive to existing treatments, and among those who do obtain symptomatic relief, the majority subsequently experience relapse. This unmet medical need is being addressed by the introduction of novel medications and adjunctive treatment strategies. Typical antipsychotic agents such as haloperidol have been used extensively, either alone or in combination with other agents, for the treatment for bipolar disorder. In a metaanalysis of published reports through the year 2000, Tohen et al. (2001) found that 89% of hospitalized manic patients and 64% of outpatients with mania were treated with typical antipsychotics. While the efficacy of conventional antipsychotic agents for this condition has been well established, considerable concerns have been raised regarding their associated side effects, especially the long-term ones (Kane and Smith, 1982). The most prominent of these are extrapyramidal symptoms (EPS), of which tardive dyskinesia is the most serious. More importantly, recent studies have reported an increased risk of relapse into depression and higher rates of discontinuation in patients with mania who received mood stabilizer combined with typical antipsychotic, compared with mood stabilizers alone (Zarate, Jr. and Tohen, 2004). Thus, the clinical benefits of typical antipsychotic use in bipolar disorder are frequently offset by poor tolerability and the risk of noncompliance. The development of clozapine as an antipsychotic agent for both schizophrenic (Naber and Hippius, 1990; Hippius, 1999; Meltzer et al., 2003) and bipolar disorder (Calabrese et al., 1996; Shulman, Singh and Shulman, 1997; Frye et al., 1998) heralded a major change in the treatment for psychosis and was the first of a new generation of antipsychotic drugs. Despite the unfavorable side-effect profile and Bipolar Psychopharmacotherapy: Caring for the Patient Edited by Hagop S. Akiskal and Mauricio Tohen # 2006 John Wiley & Sons, Ltd ISBN: 0-470-85607-6
c06.fm Page 86 Wednesday, October 19, 2005 9:14 AM
86
Bipolar Psychopharmacotherapy
the need for blood monitoring for aganulocytosis, clozapine showed efficacy in refractory schizophrenic and bipolar disorders. In addition, it was often effective in reversing tardive dyskinesia. But all of these findings came from open clinical reports. Nonetheless, it served as a model for the development of better tolerated atypical antipsychotics. The term “atypical” was first used to describe clozapine, since its pharmacological properties were very different from those of older typical antipsychotic drugs. According to Lieberman and Duncan (2000), as a broad class, atypical antipsychotic drugs are characterized by: (a) lower incidence of extrapyramidal symptoms and tardive dyskinesia; (b) superior antipsychotic efficacy and a broader sprectrum of efficacy; (c) minimal chronic elevation of prolactin levels; (d) low potential to cause catalepsy in preclinical animal studies; and (e) lower dopamine (D2) receptor affinity and higher serotonin (5-HT) receptor affinity. Atypical antipsychotic agents offer distinct advantages over typical agents in the treatment for bipolar disorder with respect to tolerability, reduced adverse-event liability and, in turn, improved treatment compliance and response to medication. However, atypical antipsychotic drugs also carry a higher risk of weight gain and hyperlipidemia (Meyer, 2001; Koponen et al., 2002). Olanzapine was the first atypical antipsychotic drug to be approved in the United States and in the European Union for the treatment of acute bipolar mania and, more recently, bipolar maintenance/relapse prevention. In common with clozapine, olanzapine has a broad pharmacology and binds with high affinity to dopaminergic, serotonergic, adrenergic, muscarinic and histaminergic receptors. The binding characteristics of olanzapine to dopamine D2 receptors is consistent with the hypothesis that functional D2 receptor antagonism is an important factor in antipsychotic efficacy (Seeman and Kapur, 2000). Olanzapine’s higher dissociation constant at the D2 receptor, relative to haloperidol and other typical antipsychotic drugs, may account for its lower propensity to induce EPS or tardive dyskinesia (Seeman and Kapur, 2000). The unique pattern of binding of olanzapine to other receptor sites may provide multiple potential mechanisms of therapeutic action and may account for its efficacy in the complex symptoms of bipolar disorder (Bymaster et al., 1996). This chapter reviews the rationale behind the study design and the data from double-blind randomized controlled trials that have evaluated the efficacy for olanzapine monotherapy and olanzapine combination therapy in the treatment for bipolar disorder. The safety and tolerability of olanzapine is also briefly reviewed.
RATIONALE BEHIND THE CLINICAL TRIAL DEVELOPMENT OF OLANZAPINE Considering the complex nature of bipolar disorder, it is essential to evaluate the potential therapeutic value of new treatments in all phases of the illness-mania,
c06.fm Page 87 Wednesday, October 19, 2005 9:14 AM
Olanzapine
87
depression and maintenance of euthymia. The approach adopted in the evaluation of olanzapine was to establish first the safety and efficacy of the drug for treatment of acute mania. The value of adjunctive therapy to improve efficacy for the treatment of acute mania was also explored using olanzapine in combination with existing treatments, such as lithium or valproate. This was followed by the evaluations of efficacy and safety for the treatment of acute bipolar depression with olanzapine and olanzapine–fluoxetine combination. Once efficacy and safety were determined for the acute phases of the disorder, olanzapine was studied for relapse prevention or maintenance of response. Thus, a comprehensive evaluation of olanzapine, both as monotherapy and in combination therapy, has led to regulatory approvals for all phases of bipolar disorder, and has increased the number of options available to physicians for the treatment of this disorder.
EFFICACY IN THE TREATMENT FOR ACUTE MANIA Two randomized, double-blind, placebo-controlled trials of 3 and 4 weeks’ duration compared olanzapine with placebo in 139 and 115 patients respectively, with a DSM-IV diagnosis of bipolar I disorder (Tohen et al., 1999, 2000, 2001). In both studies, patients treated with olanzapine showed significantly greater mean improvements in Young Mania Rating Scale (YMRS) total score, the primary efficacy measure, compared with placebo-treated patients (olanzapine vs placebo: −10.3 vs −4.9; p < 0.019 (Tohen et al., 1999) and −14.8 vs −8.1; p < 0.001 (Tohen et al., 2000)). Based on clinical response criteria, defined as an improvement of ≥50% in YMRS total score from baseline to endpoint and an endpoint YMRS total score ≥12, significantly more olanzapine-treated patients responded compared with placebo-treated patients (olanzapine vs placebo: 49% vs 24%; p < 0.004 (Tohen et al., 1999) and 65% vs 43%; p = 0.02 (Tohen et al., 2000)). In both trials the mean modal dose was similar (14.9 mg and 16.4 mg), even though the starting dose was 10 mg in the trial from Tohen et al. (1999) and 15 mg for the trial from Tohen et al. (2000). There were no statistically significant differences with respect to the measures of Parkinsonism, akathisia and dyskinesia between olanzapine- and placebo-treated patients in either study. The results from these two studies suggest that relative to placebo, olanzapine had superior efficacy for the treatment of acute mania symptoms and was generally well tolerated. As noted above, the two trials differed in the starting dose of olanzapine; 10 mg/day in the first, and 15 mg/day in the second study. Statistically significant differences in mania symptoms relative to placebo were observed at week 3 in the first study, and at week 1 in the second. The benefits of early response to treatment may be partially reflected in a significantly lower rate of premature discontinuation due to lack of efficacy in the second study (26% olanzapine vs 48% placebo during 4 weeks; p = 0.02). Notably, there were no clinically meaningful differences in adverse events between the two studies. Based on the observations of an earlier
c06.fm Page 88 Wednesday, October 19, 2005 9:14 AM
88
Bipolar Psychopharmacotherapy
onset of action and the lack of increased adverse event risk, subsequent acute mania studies used a starting dose of 15 mg/day. The efficacy of olanzapine for the treatment of acute mania has also been examined in relation to other psychotropic agents. Efficacy, safety and quality-of-life measures were assessed in a direct comparison between olanzapine (5–20 mg/day, n = 234) and haloperidol (3–15 mg/day, n = 219) in a randomized controlled trial consisting of two successive, 6-week, double-blind periods in patients with bipolar mania (Tohen et al., 2003b). In addition to the assessment of mania symptoms, this trial also included scales to assess symptoms of depression to evaluate the potential risk of depressogenic effects associated with these treatments. Rates of remission, defined as YMRS scores ≤12 and Hamilton Rating Scale for Depression scale-21 item (HAMD-21) scores ≤8 at week 6 of treatment, were similar for olanzapine- and haloperidol-treated patients (52.1% vs 46.1% respectively; p=0.15), suggesting a similar efficacy for both agents. However, for a subgroup of patients whose index episode did not include psychotic features, rates of remission were significantly greater for olanzapine-treated patients relative to the haloperidol group (56.7% vs 41.6%; p = 0.04). For the subset of patients who entered the study nondepressed but became depressed during the course of the trial, haloperidol treatment was associated with a statistically significantly shorter time to switch into depression (p = 0.04) (Figure 6.1). Moreover, olanzapine compared favorably with haloperidol on two dimensions of the quality-of-life scale (Medical Outcomes Study 36-Item Short-Form Health Survey [SF-36]), namely general health and role limitations due to emotional problems. On all measures assessing EPS, both patient-reported and scale-defined, significantly more haloperidol-treated patients experienced a worsening of symptoms. Divalproex, an anticonvulsant, has been shown to have efficacy in the treatment for acute bipolar mania (Pope, Jr. et al., 1991; Bowden et al., 1994). Olanzapine was compared with divalproex in a randomized, double-blind trial with patients hospitalized for acute bipolar manic or mixed episodes (Tohen et al., 2002a). This trial consisted of a 3-week acute phase, followed by a 44-week phase to assess maintenance of response and relapse prevention. The results of the 44-week extension phase will be discussed at a later point in this chapter. The primary efficacy measure was baseline to endpoint change in total YMRS score at 3 weeks. Relative to divalproex (500–2500 mg/day, n = 123), olanzapine treatment (5–20 mg/day, n = 125) was more effective in reducing the symptoms of mania. On the primary efficacy measure, YMRS total score, the mean change was −13.4 points for olanzapine-treated patients and −10.4 points for divalproex-treated patients (p =0.03). With respect to treatment response, as defined by an improvement of ≥50% in YMRS score from baseline to endpoint, more patients in the olanzapine group responded than did in the divalproex group (54.4% vs 42.3% respectively), although this difference did not reach statistical significance (p=0.06). However, a significantly greater number of olanzapine-treated patients achieved remission, as
c06.fm Page 89 Wednesday, October 19, 2005 9:14 AM
Olanzapine
89 1.00
Probability of Not Switching to Depression
0.80
0.60
0.40 p = 0.04 Olanzapine, n = 12 Haloperidol, n = 22
0.20
0.00 0
10
20
30
40
50
60
70
80
90
100
Time to Switching to Depression (Days)
Figure 6.1: Time to switch to depression for patients who were not clinically depressed at baseline (HAMD-21 ≤8). Time to switch to depression (HAMD-21 ≥15) was significantly longer (log-rank test χ21 = 4.1; p = 0.04) for the olanzapine group compared with the haloperidol group. During the 12-week period, 22 haloperidol- and 12 olanzapinetreated patients switched to depression. The number of patients who experienced a switch to depression by days 15, 30 and 60 were 3, 9 and 18 for the haloperidol group and 1, 3 and 8 for the olanzapine group (Tohen et al., 2003b). Reprinted by permission from Archives of General Psychiatry (JAMA) (Tohen et al., 2003b) Abbreviations: HAMD-21, Hamilton Depression Rating Scale-21 item.
defined by an endpoint YMRS total score ≤12, compared with the divalproex group (47.2% vs 34.1% respectively; p = 0.04). Patients treated with olanzapine also achieved remission in a statistically significantly shorter period of time than did divalproex-treated patients (estimated 25th percentile for time to remission was 3 days for olanzapine patients and 6 days for divalproex patients; p < 0.04). In a separate randomized, 12-week, double-blind study, olanzapine (5–25 mg/ day, n = 57) was compared with divalproex (750–3250 mg/day, n = 63) in patients with bipolar disorder hospitalized for acute mania (Zajecka et al., 2002). YMRS total scores decreased from baseline to day 21 of treatment in both treatment groups (−17.2 for olanzapine and −14.8 for divalproex). This difference between groups, however, was not statistically significantly different (p = 0.210). Historically, antipsychotic agents have been used in combination with mood stabilizers for the treatment of acute mania, and the accumulated evidence supports the contention that adjunctive therapy with these two classes of compounds yields greater efficacy and more rapid onset of response (Klein et al., 1984; Muller-Oerlinghausen et al., 2000). The use of olanzapine in combination with either lithium or valproate for the treatment of acute mania was examined in 344 patients in a 6-week, double-blind, randomized, placebo-controlled study (Tohen
c06.fm Page 90 Wednesday, October 19, 2005 9:14 AM
90
Bipolar Psychopharmacotherapy
et al., 2002b). Patients diagnosed with bipolar disorder presenting with manic or mixed episodes who were inadequately responsive to at least 2 weeks of lithium or valproate treatment alone were randomized to receive “olanzapine cotherapy” (n=229) (olanzapine, 5–20mg/day+lithium or valproate) or “monotherapy” (n=115) (placebo + lithium or valproate). It should be noted that this group of patients would not be considered treatment resistant, since they failed to respond only to one agent at a therapeutic blood level for at least 2 weeks. The design of this study was intended to address a common treatment dilemma faced by practitioners. Namely, should a physician continue treatment with the original therapeutic agent under careful observation, even if patients do not demonstrate a response within the first two weeks, or should another drug be added? Patients who received olanzapine cotherapy had significantly greater mean improvements in YMRS total scores than those who received monotherapy (−13.1 vs −9.1 respectively; p = 0.003). Rates of clinical response, defined as ≥50% improvement in YMRS total scores from baseline to endpoint, were also significantly higher with cotherapy (68% vs 45%, p < 0.001). In addition, time to response was significantly shorter for cotherapy (p = 0.002), with a median response time of 18 days for cotherapy versus 28 days for monotherapy. The results of this study also demonstrated substantial efficacy of olanzapine plus lithium or valproate cotherapy in treating depressive symptoms present at randomization. For the study population as a whole, olanzapine cotherapy improved HAMD-21 total scores significantly more than did monotherapy with lithium or valproate (5.0 vs 0.9 points, p < 0.001). Furthermore, in a subset of patients presenting with moderate-to-severe depressive symptoms (DSM-IV mixed episode and HAMD-21 ≥20 at baseline), olanzapine cotherapy improved HAMD-21 scores by 10.3 points compared with 1.6 for monotherapy (p < 0.001). Also, within this subset of patients, more than four times as many patients in the cotherapy group showed at least a 50% improvement in depressive symptoms (43% vs 10%, p = 0.006). EPS, as assessed by the Simpson–Angus, Barnes Akathisia and Abnormal Involuntary Movement scales, were not significantly changed from baseline to endpoint in either treatment group. Compared with the use of lithium or valproate alone, addition of olanzapine provided superior efficacy in the treatment for manic or mixed bipolar episodes. Patients who suffer from mania with severe agitation are in need of immediate treatment in order to avoid harm to themselves or others. For pharmacokinetic reasons, the intramuscular administration of a molecule provides a faster onset of action than the oral use of the drug. For this reason, the efficacy and safety of intramuscular injections of olanzapine for the treatment of acutely agitated patients with bipolar mania were examined in a double-blind randomized study (Meehan et al., 2001). In this study, 201 agitated patients with bipolar mania were randomly assigned to receive one to three injections of olanzapine (n = 99), lorazepam (n = 51) or placebo (n = 51) within a 24-hour period. The doses of
c06.fm Page 91 Wednesday, October 19, 2005 9:14 AM
Olanzapine
91
olanzapine for the first and second injections were 10 mg and for the third injection, 5 mg. The doses of lorazepam for the first and second injections were 2 mg and for the third injection, 1 mg. For placebo-treated patients, the first and second injections were placebo and the third injection was olanzapine, 10 mg. Agitation was measured at baseline, every 30 minutes for the first 2 hours, and at 24 hours after the first injection using the Positive and Negative Syndrome Scale-Excited Component (PANSS-EC) subscale as the primary scale, and two additional scales: the Agitated Behavior Scale (ABS) and the Agitation-Calmness Evaluation Scale (ACES). At 2 hours after the first injection, patients treated with olanzapine showed a statistically significantly greater reduction in scores on all agitation scales compared with patients treated with either placebo (PANSS-EC, ABS, ACES; p < 0.001) or lorazepam (PANSS-EC, ABS, ACES; p < 0.01) (Figure 6.2). At 24 hours after the first injection, olanzapine remained statistically significantly superior to placebo in reducing agitation in patients with acute mania (PANSS-EC, p = 0.025), whereas such improvements in patients treated with lorazepam were not statistically significantly different from those treated with placebo or olanzapine (PANSS-EC, lorazepam vs placebo, p = 0.08; lorazepam vs olanzapine, p = 0.81). There were no statistically significant differences among the three treatment groups in safety measures, including treatment-emergent EPS, the incidence of acute dystonia or QTc interval changes.
Olanzapine
Lorazepam
Placebo
Change in PANSS-EC Score
0 –2 –4 2 hrs –6
‡
24 hrs
–8 –10
* †
–12
Figure 6.2: Mean change in PANSS-EC scores at 2 and 24 hours after the first intramuscular injection (LOCF) (*olanzapine vs placebo, p<0.001; †olanzapine vs lorazepam, p=0.001; ‡ olanzapine vs placebo, p = 0.025) Abbreviations: PANSS-EC – Positive and Negative Syndrome Scale-Excited Component; LOCF – last observation carried forward.
c06.fm Page 92 Wednesday, October 19, 2005 9:14 AM
92
Bipolar Psychopharmacotherapy
EFFICACY IN THE TREATMENT FOR BIPOLAR DEPRESSION In the treatment for bipolar disorder, the major challenge is perhaps not the management of manic episodes, but rather the management of episodes of depression. To date there is no pharmaceutical product with a regulatory approval for this phase of the illness. Bipolar depression, or the depressive phase of bipolar disorder, is a particularly difficult condition to treat and is often inadequately managed with currently available therapeutics. Thus, there is a great need to develop alternative strategies that ameliorate the depressive symptoms of bipolar disorder without inducing mania or hypomania, or accelerating cycling. As reviewed above, olanzapine has demonstrated efficacy in the treatment for acute bipolar mania (Tohen et al., 1999, 2000, 2002a,b, 2003b; Zajecka et al., 2002), and has also been found to improve depressive symptoms in patients with schizophrenia (Tollefson et al., 1998). The potential efficacy of olanzapine monotherapy or combination therapy with the antidepressant fluoxetine for the treatment for bipolar depression was therefore explored in a randomized, double-blind, placebo-controlled study (Tohen et al., 2003d). In this 8-week trial, olanzapine (5–20 mg/day) was compared with placebo and an olanzapine/fluoxetine combination (OFC; olanzapine and fluoxetine: 6 and 25; 6 and 50; or 12 and 50 mg/day) in 833 patients with bipolar depression (baseline Montgomery–Asberg Depression Rating Scale [MADRS] scores of ≥20). Starting at week 1, both olanzapine- and OFC-treated patients showed statistically significant improvements in depressive symptoms compared with placebo, and the treatment effect was also statistically significantly larger with OFC therapy compared with olanzapine monotherapy beginning at week 4 through the end of 8 weeks (Table 6.1 and Figure 6.3). The mean changes in MADRS total score between baseline and endpoint were −18.5 for OFC and −15.0 for olanzapine, both of which were significantly greater than placebo (−11.9; p < 0.001). The response rate, defined as a ≥50% reduction in MADRS total score, was significantly higher for the OFC treatment group (56%) relative to both olanzapine (39%, p=0.006) and placebo (30%, p<0.001). Similarly, the rate of remission, as defined by a MADRS total score ≤12 at endpoint and completion of at least 4 weeks of study, was significantly higher for OFC (49%) relative to olanzapine (33%, p = 0.007) and placebo (25%, p < 0.001). Time to remission was significantly shorter for the olanzapine group compared with the placebo group (p = 0.02) and again significantly shorter for the OFC group compared with placebo (p < 0.001) and olanzapine (p = 0.01) groups. In the Tohen et al. (2003d) study, the incidence of treatment-emergent mania was low, and there were no statistically significant differences among the three treatment groups (6.4% OFC, 5.7% olanzapine and 6.7% placebo). Thus, neither olanzapine nor OFC induced switches to mania or hypomania, an effect known to occur with some antidepressant drugs when they are given alone (Wehr and Goodwin, 1987; Altshuler et al., 1995). The results of this study suggest that
6.
5.
4.
3.
2.
Treatment
Placebo Olanzapine OFC Reported Sadness Placebo Olanzapine OFC Inner Tension Placebo Olanzapine OFC Reduced Sleep Placebo Olanzapine OFC Reduced Appetite Placebo Olanzapine OFC Concentration Difficulties Placebo Olanzapine OFC
1. Apparent Sadness
Items 3.5 ± 0.1 3.8 ± 0.1 3.6 ± 0.1 4.0 ± 0.1 4.1 ± 0.1 3.8 ± 0.1 3.3 ± 0.1 3.4 ± 0.1 3.2 ± 0.1 3.1 ± 0.1 3.2 ± 0.1 3.2 ± 0.2 1.8 ± 0.1 2.0 ± 0.1 1.6 ± 0.2 3.4 ± 0.1 3.4 ± 0.1 3.3 ± 0.1
−1.3 ± 0.1 (−1.5, −1.1) −1.5 ± 0.1 (−1.7, −1.3) −2.1 ± 0.2 (−2.4, −1.7) −1.5 ± 0.1 (−1.8, −1.3) −1.8 ± 0.1 (−2.0, −1.5) −2.2 ± 0.2 (−2.6, −1.8) −1.0 ± 0.1 (−1.2, −0.8) −1.4 ± 0.1 (−1.5, −1.2) −1.7 ± 0.2 (−2.0, −1.4) −1.3 ± 0.1 (−1.6, −1.0) −2.0 ± 0.1 (−2.3, −1.8) −2.3 ± 0.2 (−2.8, −1.9) −0.7 ± 0.1 (−1.0, −0.5) −1.4 ± 0.1 (−1.6, −1.1) −1.2 ± 0.2 (−1.7, −0.8) −1.4 ± 0.1 (−1.7, −1.2) −1.7 ± 0.1 (−1.9, −1.5) −1.6 ± 0.2 (−2.0, −1.2)
Mean Baseline ± SE Mean Change ± SE; (95% CI) NA −1.74 −3.69 NA −1.48 −2.98 NA −2.56 −3.46 NA −4.05 −3.83 NA −3.98 −2.09 NA −1.59 −0.72
t NA 2439 2122 NA 550 537 NA 2522 2240 NA 2298 1986 NA 1938 1643 NA 554 538
df
p NA .08 <.001 NA .14 .003 NA .01 <.001 NA <.001 <.001 NA <.001 .04 NA .11 .47
vs Placebo
NA NA −2.56 NA NA −2.01 NA NA −1.75 NA NA −1.12 NA NA 0.55 NA NA 0.36
t
NA NA 2034 NA NA 532 NA NA 2153 NA NA 1903 NA NA 1577 NA NA 533
df
NA NA .01 NA NA .045 NA NA .081 NA NA .26 NA NA .58 NA NA .72
p
vs Olanzapine
Table 6.1: Baseline-to-week-8 mean change in MADRS items (MMRM). Reprinted by permission from Archives of General Psychiatry (JAMA) (Tohen et al., 2003d)
c06.fm Page 93 Wednesday, October 19, 2005 9:14 AM
Placebo Olanzapine OFC Placebo Olanzapine OFC Placebo Olanzapine OFC Placebo Olanzapine OFC
7. Lassitude
3.5 ± 0.1 3.5 ± 0.1 3.7 ± 0.1 3.6 ± 0.1 3.6 ± 0.1 3.5 ± 0.1 3.3 ± 0.1 3.3 ± 0.1 3.2 ± 0.1 1.9 ± 0.1 2.0 ± 0.1 1.8 ± 0.1
−1.5 ± 0.1 (−1.7, −1.2) −1.5 ± 0.1 (−1.7, −1.2) −2.1 ± 0.2 (−2.5, −1.6) −1.6 ± 0.1 (−1.9, −1.4) −1.6 ± 0.1 (−1.9, −1.4) −2.3 ± 0.2 (−2.7, −1.9) −1.3 ± 0.1 (−1.5, −1.1) −1.4 ± 0.1 (−1.6, −1.2) −2.0 ± 0.2 (−2.3, −1.6) −0.9 ± 0.1 (−1.1, −0.7) −1.1 ± 0.1 (−1.3, −0.9) −1.2 ± 0.2 (−1.5, −0.9)
Mean Baseline ± SE Mean Change ± SE; (95% CI) NA −0.01 −2.48 NA −0.13 −3.13 NA −1.07 −3.35 NA −1.68 −1.69
t
p
NA NA 2388 .99 2063 .01 NA NA 2469 .90 2157 .002 NA NA 2471 .29 2140 <.001 NA NA 2149 .09 1830 .09
df
vs Placebo
NA NA −2.51 NA NA −3.10 NA NA −2.67 NA NA −0.57
t
NA NA 1976 NA NA 2069 NA NA 2050 NA NA 1753
df
NA NA .01 NA NA .002 NA NA .008 NA NA .57
p
vs Olanzapine
The MMRM analysis used a banded Toeplitz structure for the within-patient error covariance structure based on maximum Schwartz’s Bayesian criterion for items 1, 3, 4, 5, 7, 8, 9 and 10 and a heterogeneous banded Toeplitz structure for the within-patient error covariance structure based on maximum Schwartz’s Bayesian criterion for items 2 and 6. Abbreviations: MADRS – Montgomery–Asberg Depression Rating Scale; MMRM – mixed-effects model repeated measures; SE – standard error; CI – confidence interval; OFC – olanzapine/fluoxetine combination (Tohen et al., 2003d).
10. Suicidal Thoughts
9. Pessimistic Thoughts
8. Inability to Feel
Treatment
Items
Table 6.1: (Continued)
c06.fm Page 94 Wednesday, October 19, 2005 9:14 AM
c06.fm Page 95 Wednesday, October 19, 2005 9:14 AM
Olanzapine
95
MADRS Total Score Mean Change from Baseline
0 Olanzapine (n = 351) Placebo (n = 355) OFC (n = 82)
–5
–10
–15
–20 0
1
2
3
4
5
6
7
8
Week
Figure 6.3: Least-squares mean change in MADRS scores during the 8-week study period. Improvement in MADRS scores with olanzapine and olanzapine/fluoxetine combination was significantly greater than that with placebo throughout the study period (p < 0.001). Improvement in MADRS with olanzapine/fluoxetine combination was significantly greater than that with olanzapine at weeks 4–8 (p < 0.02) (Tohen et al., 2003d). Reprinted by permission from Archives of General Psychiatry (JAMA) (Tohen et al., 2003d) Abbreviation: MADRS – Montgomery–Asberg Depression Rating Scale.
although olanzapine appears to be effective in the treatment of patients with bipolar depression, cotherapy with fluoxetine greatly enhanced its therapeutic effects. Importantly, the enhanced efficacy of olanzapine/fluoxetine combined therapy was not associated with a greater risk of treatment-emergent mania.
EFFICACY IN BIPOLAR MAINTENANCE/RELAPSE PREVENTION Until recently, the long-term efficacy and relapse prevention of most pharmacotherapies used in bipolar disorder was poorly studied. Yet, there is an acute need for prophylactic treatments to minimize the risk of relapse because bipolar disorder is a chronic recurring condition. Repeated relapses into either manic, mixed or depressive phases of bipolar disorder have negative implications for disease progression and patients’ responsiveness to subsequent treatments: essentially, patients with a history of multiple relapses are likely to be less responsive to pharmacotherapeutics. Several studies have been performed to explore the role of olanzapine in long-term prophylactic treatment for bipolar disorder (Tohen et al., 2003a,c).
c06.fm Page 96 Wednesday, October 19, 2005 9:14 AM
96
Bipolar Psychopharmacotherapy
In a randomized double-blind study, described previously, the long-term efficacy of flexibly dosed olanzapine (5–20 mg/day) was compared with divalproex (500–2500 mg/day) in 251 patients with bipolar disorder during 47 weeks (Tohen et al., 2003c). Relative to divalproex-treated patients, olanzapine-treated patients had a significantly greater mean improvement at endpoint in YMRS total score, the primary efficacy measure (p = 0.03). The median time to symptomatic remission of mania (YMRS total score ≤12) was significantly shorter for olanzapine-treated patients than for those treated with divalproex (14 vs 62 days respectively; p = 0.05). However, no statistically significant differences occurred between treatments in the rates of remission during the 47 weeks (56.8% olanzapine and 45.5% divalproex respectively) or subsequent rates of relapse into mania or depression (42.4% olanzapine and 56.5% divalproex respectively). Olanzapine’s efficacy in relapse prevention has also been assessed when given in combination with mood stabilizers. The relative efficacy of olanzapine cotherapy (olanzapine in combination with lithium or valproate) versus monotherapy (either lithium or valproate alone) in preventing relapse was evaluated in an 18-month, double-blind study (Tohen et al., 2004). Patients who had previously achieved syndromic remission (DSM-IV) after 6 weeks’ treatment with olanzapine cotherapy (Tohen et al., 2004) were re-randomized to either olanzapine cotherapy or monotherapy (lithium or valproate) and followed for up to 18 months. No statistically significant differences occurred between the treatment groups for time to relapse into an affective episode (based on DSM-IV criteria) or for rates of relapse into either mania or depression when relapse was defined using a symptom-rating scale. However, in a subset of patients who met both symptomatic and syndromic remission criteria (the latter defined as YMRS ≤12 and HAMD-21 ≤8) at the outset of the study, the time to symptomatic relapse into either mania (YMRS ≥15) or depression (HAMD-21 ≥15) was significantly longer for the olanzapine cotherapy group relative to the monotherapy group (median times 163 vs 42 days respectively; p = 0.023). For over 30 years, lithium has been the “gold standard” for relapse prevention in bipolar disorder. To demonstrate a clear value for new treatments, comparisons to lithium are essential. Olanzapine was compared with lithium in a randomized, double-blind study of relapse prevention in bipolar disorder (Tohen et al., 2005). Patients with a diagnosis of bipolar disorder, manic or mixed type, with a history of at least two manic or mixed episodes within 6 years, and a YMRS total score ≥20 received open-label treatment with a combination of olanzapine and lithium for 6–12 weeks. By using a combination of both agents to treat the acute episode, the potential bias of including patients who were not tolerant of either treatment was avoided. Furthermore, a past history of non-tolerance or non-response to either treatment was an important exclusion criterion. Patients who achieved symptomatic remission, defined as a YMRS total score ≤12 and an HAMD-21 total score ≤8, were randomly assigned to receive monotherapy with either
c06.fm Page 97 Wednesday, October 19, 2005 9:14 AM
Olanzapine
97
olanzapine (n = 217) (5–20 mg/day) or lithium (n = 214) (300–1800 mg/day) for 52 weeks. Relapse to an affective episode, defined as a YMRS total score ≥15 and/or an HAMD-21 total score ≥15, occurred in 30% of olanzapine-treated and 39% of lithium-treated patients (p = 0.055). Olanzapine-treated patients had a statistically significantly lower incidence of relapse into a manic episode than lithium-treated patients (14% vs 28% respectively; p < 0.001), whereas both groups had similar incidences of relapse into a depressive episode (16% vs 15% respectively; p=0.895). The incidence of hospitalization for an affective episode was significantly lower for olanzapine-treated patients compared with lithium-treated patients (14% vs 23%; p=0.026). Significantly more olanzapine-treated patients (47%) completed the 52-week trial than those on lithium (33%; p = 0.004). The rates of discontinuation due to adverse events were 19% for the olanzapine group and 26% for the lithium group (p = 0.105). The efficacy of olanzapine for relapse prevention in bipolar disorder was assessed further in a year-long randomized double-blind placebo-controlled study (Tohen et al., 2003a). Patients with acute manic or mixed episodes of bipolar disorder received open-label treatment with olanzapine (5–20 mg/day) for 6–12 weeks. Those patients who achieved symptomatic remission, defined as a YMRS total score ≤12 and an HAMD-21 total score ≤8, were randomized to receive olanzapine (n = 225) (5–20 mg/day) or placebo (n = 136) for 52 weeks. Relative to placebo, olanzapine statistically significantly increased time to relapse to an affective (manic, depressive, or mixed) episode, defined as a YMRS total score ≥15 and/or an HAMD-21 total score ≥15 and/or psychiatric hospitalization (p < .001). Relapse to an affective episode occurred in 46.7% of olanzapine-treated patients and 80.1% of placebo-treated patients (p < 0.001). Olanzapine-treated patients had a statistically significantly lower rate of relapse into a manic episode (16.4% olanzapine vs 41.2% placebo; p < 0.001), or a depressive episode (34.7% olanzapine vs 47.8% placebo; p = 0.015) compared with the placebo-treated patients. Significantly more patients in the olanzapine group completed the 52-week trial than those in the placebo group (23.6% olanzapine vs 9.6% placebo; p = 0.001) with approximately twice as many placebo-treated patients discontinuing due to lack of efficacy (28% olanzapine vs 57% placebo; p = 0.001).
SAFETY AND TOLERABILITY SHORT-TERM STUDIES In the two placebo-controlled registration trials for acute mania (Tohen et al., 1999, 2000), short-term treatment with olanzapine for acute manic or mixed episodes in bipolar disorder was generally well tolerated. Very few patients in either study discontinued due to adverse events (0/70 olanzapine-treated patients and 2/69 placebo-treated patients in one study [0%, 2.9%]; and 2/55
c06.fm Page 98 Wednesday, October 19, 2005 9:14 AM
98
Bipolar Psychopharmacotherapy
olanzapine-treated patients and 1/60 placebo-treated patient in the other study [3.6%, 1.7%]). In the second study, the only adverse event that occurred statistically significantly more often in olanzapine-treated patients than in placebo-treated patients was somnolence; in the other, statistically significantly more common events included somnolence, dry mouth, dizziness and weight gain. Olanzapine-treated patients gained averages of 1.65 and 2.11kg in the two studies, whereas placebotreated patients either lost weight (0.44 kg) or gained a lesser amount (0.45 kg). In both studies, no clinically important laboratory, vital sign or ECG findings were observed, and EPS were infrequent. The safety and tolerability of olanzapine were further demonstrated in three short-term studies comparing olanzapine with other commonly used medications: a 6-week study comparing olanzapine to haloperidol (Tohen etal., 2003b), a 3-week study comparing olanzapine with divalproex (Tohen et al., 2002a) and a 12-week study comparing olanzapine with divalproex (Zajecka et al., 2002). Rates of discontinuations due to adverse events were similar across all three studies regardless of study duration or medication, suggesting similar tolerability for all of the studied medications (olanzapine vs haloperidol, 8.1% vs 11.4% (Tohen et al., 2003b); olanzapine vs divalproex, 9.6% vs 7.3% (Tohen et al., 2002a); and 8.8% vs 11.1% (Zajecka et al., 2002) respectively). In the haloperidol-controlled study, adverse events that occurred statistically significantly more often in olanzapinetreated patients than in haloperidol-treated patients included somnolence, weight gain, infection, dizziness and fever. Events that were statistically significantly more common for olanzapine-treated patients than for divalproex-treated patients in the 3-week study included dry mouth, increased appetite and somnolence; in the 12-week study, somnolence, weight gain, rhinitis, edema and slurred speech. Olanzapine-treated patients gained more weight than comparator-treated patients, with a mean gain of 2.82 kg in the haloperidol-controlled study and gains of 2.49 kg and 4.0 kg in the divalproex-controlled studies, compared with 0.02 kg for haloperidol and 0.92 and 2.5 kg in the respective divalproex treatment groups. In all three studies, there were no clinically important laboratory, vital sign or ECG findings, and EPS were infrequent for olanzapine-treated patients. The frequency of EPS was significantly lower among olanzapine-treated patients than among haloperidol-treated patients, with no differences observed between olanzapinetreated patients and divalproex-treated patients. These safety findings are consistent with a 6-week study comparing olanzapine combined with lithium or valproate (“olanzapine cotherapy”) with lithium or valproate alone (“monotherapy”) (Tohen et al., 2002b). In this study, cotherapy patients were more likely than monotherapy patients to discontinue due to adverse events (10.9% vs 1.7%). Adverse events that occurred statistically significantly more often in olanzapine cotherapy patients than in monotherapy patients included somnolence, dry mouth, weight gain, increased appetite, tremor and slurred speech. However, of these, only somnolence and weight gain occurred with sufficient severity to cause
c06.fm Page 99 Wednesday, October 19, 2005 9:14 AM
Olanzapine
99
treatment discontinuation in the olanzapine cotherapy group (2.6% and 1.3% respectively). As in the previous studies, weight gain was higher for patients in the olanzapine cotherapy group (3.08 vs 0.23 kg). Other than a greater incidence of treatment-emergent elevated prolactin in the olanzapine cotherapy group, no clinically important differences occurred in vital signs or laboratory and ECG findings.
LONGER-TERM STUDIES Olanzapine’s safety and tolerability were assessed in four long-term studies of relapse prevention. In a 47-week comparison of olanzapine and divalproex (Tohen etal., 2003c), patients receiving olanzapine experienced a higher incidence of dry mouth, somnolence, increased appetite, weight gain, akathisia and abnormal liver function tests than those on divalproex. Olanzapine and divalproex treatment groups did not differ in dropout rates due to adverse events. Based on the last-observation-carried forward analysis, patients in the olanzapine group gained significantly more weight than those in the divalproex group (3.44 vs 1.72kg; p=0.045). Based on the observed-case analysis for patients who completed the 47 weeks, weight increase did not differ for those completing 19 weeks or more of treatment (Figure 6.4). WEIGHT CHANGE FROM BASELINE (OC) 6
Change in Weight (kg)
5 4 3 2 Olanzapine Divalproex
1 0 –1 0
5
10
15
20 25 30 Weeks in Treatment
35
40
45
Olanzapine-treated patients gained significantly more weight than divalproex-treated patients from day 3 to week 15. By weeks 19 to 47, weight gain did not differ by treatment group.
Figure 6.4: Mean change in weight (observed case analysis) in a study of olanzapine versus divalproex (Tohen et al., 2003c). Reprinted by permission from American Journal of Psychiatry (Tohen et al., 2003c)
c06.fm Page 100 Wednesday, October 19, 2005 9:14 AM
100
Bipolar Psychopharmacotherapy
In an 18-month comparison of olanzapine cotherapy with lithium or valproate monotherapy in patients who had completed 6 weeks’ treatment with cotherapy (Tohen et al., 2004), the only adverse event observed statistically significantly more often in cotherapy patients than in monotherapy patients was weight gain (19.6% vs 6.3%). There were no common or clinically important differences in vital signs, ECGs or laboratory evaluations in either study. In a year-long comparison of olanzapine and placebo in patients who had achieved remission while receiving 6–12 weeks of olanzapine therapy (Tohen etal., 2003a), patients receiving olanzapine experienced a statistically significantly higher incidence of weight increase, fatigue and akathisia than those on placebo. While a slightly higher proportion of olanzapine-treated patients than placebo-treated patients discontinued due to adverse events, the difference was not statistically significant. Conversely, placebo-treated patients were statistically significantly more likely to discontinue due to lack of efficacy. In the one-year-long relapse prevention study that compared olanzapine with lithium (Tohen et al., 2003a), slightly more lithium-treated patients than olanzapine-treated patients discontinued due to adverse events, although the difference was not statistically significant. Weight gain across the double-blind therapy phase was statistically significantly greater in the olanzapine group compared with the lithium group (1.79 vs −1.38 kg respectively; p < 0.001).
SUMMARY In summary, data based on randomized double-blind controlled trials suggest that olanzapine has efficacy in the treatment for acute mania, bipolar depression and relapse prevention. The data, however, suggest more robust efficacy in the treatment for acute mania than bipolar depression and in the prevention of mania compared to the prevention of depression. The adverse events that were seen most commonly in olanzapine-treated patients at significantly greater rates than in comparator-treated patients were events related to somnolence (somnolence, fatigue or hypersomnia) and weight gain (weight gain, increased weight or increased appetite). Moreover, a larger proportion of olanzapine-treated patients than comparator-treated patients experienced clinically important weight gain.
REFERENCES Altshuler, L. L., Post, R. M., Leverich, G. S., Mikalauskas, K., Rosoff, A., Ackerman, L., 1995. Antidepressant-induced mania and cycle acceleration: A controversy revisited. Am J Psychiatry. 152, 1130–1138. Bowden, C. L., Brugger, A. M., Swann, A. C., Calabrese, J. R., Janicak, P. G., Petty, F., Dilsaver, S. C., Davis, J. M., Rush, A. J., Small, J. G., 1994. Efficacy of divalproex vs
c06.fm Page 101 Wednesday, October 19, 2005 9:14 AM
Olanzapine
101
lithium and placebo in the treatment of mania. The Depakote Mania Study Group. JAMA. 271, 918–924. Bymaster, F. P., Calligaro, D. O., Falcone, J. F., Marsh, R. D., Moore, N. A., Tye, N. C., Seeman, P., Wong, D. T., 1996. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 14, 87–96. Calabrese J. R., Kimmel S. E., Woyshville M. J., Rapport J. D., Faust C. J., Thompson P. A., Meltzer H. Y., 1996. Clozapine for treatment-refractory mania. Am J Psychiatry. 153, 759–64. Frye, M. A., Ketter T. A., Altshuler, L. L., Denicoff K., Dunn R. T., Kimbrell, T. A., Cora-Locatelli, G., Post, R. M., 1998. Clozapine in bipolar disorder: Treatment implications for other atypical antipsychotics. J Affect Disord. 48, 91–104. Hippius, H., 1999. A historical perspective of clozapine. J Clin Psychiatry. 60 (Suppl. 12), 22–3. Kane, J. M., Smith, J. M., 1982. Tardive dyskinesia: Prevalence and risk factors, 1959 to 1979. Arch Gen Psychiatry. 39, 473–481. Klein, E., Bental, E., Lerer, B., Belmaker, R. H., 1984. Carbamazepine and haloperidol v placebo and haloperidol in excited psychoses. A controlled study. Arch Gen Psychiatry. 41, 165–170. Koponen, H., Saari, K., Savolainen, M., Isohanni, M., 2002. Weight gain and glucose and lipid metabolism disturbances during antipsychotic medication: A review. Eur Arch Psychiatry Clin Neurosci. 252(6), 294–298. Lieberman, J. A., Duncan, G., 2000. What Makes Olanzapine an Atypical Antipsychotic? In: Tran, P., Bymaster, F. P., Tye, N. C., Herrera, J. M., Breier, A., Tollefson, G.(eds), Olanzapine (Zyprexa): A Novel Antipsychotic. Lippincott Williams and Wilkins, Philadelphia, xxiii–xxvii. Meehan, K., Zhang, F., David, S., Tohen, M., Janicak, P., Small, J., Koch, M., Rizk, R., Walker, D., Tran, P., Breier, A., 2001. A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol. 21, 389–397. Meltzer H. Y., Alphs L., Green A. I., Altamura A. C., Anand R., Bertodi A., Bourgeois M., Chouinard G., Islam M. Z., Kane J., Krishman R., Lindenmayer J. P., Potkin S., 2003. International Suicide Prevention Trial Study Group. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry. 60, 82–91. Meyer, J. M., 2001. Effects of atypical antipsychotics on weight and serum lipid levels. J Clin Psychiatry. 62, Suppl. 34. Muller-Oerlinghausen, B., Retzow, A., Henn, F. A., Giedke, H., Walden, J., 2000. Valproate as an adjunct to neuroleptic medication for the treatment of acute episodes of mania: a prospective, randomized, double-blind, placebo-controlled, multicenter study. J Clin Psychopharmacol. 20, 195–203. Naber, D., Hippius, H., 1990. The European experience with use of clozapine. Hosp Community Psychiatry. 41, 886–90. Pope, H. G., Jr., McElroy, S. L., Keck, P. E., Jr., Hudson, J. I., 1991. Valproate in the treatment of acute mania. A placebo-controlled study. Arch Gen Psychiatry. 48, 62–68. Seeman, P., Kapur, S., 2000. What Makes Olanzapine an Atypical Antipsychotic? In: Tran, P., Bymaster, F. P., Tye, N. C., Herrera, J. M., Breier, A., Tollefson, G. (eds), Olanzapine (Zyprexa): A Novel Antipsychotic. Lippincott Williams and Wilkins, Philadelphia, 3–24.
c06.fm Page 102 Wednesday, October 19, 2005 9:14 AM
102
Bipolar Psychopharmacotherapy
Shulman, R.W., Singh, A., Shulman, K.I., 1997. Treatment of elderly institutionalized bipolar patients with clozapine. Psychopharmacol Bull. 33, 113–8. Tohen, M., Baker, R. W., Altshuler, L. L., Zarate, C. A., Suppes, T., Ketter, T. A., Milton, D. R., Risser, R., Gilmore, J. A., Breier, A., Tollefson, G. A., 2002a. Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry. 159, 1011–1017. Tohen, M., Bowden, C., Calabrese, J., Chou, J., Jacobs, T. G., Baker, R. W., Williamson, D., Evans, A. R., 2003a. Olanzapine’s efficacy for relapse prevention in bipolar disorder: a randomized double-blind placebo-controlled 12-month trial. Bipol Disord. 5 (Suppl. 1), 89. Tohen, M., Calabrese, J. R., Sachs, G. S., Banov, M. D., Detke, H. C., Risser, R., Baker, R. W., Chou, J. C. Y., Bowden, C. L. (In Press). A randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute olanzapine treatment. Am J Psych. Tohen, M., Chengappa, K. N., Suppes, T., Baker, R. W., Zarate, C., Bowden, C., Sachs, G., Kupfer, D. J., Ghaemi, S. N., Feldman, P. D., Risser, R., Evans, A. R., Calabrese, J., 2004. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br J Psychiatry. 184, 337–345. Tohen, M., Chengappa, K. N., Suppes, T., Zarate, C. A., Jr., Calabrese, J. R., Bowden, C. L., Sachs, G. S., Kupfer, D. J., Baker, R. W., Risser, R. C., Keeter, E. L., Feldman, P. D., Tollefson, G. D., Breier, A., 2002b. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry. 59, 62–69. Tohen, M., Goldberg, J. F., Gonzalez-Pinto Arrillaga, A. M., Azorin, J. M., Vieta, E., Hardy-Bayle, M. C., Lawson, W. B., Emsley, R. A., Zhang, F., Baker, R. W., Risser, R. C., Namjoshi, M. A., Evans, A. R., Breier, A., 2003b. A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Arch Gen Psychiatry. 60, 1218–1226. Tohen, M., Greil, W., Calabrese, J., Sachs, G. S., Yatham, L. N., Oerlinghausen, B. M., Koukopoulos, A., Cassano, G. B., Grunze, H., Licht, R. W., Dell’Osso, L., Evans, A. R., Risser, R., Baker, R. W., Crane, H., Dossenbach, M. R., Bowden, C. L., 2005. Olanzapine versus Lithium in the maintenance treatment of bipolar disorder: A 12-month, randomized, double-blind, controlled clinical trial. Am J Psych. 162, 1281–1290. Tohen, M., Jacobs, T. G., Grundy, S. L., McElroy, S. L., Banov, M. C., Janicak, P. G., Sanger, T., Risser, R., Zhang, F., Toma, V., Francis, J., Tollefson, G. D., Breier, A., 2000. Efficacy of olanzapine in acute bipolar mania: A double-blind, placebo-controlled study. Arch Gen Psychiatry. 57, 841–849. Tohen, M., Ketter, T. A., Zarate, C. A., Suppes, T., Frye, M., Altshuler, L., Zajecka, J., Schuh, L. M., Risser, R. C., Brown, E., Baker, R. W., 2003c. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: A 47-week study. Am J Psychiatry. 160, 1263–1271. Tohen, M., Marneros, A., Greil, W., Calabrese, J. R., Sachs, G., Yatham, M. B., Muller-Oerlinghausen, B., Koukopoulis, A., Cassano, G. B., Grunz, H., Licht, R. W., Dell’Osso, L., Evans, A. R., Risser, R., Baker, R. W., Crane, H., Dossenboch, M. R., Bowden, C., 2005. Olanzapine versus lithium in maintenance of response in bipolar disorder: a randomized double-blind controlled 12-month clinical trial. Am J Psychiatry. 162: 1–10. Tohen, M., Sanger, T. M., McElroy, S. L., Tollefson, G. D., Chengappa, K. N., Daniel, D. G., Petty, F., Centorrino, F., Wang, R., Grundy, S. L., Greaney, M. G., Jacobs, T. G., David, S. R., Toma, V., 1999. Olanzapine versus placebo in the treatment of acute mania. Am J Psychiatry. 156, 702–709.
c06.fm Page 103 Wednesday, October 19, 2005 9:14 AM
Olanzapine
103
Tohen, M., Vieta, E., Calabrese, J., Ketter, T. A., Sachs, G., Bowden, C., Mitchell, P. B., Centorrino, F., Risser, R., Baker, R. W., Evans, A. R., Beymer, K., Dube, S., Tollefson, G. D., Breier, A., 2003d. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry. 60(11), 1079–1088. Tohen, M., Zhang, F., Taylor, C. C., Burns, P., Zarate, C., Sanger, T., Tollefson, G., 2001. A meta-analysis of the use of typical antipsychotic agents in bipolar disorder. J Affect Disord. 65(1), 85–93. Tollefson, G. D., Sanger, T. M., Lu, M. K., Thieme, M. E., 1998. Depressive signs and symptoms in schizophrenia – a prospective blinded trial of olanzapine and haloperidol. Arch Gen Psychiatry. 55, 250–258. Wehr, T. A., Goodwin, F. K., 1987. Can antidepressants cause mania and worsen the course of affective illness? Am J Psychiatry. 144(11), 1403–1411. Zajecka, J. M., Weisler, R., Sachs, G., Swann, A. C., Wozniak, P., Sommerville, K. W., 2002. A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry. 63(12), 1148–1155. Zarate, C. A., Jr., Tohen, M., 2004. Double-blind comparison of the continued use of antipsychotic treatment versus its discontinuation in remitted manic patients. Am J Psychiatry. 161(1), 169–171.
c19.fm Page 367 Wednesday, October 19, 2005 9:59 AM
c07.fm Page 105 Wednesday, October 19, 2005 9:14 AM
CHAPTER
7 Haloperidol and Risperidone in Mania John Cookson The Royal London Hospital, London, UK
INTRODUCTION In 1958 the creative genius of Paul Janssen, the Belgian clinician and chemist, and founder of the Janssen pharmaceutical company, led to the introduction of haloperidol, a butyrophenone with antipsychotic properties. This had been synthesized as a variant of the pethidine molecule and it was observed to antagonize the effects of amphetamines in animals. The fact that amphetamines were associated with psychotic reactions in cyclists, who were taking them to enhance their performance, led Janssen to study the effects of haloperidol in schizophrenia and mania. The occurrence of neurological (Parkinsonian) side effects with the phenothiazines such as chlorpromazine (discovered in 1952) had indicated that these drugs affected neurones, and the name “neuroleptic” (“seizes neurones”) was used to describe the phenothiazines and later haloperidol; the term “antipsychotic” is now preferred. Later, newer drugs called “atypical,” “second generation” or “new generation” antipsychotics were developed to avoid these side effects. Risperidone is an atypical antipsychotic that was developed by Janssen pharmaceuticals.
ACUTE TRANQUILLIZATION IN MANIA The acutely manic patient presents an immediate challenge to medical and nursing staff, and usually requires medication to reduce aggressive or violent behavior, agitation and the behavioral consequences of psychotic thinking. The violent patient presents the most extreme challenge to the psychiatrist of how to combine psychology and pharmacology, compassion and safety in effective proportion. Drugs are used both to treat the underlying manic state and to reduce aggression and arousal (Royal College of Psychiatrists, 1998; Cookson, Taylor and Katona, 2002a). The aim of acute tranquillization is to calm or sedate the Bipolar Psychopharmacotherapy: Caring for the Patient Edited by Hagop S. Akiskal and Mauricio Tohen # 2006 John Wiley & Sons, Ltd ISBN: 0-470-85607-6
c07.fm Page 106 Wednesday, October 19, 2005 9:14 AM
106
Bipolar Psychopharmacotherapy
patient sufficiently to minimize the risk posed to the patient and to others. Often it is used for sedation, but sometimes it addresses also the underlying illness, particularly mania. When an antipsychotic is used, haloperidol is often the drug of first choice, especially if intramuscular administration is necessary – 5–10 mg may be given intramuscularly for the first injection and repeated. In some countries, a lower dose is started. A combination of haloperidol with a benzodiazepine such as lorazepam, which may also be given intramuscularly (1–2 mg), has been the commonest approach for rapid tranquillization of acutely disturbed patients, many of whom have mania. There is little evidence concerning the optimal dose of haloperidol for this use. Mania may improve rapidly following parenteral haloperidol. Ratings of mania improved by 30% within 20 minutes after intravenous injection of 2.5–5mg, and such improvement was seen before patients slept (Cookson et al., 1983).
SEDATION IS NOT REQUIRED FOR ANTIPSYCHOTICS TO IMPROVE MANIA Chlorpromazine was the most widely investigated antipsychotic in early comparative trials in mania, but drugs with more specific dopamine-receptor blocking actions have antimanic properties, although these drugs – such as pimozide and haloperidol – are less sedative, being without blocking actions at histamine receptors. The efficacy of these non-sedative drugs in mania highlights the importance of dopamine (DA) receptor blockade in the antimanic effects of antipsychotic drugs (Post et al., 1980), and indicates that antimanic activity can occur independently of sedation (Cookson, Silverstone and Wells, 1981).
HALOPERIDOL IN MANIA In the 1990s, the preference of American (New York) psychiatrists for high potency antipsychotics such as haloperidol in mania was illustrated in a study by Chou etal. (1996) of 528 manic patients in New York state hospitals in 1990. During the first three weeks of hospitalization for mania, 92% received antipsychotic medication, 61% lithium, 54% both and 22% benzodiazepines – mainly lorazepam. Haloperidol (38% of prescriptions) was the most widely used antipsychotic drug, followed by fluphenazine (20%) and chlorpromazine (18%). Since haloperidol was the most commonly prescribed antipsychotic in mania, the study by Shopsin et al. (1975) is important. This compared haloperidol (up to 36 mg/day) with chlorpromazine (up to 1800 mg/day) and lithium in a three-week study with only ten patients in each treatment group. Lithium appeared to produce a broader improvement in manic symptoms than the antipsychotics; seven patients were well enough to be discharged after treatment with lithium compared to only
c07.fm Page 107 Wednesday, October 19, 2005 9:14 AM
Haloperidol and Risperidone
107
one patient on chlorpromazine and two patients on haloperidol. However, the clinical ratings (Clinical Global Impression) showed almost identical levels of improvement at three weeks for lithium and haloperidol, both of which were superior to chlorpromazine. The authors described haloperidol as more effective than lithium in reducing hyperactivity, while lithium produced greater effects on mood and ideation; however, the Brief Psychiatric Rating Scale did not show significant differences in individual items for the three treatments. Haloperidol had a more pronounced antimanic effect than chlorpromazine and this was not accompanied by sedation. The authors argued that the control of symptoms by haloperidol was “a suppressive lid,” as opposed to the “more total normalization of affect, ideation and behavior” on lithium. An alternative view was expressed as early as 1972 by Prien et al., who found “no evidence the treatments worked differently on the underlying manic process” and were “unable to confirm . . . the claims that lithium treats the underlying manic process while chlorpromazine controls . . . behaviour through sedation without affecting underlying mood and ideation.” The high rate of remission within three weeks on lithium in this study by Shopsin et al. (1975) is in contrast to the lower rates seen in more recent studies such as that by Bowden et al. (1994). Conversely, the very low rate of remission on haloperidol contrasts with the dose-finding study of 47 severely ill manic patients by Rifkin et al. (1994), in which 45% of patients, treated with haloperidol, remitted within six weeks. The latter study was important in failing to show a significantly greater improvement with doses of haloperidol above 10 mg/day and up to 80 mg/day. However, the numbers involved were small and the confidence limits overlapped in all three dose ranges. There was a distinct trend for patients on 30 mg/day or more to do better than those on only 10 mg/day. Further studies are needed to identify the optimal doses for haloperidol in mania. In the largest randomized comparative study of haloperidol (Tohen et al., 2003), the drug was compared with olanzapine over 6–12 weeks. Among patients on haloperidol (up to 15 mg/day, mean dose at sixth week 7 mg/day), the proportion responding (50% reduction in YMRS score) at 6 weeks was 74%; the proportion showing syndromal remission (according to DSM-IV) was 44%, a figure similar to that found by Rifkin et al. (1994). In patients who had low levels of depressive symptoms at commencement on haloperidol, a total of 16.8% switched into depression within 12 weeks. However, as there was no placebo group, it is not known whether this represents the natural history of the patients’ mood cycles, perhaps accelerated by effective treatment for mania, or some additional depressant effect of haloperidol. In patients who remain disturbed on standard doses of haloperidol, additional sedation may be achieved by benzodiazepines, especially lorazepam, a practice that carries less risk of cardiotoxicity than using higher doses of antipsychotics
c07.fm Page 108 Wednesday, October 19, 2005 9:14 AM
108
Bipolar Psychopharmacotherapy
(Lenox et al., 1992; Busch, Miller and Weiden, 1989). However, a combination of two antimanic drugs from different classes should also be considered, for example an antipsychotic with lithium.
COMBINATION TREATMENT WITH LITHIUM AND HALOPERIDOL If, as Shopsin etal. (1975) found, lithium is superior to haloperidol, and acts through different mechanisms to exert its antimanic effect, one would expect that patients treated with a combination of lithium and haloperidol would respond significantly better than patients treated with either drug alone. One small study (with seven patients in each group and therefore not sufficiently powered to explore the question conclusively) addressed this comparison in mania (Garfinkel, Stancer and Persaud, 1980). Haloperidol appeared superior to lithium alone, and the combination gave no additional advantage during three weeks of treatment. One of the recent combination studies of atypical antipsychotics plus “mood stabilizers” included haloperidol as an active comparator (which will be discussed later in this chapter; see Table 7.2).
HORMONE CHANGES AND MECHANISMS OF ANTIMANIC EFFECTS OF ANTIPSYCHOTICS CORTISOL Elevated serum cortisol levels are found in mania. During treatment with haloperidol, there is dissociation between an early normalization of cortisol levels within three days and a more gradual clinical improvement during two weeks of treatment (Cookson et al., 1985). This may occur because haloperidol blocks noradrenaline alpha-1 receptors in humans (Szabadi, Gaszner and Bradshaw, 1981). Alpha-1 receptor blockade is also thought to contribute to transient sedative effects of antipsychotics (Peroutka and Snyder, 1980). It may account for the early transient sedative effects seen in mania with haloperidol (Cookson et al., 1983).
PROLACTIN Dopamine (DA-2) receptors in the prolactin-secreting cells of the anterior pituitary gland are blocked by classical antipsychotic agents, and by risperidone. The resulting elevation of serum prolactin levels provides a biological marker of this dopamine receptor blockade; it may also have clinical consequences including side effects such as galactorrhea, amenorrhea, reduced libido and reduced bone density. During treatment with haloperidol, prolactin levels increase in the plasma
c07.fm Page 109 Wednesday, October 19, 2005 9:14 AM
Haloperidol and Risperidone
109
over the course of 14 days, with a pattern of rise similar to the timecourse of clinical improvement. However, more detailed analysis using intravenous “test doses” of haloperidol, shows an initial rise in serum prolactin levels, which is partly transient after the first intravenous dose and cannot be exceeded by giving larger doses of haloperidol (Cookson et al., 1983). This is followed by a gradual rise during the following 2–4 weeks. Within two weeks, prolactin secretion by the pituitary becomes sensitive over a wider range of doses of haloperidol than in the drug-naive patient. These compensatory changes, in the control of prolactin secretion, are thought to include changes in the level of dopamine in the portal pituitary blood supply during prolonged treatment with haloperidol. If similar compensatory changes occur in the DA pathways of the limbic system, doses of haloperidol that are effective in the drug-naive manic patient may not be sufficient to control patients in later stages of mania, who have received prolonged treatment with antipsychotic drugs.
ANTIPSYCHOTICS AS MOOD STABILIZERS Antipsychotic drugs are used extensively in the maintenance treatment of bipolar patients (Sernyak et al., 1994; Sernyak and Woods, 1998; Cookson and Sachs, 1999; Cookson, 2001). For patients who are unresponsive to lithium (and anticonvulsants), and particularly for those whose compliance with oral medication is poor, depot formulations of antipsychotic drugs including haloperidol decanoate have the advantage of providing a sustained and reliable delivery of a drug for periods of weeks. For rapid cycling bipolar patients, the depot antipsychotic haloperidol decanoate stabilized mood swings (Lowe and Batchelor, 1990). In a minority of bipolar outpatients, depot antipsychotic medication is used and can reduce the time spent in both manic and depressed phases (Littlejohn, Leslie and Cookson, 1994).
RISPERIDONE Atypical antipsychotic drugs may be classified according to the breadth of their pharmacological activity. The term “Serotonin and Dopamine Receptor Antagonist” (SDRA) is used to describe risperidone, ziprasidone and sertindole. All three are structurally similar to haloperidol with its central ringed (piperidine) nitrogen. 5HT-2A receptors facilitate excitatory effects on cortical and other neurones. Risperidone is an antagonist as are many other atypical antipsychotics including clozapine, olanzapine, zotepine and ziprasidone, but not sulpiride or amisulpride. 5HT-2A antagonists increase slow-wave sleep and decrease paradoxical (REM) sleep; they may also reduce anxiety. They have interesting effects to restore DA cell firing
c07.fm Page 110 Wednesday, October 19, 2005 9:14 AM
110
Bipolar Psychopharmacotherapy
and increase dopamine release; this may lead to less EPSE, less cognitive impairment and less reduction of drive as compared with the classical antipsychotics.
PHARMACOLOGY Risperidone (Risperdal) is a benzizoxazole. It resembles clozapine in that it is a potent 5HT-2A and D2 antagonist, but differs in that it has less affinity for D3 and D4 receptors. It also blocks H1, NA alpha-1 and alpha-2 but not ACh receptors. It is effective in schizophrenia, with a much lower incidence of extrapyramidal side effects than haloperidol. With oral risperidone, doses of 2–6 mg/day occupy 65–80% of the D2 receptors in the basal ganglia visualized by raclopride; higher doses occupy more than 80% of the receptors and are liable to produce EPSE. Using labeled setoperone to visualize 5-HT-2 receptors, it is known that even the lowest therapeutic doses, such as 2 mg of risperidone, produce substantial blockade of 5-HT-2 receptors in the brain, approaching saturation.
PHARMACOKINETICS Risperidone is metabolized partly by liver hydroxylase (CYP IID6) and has an active metabolite hydroxyrisperidone with similar pharmacological properties that is excreted by the kidneys. The combined half-life is said to be about 24 hours. About 7–10% of Caucasians have low levels of this enzyme and are slow metabolizers of risperidone. They can be detected by their slow metabolism of debrisoquine or dextromethorphan. Some drugs inhibit the hydroxylase enzymes – for instance phenothiazines, fluoxetine and paroxetine – leading to increases in the level of risperidone but lower levels of hydroxyrisperidone. However, carbamazepine induces liver enzymes and reduces serum levels of many commonly employed drugs, including haloperidol and risperidone (Yatham et al., 2003).
RISPERIDONE LONG ACTING INJECTION Although the metabolite could be esterified to produce a depot formulation, this has not been developed. Instead there is a long acting intramuscular injection (Risperdal Consta), based on encapsulation of risperidone in microspheres of a biodegradable polymer, glycolic acid-lactate, that is also used for sutures. Gradual hydrolysis of the polymer at the site of injection gives a slow release of risperidone, beginning three weeks after the first injection, achieving optimal blood levels between 4 and 6 weeks. A dose of up to 50 mg is given as an aqueous suspension, every two weeks, being equivalent to up to 4 mg oral risperidone daily. However, as the injected form
c07.fm Page 111 Wednesday, October 19, 2005 9:14 AM
Haloperidol and Risperidone
111
avoids first-pass metabolism in the liver it is difficult to state a bio-equivalent dose with confidence.
CLINICAL EFFECTS OF RISPERIDONE In chronic schizophrenia with persistent symptoms it provides a slightly greater overall improvement than older antipsychotics. However, these advantages are greatest in a narrow range of doses, 1–8 mg daily (Marder and Meibach, 1994; Peuskens et al., 1995). The advantage over haloperidol on negative symptoms in schizophrenia is due in part to the lesser incidence of extrapyramidal side effects, and greater improvement in depression. Comparisons with haloperidol have also shown that risperidone produces greater cognitive improvement, so that attention and working memory improve. It is also associated with less severe depressive symptoms during short-term follow-up. Risperidone produces less impairment of working memory than haloperidol, but longstanding deficits remain. Risperidone is associated with less depression than haloperidol, during follow up in schizophrenia.
ADVERSE EFFECTS Postural hypotension and mild sedation can be avoided by increasing the dose gradually. Reports of cerebrovascular events in elderly patients on risperidone have led to a special warning by the FDA. At doses above 6mg/day there is an increasing incidence of EPSE. Weight gain occurs to a greater extent than with haloperidol, and occasionally impairment of ejaculation or orgasm, and blurred vision. Risperidone blocks D2 receptors in the pituitary and increases prolactin levels to a slightly greater extent than haloperidol. There is a correlation between raised prolactin levels and reduced libido (Kleinberg etal., 1999). Risperidone produces less tardive dyskinesia than classical antipsychotics in the elderly. A slight increase in the incidence of diabetes in patients with schizophrenia under the age of 40 treated with risperidone has been observed (Sernyak et al., 2002). It remains to be seen whether weight gain and metabolic changes including hyperglycemia are also problems to the same extent in the treatment for bipolar disorder.
RISPERIDONE IN MANIA AND HYPOMANIA Interest in antipsychotics in mania includes their ability to not only improve and control mania and hypomania but also avoid subsequent ‘post-manic’ depression, as well as their ability to maintain improvement after remission of mania and prevent further recurrences of mania or of depression. It is also important to know how their profile of side effects compares with older antipsychotics,
c07.fm Page 112 Wednesday, October 19, 2005 9:14 AM
112
Bipolar Psychopharmacotherapy
particularly regarding acute extrapyramidal side effects but also later tardive dyskinesia. Evidence for the use of risperidone in bipolar disorder is available from open series, double-blind comparative trials, and – most revealingly of all – from placebo-controlled comparisons. Risperidone improves mania in patients with AIDS, who are particularly sensitive to developing extrapyramidal side effects with typical antipsychotics (Singh, Golledge and Catalan, 1997). Several open series attest to the efficacy of risperidone in mania (Tohen et al., 1996; Licht, Bysted and Christensen, 2001; Vieta et al., 2002). In a comparative trial in mania, in which additional lorazepam was permitted, risperidone was of similar efficacy to haloperidol or lithium (Segal, Berk and Brook, 1998). An open study of 44 bipolar II patients with hypomania followed them for 6 months; it found an improvement in mania, and only 4% had a relapse of hypomania, but 14% had a depressive recurrence (Vieta et al., 2001).
PLACEBO-CONTROLLED DESIGN To prove the efficacy of a drug in a psychiatric condition, it is essential to conduct randomized double-blind placebo-controlled trials. The challenges of conducting such trials in mania have only been met in recent years, and in the course of developing novel anticonvulsant and atypical antipsychotic treatments. These recent trials are therefore providing answers to questions that have long remained unresolved about the treatment for bipolar disorder. Analysis of the results of these trials requires attention not only to the statistical significance of differences in special rating scales, but also to the size of the effect, and to the generalizability of results based on highly selected patients in clinical trial centers to other groups of patients with mania in routine practice. It is also important to consider how dropouts from the studies may have biased the interpretation of results.
PLACEBO-CONTROLLED MONOTHERAPY TRIALS OF RISPERIDONE There have been three parallel-group randomized placebo-controlled trials of risperidone in mania (Hirschfeld et al., 2004; Smulevich et al., 2005; Khanna et al., 2005). Table 7.1 displays these studies using a “Number Needed to Treat” (NNT) analysis and showing the dropouts rates for reasons of adverse events, lack of efficacy and other reasons. The NNT is calculated by dividing the difference in response rate of active drug and placebo into 100 and correcting to the next highest integer. It represents the number of patients who must be treated in order for one patient to achieve the defined response (usually a 50% reduction in rating scale score) as a result of the pharmacological effect of the drug. The NNT thus provides a measure of the
2.1 4
14.6 3
50% reduction YMRS
DSM-IV Manic 3 weeks Extended to YMRS ≥ 20 12 weeks without placebo Smulevich et al. MADRS ≤ 20 (2005) International LZP, chloral or diazepam for 10 days
3.4
4.8
DSM-IV Manic or mixed YMRS ≥ 20
Risperidone N = 154 Mean modal 4.2 mg/day
6
36
50% reduction in YMRS
3 weeks Khanna et al. (2005) India LZP for 10 days
8
14
3 weeks Hirschfeld et al. DSM-IV Manic (2004) USA YMRS ≥20 LZP for 10 days MADRS ≤ 20
4
12.5
2.8
16
22
48
36
73
24
43
15
37
19
7 (4–26)
3 (2–4)
6 (4–13)
Difference Other Dropouts Inclusion criteria Dropouts for Inefficacy for Adverse Dropouts Response from Criterion for placebo Number-Needed-To-Treat % % events % % Response
Risperidone N = 146 Mean modal 5.6 mg/day Placebo N = 144
Risperidone N = 134 Mean modal 4.1 mg/day Placebo N = 125
Treatment Mean Dose/day Numbers Duration Authors for ITT Sites Extra drugs
Table 7.1: Placebo-controlled parallel-group randomized trials of monotherapy with risperidone or haloperidol in mania
c07.fm Page 113 Wednesday, October 19, 2005 9:14 AM
10.1
10.1
5.9
28.7
Haloperidol N = 98 Mean day 21: 5.2 mg/day
4.9
17.6
Quetiapine N = 102 Responders day 21: Mean 559 mg/day Placebo N = 100 DSM-IV Manic YMRS ≥ 20 50% reduction YMRS
3
1
Haloperidol N = 144 Mean modal 8 mg/ day
3 weeks extended to 12 weeks) McIntyre et al. (ECNP), 2005 LZP for 10 days Hypnotics for insomnia
5
6
25.3
23.9
23.5
6
8 (4–36)
3/52: 7 3/52: NSD 15 (−16 to +5) 12/52: 21 12/52: 5 (3–14)
14
3/52: 55 3/52: 20 3/52: 5 (3–16) 12/52: 70 12/52: 31 12/52: 4 (3–6)
3/52: 35 12/52: 39
3/52: 42 12/52: 60
47
33
50% reduction YMRS
Placebo N = 140 4
Difference Other Dropouts Inclusion criteria Dropouts for Inefficacy for Adverse Dropouts Response from Criterion for placebo Number-Needed-To-Treat % % events % % Response
Treatment Mean Dose/day Numbers Duration Authors for ITT Sites Extra drugs
Table 7.1: (Continued)
c07.fm Page 114 Wednesday, October 19, 2005 9:14 AM
c07.fm Page 115 Wednesday, October 19, 2005 9:14 AM
Haloperidol and Risperidone
115
size of effect that can be expected of the drug in a clinical situation. For a drug to be useful monotherapy as a first-line treatment in a common and severe disorder such as mania, the NNT for 50% improvement in severity should be in the order of 2–4 (Cookson, Taylor and Katona, 2002b). All three studies were of 3 weeks duration and there was a placebo response rate of 24–36%, reflecting the effects of a variety of possible non-specific factors such as hospitalization, extra medication with benzodiazepines or chloral allowed during the first 10 days, and bias in the raters. In the trial of Hirschfeld et al. (2004), the dose of risperidone was increased gradually over 4 days to a maximum of 6 mg/day, and was effective compared with placebo from day 3. However, the NNT was 6 (95% confidence interval 4–13). Side effects on risperidone were somnolence (28% vs 7% on placebo) and hyperkinesias (Parkinsonism) in 16% vs 5%. The study by Khanna et al. (2005) was conducted in India, and was distinguished by relatively high YMRS scores on entry (about 10 points higher than in most other studies of atypical antipsychotics in mania), and by a high rate of study completion on risperidone with low dropout rates particularly for lack of efficacy. Although having the same protocol for increase in dose, the mean modal dose in this study was higher (5.4 mg/day). The rate of response on risperidone was highest in this study and the NNT was impressively low at 3 (95% confidence interval 2–4). Initial depression scores were already low but improved further, the change being greater on risperidone than placebo even by day 3. Extrapyramidal side effects occurred in 35% of those on risperidone, and 6% on placebo. The study by Smulevich et al. (2005) was conducted at international centers and allowed a slightly slower dosing schedule reaching a maximum of 6 mg/day by day 5. This study also had a haloperidol comparator group with a mean modal dose of 8mg/day (Table 7.1). Both active drugs were effective compared with placebo from day 7. By day 21 the NNT for 50% improvement was 7 (95% confidence interval 4–26) for risperidone and similar for haloperidol at 8 (95% confidence interval 4–36). MADRS depression scores, low at the start, fell more on risperidone than on placebo from week 1, and on haloperidol only at week 2. Side effects on risperidone included extrapyramidal symptoms (17% compared with 40% on haloperidol). In all three of these studies, the improvement in mania occurred in patients with or without psychotic symptoms. In the studies of Khanna et al. and of Smulevich et al., the improvement on active treatments was continuing to develop during the third week of treatment; the extension to 12 weeks in the Smulevich study demonstrated further improvement in YMRS scores with active treatment up to 12 weeks, suggesting that the dose initially administered may not have been sufficient to achieve maximum improvement. On the other hand, in the study of Hirschfeld et al., the improvement appeared to be complete within 2–3 weeks. Risperidone, possibly in a dose-related manner (Aubrey, Simon and Bertsky, 2000), has been described as worsening or precipitating mania in predisposed
c07.fm Page 116 Wednesday, October 19, 2005 9:14 AM
116
Bipolar Psychopharmacotherapy
patients, mainly those with schizophrenia, schizoaffective disorder or organic brain disease. No evidence of such exacerbation of mania was found in these placebo-controlled trials of risperidone.
PLACEBO-CONTROLLED MONOTHERAPY TRIALS OF HALOPERIDOL IN MANIA Two of the recent monotherapy studies of atypical antipsychotics in mania have included haloperidol as an active comparator (see Table 7.1): the risperidone study of Smulevich et al. (2005), and the quetiapine study of McIntyre et al. (2005). In the study of Smulevich etal. (2005) reviewed, the haloperidol dose started at 4mg/day and was adjusted to 2–12mg/day by day 5. The timecourse of improvement was similar to that with risperidone, and by day 21 the NNT was 8 (95% confidence interval 4–36), far larger than one would usually associate with the most commonly used antimanic drug of the previous decade; this might be because the mean modal dose of haloperidol was only 8mg/day or because the patients in the trial were in some way not typical of routine clinic patients and more resistant to treatment. Finally, a comparator group on haloperidol (up to 8 mg/day) was included in the study reported by McIntyre etal. (2005) of quetiapine (up to 800mg/day) and placebo, analyzed at 3 and 12 weeks. At 3 weeks the response rate (50% reduction in YMRS score) on haloperidol, on a mean dose of only 5.2mg/day, was 55% compared with 35% on placebo, giving an NNT of 5 (95% confidence interval 3–16). There were more dropouts on placebo than on haloperidol or quetiapine, so that the analysis using last observations carried forward was biased in favor of the active drugs, and especially so after three weeks when more patients on placebo or haloperidol than on quetiapine dropped out. By 12 weeks the response rate on haloperidol was 70% and on placebo 39%, giving an NNT of 4 (3–6). Depression scores (MADRS) improved by day 21 on both quetiapine and haloperidol more than on placebo. On the other hand, the switch rates into depression were similar for haloperidol (8.1%) and placebo (8.9%), and tended to be lower for quetiapine (2.9%). Side effects in the form of extrapyramidal symptoms were much more common on haloperidol (59.6%) than on placebo (15.8%), as was akathisia (33.3% on haloperidol and 5.9% on placebo). Somnolence occurred more often with haloperidol (9.1%) than placebo (5%).
TRIALS OF COMBINATION THERAPY USING RISPERIDONE OR HALOPERIDOL WITH A “MOOD STABILIZER” (LITHIUM, VALPROATE OR CARBAMAZEPINE) Two studies of risperidone (1–6 mg daily) added for 3 weeks to treatment with lithium or valproate (or carbamazepine in one study) have demonstrated an
c07.fm Page 117 Wednesday, October 19, 2005 9:14 AM
Haloperidol and Risperidone
117
advantage of risperidone over placebo (Sachs et al., 2002; Yatham et al., 2003). The NNTs for the combination of risperidone or haloperidol with “mood stabilizers” (lithium or valproate) are tabulated in Table 7.2. These large studies included 156 and 150 patients respectively and the former included a group on haloperidol (2–12 mg/day). In both studies, the antipsychotics (risperidone or haloperidol) were effective in patients with or without psychotic features. There was no evidence of worsening of mania by risperidone. In the study of Sachs et al. (2002), response rates based on a Clinical Global Impression (CGI-I) of much or very much improvement were 30% on mood stabiliser plus placebo and 53% on combination of mood stabilizer with risperidone (in a mean modal dose of only 3.8 mg/day); this difference corresponds to an NNT of 5 (95% confidence interval 3–23) for response to risperidone. Combination with haloperidol (mean modal dose 6.2 mg/day) and lithium or valproate showed an NNT of 5 (95% confidence interval 3–64). The higher total dropout rate on haloperidol (53%) than on risperidone (35%) or placebo combination (49%) would bias the analysis of efficacy against this drug. Of all the patients, 63% had already received lithium or valproate before randomization to risperidone or placebo, and might therefore be considered non-responders to the mood stabilizer; the rest commenced on lithium or valproate at the same time as being randomized to start on risperidone or placebo. The benefit of additional antipsychotic medication was much less apparent in the latter group. Significant improvement in response to either risperidone or haloperidol was limited to patients with pure mania and was not evident in those with mixed manic states, who comprised 21% of patients. No patients achieved a CGI rating of very much improved on lithium or valproate plus placebo, but 25% of those receiving additional risperidone did so, as did 16% of those receiving additional haloperidol. A rating scale for depression was not used. Although dropouts due directly to side effects were few in all groups (2–4%), among patients receiving haloperidol plus lithium or valproate, 28% reported extrapyramidal side effects and 38% received antiparkinsonian medication, compared with 13% and 17% on risperidone in combination, and 4% and 8% on placebo in combination with lithium or valproate. Weight gain was greater on risperidone than on haloperidol or placebo, plus mood stabilizer. Somnolence was slightly more common on haloperidol (30%) than on risperidone (25%) or on placebo (12%), plus mood stabilizer. The international study of Yatham et al. (2003) used a similar design, but allowed carbamazepine as one of the “mood stabilizers.” The mean modal dose of risperidone was 4 mg/day. Unfortunately, carbamazepine was associated with a 40% reduction in blood levels of risperidone and its active metabolite, thus reducing the overall power of the study to detect benefits of risperidone. Nevertheless, the proportion of patients (59%) responding (with a 50% improvement in YMRS) on risperidone plus lithium, valproate or carbamazepine was greater than for mood stabilizer plus placebo (41%), with an NNT of 6 (95% confidence interval 3–56).
Manic or mixed YMRS ≥ 20 CGI much or very much improved
Combination with Valproate N = 69 50% less antipsychotics 3 weeks Placebo N = 67 Y-MRS Muller-Oerlinghausen et al. (2000)
Haloperidol 6.2 mg/day N = 53 Placebo N = 51 Risperidone 3.8 mg/day N = 52
Sachs et al. (2002) Combination with Li or valproate 3 weeks USA Benzodiazepines for sleep, LZP 4 mg/day for 7 days 9 13
4 4
10 6 1 3
2
6
36 (all reasons) 52 (all reasons)
35 25
45
70 46
30 53
50
41
59
24
23
20
18
5 (3–13)
5 (3–23)
5 (3–64)
6 (3–56)
Inclusion criteria Dropouts Dropouts Other Difference Number-Needed-to-Treat Criterion of for for Adverse Dropouts Response from Response Inefficacy % Events % % % placebo % (95% C.I.) Manic or mixed YMRS ≥ 20 50% less Y-MRS
Treatments Mean modal dose Numbers
Risperidone Yatham et al. (2003) 4.0 mg/day N = 69 Combination with Li, valproate or Placebo N = 73 carbamazepine 3 weeks International Benzodiazepines, LZP 4 mg/day for 7 days
Authors Treatment Duration Sites Extra drugs
Table 7.2: NNTs for combination of risperidone or haloperidol with “mood stabilizer” (lithium or valproate)
c07.fm Page 118 Wednesday, October 19, 2005 9:14 AM
c07.fm Page 119 Wednesday, October 19, 2005 9:14 AM
Haloperidol and Risperidone
119
The advantage of risperidone over placebo was far more evident in those who had already been on a mood stabilizer for at least two weeks before randomization, than in those who started the mood stabilizer shortly before starting risperidone or placebo. Response to risperidone was independent of the presence or absence of psychotic symptoms. Side effects related to extrapyramidal symptoms were commoner on risperidone plus mood stabilizer (21%) than on placebo plus mood stabilizer (8%). Conversely, in a 3-week study with 136 patients, the addition of valproate to classical antipsychotics (mainly haloperidol) has been shown to produce greater improvement than addition of placebo (Muller-Oerlinghausen et al., 2000), where 70% improved (at least 50% reduction in Y-MRS score) compared with 46% on antipsychotic plus placebo (NNT = 5; 95% CI 3–13).
RAPID CYCLING There is no mention of rapid cycling in any of the placebo-controlled studies of risperidone reviewed earlier. However, open studies suggest risperidone may be of benefit (Vieta et al., 1998), and a chart review suggested that risperidone, usually as augmentation to lithium or valproate, was beneficial in a group of 25 patients (Coconcea et al., 2003).
PHARMACOECONOMICS McGarry etal. (2003) conducted a cost-effectiveness analysis of atypical antipsychotics and competing treatment strategies in the treatment for mania, employing published costs and probabilities of outcomes, and the standard-gamble method to estimate total quality-adjusted life-years (QALY). Although haloperidol plus mood stabilizer was the least costly treatment strategy, risperidone plus mood stabilizer cost an additional £1000 per QALY. This compares with the customary threshold of £30 000 per QALY to justify new treatments.
CONCLUSIONS There is now overwhelming evidence from clinical trials that risperidone has antimanic properties, and that these are of a similar order of magnitude to the antimanic action of haloperidol but entail a much lower rate of extrapyramidal side effects. Although the trials do not show that patients on haloperidol are more likely to drop out through recognized adverse events than patients on risperidone, troublesome extrapyramidal side effects occur in the majority of patients on haloperidol and require treatment with additional anticholinergic medication. Risperidone is associated with greater weight gain than haloperidol, but whether
c07.fm Page 120 Wednesday, October 19, 2005 9:14 AM
120
Bipolar Psychopharmacotherapy
this is clinically important in bipolar disorder, as it can be in schizophrenia, remains to be seen. The trials showed that the antimanic effects of both risperidone and haloperidol were independent of whether the patients had psychotic symptoms. Therefore the trials justify the conclusion that these drugs are “antimanic” as well as antipsychotic (Cookson, 2001). Only one of the trials (Khanna et al., 2005) demonstrated a size of effect for risperidone that would be desirable for a first-line monotherapy in mania with NNT of 3 (95% confidence interval 2–4). However, in these studies, the “gold standard” antimanic drug haloperidol had a rather small effect size with NNTs of 5 and 8, perhaps reflecting that the patients taking part in the trials were resistant to treatment, or that inadequate doses of haloperidol were used in the trials. Many patients with mania will require combination treatment with an antipsychotic and lithium or valproate. The trials of such combination therapy with risperidone indicate that for patients who have not responded to two weeks treatment with lithium or valproate, additional treatment with risperidone conveys further efficacy. The NNT for this improvement is rather large (about 5), but the trials include patients who started on the antipsychotic and mood stabilizer at the same time. These trials did not provide evidence to support commencing patients with mania on a combination of antipsychotic with lithium or valproate, if their responsiveness to individual drug treatments is not already known. There is no evidence that treatment for mania with risperidone leads to less post-manic depression than treatment with haloperidol, but this phenomenon has not been fully explored. Further clinical trials are needed to elucidate a role for risperidone beyond the phase of acute mania. Studies, with a more pragmatic or naturalistic design, are needed to establish the role of risperidone in routine clinical practice.
REFERENCES Aubrey, A. M., Simon, A. E. and Bertsky, C. (2000) Possible induction of mania and hypomania by olanzapine or risperidone: a critical review of reported cases. Journal of Clinical Psychiatry, 61, 649–655. Batchelor, D. H. and Lowe, M. R. (1990) Reported neurotoxicity with the lithium/ haloperidol combination and other neuroleptics – a literature review. Human Psychopharmacology, 5, 275–280. Bowden, C. L., Brugger, A. M., Swann, A. C., et al. (1994) Efficacy of Divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. Journal of the American Medical Association, 271, 918–924. Busch, F. N., Miller, F. T. and Weiden, P. J. (1989) A comparison of two adjunctive treatment strategies in acute mania. Journal of Clinical Psychiatry, 50, 453–455. Chou, J. C., Zito, J. M., Vitrai, J., et al. (1996) Neuroleptics in acute mania: A pharmacoepidemiologic study. Annals of Pharmacotherapy, 30, 1396–1398.
c07.fm Page 121 Wednesday, October 19, 2005 9:14 AM
Haloperidol and Risperidone
121
Coconcea, C, Shelton, M. D., Delgado, P., Amawi, L., and Calabrese, J. R. (2003) Risperidone augmentation in rapid cycling bipolar disorder. Poster presentation: Fifth International Conference on Bipolar Disorder, Pittsburg. Cookson, J. C. (2001) Use of Antipsychotic Drugs and Lithium in Mania. British Journal of Psychiatry, 178, Suppl. 41: s148–s156. Cookson, J. C. and Sachs, G. S. (1999) Lithium: Clinical use in mania & prophylaxis of affective disorders. In: Schizophrenia and Mood Disorders: The New Drug Therapies in Clinical Practice, eds P. F. Buckley and J. L. Waddington, Butterworth-Heinemann, Oxford. Cookson, J. C., Silverstone, T. and Wells, B. (1981) A double-blind comparative clinical trial of pimozide and chlorpromazine in mania: A test of the dopamine hypothesis. Acta Psychiatrica Scandinavica, 64, 381–397. Cookson, J. C., Moult, P. J. A., Wiles, D., et al. (1983) The relationship between prolactin levels and clinical ratings in manic patients treated with oral and intravenous test doses of haloperidol. Psychological Medicine, 13, 279–285. Cookson, J. C., Silverstone, T., Williams, S., et al. (1985) Plasma cortisol levels in mania: Associated clinical ratings and change during treatment with haloperidol. British Journal of Psychiatry, 146, 498–502. Cookson, J. C., Taylor, D., Katona, C. (2002a) Chapter 14. Violence: Assessing Risk And Acute Tranquillisation. In Use of Drugs in Psychiatry: The Evidence From Psychopharmacology, pp. 117–131. Gaskell Press, London. Cookson, J. C., Taylor, D., Katona, C. (2002b) Chapter 5. Placebo Effects, Evaluating Evidence, And Combining Psychotherapy. In Use of Drugs in Psychiatry: The Evidence From Psychopharmacology, pp. 117–131. Gaskell Press, London. Garfinkel, P. E., Stancer, H. C. and Persaud, E. (1980) A comparison of haloperidol, lithium carbonate and their combination in the treatment of mania. Journal of Affective Disorders, 2, 279–288. Hirschfeld, R., Keck, P. E., Karcher, K., Kramer, M., Canuso, C., Eerdekens, M. and Grossman, F. (2004) Rapid antimanic effect of risperidone monotherapy: A 3-week multicenter, double-blind, placebo-controlled trial. American Journal of Psychiatry, 161, 1057–1065. Khanna, S., Vieta, E., Lyons, B., Grossman, F., Eerdekens, M. and Kramer, M. (2005) Risperidone in the treatment of acute mania: Double-blind, placebo-controlled study. British Journal of Psychiatry, 187, 229–234. Kleinberg, D. C., Davis, J. M., De Coster, R. et al. (1999). Prolactin levels and adverse events in patients treated with risperidone. Journal of Clinical Psychopharmacology, 19, 57–61. Lenox, R. H., Newhouse, P. A., Creelman, W. L., et al. (1992) Adjunctive treatment of manic agitation with lorazepam versus haloperidol: A double-blind study. Journal of Clinical Psychiatry, 53, 47–52. Licht, R. W., Bysted, M. and Christensen, H. (2001) Fixed-dose risperidone in mania: an experimental trial. International Clinical Psychopharmacology, 16, 193–110. Littlejohn, R., Leslie, F. and Cookson, J. (1994) Depot antipsychotics in the prophylaxis of bipolar affective disorder. British Journal of Psychiatry, 165, 827–829. Lowe, M. R. and Batchelor, D. H. (1990) Lithium and neuroleptics in the management of manic-depressive psychosis. Human Psychopharmacology, 5, 267–274. Marder, S. R. and Meibach, R. C. (1994) Risperidone in the treatment of schizophrenia. American Journal of Psychiatry, 151, 825–835.
c07.fm Page 122 Wednesday, October 19, 2005 9:14 AM
122
Bipolar Psychopharmacotherapy
McGarry, L., Bird, A. P., Thompson, D., Cookson, J., Martin, S. C., and Weinstein, M. C. (2003) Cost-effectiveness of atypical antipsychotics for treatment of acute mania in the UK. Poster 1.203 at European College of Neuropsychopharmacology (ECNP) Meeting, Prague. McIntyre, R. S., Brecher, M., Paulsson, B., Huizar, K. and Mullen, J. (2005) Quetiapine or haloperidol as monotherapy for bipolar mania: A 12-week, double-blind, randomised, parallel-group, placebo-controlled trial. European Neuropsychopharmacology, 15, 573–585. Muller-Oerlinghausen, B., Retzow, A., Henn, F. A., Giedke, H., Walden, J. (2000) Valproate as an adjunct to neuroleptic medication for the treatment of acute episodes of mania: A prospective, randomized, double-blind, placebo-controlled, multicentre study. Journal of Clinical Psychopharmacology, 20, 195–203. Peroutka, S. J. and Snyder, S. H. (1980) Relationship of neuroleptic drug effects at brain dopamine, serotonin, alpha-adrenergic, and histamine receptors to clinical potency. American Journal of Psychiatry, 137, 1518–1522. Peuskens, J. and the Risperidone Study Group (1995) Risperidone in the treatment of patients with chronic schizophrenia: A multi-national, multi-centre, double-blind, parallelgroup study versus haloperidol. British Journal of Psychiatry, 166, 712–726. Post, R. M., Jimerson, D. C., Bunney, W. F., et al. (1980) Dopamine and mania: Behavioural and biochemical effects of the dopamine receptor blocker pimozide. Psychopharmacology, 67, 297–305. Prien, R. F., Caffey, E. M. and Klett, C. J. (1972) Comparison of lithium carbonate and chlorpromazine in the treatment of mania. Archives of General Psychiatry, 26, 146–153. Rifkin, A., Doddi, S., Karajgi, B., et al. (1994) Dosage of haloperidol for mania. British Journal of Psychiatry, 165, 113–116. Royal College of Psychiatrists (1998) Management of Imminent Violence. Clinical practice guidelines to support mental health services. Occasion paper OP41. London: The Royal College of Psychiatrists. Sachs, G. S., Grossman, F., Ghaemi, S. N., Okamoto, A. and Bowden, C. L. (2002) Combination of a Mood Stabilizer With Risperidone or Haloperidol for Treatment of Acute Mania: A Double-Blind, Placebo-Controlled Comparison of Efficacy and Safety. American Journal Psychiatry, 159, 1146–1154. Segal, J., Berk, M. and Brook, S. (1998) Risperidone compared with both lithium and haloperidol in mania: a double blind randomized controlled trial. Clinical Neuropharmacology, 21, 176–180. Sernyak, M. J. and Woods, S. W. (1998) Chronic neuroleptic use in manic-depressive illness. Psychopharmacology Bulletin, 29, 375–381. Sernyak, M. J., Griffin, R. A., Johnson, R. M., et al. (1994) Neuroleptic exposure following inpatient treatment of acute mania with lithium and neuroleptic. American Journal of Psychiatry, 151, 133–135. Sernyak, M. J., Leslie, D., Alarcon, R. D., Losonczy, M. F. and Rosenheck, R. (2002) Association of Diabetes Mellitus With Use of Atypical Neuroleptics in the Treatment of Schizophrenia. American Journal of Psychiatry, 159, 561–566. Shopsin, B., Gershon, S., Thompson, H., et al. (1975) Psychoactive drugs in mania: a controlled comparison of lithium carbonate, chlorpromazine, and haloperidol. Archives of General Psychiatry, 32, 34–42. Singh, A. N., Golledge, H. and Catalan, J. (1997) Treatment of HIV-related psychotic disorders with risperidone: A series of 21 cases. Journal of Psychosomatic Research, 42, 489–493.
c07.fm Page 123 Wednesday, October 19, 2005 9:14 AM
Haloperidol and Risperidone
123
Smulevich, A. B., Khanna, S., Eerdekens, M., Kramer, M. and Grossman, F. (2005) Acute and continuation risperidone monotherapy in bipolar mania: A 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol. European Neuropsychopharmacology, 15, 75–84. Szabadi, E., Gaszner, P. and Bradshaw, C. M. (1981) An investigation of the alphaadrenoceptor blocking properties of neuroleptics in the human iris in vivo. British Journal of Clinical Pharmacology, 11, 416–417. Tohen, M., Zarate, C. A., Centorrino, Hegarty, J. I., Froeschl, M. and Zarate, S. (1996) Risperidone in the treatment of mania. Journal of Clinical Psychiatry, 57, 249–253. Tohen, M., Goldberg, J. F., Gonzalez-Pinto, A. M., Azorin, J. M., Vieta, E., Hardy-Bayle, M. C., Lawson, W. P., Emsley, R. A., Baker, R. W., Risser, R. C., Namjoshi, M. A., Evans, A.R., Breier, A. (2003) A 12-week double-blind comparison of olanzapine versus haloperidol in the treatment of acute mania. Archives of General Psychiatry, 60, 1218–1226. Vieta, E., Gasto, C., Colom, F. et al. (1998) Treatment of refractory rapid cycling bipolar disorder with risperidone. Journal of Clinical Psychopharmacology, 18, 172–174. Vieta, E., Gasto, C., Colom, F., Reinares, M., Martinez-Aran, A., Benabarre, A. and Akiskal, H.S. (2001) Role of risperidone in bipolar-II: An open 6-month study. Journal of Affective Disorders, 67, 213–219. Vieta, E., Herraiz, M., Parramon, G. et al. (2002) Risperidone in the treatment of mania: Efficacy and safety results from a large, multicentre, open study in Spain. Journal of Affective Disorders, 72, 15–19. Yatham, L. N., Grossman, F., Augustyns, I., Vieta, E. and Ravindran, A. (2003) Mood stabilisers plus risperidone or placebo Mood stabilisers plus risperidone or placebo in the treatment of acute mania in the treatment of acute mania: International, double-blind, randomised controlled trial. British Journal of Psychiatry, 182, 141–147.
c19.fm Page 367 Wednesday, October 19, 2005 9:59 AM
c08.fm Page 125 Wednesday, October 19, 2005 9:15 AM
CHAPTER
8 A Comparison of “Second Generation Antipsychotics” in the Treatment for Bipolar Disorder: Focus on Clozapine, Quetiapine, Ziprasidone and Aripiprazole Paul E. Keck, Jr. and Susan L. McElroy Department of Psychiatry, University of Cincinnati College of Medicine, USA
INTRODUCTION The term “second generation antipsychotics” in this chapter refers to antipsychotics introduced after the classical neuroleptics. The concept as to what is an “atypical antipsychotic” is not without controversy. As these agents exert more than antipsychotic action for these disorders, the term “antipsychotic” in the rubric of “atypical antipsychotic” has been questioned. These are clearly agents with broad efficacy, and in the absence of better terminology, we are using “second generation atypical antipsychotics” to classify the three agents reviewed in this chapter – beyond the classic neuroleptics – with evidence for clinical utility in bipolar disorders. In the early 1990s, several reports suggested that the prototypical atypical antipsychotic, clozapine, had therapeutic efficacy in patients with treatmentrefractory bipolar disorder (McElroy et al., 1991; Banov et al., 1994; Kimmel et al., 1994; Zarate et al., 1995a,b). In these reports, clozapine appeared to be exerting mood-stabilizing effects with sustained treatment, beyond the unimodal antimanic effects which were commonly observed with typical antipsychotics (neuroleptics). Moreover, favorable responses to clozapine were reported across a spectrum of presentations of bipolar disorder, including in nonpsychotic, Bipolar Psychopharmacotherapy: Caring for the Patient Edited by Hagop S. Akiskal and Mauricio Tohen # 2006 John Wiley & Sons, Ltd ISBN: 0-470-85607-6
c08.fm Page 126 Wednesday, October 19, 2005 9:15 AM
126
Bipolar Psychopharmacotherapy
mixed and rapid cycling patients (Suppes et al., 1992, 1994). Subsequent reports have continued to suggest that clozapine may be efficacious in patients with treatmentrefractory bipolar disorder (Calabrese et al., 1996; Mahmood et al., 1997; Ciapparelli et al., 2000, 2003; Green et al., 2000). Since these observations, there has been considerable interest in the thymoleptic profiles and potential therapeutic role of subsequently developed atypical or second generation antipsychotics (SGAs) in bipolar disorder (McElroy and Keck, 2000). In addition to these initial observations regarding clozapine’s efficacy, two other lines of evidence supported the examination of SGAs in bipolar disorder: (1) their distinct pharmacological properties predictive thymoleptic activity; and, (2) reports of improvement in mood symptoms in clinical trials of these agents in patients with schizophrenia and schizoaffective disorder (Hillert, Maier and Wetzel, 1992; Keck et al., 1994, 2001; Frye et al., 1998; Muller-Siecheneder et al., 1998; Janicak et al., 2001; Sajatovic et al., 2002). In this chapter, we review the pharmacological mechanisms of SGAs associated with thymoleptic activity and the evidence of their efficacy from randomized, controlled clinical trials in acute bipolar mania, depression, and as maintenance therapy for bipolar disorder. In this chapter, we focus on the last three second generation antipsychotics approved for mania by the FDA, as well as the classical prototype “atypical” clozapine, extensively used in refractory bipolar disorders which has not been submitted for FDA approval for this indication.1
PHARMACOLOGICAL MECHANISMS ASSOCIATED WITH THYMOLEPTIC ACTIVITY ANTIMANIC ACTIVITY In a small number of randomized, controlled trials, all typical antipsychotics exerted antimanic efficacy in addition to their antipsychotic effects (Keck and McElroy, 2003a). Central dopaminergic hyperactivity has long been implicated as a mechanism in mania (Gerner, Post and Bunney, 1976). Thus, typical and SGAs are presumed to exert antimanic effects by their actions, at least in part, as dopamine D2 receptor antagonists. These effects do not distinguish SGAs from typical agents, but rather suggest that both groups of medications should have antimanic activity. Aripiprizole, in contrast, presumably exerts its antimanic efficacy via its partial dopamine D2 receptor agonist activity, diminishing excess dopamine neurotransmission via this mechanism (Keck and McElroy, 2003). A related mechanism has been described for quetiapine: Kapur and Seeman (2001) have proposed the hypothesis that quetiapine, in its fast dissociation from the D2 receptor, 1 Since olanzapine and risperidone are covered extensively elsewhere in this book (see Chapters 7 and 8), the focus of this chapter is on a comparative analysis of the four other second-generation antipsychotics – clozapine, quetiapine, ziprasidone and aripiprazole – Eds.
c08.fm Page 127 Wednesday, October 19, 2005 9:15 AM
“Second Generation Antipsychotics”
127
exerts a “flexible” antipsychotic action – and possibly, by extension, antimanic action – in that dopamine blockage is dissipated when such action is no longer needed. Thereby, so goes the reasoning, extrapyramidal and hyperprolactinemia are largely avoided.
ANTIDEPRESSANT ACTIVITY Second generation antipsychotics, individually and as a group, differ considerably from typical antipsychotics in their interactions with serotonergic and noradrenergic systems (Frye et al., 1998). All SGAs are antagonists at the 5HT2 receptor, a mechanism associated with antidepressant activity (Aprison, Takahashi and Tachiki, 1978). Ziprasidone and aripiprazole exert partial or full agonist activity at the 5HT1A receptor which may be associated with improvement in depression, anxiety and cognition (Frye et al., 1998; Keck and McElroy, 2003b; Keck et al., 2001a). Ziprasidone is an 5HT1D receptor antagonist; inhibiting this presynaptic autoreceptor increases serotonin release. Ziprasidone and aripiprazole are moderate inhibitors of the serotonin transporter, thereby blocking serotonin reuptake (Keck et al., 2001a; Keck and McElroy, 2003b). In addition, ziprasidone is also a moderate inhibitor of the norepinephrine transporter, blocking norepinephrine reuptake (Keck et al., 2001a). Clozapine and quetiapine are alpha2 adrenergic antagonists, an action that predicts increased presynaptic noradrenergic release (Frye et al., 1998). These various effects on serotonin and norepinephrine receptors and transporters among SGAs predict antidepressant activity lacking in typical antipsychotics.
RANDOMIZED CONTROLLED TRIALS IN ACUTE BIPOLAR MANIA The randomized, controlled trials of four SGAs in acute bipolar mania described below are summarized in Table 8.1 (McElroy and Keck, 2000).
CLOZAPINE Barbini et al. (1997) reported the only randomized, controlled trial of clozapine in acute bipolar mania. This 3-week trial compared clozapine (mean dose 166 mg/ day) with chlorpromazine (mean dose 310 mg/day) in 30 hospitalized patients. Although there were no significant differences in efficacy between the two agents at the study endpoint, patients receiving clozapine displayed significantly greater reductions in manic symptoms (mean YMRS total score) by the second week of the trial, suggesting a possibly more rapid rate of onset despite a relatively low mean dose of clozapine. This study was also not adequately powered to find a significant difference in efficacy at study endpoint.
c08.fm Page 128 Wednesday, October 19, 2005 9:15 AM
128
Bipolar Psychopharmacotherapy
Table 8.1: Randomized, controlled trials of Clozapine, Quetiapine, Ziprasidone and Aripiprazole in acute bipolar mania Study Clozapine Barbini et al., 1997 Quetiapine DelBello et al., 2002 Mullen, Devine and Sweitzer 2003a Mullen and Paulsson 2003b Brecher and Huizar 2003 Paulsson, 2003 Ziprasidone Keck et al. 2003a Segal et al. 2003 Weisler, 2003 Aripiprazole Keck et al. 2003b Bourin et al. 2003a Bourin et al. 2003b
Duration (weeks)
N
Mean dose (mg/d)
Results
Response Rates (%)
3
30
Clz 166 Cpz 310
Clz ≥ Cpz
ND
6 3
30 191
Qtp 435 Qtp 580
Qtp > P Qtp > P
Qtp 80; P 50 Qtp 54; P 33
3
402
Qtp 492
Qtp > P
Qtp 56; P 42
12
302
Qtp 559
Qtp > P
Qtp 42; P 34
12
302
Qtp 586
Qtp > P
Qtp 52; P 28
3 3 3
210 202 205
Zpr 133 Zpr 112 ND
Zpr > P Zpr > P Zpr = P
Zpr 50; P 35 Zpr 46; P 29 ND
3 3 12
245 272 347
Ari 28 Ari 28 Ari 22
Ari > P Ari > P Ari = Hal
Ari 40; P 19 Ari 51; P 31 Ari 50; Hal 28
Key: Clz = clozapine; Cpz = chlorpromazine; P = placebo; Qtp = quetiapine; Zpr = ziprasidone; Ari = aripiprazole; ND = no data.
QUETIAPINE Three studies examined the efficacy of quetiapine in combination with lithium or divalproex (DelBello et al., 2002; Mullen, Devine and Sweitzer, 2003a; Mullen and Paulsson, 2003b) and two studies examined quetiapine monotherapy in acute bipolar mania (Paulsson, 2003; Brecher and Huizar, 2003). DelBello et al. (2002) compared the combination of quetiapine and divalproex loading with placebo plus divalproex loading in hospitalized adolescents with bipolar mania. Patients in the combination therapy group displayed significantly greater response rates and mean reductions in YMRS total scores from baseline to endpoint compared with patients in the placebo/divalproex group. Notably, this is the only placebocontrolled, randomized combination drug trial conducted to date in a pediatric group of acutely manic patients. These findings were replicated in two combination therapy trials in adults (Mullen et al., 2003a,b). Jones and Huizar (2003) presented pooled data from the 12-week two placebo-controlled monotherapy trials (Brecher and Huizar, 2003; Paulsson, 2003) and found that quetiapine (mean dose 575 mg/day)
c08.fm Page 129 Wednesday, October 19, 2005 9:15 AM
“Second Generation Antipsychotics”
129
produced significant reductions in YMRS total scores compared with placebo. Superior efficacy for quetiapine was evident by day 4 of treatment and was sustained through the 12 week trials. Each trial included an active comparator for assay sensitivity, haloperidol (Brecher and Huizar, 2003) and lithium (Paulsson, 2003) respectively. Although these trials were not powered to find significant differences in efficacy between active treatments, quetiapine produced comparable improvement in manic symptoms compared with haloperidol and lithium monotherapy. Common side effects associated with quetiapine in these trials included somnolence, dizziness and modest weight gain.
ZIPRASIDONE In a post hoc analysis of mood symptom improvement in patients with schizoaffective disorder, Keck et al. (2001b) found significant dose-related improvement in BPRS manic items in patients receiving ziprasidone compared with placebo. These initial findings were confirmed in a 3-week, placebo-controlled, monotherapy trial in patients with acute bipolar mania (Keck et al., 2003a). Patients received ziprasidone 80 mg/day on day 1 and 160 mg/day on day 2 with a mean dose of 130 mg/day on days 15–21. The ziprasidone group displayed significantly greater reductions in total MRS scores compared with the placebo group beginning at day 2 and extending through the remainder of the study. Not surprisingly, ziprasidone-treated patients also had significantly greater improvement in measures of psychosis and global ratings compared with patients receiving placebo. Segal et al. (2003) recently reported on the results of a second placebo-controlled trial of ziprasidone in acute bipolar mania. Dose titration proceeded more slowly than in the first trial (80 mg/day on day 1, with adjustment upward by 40 mg/day thereafter). Nevertheless, significant differences in efficacy in favor of ziprasidone were again evident by the end of day 2 and sustained throughout the 3-week trial. Response rates were significantly higher in the ziprasidone group (46%) compared with the placebo group (29%) at the end of three weeks. Weisler (2003) presented the results of a 3-week, placebo-controlled trial of ziprasidone in combination with lithium in acute 205 patients with acute bipolar I mania. Patients receiving ziprasidone in combination with lithium displayed significantly greater reductions in mean total MRS, CGI and HAMD scores at day 4 compared with patients receiving lithium and placebo. Patients in the ziprasidone arm also displayed significantly greater reductions in PANSS total, and PANSS positive and negative subscale scores at day 21. However, there was no significant difference in reduction of MRS total score between the ziprasidone and placebo groups at day 14 or 21, presumably because the therapeutic effect of lithium had become manifest by then. Common side effects associated with ziprasidone in these studies included somnolence, hypertonia, akathisia, headache and GI complaints.
c08.fm Page 130 Wednesday, October 19, 2005 9:15 AM
130
Bipolar Psychopharmacotherapy
ARIPIPRAZOLE Three randomized, controlled trials examined the efficacy of aripiprazole in acute bipolar mania (Keck et al., 2003b; Bourin et al., 2003a,b). In the first placebo-controlled monotherapy trial, aripiprazole (mean dose at endpoint 27.9 mg/day) had significantly greater efficacy compared with placebo in reduction of total YMRS scores from baseline to endpoint. The second placebo-controlled monotherapy trial which also utilized an initial starting dose of aripiprazole 30 mg/day yielded comparable findings (Bourin et al., 2003). The third aripiprazole trial was a 12-week direct comparison with haloperidol without a placebo arm (Bourin et al., 2003). Patients in both treatment groups experienced significant reductions in manic symptoms which were sustained out to 12 weeks, although a significant proportion of patients receiving haloperidol dropped out of the trial due to EPS. Common side effects associated with aripiprazole in these studies included somnolence, activation, akathisia and GI complaints.
RANDOMIZED CONTROLLED TRIALS IN ACUTE BIPOLAR DEPRESSION QUETIAPINE To date, of the new SGAs covered in this chapter, only quetiapine has been studied in a randomized controlled trial in bipolar depression (Calabrese et al., 2004). This trial compared quetiapine 300 mg/day, 600 mg/day and placebo in 511 patients with bipolar I (67%) and bipolar II (33%) depression in an 8-week acute treatment study. Both quetiapine groups had significantly greater reductions in mean total MADRS scores from baseline to endpoint, beginning at week 1. There were no significant differences among the three groups in switch rates. The effect size for the quetiapine groups were large: 0.75 for 600 mg/day and 0.64 for 300 mg/day. Quetiapine-treated patients displayed significantly greater improvement in all but one item (increased appetite) of the MADRS compared with patients receiving placebo. In addition, both quetiapine groups had significantly greater improvement in mean total reductions in HAMD and HAMA scores, and significantly greater improvement in sleep quality and quality-of-life measures.
RANDOMIZED CONTROLLED LONG-TERM TREATMENT TRIALS As far as maintenance treatment for bipolar disorder is concerned, there are only two randomized, controlled trials of the new SGAs covered in this chapter.
c08.fm Page 131 Wednesday, October 19, 2005 9:15 AM
“Second Generation Antipsychotics”
131
CLOZAPINE Suppes et al. (1999) compared clozapine with treatment as usual (TAU) in a 1-year open-label randomized of 38 patients with bipolar disorder or schizoaffective disorder, bipolar type with treatment-refractory mania. Patients receiving clozapine had significantly greater improvement on measures of positive and negative symptoms of psychosis, overall functioning and use of adjunctive medications compared with patients receiving TAU. Consistent with reports of clozapine’s efficacy in acute mania, clozapine was equally efficacious in patients with and without psychotic symptoms in this trial.
ARIPIPRAZOLE Marcus et al. (2003) reported the results of a 26-week, double-blind maintenance study of aripiprazole in 161 patients with bipolar I disorder. Patients were initially stabilized on aripiprazole 15–30 mg/day for 6–18 weeks, then randomized to aripiprazole or placebo. Time to relapse of mood symptoms was significantly longer in patients receiving aripiprazole compared with placebo. The total number of mood episodes relapses in the aripiprazole group was also significantly lower.
SUMMARY Establishing the efficacy of an agent as a mood-stabilizer usually begins with trials demonstrating antimanic effects (Keck et al., 2002). Randomized, controlled trials of SGAs have yielded convincing evidence of efficacy for these agents in the treatment for acute bipolar mania, as monotherapy and in combination with lithium or divalproex. This is true for olanzapine and risperidone (covered in Chapters 7 and 8 in this book) as well as the new SGAs quetiapine, ziprasidone and aripiprazole covered in this chapter. These agents had a rapid onset of action, efficacy in psychotic and non-psychotic patients, and where data were available, efficacy in mixed and manic, as well as rapid and non-rapid cycling patients. In combination therapy trials, combination therapy produced consistently greater and more rapid response rates compared with monotherapy with lithium or divalproex. Thus, the efficacy of SGAs in the treatment for acute bipolar mania, alone or as components of combination therapy is well established. These agents generally have superior tolerability (lower rates of EPS and risk of depressive symptom exacerbation) over typical antipsychotics. The side effect profile, among the four SGAs covered in this chapter, varies among different agents, with weight gain occurring in a significant proportion of patients receiving clozapine and, to a lesser extent, quetiapine. EPS risk appears to be least with clozapine and quetiapine. Prolactin elevation is not a clinically significant side effect with any of these agents. The effects of ziprasidone on QTc prolongation appear to be of concern
c08.fm Page 132 Wednesday, October 19, 2005 9:15 AM
132
Bipolar Psychopharmacotherapy
primarily in patients with a family history of sudden death, cardiac disease, electrolyte disturbances and when co-administered with other agents that themselves have significant QTc prolonging effects. GI disturbances appear most commonly with ziprasidone and aripiprazole. Demonstration of true mood-stabilizing effects also requires evidence of antidepressant and maintenance efficacy in bipolar disorder. To date, among the new SGAs covered in this chapter, only quetiapine has demonstrated efficacy in the treatment for acute bipolar depression; only aripiprazole has efficacy data from one randomized, controlled discontinuation 6-month trial. Further studies of other second generation antipsychotics in acute bipolar depression and as maintenance treatment are needed to clarify their efficacy beyond their use in acute bipolar mania.2
REFERENCES Aprison MH, Takahashi R, Tachiki K (1978) Hypersensitive serotonergic receptors involved in clinical depression—a theory. In Neuropharmacology and Behavior, Haber B, Aprison MH (eds), Plenum, New York, pp. 23–48. Banov MD, Zarate CA, Tohen M, Scialabba D, Wines JD, Kolbrener M, Kim JW, Cole JO (1994) Clozapine therapy in refractory affective disorders: Polarity predicts response in long-term follow-up. J Clin Psychiatry, 55, 295–300. Barbini B, Scherillo P, Benedetti F, Crespi B, Colombo C, Smeraldi E (1997) Response to clozapine in acute mania is more rapid than that of chlorpromazine. Int Clin Psychopharmacol, 12, 109–112. Bourin M, Auby P, Marcus RN, Swanik R, McQuade RD, Iwamoto T, Sanchez R (2003) Aripiprazole versus haloperidol for maintained treatment effect of acute mania. American Psychiatric Association Annual Meeting, San Francisco, CA, May 17–22. Brecher M, Huizar K (2003) Quetiapine monotherapy for acute mania associated with bipolar disorder. Fifth International Conference on Bipolar Disorder, Pittsburgh, PA, June 12–14. Calabrese JR, Kimmel SE, Woyshville MJ, Rapport DJ, Faust CJ, Thompson PA, Meltzer HY (1996) Clozapine for treatment-refractory mania. Am J Psychiatry, 153, 759–764. Calabrese JR, Macfadden W, McCoy R, Minkwitz M, Wilson E, Mullen J (2004) Doubleblind, placebo-controlled study of quetiapine in bipolar depression. Abstracts of the American Psychiatric Association Annual Meeting, New York, NY, May 5, NR 756. Ciapparelli A, Dell’Osso L, Pini S, Chiavacci MC, Fenzi M, Cassano GB (2000) Clozapine for treatment-refractory schizophrenia, schizoaffective disorder, and psychotic bipolar disorder: A 24-month naturalistic study. J Clin Psychiatry, 61, 329–334. Ciapparelli A, Dell’Osso L, Bandettini di Poggio A, Carmassi C, Cecconi C, Fenzi M, Chiavacci MC, Bottai M, Ramaciotti CE, Cassano GB (2003) Clozapine in treatmentresistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: A naturalistic 48-month follow-up study. J Clin Psychiatry, 64, 451–458. DelBello MP, Schwiers ML, Rosenberg HL, Strakowski SM (2002) A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. J Am Acad Child Adolesc Psychiatry, 41, 1216–1223. 2
Further details on this important clinical topic are covered in Chapters 7, 8, 10 and 12 – Eds.
c08.fm Page 133 Wednesday, October 19, 2005 9:15 AM
“Second Generation Antipsychotics”
133
Frye MA, Ketter TA, Altshuler LL, Denicoff K, Dunn RT, Kimbrell TA, Cora-Locatelli G, Post RM (1998) Clozapine in bipolar disorder: Treatment implications for other atypical antipsychtoics. J Affect Disord, 48, 91–104. Gerner RH, Post RM, Bunney WE (1976) A dopaminergic mechanism in mania. Am J Psychiatry, 133, 1177–1180. Green AI, Tohen M, Patel JK, Banov M, DuRand C, Berman I, Chang H, Zarate C, Posener J, Lee H, Dawson R, Richards C, Cole JO, Schatzberg AF (2000) Clozapine in the treatment of refractory psychotic mania. Am J Psychiatry, 157, 982–986. Hillert A, Maier W, Wetzel H (1992). Risperidone in the treatment of disorders with a combined psychotic and depressive syndrome—a functional approach. Pharmacopsychiatry 25, 213–217. Janicak PG, Keck PE, Jr, Davis JM, Kasckow JW, Tugrul KC, Dowd SM, Strong J, Sharma RP, Strakowski SM (2001). A double-blind, randomized, prospective evaluation of the efficacy and safety of risperidone versus haloperidol in the treatment of schizoaffective disorder. J Clin Psychopharmacol 21, 360–368. Jones M, Huizar K (2003) Quetiapine monotherapy for mania associated with bipolar disorder. Fifth International Conference on Bipolar Disorder, Pittsburgh, PA, June 12–14. Kapur S, Seeman P (2001) Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics?: A new hypothesis. Am J Psychiatry, 158, 360–369. Keck PE, Jr., McElroy SL (2003a) Redefining mood stabilization. J Affect Disord 73, 163–169. Keck PE, Jr., McElroy SL (2003b) Aripiprazole: A partial dopamine D2 receptor agonist antipsychotic. Expert Opin Investig Drugs 12, 655–662. Keck PE, Jr, Wilson DR, Strakowski SM (1994). Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders. J Clin Psychiatry, 56, 466–470. Keck PE, Jr., McElroy SL, Arnold LM (2001a) Ziprasidone: A new atypical antipsychotic. Expert Opin Pharmacother 2, 1033–1042. Keck PE, Jr., McElroy SL, Strakowski SM, West SA (1994) Pharmacologic treatment of schizoaffective disorder. Psychopharmacology, 114, 529–538. Keck PE, Jr., McElroy SL, Richtand N, Tohen M (2002) What makes a drug a primary mood stabilizer? Mol Psychiatry, 7 (Suppl.), s8–s14. Keck PE, Jr., Nelson EB, McElroy SL (2003) Advances in the pharmacologic treatment of bipolar depression. Biol Psychiatry 53, 671–679. Keck PE, Jr., Reeves KR, Harrigan EP, and the Ziprasidone Study Group (2001b) Ziprasidone in the short-term treatment of patients with schizoaffective disorder: Results from two double-blind, placebo-controlled trials. J Clin Psychopharmacol, 21, 27–35. Keck PE, Jr., Versiana M, Potkin S, West SA, Giller E, Ice K (2003a) Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry, 160, 741–748. Keck PE, Jr., Marcus R, Tourkodimitris S, Ali M, Liebeskind A, Saha A, Ingenito G, and the Aripiprazole Study Group (2003b) Am J Psychiatry, 160, 1651–1658. Kimmel SE, Calabrese JR, Woyshville MJ, Meltzer HY (1994) Clozapine in treatmentrefractory mood disorders. J Clin Psychiatry, 55 (Suppl. B), 91–93. Mahmood T, Devlin M, Silverstone T (1997) Clozapine in the management of bipolar and schizoaffective manic episodes resistant to standard treatment. Aust N Z J Psychiatry, 31, 424–426. Marcus R, Carson WE, McQuade RD, Sanchez R, Iwamoto T, Stock E (2003) Long-term efficacy of aripiprazole in the maintenance treatment of bipolar disorder. Abstracts of
c08.fm Page 134 Wednesday, October 19, 2005 9:15 AM
134
Bipolar Psychopharmacotherapy
the Annual Meeting of the American College of Neuropsychopharmacology, San Juan, PR, December 8–11. McElroy SL, Keck PE, Jr. (2000) Pharmacologic agents for the treatment of acute bipolar mania. Biol Psychiatry, 48, 539–557. McElroy SL, Dessain EC, Pope HG, Jr., Cole JO, Keck PE, Jr., Frankenberg FR, Aizely HG, O’Brien S (1991) Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia. J Clin Psychiatry, 52, 411–414. Mullen JA, Devine NA, Sweitzer DE (2003a) Quetiapine adjunctive therapy for mania associated with bipolar disorder. Fifth International Conference on Bipolar Disorder, Pittsburgh, PA, June 12–14. Mullen JA, Paulsson B (2003b) Quetiapine in combination with lithium or divalproex for the treatment of mania associated with bipolar disorder. Fifth International Conference on Bipolar Disorder, Pittsburgh, PA, June 12–14. Muller-Siecheneder F, Muller FJ, Hillert A (1998). Risperidone versus haloperidol and amitriptyline in the treatment of patients with a combined psychotic and depressive syndrome. J Clin Psychopharmacol 18, 111–120. Paulsson B (2003) Quetiapine monotherapy for the treatment of bipolar mania. Fifth International Conference on Bipolar Disorder, Pittsburgh, PA, June 12–14. Sajatovic M, Mullen JA, Sweitzer DE (2002) Efficacy of quetiapine and risperidone against depressive symptoms in outpatients with psychosis. J Clin Psychiatry, 63, 1156–1163. Segal S, Reisenberg RA, Ice K, English P (2003) Ziprasidone in mania: A double-blind, placebo-controlled trial. Abstracts of the Annual Meeting of the American College of Neuropsychopharmacolgy, San Juan, Puerto Rico, December 8–11. Suppes T, McElroy SL, Gilbert J, Dessain EC, Cole JO (1992) Clozapine in the treatment of dysphoric mania. Biol Psychiatry, 32, 270–280. Suppes T, Phillips KA, Judd CR (1994) Clozapine treatment of nonpsychotic rapid cycling bipolar disorder: a report of three cases. Biol Psychiatry, 36, 338–340. Suppes T, Webb A, Paul B, Carmody T, Kraemer H, Rush AJ (1999) Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatmentresistant illness and a history of mania. Am J Psychiatry, 156, 1164–1169. Weisler RH Ziprasidone versus placebo in combination with lithium in acute mania. Abstracts of the European College of Neuropsychopharmacology Annual Meeting, September 2003. Zarate CA, Tohen M, Baldessarini RJ (1995a) Clozapine in severe mood disorders. J Clin Psychiatry, 56, 411–417. Zarate CA, Tohen M, Banov MD, Weiss MK, Cole JO (1995b) Is clozapine a mood stabilizer? J Clin Psychiatry, 56, 108–112.
c09.fm Page 135 Wednesday, October 19, 2005 9:15 AM
CHAPTER
9 Complex Combination Therapy: The Evolution Toward Rational Polypharmacy in Lithium-Resistant Bipolar Illness Robert M. Post, Andrew M. Speer and Gabriele S. Leverich Biological Psychiatry Branch, National Institute of Mental Health, NIH, DHHS, Bethesda, MD, USA
INTRODUCTION: PREVALENCE AND RATIONALES Twenty to thirty years ago, bipolar patients were treated largely with lithium carbonate as augmented by antidepressants, benzodiazepines and antipsychotic agents as necessary. This often complex, rapidly changing treatment was still called “monotherapy” because lithium was the basic component of the regimen and the only accepted mood stabilizer. However, this pattern has changed dramatically in the last 30 years in many academic outpatient clinics and private practice settings, wherein not only combination therapy of the type noted above, but also complex combination therapy (two or more mood stabilizers plus adjuncts), appears to be the norm in the treatment of bipolar illness. Much of this change has been accounted for by the availability of a host of new anticonvulsants, atypical antipsychotics, antidepressants and other adjunctive modalities (Table 9.1), and the recently recognized goal of attempting to treat patients to remission rather than just symptomatic improvement.
POLYTHERAPY FOR INPATIENTS An example of this change in treatment patterns is the number of medications that were required for acute mood stabilization at discharge from the National Institute of Mental Health (NIMH) following completion of formal controlled clinical trials and protocols (Frye et al., 2000). Despite the fact that patients were often admitted with lithium-refractory bipolar illness and antidepressant-refractory Bipolar Psychopharmacotherapy: Caring for the Patient Edited by Hagop S. Akiskal and Mauricio Tohen # 2006 John Wiley & Sons, Ltd ISBN: 0-470-85607-6
MAOIs
tertiary tricyclics
VNS
T3, TRH, Supraphysiological T4 St. Johns Wart, O-3-Fatty Acids, cognitive/behavioral psychoeducational
rTMS
(gabapentin)
Folate
MST
valproate lamotrigine (oxcarbazepine)
RIMAs SNRIs bupropion
sleep deprivation, light therapy
buspirone
carbamazepine valpromide
SSRIs
2000s
olanzapine ziprasidone risperidone quetiapine aripiprazole
1990s
MAOIs, monoamine oxidase inhibitors; SSRIs, Serotonin-Selective reuptake inhibitors; SNRIS, Serotonin-norepinephrine reuptake inhibitors; RIMAs, reversible inhibitors of monoamine oxidase A; rTMS, repetitive transcranial magnetic stimulation; VNS, Vagus nerve stimulation; MST, magnetic seizure therapy; T4, levothyroxine; T3, triiodothyronine; TRH, thyrotropin-releasing hormone; 0–3, Omega-3; SAMe, S-adenoslmethionine; ECT, electroconvulsive therapy; PTZ, pentylene tetrazol
T4, SAMe, interpersonal
acupuncture
benzodiazepines
lithium
secondary tricyclics
clozapine
chlorpromazine haloperidol (phenothiazines) (butyrophenones) (thiothixenes)
Minor Tranquilizers bromides barbituates Physiological Approaches insulin/PTZ seizures ECT (bilat. → unilat.) Adjuncts Thyroid: extract, Others: Psychotherapy: analytic, dynamic
Mood Stabilizers
Antidepressants
reserpine
1980s atypicals
1970s
typicals
1960s
Antipsychotics/antimanics
1950s
Table 9.1: Evolution of 50 years of psychopharmacology of bipolar illness
c09.fm Page 136 Wednesday, October 19, 2005 9:15 AM
c09.fm Page 137 Wednesday, October 19, 2005 9:15 AM
Complex Combination Therapy
137
unipolar illness, patients were often discharged on monotherapy or close to monotherapy regimens in the 1970s. However, by the late 1990s, patients were discharged on an average of 3.3 medications and, in the most recent iterations, four or more medications. This greater number of medications (Figure 9.1) was required to achieve approximately the same 75–80% acute response rate upon discharge across all of the epochs. To explore some of the reasons for the increase in medications required upon NIMH discharge, we examined a variety of demographic variables (Frye et al., 2000). We found that there was an inverse relationship between a later date of discharge from the hospital and an earlier age of onset of affective illness (Figure 9.2; r = −0.30; n = 160; p < 0.001), an increased amount of total time depressed prior to NIMH admission, and a markedly higher incidence of rapid cyclers (those with four or more episodes per year) in those admitted for study and treatment. The same screening procedures had remained in place over the three decades, such that patients with major personality disorders or medical or substance abuse comorbidity were excluded from clinical trials. Nevertheless, it was unclear whether this reflected a general trend in the population or whether patients were more recently being more vigorously treated in the community and a more select subgroup of highly treatment-refractory patients was being referred to the NIMH. The former is likely as Lange and McInnis (2002) have documented the existence of both a year of birth, or cohort effect (decreasing age of onset) and a generational, or anticipation effect (increase in disease severity) present in most studies of bipolar illness. These population trends could be related to the general observations of earlier onset and greater treatment resistance in the community.
Number of medications
6 5
r = 0.45 p < 0.0001 N = 178
4 3 2 1
BP UP
0 1971
1976
1981
1986
1991
1996
Discharge date
Figure 9.1: Increasing polypharmacotherapy in more recent NIMH discharges. Line in middle of figure represents the mean
c09.fm Page 138 Wednesday, October 19, 2005 9:15 AM
138
Bipolar Psychopharmacotherapy 70
Age at first symptom
60 50 40 30 20 BP UP
10 0 1971
1976
1981
1986
1991
1996
Discharge date
Figure 9.2: Earlier onset of symptoms in more recent NIMH cohorts. Line in middle of figure represents the mean
POLYTHERAPY IN OUTPATIENTS In a number of other clinics in Pittsburgh (Levine et al., 2000; Kupfer et al., 2002), New York (Goldberg, Harrow and Sands, 1996a), London (Frangou, Raymont and Bettany, 2002), Los Angeles (Gitlin et al., 1995), in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) program (Sachs et al., 2003) and at many centers across the U.S. and abroad, there is a similar trend for use of multiple medication strategies simultaneously in the treatment of outpatients with bipolar illness. We also observed this necessity in the Stanley Foundation Bipolar Network (SFBN) where 258 outpatients followed prospectively for one year were treated with an average of 4.1 medications (Post et al., 2003a). In a larger series of 539 patients, those without rapid cycling patterns (n = 333) were treated with 3.5 ± 1.8 different categories or classes of drugs, whereas the 38% of patients with rapid cycling presentations (n = 206) were treated with an average of 4.6 ± 1.8 (p < 0.01) different classes of medications (Kupka et al., 2005). Thus, while lithium monotherapy was initially touted as effective in 60–80% of bipolar patients, this high rate often included highly selected patients meeting clinical trials criteria for purer and more uncomplicated forms of the illness (Baldessarini and Tondo, 2000). Primary lithium therapy (i.e., even as supplemented by antidepressants, anxiolytics and antipsychotics) is increasingly recognized as less than optimal (Bowden, 1995; Aagaard and Vestergaard, 1990) for many patients with specific bipolar subtypes, common comorbidities, demographics, and illness course characteristics, as outlined in Table 9.2. These correlates of relatively poor response are not inconsequential, because rapid cyclers comprise 38% of our SFBN prospectively confirmed outpatient sample (Kupka et al., 2005) and 40–42% have a substance
c09.fm Page 139 Wednesday, October 19, 2005 9:15 AM
Complex Combination Therapy
139
Table 9.2: Correlates of relative lithium non-responsiveness Factors Episode Characteristics 1. Rapid or Faster Cycling 2. Episode Contiguity 3. Sequence Pattern 4. Number of Episodes Prior to Starting Prophylaxis 5. Quality of Mania 6. Insight/Compliance Comorbidities 7. History (Hx) of Substance Abuse 8. Hx of Anxiety Disorder Genetic Background 9. Family History of Anxiety Disorder 10. Family Hx of Bipolar Illness and Especially Lithium Response
Good Response Rates Low Response Rates (About 60–80%) (About 20–40%)
Strength of Evidence
No Intermittent, i.e., with a well interval (I) Mania |Depression |I M-D-I 3 or fewer
Yes Continuous, i.e., no well interval (I) Depression |Mania |I D-M-I 4–10 or more
+++ (12) +
Euphoric Good
Dysphoric Poor
+++ (4) +
Negative
Positive
+
Negative
Positive
++
Negative
Positive
++
Positive
Negative
+++
+++ (4) +++ (9)
+, Reported by several clinician observers ++, Reported in several studies +++, Well-documented (# = approximate number of supportive studies in literature)
abuse or anxiety disorder comorbidity (Suppes et al., 2001; McElroy et al., 2001). The number of episodes prior to starting lithium is also a risk factor for poor lithium response in most (Table 9.3), but not all (Baldessarini and Tondo, 2000), studies. Table 9.3: More episodes prior to starting lithium is associated with poor prophylactic response Investigator
Correlates of Poor Response to Lithium
Prien, Caffey and Klett (1974) Sarantidis and Waters (1981) Abou-Saleh and Coppen (1986) Gelenberg et al. (1989) O’Connell et al. (1991) Goldberg et al. (1996b) Denicoff et al. (1997a) Maj et al. (1998) Swann et al. (1999) Frye et al. (2003)
↑ # of hospitalizations ↑ episodes/year ↑ episodes >3 prior episodes ≥3.8 mean episodes ≥2 prior hospitalizations ≥2 prior hospitalizations for mania ≥7.2 mean episodes ≥10 prior episodes ≥3 prior episodes (Li or LTG)
Li – Lithium; LTG – Lamotrigine
c09.fm Page 140 Wednesday, October 19, 2005 9:15 AM
140
Bipolar Psychopharmacotherapy
POLYTHERAPY IN PEDIATRIC BIPOLAR ILLNESS Polytherapy is also typical in the management of childhood and adolescent bipolar illness. Biederman etal. (1998), in an academic center, noted a high incidence of the use of mood stabilizers, antipsychotics, antidepressants and psychomotor stimulants. Likewise, in the Child and Adolescent Bipolar Foundation (CABF) of Hellander and associates, multimodal pharmacotherapy is the norm (Hellander, 2003). In one retrospective chart review, 78% of children with early onset bipolar illness (average study age 9.6 ± 3.5 years) required combination drug therapy just to achieve a measure of symptomatic control, i.e., 50% improvement (Tramontina et al., 2003). In another retrospective chart review of risperidone effectiveness in juvenile mania, 96% of children were on other medications (Frazier et al., 1999). A more systematic study of the need for combination treatment in pediatric bipolar patients was done by Kowatch et al. (2000). After a 6–8-week randomization to monotherapy with valproate, lithium or carbamazepine for mania (Kowatch et al., 2000), an open extension phase of 16 weeks was performed in 35 bipolar patients (mean age 11-years old) (Kowatch et al., 2003). As summarized in Table 9.4, response rates to initial monotherapy treatment ranged from about
Table 9.4: Response to mood stabilizers in pediatric mania
Acute Phase (n = 42; 6–8 weeks) Effect Size (Cohen’s d) CGI (Score of 1 or 2) YMRS (50% improvement) Extension Phase (n = 35; 16 weeks) 1. Acute responders (n = 18) who required 2nd mood stabilizer 2. Acute non-responders (n = 17) responded to Persistent nonresponders despite
Divalproex (VPA)
Lithium (Li)
Carbamazepine (CBZ)
1.63 40%
1.06 46%
1.00 31%
53%
38%
38%
2/8
3/6
0/4
3/5 + Li 2/5 + RIS (VPA + Li)
4/5+VPA 2/2 changed to VPA 1/5 changed to VPA (Li + VPA + RIS) (VPA, VPA + Li, VPA + Li + RIS)
RIS – risperidone; CGI – Clinical Global Impression; YMRS – Young Mania Rating Scale Source: Kowatch et al. (2000, 2003).
c09.fm Page 141 Wednesday, October 19, 2005 9:15 AM
Complex Combination Therapy
141
30–50%. Dual combination therapy was required in 58%, with a triple combination in 51%, consisting of two mood stabilizers and either a stimulant (34%), an antipsychotic (11%) or an antidepressant (6%). Expert consensus suggests that initial treatment of bipolar I, II and not otherwise specified (NOS) children with antidepressant or stimulant monotherapy is usually unsuccessful and may exacerbate the course of illness (Kowatch et al., 2005). Mood stabilizers (lithium and the anticonvulsants valproate, carbamazepine and oxcarbazepine) and atypical antipsychotics are widely used as first-line treatment with small doses of stimulants added adjunctively for residual attention-deficit hyperactivity disorder (ADHD) symptoms. Here it would appear that the sequence of treatment additions is important to a successful outcome (Kowatch et al., 2003). The lack of controlled trials and algorithms to develop systematic strategies for polytherapy is even more problematic in children than adults as the first controlled studies of monotherapy are just beginning to be performed and reported in this population. Given that many children will need complex combination therapy to achieve and maintain remission, such studies should be given very high priority. In one of the few formal combination studies, DelBello et al. (2002) found the combination of divalproex and quetiapine more effective in the treatment for adolescent mania than divalproex alone (i.e., divalproex plus placebo).
THE INADEQUACY OF TWO MOOD STABILIZERS IN COMBINATION IN SYSTEMATIC STUDIES In the studies of Denicoff and colleagues (1997a,b), relatively low response rates were observed in outpatients with bipolar illness who were treated on a double-blind basis with either lithium or carbamazepine monotherapy in the first year of study, were crossed over to the other agent in the second year, and then placed on the combination of both drugs in the third year. Open augmentation with benzodiazepines, antidepressants and antipsychotics was allowed as necessary. Despite this liberal use of rescue medicines, there was a response rate of 41.2% to lithium and 53.8% to carbamazepine. In the rapid cycling subgroup, only 28% responded to lithium, 19% to carbamazepine, but 56% of patients responded in the third year to these two agents in combination. When a fourth year on lithium and valproate was offered to nonresponders, and then a fifth year on triple combination therapy with lithium, carbamazepine and valproate (Denicoff et al., 1997b), 37% of the original cohort still had failed to have an overall much improved year on any of the five pharmacological regimens, indicating a high degree of treatment-resistance.
c09.fm Page 142 Wednesday, October 19, 2005 9:15 AM
142
Bipolar Psychopharmacotherapy
The data of Calabrese et al. (2003a) for lithium and valproate are even more striking. They intended to treat a cohort of 272 rapid cycling patients to remission on the combination of lithium and valproate and then randomize individuals to either monotherapy. Surprisingly, only 24% of the 211 patients treated for four weeks and 18% of the intent-to-treat sample was sufficiently well on the combination of lithium and valproate in order to be randomized. Thus, in this highly prevalent subtype of bipolar illness, 75–80% of the outpatients failed to respond adequately to two of the best drugs for bipolar illness (lithium and valproate). Even though it may be reasonably argued that these studies are examining patients with a high degree of treatment resistance, and a form of the illness (rapid cycling) that in itself is relatively treatment resistant, it nonetheless appears that a very large segment of the bipolar population is poorly responsive to regimens of lithium plus either of two well-established mood stabilizing anticonvulsants, carbamazepine or valproate.
DEPRESSION AND CORRELATES OF POOR RESPONSE TO NATURALISTIC POLYTHERAPY In our entire cohort of patients in the SFBN, a high degree of treatment-resistance was also observed with patients remaining mildly to moderately depressed approximately 30% of the days of the year, which was three times greater an amount of time than days hypomanic or manic (Post et al., 2003a; Nolen et al., 2004; Kupka et al., 2005); these data parallel those of Judd et al. (2002). Thus, based on these large studies, the depressive phase of the illness is relatively more treatment-resistant than mania. In the SFBN study, this imbalance occurred in patients despite the use of a wide range of mood stabilizers (97%), typical (17%) and atypical antipsychotics (21%), benzodiazepines (49%), antidepressants (53%) and thyroid hormone supplementation (32%) (Figure 9.3). The recently approved anticonvulsant for prophylaxis, lamotrigine, was being used on an “as needed” basis as well. Correlates of poor response to this intensive naturalistic pharmacotherapy included adversity in childhood (physical and/or sexual abuse), earlier age of onset of illness, a prior history of a greater number of episodes and a prior history of rapid cycling (Nolen et al., 2004). In a subgroup of patients followed on a daily basis on the NIMH-Life Chart Method (LCM) for up to five years, there was a gradual reduction in the percentage of patients displaying rapid cycling from 38% in the first year of follow-up to 20.2% in the fifth year. However, a prior history of a greater number of episodes and current rapid cycling appeared to convey a relatively
c09.fm Page 143 Wednesday, October 19, 2005 9:15 AM
Complex Combination Therapy
143
60 20.93% 50
18.22% 17.05%
Number of patients
40 12.02% 12.02% 30
20
6.59%
6.59%
3.10%
10
1.94% 0.78%
0.78% 0 0
1
2
3
4
5
6
7
8
9
10
Total number of medications
Figure 9.3: Average number of medications in 258 bipolar outpatients followed prospectively for one year
poor prognosis for shifting and staying out of the rapidly recurrent phase of the illness (Kupka et al., 2005). As noted above, rapid cyclers were treated with a significantly greater number of medications compared with those patients with nonrapid cycling presentations. These data obviously have two very different interpretations. The more likely one is that these patients with more treatment-refractory presentations were being treated more aggressively in an effort to decrease the morbidity of recurrent episodes. However, it is also possible that some of the multiple medications used (such as antidepressants in slightly more than 50% of the subjects) could have contributed to the mood destabilization. Arguing against this latter proposition are the clinical observations that with the right mix of a sufficient number of medications, a substantial group of otherwise severely ill patients with rapid recurrences will enter a remission (Frye et al., 2000; Figures 9.4 and 9.5). The vexing question as to what is “the right mix” of medications for the different illness presentations remains to be answered.
c09.fm Page 144 Wednesday, October 19, 2005 9:15 AM
144
Bipolar Psychopharmacotherapy
Figure 9.4: Life chart showing response to combination therapy in a refractory bipolar patient. Bottom shows exploded view of response to five medications (T3, T4, valproic acid, bupropion and lithium) leading to remission of episodes and beginning of a persisting remission for 14 years
c09.fm Page 145 Wednesday, October 19, 2005 9:15 AM
Complex Combination Therapy
145
MOOD STABILIZATION WITH COMPLEX COMBINATION THERAPY: 7 Medication Classes 1.5 0.5
0.5 mg/prn O
1
0.5
0.5 mg
1
0.25 1 1 0.75 O OO O O O O O O O O 1.25
0.5 0.25 OOOOO OOOOOOOO
0.5 O
0.25
0.25
0.5
5 mg
CLONAZEPAM
O O O O O O O O O O O O O O O O O O O O OO O O O OO O O O O OO O 0.5
2.5 5
2.5 Blind 50 mg
OLANZAPINE
0.25
3a 100
5 2.5 5
7.5
5 6000 mg 3000 OOOOOOOOO 5 OM3 BLIND MED 6000 OO O O O O OO O O O O OM3 OPEN
50
SERTRALINE vs. 75 mg
4800 mg
4800 900 2400
3600
2100 4500 2700 1800
150
75
1 dose O OMEGA-3
BUPROPION HCL 2400 1800
1500
25 mcg
600 2100 1200
4
Severe
2
High Moderate
25 mg 200
225 250
275
300
325 75
T TTTTTTTTT 3
CYTOMEL
GGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGG
GABAPENTIN
20 mg 30 OOOOO CITALOPRAM
100
75 50
LAMOTRIGINE GABAPENTIN D/C
Low Moderate Mild
Mild Low Moderate High Moderate
YEARLY
Severe
1997
1998
7 5 mg
2.5
5
1999
2000
CHOLINESTERASE INHIBITOR 5 mg 7.5 10 O O OO O O O O OO O O O O OO O O OO O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O OO O O O O OO O O O O OO O O O OO O O O
Donezepil
ATYPICAL
LAMOTRIGINE 50 mcg
THYROID
37.5
T TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT 3
CYTOMEL Severe
6
High Moderate
7
2.5
OLANZAPINE ANTIDEPRESSANT 30 mg 40 O O O O O O O O OO O O O OO O O O O OO O O O O OO O O O OO O O O O O O O O O O O O O O O O O O O O O O O O O O OO O O O O O O O O O O O O O O O O O O O O O OO O O O O OO O O O O OO O O O OO O O O O OO O O O O OO O O O O O O O O O CITALOPRAM ATYPICAL 20 mg 40 60 5 mg 0.125 mg O O O O O O O O O O O O O O O O O O O O O O O O O OO OO 3b ZIPRASIDONE PROCARDIA DIGOXIN BENZODIAZEPINE 0.25 mg KLONOPIN ANTICONVULSANT 50 mg
TTTTTTTTTTTTTTTTTTTTT
STIMULANT 5 mg 12.5 15 12.5 15 5 O OO O O O O OO O O O O O O O O O O O O O O O O O O O O O O O O OO O O O O O O O O O O O O O O O O O O O O O O O OO O O O O OO O O O O OO O O O OO O O O O OO O O O O O O O O O O O O O Dextroamphetamine
5 3 1 2 4 6
Low Moderate Mild
Mild Low Moderate High Moderate Severe
12-00
MONTHLY 1-01
2-01
3-01
4-01
5-01
6-01
7-01
8-01
9-01
10-01
11-01
12-01
Figure 9.5: Based on the retrospective life chart, this patient was not responsive to lithium, valproate, carbamazepine, sertraline, fluoxetine, venlfaxine, nefazodone, clonazepam and gabapentin. The patient, as seen in the life chart, was eventually responsive to the combination of: (a) clonazepam, a high-potency benzodiazepine, for sleep, anxiety and agitation symptoms; (b) lamotrigine, an anticonvulsant, for bipolar II ultra-rapid cycling and depression; (c) olanzapine, an atypical antipsychotic, for breakthrough recurrent brief hypomanias (RBHs) and ultra-rapid cycling; (d) ziprasidone, another atypical antipsychotic, with better tolerability and no weight gain; (e) triiodothyronine (T3), a thyroid hormone, as antidepressant augmentation; (f) citalopram, an antidepressant, for residual chronic depression; (g) dextroamphetamine, a psychomotor stimulant, for residual fatigue and anergia; and (h) donepezil, an acetylcholine esterase inhibitor, because of a lack of cognitive clarity. The “off” response (i.e., exacerbation of depression) upon gabapentin discontinuation in 1997 (at the dotted arrow) in retrospect suggests that gabapentin may have had a partial helpful role in preventing more severe depressions. This evidence was overlooked in the elimination of gabapentin from the regimen. An earlier antidepressant trial in late 1998 (sertraline vs bupropion) prior to addition of the atypical olanzapine resulted in re-emergence of ultra-rapid cycling
CASE EXAMPLES OF RESPONSE TO COMPLEX COMBINATION THERAPY COMPLETE RESPONSE ON FIVE DRUGS The patient’s illness and treatment course illustrated in Figure 9.4 are not unusual in the subgroup of patients requiring moderately complex combination
c09.fm Page 146 Wednesday, October 19, 2005 9:15 AM
146
Bipolar Psychopharmacotherapy
therapy to achieve a more complete therapeutic response, if not a complete remission (as observed in this instance). This patient’s life chart represents the course of illness in a 30-year-old female who continuously cycled into 2–3-month periods of profound depression with psychomotor retardation, complete incapacitation including inability to perform any of the usual activities of daily living activities, a subjective sense of profound memory loss, notable speech latency, and extreme degrees of suicidal ideation alternating with brief periods of either euphoric or dysphoric (and dysfunctional) hypomania for about eight years. These incapacitating cycles of depression were not responsive to traditional antidepressants, monoamine oxidase inhibitors (MAOIs), mood stabilizers such as lithium and carbamazepine (both alone and in combination with thyroid augmentation), and benzodiazepines. Several initial periods of partial response to carbamazepine, particularly for depression, eventually resulted in loss of efficacy and resumption of severe mood cycling. At the NIMH (see insert at bottom of Figure 9.4) this patient underwent sequential double-blind clinical trials in which placebo was replaced first by nimodipine (360 mg/day, peak dose) without therapeutic success (Pazzaglia et al., 1993, 1998). The patient subjectively reported improvement in her memory, however. She was maintained on both T4 and T3 in light of her history of thyroiditis and abnormal thyroid indices and initial case reports of better response to the combination than to T4 alone by Cooke, Joffe and Levitt (1992), and the subsequent systematic study of Bunevicius et al. (1999). Treatment with valproate resulted in attenuation of only her manic episodes, and the addition of carbamazepine was without effect on her next depression. Bupropion treatment appeared to have a partial effect on her depression, but it was not until lithium was added to the four other agents (T3, T4, valproate and bupropion) that the patient began to show marked attenuation of her depressive episodes, and then stopped cycling altogether. The effect of the addition of lithium is particularly interesting, considering it was previously ineffective when used alone and in combination with multiple antidepressants, antipsychotics, and carbamazepine (Figure 9.4, top). The patient had a relatively mild side-effects burden despite these five agents, with mild to moderate tremor being the only problematic one. At discharge, she elected to remain on this combination of five agents. Not only was she able to return to work shortly after discharge for the first time in six years, but equally dramatic improvement occurred in other aspects of her life. She has remained well over the past 14 years on essentially this regimen.
CASE B: COMPLETE RESPONSE ON EIGHT MEDICATIONS This 64-year-old male had a 46-year history of bipolar-II illness with severe prolonged and incapacitating depressions and hypomanias unresponsive to traditional therapeutic modalities including the mood stabilizers, antidepressants and benzodiazepines (Figure 9.5 [see legend]). Following sequential adjunctive treatments, discontinuations
c09.fm Page 147 Wednesday, October 19, 2005 9:15 AM
Complex Combination Therapy
147
and switching of medications for tolerability, treatment with seven different classes of medications was associated with his first persistent remission of symptoms.
SOME TREATMENT PRINCIPLES FOR COMPLEX COMBINATION THERAPY SIGNS, SYMPTOMS AND TARGETS What are the general treatment principles that may lead to such fortunate outcomes with complete and persistent remissions of the type of illness in Figures 9.4 and 9.5? Herein lies the difficulty because there is not, as yet, a systematic literature on complex combination therapy to guide the clinician. Clinicians are thus forced to adopt strategies that have some empirical backing and a modicum of support by expert opinion (Table 9.5). We suggest the utility of considering a wide variety of variables in initial and subsequent choice of medications, including: cycle pattern and frequency; the symptomatic presentation of manic, depressive and mixed episodes; concomitant Axis I, II and III comorbidities; and neurobiological findings such as endocrine or cerebrospinal fluid abnormalities. Following the use of these therapeutic targets, one must consider tolerability not only of the drug to be added, but also of the entire regimen and potential pharmacokinetic as well as pharmacodynamic factors. If one is careful in dose titration, one can use a wide range of drugs in combination and actually reduce rather than increase side-effects burden, because no one single agent has to be pushed to or above an individual’s side-effects threshold in order to achieve a complete therapeutic response.
RAPID CYCLING AND DIFFERENT TYPES OF BREAKTHROUGH SYMPTOMATOLOGY In light of the poor response to monotherapy in the case examples noted above, for the patient presenting with initial rapid cycling, we suggest the combination of lithium with either carbamazepine, valproate or lamotrigine, depending on the wave form of the illness (predominance of mania versus depression) and other clinical and familial predictors of treatment responsivity as outlined in Tables 9.6 and 9.7. To the extent that the patient continues to cycle and/or show psychotic components of their illness, an atypical antipsychotic might then be added to the regimen. If the patient had a chronic refractory depression, one might consider adding a second-generation antidepressant instead. If the patient were overweight, one might consider topiramate or zonisamide because these have been shown to be helpful in weight loss in psychiatric and neurological patients and in those with psychotropic-induced weight gain. If the patient had comorbid alcoholism or post-traumatic stress disorder (PTSD), one might choose topiramate
c09.fm Page 148 Wednesday, October 19, 2005 9:15 AM
148
Bipolar Psychopharmacotherapy
Table 9.5: Some principles of rational polypsychopharmacology 1. Add one drug at a time (to distinguish individual drug efficacy and side effects) 2. Augmentation (with a new drug with a new mechanism) saves time over substitution 3. Substitution (within the same class) is appropriate in the face of drug intolerance 4. Consider drug which targets: (a) predominant symptom presentation (i.e., mania, depression, mixed state) (b) existing comorbidities (try for a two-for-one response) (c) good side effects profile and overall tolerability in combination (d) different mechanisms of action 5. Titrate toward (below) a patient’s side effects threshold (not to conventional doses and blood levels) 6. Anticipate and prevent pharmacokinetic interactions 7. Consider suicidality (lithium and psychotherapy) 8. Attend to ease of use to enhance compliance (i.e., only H.S. or A.M. dosing if possible) 9. Treat breakthrough symptoms aggressively 10. Consider the risk-to-benefit ratio in relation to both evidence and likelihood of efficacy and side effects 11. Have patient (or family) daily chart mood, sleep, comorbid symptoms, medications, and side effects 12. Monitor side effects (cognition/sedation/unsteadiness) as carefully as mood 13. Decrease dose of drug most likely associated with side effects 14. In face of good response, be conservative and maintain full-dose treatment into continuation and prophylaxis (in absence of side effects) 15. In absence of efficacy, consider augmentation strategies; changes in the major treatment strategies (i.e., the core mood stabilizers); and more experimental approaches as necessary 16. Develop a support system and the patient’s approach to: (a) an Early Warning System (EWS); identify symptoms most likely to herald onset of manic or depressive episode (b) an Emergency Action Plan (EAP, i.e., a fire drill); what to do and who to call should dangerous behavior emerge 17. Consider a sequential and evolving approach to both: (a) illness education in: (1) acute phases; (2) resolution/continuation; and (3) prophylaxis (b) type of psychotherapy: (1) cognitive behavior techniques (re: stress management/compliance); (2) interpersonal psychotherapy (re: significant other/employment); and (3) existential psychotherapy 18. Watch literature for efficacy and availability of new drug treatments and physiological approaches such as rTMS and VNS 19. Watch literature for emerging clinical, neurochemical, physiological and genetic predictors of drug response and side effects H.S., at night; rTMS – repetitive transcranial magnetic stimulation; VNS – Vagus nerve stimulation
Carbamazepine
If mania > depression Lithium
Mood stabilizer —
−
+ • Bipolar II • Family history (−) • Substance use • Schizoaffective • Paroxysmal pain (PTSD)
• Agranulocytosis (1 per million) • Aplastic anemia (5 per million) • Spina bifida (1–3%)
• Narrow therapeutic index • Irreversible cerebellar lesions in overdose • Ebstein’s anomaly
Helps Weight insomnia neutral Severe caution ±
• Bipolar I • Family history (+) • Intermittent • Euphoric • Suicide risk
+ Selection factors
Table 9.6: Initial choice of a mood stabilizer Mild caution
• Benign ↓ WBC count • Dizziness • Ataxia • Diplopia • Sedation
Tremor • Acne GI distress • Psoriasis ↑ weight Diabetes insipidus
• Hyponatremia • Severe rash • Drug–drug interactions
• • • •
Moderate caution
c09.fm Page 149 Wednesday, October 19, 2005 9:15 AM
• Bipolar I, II depression • Anxiety comorbidity • Family history of (+): Anxiety, Substance abuse (PTSD)
−
+
• Rash: SJS; TENs (1 in 5000 adults; 1 in 2500 children)
• Hepatic failure • Pancreatitis • Spina bifida (3–5%)
+
• Migraine • Anxiety • Dysphoria (PTSD) —
Helps Weight insomnia neutral Severe caution
+ Selection factors • • • • Tremor ↑ weight Alopecia (PCOS)
Moderate caution
• Benign rash • GI distress
• GI distress • ↑ Ammonia • ↓ Platelets
Mild caution
PTSD, post-traumatic stress disorder; WBC, white blood cell; PCOS, polycystic ovary syndrome SJS, Steven’s Johnson syndrome; TENs, toxic epidermal necrolysis; GI, gastro intestinal —, worsen; −, may worsen; ±, possibly effective; +, substantial open data Based on data and reviews of Duffy et al. (2002), Calabrese et al. (1993, 1996), Greil et al. (1998), Grof et al. (2003), Passmore et al. (2003), and Post et al. (1986, 1987, 2002)
Lamotrigine
If depression > mania
Valproate
Mood stabilizer
Table 9.6: (Continued)
c09.fm Page 150 Wednesday, October 19, 2005 9:15 AM
c09.fm Page 151 Wednesday, October 19, 2005 9:15 AM
Complex Combination Therapy
151
Table 9.7 Approaches to the rapid cycler with comorbid residual symptoms I. Possible Combination Treatments (in light of low response to monotherapy) A. Lithium + VPA B. Lithium + CBZ/OXC C. Lithium+LTG (Depressions (Dysphoric mania) (Schizoaffective, BPII) predominate) (Substance abuse) II. Adjunctive Treatments for co-occuring or residual symptoms A. Agitation/Anxiety/ CLONAZEPAM, LORAZEPAM, OR Insomnia ATYPICAL ANTIPSYCHOTICS (A.A) B. Psychosis ATYPICAL ANTIPSYCHOTICS (A.A) C. Persistent Cycling THIRD MOOD STABILIZER, A.A. D. Weight Loss TOPIRAMATE, ZONISAMIDE E. Alcohol Avoidance TOPIRAMATE, NALTREXONE (ACAMPROSATE); and 12-step program F. High Blood Pressure or DIHYDROPYRIDINE CALCIUM Ultradian Cycling CHANNEL BLOCKER G. Atypical Depression (SNRI + BUPROPION ≅ MAOI) H. Fatigue/Lassitude MODAFINIL, PSYCHOMOTOR STIMULANT I. Chronic Pain Syndromes GABAPENTIN, VENLAFAXINE, DULOXETINE J. Migraine VALPROATE, TOPIRAMATE K. Cognitive Dysfunction T3, CHOLINOMIMETIC (acetylcholine-esterase inhibitor), MEMANTINE (NMDA antagonist) VPA, valproate; CBZ; carbamazepine; OXC, oxcarbazepine; LTG, Lamotrigine; SNRI, serotonin and norepinephrine reuptake inhibitor; MAOI, monoamine oxidase inhibitor; T3, triiodothyronine; NMDA, N-methyl-D-aspartate; BP II, bipolar II
(Berlant, 2001; Johnson etal., 2003) over zonisamide; if one had a predominance of manic symptoms and/or sleep disorder, one might select zonisamide (at night) instead. Migraine prophylaxis can be accomplished with lithium, a calcium channel blocker, or valproate, with increasing evidence for the efficacy of topiramate for this syndrome as well. New data also support the use of topiramate in the achievement of alcohol abstinence (Johnson et al., 2003) and also possibly cocaine abstinence (Kampman et al., 2004). Comorbid anxiety symptoms are particularly important to target with focused therapy in light of their morbidity, relative resistance to lithium, and potential relationship to serious or completed suicide attempts. In this domain, the mood stabilizing anticonvulsants have much to offer over lithium carbonate, but lithium can be left in place given the evidence that it appears to possess superior antisuicide effects compared with the anticonvulsants (Baldessarini etal., 2003). For anxiety that is nonresponsive to these agents, one might consider augmentation with a high potency benzodiazepine (Beaudry etal., 1985; Charney and Woods, 1989) or with gabapentin (Pande etal., 1999, 2000; Pollack, 1993; Pollack, Matthews and Scott, 1998) since both have proven effective in many anxiety syndromes as well as in social phobia. Atypical antipsychotics may also be helpful (McIntyre and Katzman, 2003).
c09.fm Page 152 Wednesday, October 19, 2005 9:15 AM
152
Bipolar Psychopharmacotherapy
To the extent that anxiety is comorbid with a depressive core, one might consider the dual action of the serotonin-norepinephrine reuptake inhibitors (SNRIs) venlafaxine or duloxetine. These latter two compounds are also particularly useful in those with comorbid pain syndromes (Ninan, 2000; Masand and Mago, 2005), as is gabapentin.
TREATMENT-REFRACTORY DEPRESSION If the patient continued to manifest treatment-refractory depression, a variety of augmentation approaches are available (Table 9.8). T3 augmentation of an Table 9.8: Possible approaches to acute and resistant bipolar depression that can be considered Depression breaking through ongoing MS treatment (A) Single episode; No medications
(B) Non-rapid cycling
(C) Rapid cycling to ultrarapid cycling
1a. 1b. 1c. 2.
1a. 1b. 1c. 2.
Add AD Add LTG √ √
1a. 1b. 1c. 2.
Add LTG or Li Folate Add second MS (especially LTG) or Li
3.
AD plus MS vs.LTG Start folate Li augmentation of AD if start 1a Add AD if start 1b T3 potentiation
3.
√
4.
Add AA
4.
√
3. 3a. 3b. 3c. 4.
5. 6.
Revise AD Revise MS
5. 6.
√, consider SNRI √
5. 6.
7.
7. 7a. Add serotonin and High-potency noradrenaline reuptake benzodiazepine or inhibitor plus gabapentin (Neurontin) bupropion augmentation for (Wellbutrin) insomnia or anxiety 7b. Add MAOI after 4 weeks off serotonin
T3 Add AA Add third MS Add AD Add one of two other 3a, 3b or 3c options listed previously Revise AD, MS, AA For ultradian cycling consider a dihydropyridine calcium channel blocker, such as amlodipine (Norvasc), isradipine (Dynacirc) or nimodipine (Nimotop) High-dose T4
c09.fm Page 153 Wednesday, October 19, 2005 9:15 AM
Complex Combination Therapy 8. Revise AD, MS, AA
9. Discontinue T3 and add high-dose T4 10. ECT or repetitive transcranial magnetic stimulation or VNS (if and when available)
153
8. Gabapentin for insomnia, anxiety, restless legs and alcohol abuse 9. Carbamazepine for those with a history of alcohol abuse 10. √
AA, atypical antipsychotic; AD, antidepressant; ECT, electroconvulsive therapy; Li, lithium (Eskalith); LTG, Lamotrigine (Lamictal); MS, mood stabilizer; T3, triiodothyronine; T4, thyroxine; VNS, vagus nerve stimulation; √ = as in A; SNRI, serotonin-norepinephrine reuptake inhibitor; MAOI, monoamine oxidase inhibitor
antidepressant may enhance or speed up response, with a higher percentage of women than men responding (Altshuler et al., 2001). Folate augmentation may also be effective in light of the Coppen et al. data of folate’s superiority over placebo in augmentation strategies in lithium augmentation (Coppen, Chaudhry and Swade, 1986) and in unipolar depression (Coppen and Bailey, 2000). Attempting to target all three aminergic systems involved in depression with a combination of venlafaxine and bupropion (Fatemi et al., 1999) may be an alternative to the use of a monoamine oxidase inhibitor, with its more difficult safety profile and requirement for dietary restriction. If lamotrigine were not already in the treatment regimen, this drug would certainly be worthy of consideration at this time (Calabrese et al., 1999, 2003b). If the patient were on concomitant valproate treatment, the starting dose and rate of dose titration of lamotrigine should be at least half as slow as normally recommended because of the increased risk of serious rash on this combination and the ability of valproate to double (or more) lamotrigine blood levels (Guberman et al., 1999). If the patient continues to experience treatment-refractory depression, either of the chronic persistent variety or in rapidly recurrent phasic episodes, one might consider discontinuing T 3 augmentation and beginning superphysiologic high-dose T4 potentiation. This latter modality has been reported to be a successful augmentation strategy for both rapid cycling patients (Stancer and Persad, 1982; Bauer and Whybrow, 1990; Baumgartner, Bauer and Hellweg, 1994) and in persistent treatment-refractory depression in the studies of Bauer et al. (1998, 2001, 2002). They recommend slowly titrating the dose of T4 toward a target of 300–500 μg/day or a free thyroxin index of 150% of normal.
c09.fm Page 154 Wednesday, October 19, 2005 9:15 AM
154
Bipolar Psychopharmacotherapy
EVOLVING ROLE OF ATYPICAL ANTIPSYCHOTICS The antimanic effects of the typical as well as the atypical antipsychotics have now been demonstrated in controlled studies (Strakowski et al., 2003). What is less certain is the degree of antidepressant efficacy either acutely or in long-term prophylaxis of the illness. Augmentation with these agents for refractory depression would appear to be an appropriate strategy in light of the evidence of the acute antidepressant efficacy of the olanzapine/fluoxetine combination (Tohen et al., 2003) and the likely antidepressant effects of ziprasidone and aripiprazole based on their potential special mechanisms of action. In addition to dopamine receptor blockade, ziprasidone also blocks reuptake of serotonin and dopamine (Seeger et al., 1995); aripiprazole, as a partial agonist at D1, D2, D3 and 5HT1A receptors, and a full antagonist of 5HT2 receptors (Keck and McElroy, 2003), should theoretically convey some antidepressant efficacy as well. This argument is further enhanced by the findings that the full D2, D3 agonist pramipexole has antidepressant effects in bipolar depression (Goldberg, Frye and Dunn, 1999; Zarate et al., 2004; Goldberg, Burdick, and Endick, 2004) and both 5HT1A agonism and 5HT2 blockade have been associated with antidepressant effects of other modalities (Deakin, 1991). In a naturalistic study, quetiapine had promising antidepressant effects as an open adjunct (Keck, 2001) and in a controlled clinical trial was superior to placebo in augmentation treatment for obsessive-compulsive disorder (Atmaca et al., 2002). Calabrese et al. (2005) reported robust antidepressant and antianxiety effects of quetiapine, 300 mg or 600 mg, versus placebo.
EMPIRICAL AND THEORETICAL RATIONALES FOR POLYPHARMACY As noted in the introduction, the rationale for increasingly complex combination therapy as part of the routine treatment for bipolar illness is largely driven by clinical need. When the patient does not respond to monotherapy or simple combination approaches, one must consider other options (Table 9.9).
A STANDARD APPROACH IN OTHER CHRONIC MEDICAL CONDITIONS Certainly, use of combination strategies is standard practice in many other branches of medicine, most notably in many cancer chemotherapies, treatment for congestive failure, tuberculosis, AIDS, the arthritides and others. Almost a century ago Sir William Osler noted that “The true polypharmacy is the skillful combination of remedies” (Bean and Osler, 1951). The modern question remains as to how best to achieve this goal.
c09.fm Page 155 Wednesday, October 19, 2005 9:15 AM
Complex Combination Therapy
155
Table 9.9: Rationales for Complex Combination Therapy (CCT) • Need (failure to respond to monotherapy and dual-therapy) • Treatment of pleomorphic types, patterns and frequencies of illness (mania, depression and mixed states, rapid and ultra-ultra rapid cycling) • Wish to treat to full remission (using pharmacodynamic additive or synergistic effects) • Avoidance of breakthrough episodes (i.e., avoiding tolerance development by employing multiple neurotransmitter targets) • Targeting of comorbid conditions (anxiety disorders 40%, substance use 40%, weight gain 50–75%) • Avoidance of side effects (lower doses so that whole regimen is below side-effects threshold) • Different medications and psychotherapies for different stages of illness evolution and suicidality: – in acute treatment need for rapidity of response, crisis intervention and psychoeducation – in prevention/long-term efficacy use combinations in service of tolerability/ compliance, and education/cognitive-behavioral techniques in service of maintaining stability • CCT is a common and recommended mode in many other chronic medical conditions (i.e., AIDS, tuberculosis, congestive heart failure, rheumatoid arthritis, cancer)
COMBINATION OF AGENTS WITH DIFFERENT MECHANISMS In the absence of detailed studies, one would recommend using drugs with different mechanisms of action (Figure 9.6) rather than, for example, applying two different agents with similar mechanisms, such as two SSRIs. This approach targets a new neurochemical system potentially relevant to the patient’s residual symptoms, and adding a novel mechanism should make the late emergence of treatment resistance via a tolerance process less likely to eventually occur after an initially good response (Post and Weiss, 1996; Weiss et al., 1995).
MINIMIZING SIDE EFFECTS Certainly, a crucial therapeutic principle in complex combination therapy is minimizing the total side-effects burden. This can often be accomplished by slow titration of a given adjunctive agent so that not only it, but also the total medication burden, remains below an individual’s side-effects threshold. Under this rubric, titration to conventional target doses or blood levels is inappropriate, and one must be primarily guided by issues of tolerability. This issue is especially relevant in the psychopharmacology of bipolar disorder, because within a wide range of acceptable doses and drug levels there is relatively little evidence of a direct relationship of these variables to clinical response.
c09.fm Page 156 Wednesday, October 19, 2005 9:15 AM
156
Bipolar Psychopharmacotherapy
Figure 9.6: Mechanisms of anticonvulsant action. Effects grouped and schematized as anti-excitatory (left) via inhibition of glutamate release (circles) or receptor effects, or pro-inhibitory (right) via enhancing benzodiazepine receptors (Bz-R), GABA levels (squares) or receptor activity. Glutamate is released with BDNF and zinc to act on NMDA, AMPA and kainate receptors. Sodium influx through the AMPA receptor depolarizes the cell, which releases the magnesium block at the NMDA receptor, which allows the influx of calcium ions. Benzodiazepine receptors facilitate the actions of GABA-A receptors allowing chloride influx and inhibition of cell firing. Levetiracetam facilitates GABA by inhibiting the negative modulators of the GABA receptors, zinc and β-carboline. CBZ, carbamazepine; OXC, oxcarbazepine; PHT, phenytoin; LTG, lamotrigine; VPA, valproate; TPM, topiramate; ZON, zonisamide; Na+, sodium channel; BDNF, brain-derived neurotrophic factor; K+, potassium channel; Li, lithium; NMDA R, N-methyl-D-aspartate receptor; Zn, zinc; Ca++, calcium channel; AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate; Mg, magnesium; NIM, nimodipine; ISR, isradipine; AML, amlodipine; GPN, gabapentin; GABA, γ-aminobutyric acid; Benzo, benzodiazepine; Cl−, chloride channel; TIA, tiagabine; BZ-R, benzodiazepine receptor
ATTENTION TO PHARMACOKINETIC INTERACTIONS One must also carefully attend to possible pharmacokinetic interactions that may directly or covertly influence the total side-effects burden. For example, if a patient is taking the combination of carbamazepine and valproate, valproate will produce a number of effects on carbamazepine that can enhance the side-effects threshold. This includes inhibition of the epoxide hydroxylase leading to a build-up of the active
c09.fm Page 157 Wednesday, October 19, 2005 9:15 AM
Complex Combination Therapy
157
10,11-epoxide metabolite of carbamazepine (which is often not measured in routine assays) as well as valproate displacing carbamazepine from its protein-binding sites and thus adding to the level of free drug (Ketter et al., 1999). This is not to say that the combination cannot be used, but only that if one is adding valproate to a regimen with carbamazepine in place, one should consider a preventive 40–50% reduction in carbamazepine dosage in anticipation of such interactions. Similarly, if one were going to go on an erythromycin antibiotic or one of its analogs, a reduction in the dose of carbamazepine in advance of the appearance of side effects would be precautionary because of the approximate doubling of carbamazepine levels with the inhibition of the hepatic microsomal enzyme 3A4 responsible for carbamazepine metabolism.
ADVERSE PHARMACODYNAMIC INTERACTIONS Consideration of adverse pharmacodynamic interactions leading to an increased side-effects burden should also be considered. For example, while weight gain on lithium or valproate is often relatively mild and manageable, on the combination it may become excessive. If atypical antipsychotics with major weight gain liability (such as clozapine or olanzapine) are also used, the patient may be at greatly increased risk for not only problems with overweight, but also a metabolic syndrome associated with many additional medical liabilities, including hypercholesteremia, hyperlipidemia, relative insulin resistance or even overt diabetes (Nemeroff, 2003). Because depression itself is a very potent risk factor for myocardial infarction (MI) and stroke, as well as a variety of other medical syndromes (Musselman, Evans and Nemeroff, 1998), avoiding other associated and interactive risk factors such as those associated with weight gain becomes even more critical. This consideration should be factored into the initial treatment equations in the hope of preventing the development of an overweight syndrome as well as the use of weight loss modalities now that several anticonvulsant drugs used in bipolar disorder (i.e., topiramate and zonisamide) have been identified (McElroy et al., 2000, 2005; Leverich et al., 2005) as having weight loss side effects.
TARGETED PSYCHOTHERAPY IN BIPOLAR ILLNESS One of the most important treatment modalities in the use of complex combination therapy for bipolar illness is the use of psychotherapeutic techniques and their various combinations as a function of stage of treatment initiation and evolution. More than a dozen randomized controlled studies have documented the efficacy of a variety of psychotherapeutic approaches in the treatment for bipolar illness (Otto,
c09.fm Page 158 Wednesday, October 19, 2005 9:15 AM
158
Bipolar Psychopharmacotherapy
Reilly-Harrington and Sachs, 2003). These range from the early studies of couples marital therapy sessions of Davenport and colleagues (1977), to: individual, family and multifamily psychoeducational approaches (Colom et al., 2003; Fristad, Goldberg-Arnold and Gavazzi 2002; Fristad, Gavazzi and Mackinaw-Koons, 2003); cognitive and behavioral approaches (Cochran, 1984; Lam et al., 2000, 2003); symptom identification and relapse prevention (Perry et al., 1999); as well as other adjunctive approaches from psychosocial and cognitive rehabilitation techniques (Craighead and Miklowitz, 2000; Miklowitz et al., 2003), to existential psychotherapy (Palmer, Tucker and Swift, 2003).
NEED FOR EARLY INTERVENTION Given the now overwhelming data that a history of a greater number of prior episodes is a prognostic factor not only for a poor response to lithium (Table 9.3), but also for lamotrigine (Obrocea et al., 2002; Frye et al., 2005) and naturalistic treatment in general (Post et al., 2003a; Nolen et al., 2004), it becomes a clinical imperative to try to intervene at the first sign of bipolar symptoms causing impairment and attempt to prevent episode recurrence and evolution. The success of this clinical intervention is very dependent on the approach and motivation of the psychotherapist and the nature of the psychoeducational package and message delivered. Psychoeducational approaches have been shown to enhance treatment adherence and lead to more stable lithium levels as well as prevent relapse. Specific instruction about techniques for symptom recognition, plans for early intervention, and building a support system and treatment team, are all critical pieces of the psychoeducational package and are exquisitely detailed in a recent book by Miklowitz (2002). To the extent that the patient can become an active co-participant (along with the physician and clinician) in concerted action against the emergence of bipolar symptoms and full-blown episodes, treatment is even more likely to be successful. We have also found that reference to underlying neurobiological mechanisms in the illness (Post et al., 2003b) as well as positive neurochemical mechanisms of action of some of the psychopharmacological agents (Post et al., 2002 a,b) – particularly when they are neurotrophic, neuroprotective or enhance neurogenesis as does lithium (Table 9.10) – can also help patients better understand the illness and the need for careful monitoring and long-term sustained intervention.
THE ELUSIVE GOAL OF LONG-TERM PROPHYLAXIS Paradoxically, wellness can be a high risk factor for endangering long-term medical health in bipolar illness. Patients may all too readily become convinced, by themselves, by friends and relatives, and even by well-meaning clinicians and
c09.fm Page 159 Wednesday, October 19, 2005 9:15 AM
Complex Combination Therapy
159
Table 9.10: Impact of stress and psychotropic drugs on gene expression and brain structure Pathological
Adaptive
Affective Illness Stress Gluco-corticoids Lithium VPA ADs Transcription factor CREB Neurotrophic factor BDNF Anti-apoptopic factor Bcl-2 Neurite sprouting (in vitro) Neuroprotection (stroke) Neurogenesis (in vivo) Gliagenesis (in vivo) Neuronal viability (NAA by MRS in humans) Grey matter (in humans) Hippocampal volume (in humans)
↓ (↓) (↓) (↓)
↓ ↓
↓ ↓
↓ ↓ ↓ ↓ ↓
↓ ↓
↓
(↓)
↓
↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑
↑ ↑
–
↑ ↑
↑
↑ ↑
CREB, Cylic AMP response element-binding protein; BDNF, brain-derived neurotrophic factor; NAA, N-acetyl aspartate; MRS, magnetic resonance spectroscopy; VPA, valproate; AD S , antidepressants; ↑, increase; ↓, decrease; ( ), possibly
physicians, that treatment is no longer necessary. Many patients feel compelled to test this presumed reality with periods off medication, almost uniformly with disastrous consequences. The patient and family should be supplied with the appropriate statistics about the likelihood and rapidity of relapse once medications are tapered or stopped altogether. Patients should be told that after discontinuing lithium, the relapse rate is 50% within the first five months and 90% within a year and a half (Suppes et al., 1991). New evidence suggests that the rapidity of lithium taper may not be protective (Viguera, 2003), as had previously been believed (Baldessarini et al., 1996). We would still advocate a very slow taper of lithium in instances in which patients insist on such a discontinuation trial so that treatment can rapidly be reinstituted if symptoms begin to occur during the slow taper itself. Patients should be told that if relapse eventually occurs, there is no guarantee that they will either rapidly regain, or regain the full extent, of the responsivity of the previous treatment regimen. We and others have observed that about 10–15% of patients who were well for sustained periods of time, and who chose to discontinue lithium and then experienced a relapse, subsequently failed to re-respond to lithium re-institution at the same or even higher doses than those previously effective (Post etal., 1992, 1993; Bauer 1994; Koukopoulos etal., 1995; Maj, Pirozzi and Magliano, 1995; but see Berghofer and Muller-Oerlinghausen, 1996; Tondo et al., 1997). One small series that was not designed or powered to detect such an effect (Coryell etal., 1998) claimed that there was no discontinuation-induced refractoriness, although one of the patients in their study appeared to suffer from this experience,
c09.fm Page 160 Wednesday, October 19, 2005 9:15 AM
160
Bipolar Psychopharmacotherapy
and the NIMH collaborative study has indicated that every occurrence of a new depression carries an approximately 16% risk of refractoriness (Solomon etal., 2000). Thus, maintaining long-term wellness with full dose pharmacoprophylaxis is a goal that often requires considerable psychotherapeutic work and education to achieve. In complex combination therapy, reducing the total pharmacological load to reduce side effects is certainly in order. However, in the absence of further guidelines, one should consider following the general rubric that the same regimen that was required to achieve acute efficacy should be continued in long-term prophylaxis. Extrapolating from prophylaxis in unipolar illness, this full dose approach is clearly supported (Frank et al., 1993; Franchini et al., 1998; Keller, 2003). Dangers from the illness alone are great, but bipolar disorder also places the patient at increased risk for other illnesses such as comorbid use and abuse of alcohol and other substances (Sonne and Brady, 1999). To the extent that these vulnerabilities can be anticipated and prevented, an enormous benefit may also be derived.
CONCLUSIONS The psychopharmacotherapy of bipolar illness is like a team sport that requires the consistent input and good performance of a great many of its members in order to achieve success. We have outlined the apparent increasing need for very complex combination therapy for adult bipolar illness that has developed over the past 50 years, without much guidance from a systematic database. The same perspective is rapidly becoming apparent for childhood onset bipolar illness as well. We have highlighted one set of approaches to polypharmacy in bipolar illness based on the literature and a good deal of personal opinion. We hope that some of the principles elucidated in this chapter will help in the further development and refinement of these approaches and their success in assisting patient’s with bipolar illness to achieve and sustain long-term remission. However, it would appear that an entirely new set of research methodologies will need to be developed to begin to make more of the critical decisions in the polypharmacy of bipolar illness based on a strong empirical database. Until that happens, careful charting of each patient’s individual course of illness, side effects and response to treatment may prove to be one of the best tools in making the complexities and choices in combination therapy as rational as possible for each patient with bipolar illness.
REFERENCES Aagaard J, Vestergaard P. Predictors of outcome in prophylactic lithium treatment: A 2-year prospective study. J Affect Disord 1990; 18: 259–266. Abou-Saleh MT, Coppen A. Who responds to prophylactic lithium? J Affect Disord 1986; 10: 115–125.
c09.fm Page 161 Wednesday, October 19, 2005 9:15 AM
Complex Combination Therapy
161
Altshuler LL, Bauer M, Frye MA, Gitlin MJ, Mintz J, Szuba MP, Leight KL, Whybrow PC. Does thyroid supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature. Am J Psychiatry 2001; 158: 1617–1622. Atmaca M, Kuloglu M, Tezcan E, Gecici O. Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: A single-blind, placebo-controlled study. Int Clin Psychopharmacol 2002; 17: 115–119. Baldessarini RJ, Tondo L, Faedda GL, Suppes TR, Floris G, Rudas N. Effects of the rate of discontinuing lithium maintenance treatment in bipolar disorders. J Clin Psychiatry 1996; 57: 441–448. Baldessarini RJ, Tondo L. Does lithium treatment still work? Evidence of stable responses over three decades. Arch Gen Psychiatry 2000; 57: 187–190. Baldessarini RJ, Tondo L, Hennen J. Lithium treatment and suicide risk in major affective disorders: update and new findings. J Clin Psychiatry 2003; 64 Suppl. 5: 44–52. Bauer M. Refractoriness induced by lithium discontinuation despite adequate serum lithium levels (letter). Am J Psychiatry 1994; 151: 1522. Bauer MS, Whybrow PC. Rapid cycling bipolar affective disorder II. Treatment of refractory rapid cycling with high-dose levothyroxine: a preliminary study. Arch Gen Psychiatry 1990; 47: 435–440. Bauer M, Hellweg R, Graf KJ, Baumgartner A. Treatment of refractory depression with high-dose thyroxine. Neuropsychopharmacology 1998; 18: 444–455. Bauer M, Priebe S, Berghofer A, Bschor T, Kiesslinger U, Whybrow PC. Subjective response to and tolerability of long-term supraphysiological doses of levothyroxine in refractory mood disorders. J Affect Disord 2001; 64: 35–42. Bauer M, Berghofer A, Bschor T, Baumgartner A, Kiesslinger U, Hellweg R, Adli M, Baethge C, Muller-Oerlinghausen B. Supraphysiological doses of L-thyroxine in the maintenance treatment of prophylaxis-resistant affective disorders. Neuropsychopharmacology 2002; 27: 620–628. Baumgartner A, Bauer M, Hellweg R. Treatment of intractable non-rapid cycling bipolar afective disorder with high-dose thyroxine: An open clinical trial. Neuropsychopharmacology 1994; 10: 183–189. Bean RB, Osler SW. Aphorisms: From His Bedside Teaching and Writings. Springfield, Ill.: Charles C. Thomas Publisher, 1951. Beaudry P, Fontaine R, Chouinard G, Annable L. An open clinical trial of clonazepam in the treatment of patients with recurrent panic attacks. Prog Neuropsychopharmacol Biol Psychiatry 1985; 9: 589–592. Berghofer A, Muller-Oerlinghausen B. No loss of efficacy after discontinuation and reinstitution of long-term lithium treatment? In: Gallicchio VS, Birch NJ, eds Lithium: Biochemical and Clinical Advances. Cheshire: Weidner Publishing Group, 1996, pp. 39–46. Berlant JL. Topiramate in posttraumatic stress disorder: Preliminary clinical observations. J Clin Psychiatry 2001; 62 Suppl. 17: 60–63. Biederman J, Mick E, Bostic JQ, Prince J, Daly J, Wilens TE, Spencer T, Garcia-Jetton J, Russell R, Wozniak J, Faraone SV. The naturalistic course of pharmacologic treatment of children with maniclike symptoms: A systematic chart review. J Clin Psychiatry 1998; 59: 628–637. Bowden CL. Predictors of response to divalproex and lithium. J Clin Psychiatry 1995; 56 Suppl. 3: 25–30. Briley M. New hope in the treatment of painful symptoms in depression. Curr Opin Investig Drugs 2003; 4: 42–45.
c09.fm Page 162 Wednesday, October 19, 2005 9:15 AM
162
Bipolar Psychopharmacotherapy
Bunevicius R, Kazanavicius G, Zalinkevicius R, Prange AJ, Jr. Effects of thyroxine as compared with thyroxine plus triiodothyronine in patients with hypothyroidism. N Engl J Med 1999; 340: 424–429. Calabrese JR, Woyshville MJ, Kimmel SE, Rapport DJ. Predictors of valproate response in bipolar rapid cycling. J Clin Psychopharmacol 1993; 13: 280–283. Calabrese JR, Fatemi SH, Kujawa M, Woyshville MJ. Predictors of response to mood stabilizers. J Clin Psychopharmacol 1996; 16: 24S–31S. Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd GD. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry 1999; 60: 79–88. Calabrese JR, Shelton M, Rapport D, Youngstrom E, Shirley E, Elhaj O, Packer K, Bilali S, Findling RL. A 20-month, double-blind, maintenance study of lithium vs. divalproex monotherapy in bipolar I and II disorder accompanied by rapid cycling. Bipolar Disord 2003a; 5: 38–38. Calabrese JR, Vieta E, Shelton MD. Latest maintenance data on lamotrigine in bipolar disorder. Eur Neuropsychopharmacol 2003b; 13 Suppl. 2: 57–66. Calabrese JR, Keck PE, Jr, Macfadden W, Minkwitz M, Ketter TA, Weisler RH, Cutler AJ, McCoy R, Wilson E, Mullen J. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005; 162: 1351–1360. Charney DS, Woods SW. Benzodiazepine treatment of panic disorder: A comparison of alprazolam and lorazepam. J Clin Psychiatry 1989; 50: 418–423. Cochran SD. Preventing medical noncompliance in the outpatient treatment of bipolar affective disorders. J Consult Clin Psychol 1984; 52: 873–878. Colom F, Vieta E, Martinez-Aran A, Reinares M, Goikolea JM, Benabarre A, Torrent C, Comes M, Corbella B, Parramon G, Corominas J. A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar patients whose disease is in remission. Arch Gen Psychiatry 2003; 60: 402–407. Cooke RG, Joffe RT, Levitt AJ. T3 augmentation of antidepressant treatment in T4-replaced thyroid patients. J Clin Psychiatry 1992; 53: 16–18. Coppen A, Bailey J. Enhancement of the antidepressant action of fluoxetine by folic acid: A randomised, placebo controlled trial. J Affect Disord 2000; 60: 121–130. Coppen A, Chaudhry S, Swade C. Folic acid enhances lithium prophylaxis. J Affect Disord 1986; 10: 9–13. Coryell W, Solomon D, Leon AC, Akiskal HS, Keller MB, Scheftner WA, Mueller T. Lithium discontinuation and subsequent effectiveness. Am J Psychiatry 1998; 155: 895–898. Craighead WE, Miklowitz DJ. Psychosocial interventions for bipolar disorder. J Clin Psychiatry 2000; 61 Suppl. 13: 58–64. Davenport YB, Ebert MH, Adland ML, Goodwin FK. Couples group therapy as an adjunct to lithium maintenance of the manic patient. Am J Orthopsychiatry 1977; 47: 495–502. Deakin JFW. Depression and 5HT. Int Clin Psychopharmacol 1991; 6 Suppl. 3: 23–31. DelBello MP, Schwiers ML, Rosenberg HL, Strakowski SM. A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. J Am Acad Child Adolesc Psychiatry 2002; 41: 1216–1223. Denicoff KD, Smith-Jackson EE, Disney ER, Ali SO, Leverich GS, Post RM. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. J Clin Psychiatry 1997a; 58: 470–478. Denicoff KD, Smith-Jackson EE, Bryan AL, Ali SO, Post RM. Valproate prophylaxis in a prospective clinical trial of refractory bipolar disorder. Am J Psychiatry 1997b; 154: 1456–1458.
c09.fm Page 163 Wednesday, October 19, 2005 9:15 AM
Complex Combination Therapy
163
Duffy A, Alda M, Kutcher S, Cavazzoni P, Robertson C, Grof E, Grof P. A prospective study of the offspring of bipolar parents responsive and nonresponsive to lithium treatment. J Clin Psychiatry 2002; 63: 1171–1178. Fatemi SH, Emamian ES, Kist DA. Venlafaxine and bupropion combination therapy in a case of treatment-resistant depression. Ann Pharmacother 1999; 33: 701–703. Franchini L, Gasperini M, Perez J, Smeraldi E, Zanardi R. Dose-response efficacy of paroxetine in preventing depressive recurrences: A randomized, double-blind study. J Clin Psychiatry 1998; 59: 229–232. Frangou S, Raymont V, Bettany D. The Maudsley bipolar disorder project. A survey of psychotropic prescribing patterns in bipolar I disorder. Bipolar Disord 2002; 4: 378–385. Frank E, Kupfer DJ, Perel JM, Cornes C, Mallinger AG, Thase ME, McEachran AB, Grochocinski VJ. Comparison of full-dose versus half-dose pharmacotherapy in the maintenance treatment of recurrent depression. J Affect Disord 1993; 27: 139–145. Frazier JA, Meyer MC, Biederman J, Wozniak J, Wilens TE, Spencer TJ, Kim GS, Shapiro S. Risperidone treatment for juvenile bipolar disorder: A retrospective chart review. J Am Acad Child Adolesc Psychiatry 1999; 38: 960–965. Fristad MA, Goldberg-Arnold JS, Gavazzi SM. Multifamily psychoeducation groups (MFPG) for families of children with bipolar disorder. Bipolar Disord 2002; 4: 254–262. Fristad MA, Gavazzi SM, Mackinaw-Koons B. Family psychoeducation: An adjunctive intervention for children with bipolar disorder. Biol Psychiatry 2003; 53: 1000–1008. Frye M, Ketter T, Goldberg J, Antonijevic Z, Calabrese J. Previous episode burden and response to treatment in bipolar I disorder. Bipolar Disord 2003; 5: 48. Frye MA, Ketter TA, Leverich GS, Huggins T, Lantz C, Denicoff KD, Post RM. The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J Clin Psychiatry 2000; 61: 9–15. Frye MA, Obrocea G, Ketter TA, Dunn RT, Leverich GS, Luckenbaugh DA, Post RM. Efficacy of lamotrigine versus gabapentin versus placebo in refractory affective disorders: crossovers and combination therapy. Aspects of Affect 2005; 1: 46–49. Gelenberg AJ, Kane JM, Keller MB, Lavori P, Rosenbaum JF, Cole K, Lavelle J. Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder. N Engl J Med 1989; 321: 1489–1493. Gitlin MJ, Swendsen J, Heller TL, Hammen C. Relapse and impairment in bipolar disorder. Am J Psychiatry 1995; 152: 1635–1640. Goldberg JF, Harrow M, Sands JR. Lithium and the longitudinal course of bipolar illness. Psychiatric Ann 1996a; 26: 651–658. Goldberg JF, Harrow M, Leon AC. Lithium treatment of bipolar affective disorders under naturalistic followup conditions. Psychopharmacol Bull. 1996b; 32: 47–54. Goldberg JF, Frye MA, Dunn RT. Pramipexole in refractory bipolar depression (letter). Am J Psychiatry 1999; 156: 798. Goldberg JF, Burdick KE, Endick CJ. Preliminary randomized, double-blind, placebocontrolled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am. J Psychiatry 2004; 161: 564–566. Greil W, Kleindienst N, Erazo N, Muller-Oerlinghausen B. Differential response to lithium and carbamazepine in the prophylaxis of bipolar disorder. J Clin Psychopharmacol 1998; 18: 455–460. Grof P. Selecting effective long-term treatment for bipolar patients: monotherapy and combinations. J Clin Psychiatry 2003; 64 Suppl 5: 53–61. Guberman AH, Besag FM, Brodie MJ, Dooley JM, Duchowny MS, Pellock JM, Richens A, Stern RS, Trevathan E. Lamotrigine-associated rash: Risk/benefit considerations in adults and children. Epilepsia 1999; 40: 985–991.
c09.fm Page 164 Wednesday, October 19, 2005 9:15 AM
164
Bipolar Psychopharmacotherapy
Hellander M. Pediatric bipolar disorder: the parent advocacy perspective. Biol Psychiatry 2003; 53: 935–937. Johnson BA, Ait-Daoud N, Bowden CL, DiClemente CC, Roache JD, Lawson K, Javors MA, Ma JZ. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet 2003; 361: 1677–1685. Judd LL, Akiskal HS, Schettler PJ, Endicott J, Maser J, Solomon DA, Leon AC, Rice JA, Keller MB. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002; 59: 530–537. Kampman KM, Pettinati H, Lynch KG, Dackis C, Sparkman T, Weigley C, O’Brien CP. A pilot trial of topiramate for the treatment of cocaine dependence. Drug Alcohol Depend. 2004; 75: 233–240. Keck PE, Jr. New antiepileptics in the treatment of bipolar disorder. Syllabus and Proceedings Summary of the 2001 American Psychiatric Association Meeting, New Orleans, May 5–10, Abstract 34E, 93. Keck PE, Jr, McElroy SL. Aripiprazole: A partial dopamine D2 receptor agonist antipsychotic. Expert Opin Investig Drugs 2003; 12: 655–662. Keller MB. Paroxetine treatment of major depressive disorder. Psychopharmacology Bulletin 2003; 37: 42–52. Ketter TA, Frye MA, Cora-Locatelli G, Kimbrell TA, Post RM. Metabolism and excretion of mood stabilizers and new anticonvulsants. Cell Mol Neurobiol 1999; 19: 511–532. Koukopoulos A, Reginaldi D, Minnai G, Serra G, Pani L, Johnson FN. The long term prophylaxis of affective disorders. Adv in Biochem Psychopharmacol 1995; 49: 127–147. Kowatch RA, Suppes T, Carmody TJ, Bucci JP, Hume JH, Kromelis M, Emslie GJ, Weinberg WA, Rush AJ. Effect size of lithium, divalproex sodium, and carbamazepine in children and adolescents with bipolar disorder. J Am Acad Child Adoles Psychiatry 2000; 39: 713–720. Kowatch RA, Sethuraman G, Hume JH, Kromelis M, Weinberg WA. Combination pharmacotherapy in children and adolescents with bipolar disorder. Biol Psychiatry 2003; 53: 978–984. Kupfer DJ, Frank E, Grochocinski VJ, Cluss PA, Houck PR, Stapf DA. Demographic and clinical characteristics of individuals in a bipolar disorder case registry. J Clin Psychiatry 2002; 63: 120–125. Kupka RW, Luckenbaugh DA, Post RM, Suppes T, Altshuler LL, Keck PE, Jr, Frye MA, Denicoff KD, Grunze H, Leverich GS, McElroy SL, Walden J, Nolen WA. Comparison of rapid-cycling and non-rapid-cycling bipolar disorder based on prospective mood ratings in 539 outpatients. Am J Psychiatry 2005; 162: 1273–1280. Lam DH, Bright J, Jones S, Hayward P, Schuck N, Chisholm D, Sham P. Cognitive therapy for bipolar illness – A pilot study of relapse prevention. Cog Ther Res 2000; 24: 503–520. Lam DH, Watkins ER, Hayward P, Bright J, Wright K, Kerr N, Parr-Davis G, Sham P. A randomized controlled study of cognitive therapy for relapse prevention for bipolar affective disorder: outcome of the first year. Arch Gen Psychiatry 2003; 60: 145–152. Lange KJ, McInnis MG. Studies of anticipation in bipolar affective disorder. CNS Spect 2002; 7: 196–202. Leverich GS, McElroy SL, Altshuler LL, Frye MA, Grunze H, Keck PE, Jr, Kupka RW, Nolen WA, Suppes T, Walden J, Post RM. The anticonvulsant zonisamide in bipolar illness: clinical response and weight loss. Aspects of Affect 2005; 1: 53–56. Levine J, Chengappa KN, Brar JS, Gershon S, Yablonsky E, Stapf D, Kupfer DJ. Psychotropic drug prescription patterns among patients with bipolar I disorder. Bipolar Disord 2000; 2: 120–130.
c09.fm Page 165 Wednesday, October 19, 2005 9:15 AM
Complex Combination Therapy
165
Maj M, Pirozzi R, Magliano L. Nonresponse to reinstituted lithium prophylaxis in previously responsive bipolar patients: prevalence and predictors. Am J Psychiatry 1995; 152: 1810–1811. Maj M, Pirozzi R, Magliano L, Bartoli L. Long-term outcome of lithium prophylaxis in bipolar disorder: A 5-year prospective study of 402 patients at a lithium clinic. Am J Psychiatry 1998; 155: 30–35. Masand PS, Mago R. Duloxetine for pain symptoms in patients with major depressive disorder. Curr. Psychiatry Rep. 2005; 7: 203–205. McElroy SL, Suppes T, Keck PE, Frye MA, Denicoff KD, Altshuler LL, Brown ES, Nolen WA, Kupka RW, Rochussen J, Leverich GS, Post RM. Open-label adjunctive topiramate in the treatment of bipolar disorders. Biol Psychiatry 2000; 47: 1025–1033. McElroy SL, Altshuler LL, Suppes T, Keck PE, Frye MA, Denicoff KD, Nolen WA, Kupka RW, Leverich GS, Rochussen JR, Rush AJ, Post RM. Axis I psychiatric comorbidity and its relationship to historical illness variables in 288 patients with bipolar disorder. Am J Psychiatry 2001; 158: 420–426. McElroy SL, Suppes T, Keck PE, Jr, Black D, Frye MA, Altshuler LL, Nolen WA, Kupka RW, Leverich GS, Walden J, Grunze H, Post RM. Open-label adjunctive zonisamide in the treatment of bipolar disorders: A prospective trial. J Clin Psychiatry 2005; 66: 617–624. McIntyre R, Katzman M. The role of atypical antipsychotics in bipolar depression and anxiety disorders. Bipolar Disord 2003; 5 Suppl 2: 20–35. Miklowitz DJ. The Bipolar Disorder Survival Guide: What You and Your Family Need to Know. New York: Guilford Press, 2002. Miklowitz DJ, Richards JA, George EL, Frank E, Suddath RL, Powell KB, Sacher JA. Integrated family and individual therapy for bipolar disorder: Results of a treatment development study. J Clin Psychiatry 2003; 64: 182–191. Musselman DL, Evans DL, Nemeroff CB. The relationship of depression to cardiovascular disease: Epidemiology, biology, and treatment. Arch Gen Psychiatry 1998; 55: 580–592. Nemeroff CB. Safety of available agents used to treat bipolar disorder: Focus on weight gain. J Clin Psychiatry 2003; 64: 532–539. Ninan PT. Use of venlafaxine in other psychiatric disorders. Depress Anxiety 2000; 12 Suppl. 1: 90–94. Nolen WA, Luckenbaugh DA, Altshuler LL, Suppes TM, McElroy SL, Frye MA, Kupka RW, Keck PE, Leverich GS, Post RM. Correlates of 1 year prospective outcome in bipolar disorder: Results from the Stanley Foundation Bipolar Network. Am J Psychiatry 2004; 161:1447–1454. O’Connell RA, Mayo JA, Flatow L, Cuthbertson B, O’Brien BE. Outcome of bipolar disorder on long-term treatment with lithium. Br J Psychiatry 1991; 159: 123–129. Obrocea GV, Dunn RM, Frye MA, Ketter TA, Luckenbaugh DA, Leverich GS, Speer AM, Osuch EA, Jajodia K, Post RM. Clinical predictors of response to lamotrigine and gabapentin monotherapy in refractory affective disorders. Biol Psychiatry 2002; 51: 253–260. Otto MW, Reilly-Harrington N, Sachs GS. Psychoeducational and cognitive-behavioral strategies in the management of bipolar disorder. J Affect Disord 2003; 73: 171–181. Palmer A, Tucker S, Swift A. Group mindfulness based cognitive therapy for bipolar disorder. Bipolar Disord 2003; 5: 73. Pande AC, Davidson JR, Jefferson JW, Janney CA, Katzelnick DJ, Weisler RH, Greist JH, Sutherland SM. Treatment of social phobia with gabapentin: A placebo-controlled study. J Clin Psychopharmacol 1999; 19: 341–348.
c09.fm Page 166 Wednesday, October 19, 2005 9:15 AM
166
Bipolar Psychopharmacotherapy
Pande AC, Pollack MH, Crockatt J, Greiner M, Chouinard G, Lydiard RB, Taylor CB, Dager SR, Shiovitz T. Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol 2000; 20: 467–471. Passmore MJ, Garnham J, Duffy A, MacDougall M, Munro A, Slaney C, Teehan A, Alda M. Phenotypic spectra of bipolar disorder in responders to lithium versus lamotrigine. Bipolar Disord 2003; 5: 110–114. Pazzaglia PJ, Post RM, Ketter TA, George MS, Marangell LB. Preliminary controlled trial of nimodipine in ultra-rapid cycling affective dysregulation. Psychiatry Res 1993; 49: 257–272. Pazzaglia PJ, Post RM, Ketter TA, Callahan AM, Marangell LB, Frye MA, George MS, Kimbrell TA, Leverich GS, Cora-Locatelli G, Luckenbaugh D. Nimodipine monotherapy and carbamazepine augmentation in patients with refractory recurrent affective illness. J Clin Psychopharmacol 1998; 18: 404–413. Perry A, Tarrier N, Morriss R, McCarthy E, Limb K. Randomised controlled trial of efficacy of teaching patients with bipolar disorder to identify early symptoms of relapse and obtain treatment. Br Med J 1999; 318: 149–153. Pollack MH. Innovative uses of benzodiazepines in psychiatry. Can J Psychiatry 1993; 38 Suppl 4: S122–S126. Pollack MH, Matthews J, Scott EL. Gabapentin as a potential treatment for anxiety disorders (letter). Am J Psychiatry 1998; 155: 992–993. Post RM, Uhde TW, Roy-Byrne PP, Joffe RT. Antidepressant effects of carbamazepine. Am J Psychiatry 1986; 143: 29–34. Post RM, Uhde TW, Roy-Byrne PP, Joffe RT. Correlates of antimanic response to carbamazepine. Psychiatry Res 1987; 21: 71–83. Post RM, Weiss SRB. A speculative model of affective illness cyclicity based on patterns of drug tolerance observed in amygdala-kindled seizures. Mol Neurobiol 1996; 13: 33–60. Post RM, Leverich GS, Altshuler L, Mikalauskas K. Lithium-discontinuation-induced refractoriness: preliminary observations. Am J Psychiatry 1992; 149: 1727–1729. Post RM, Leverich GS, Pazzaglia PJ, Mikalauskas K, Denicoff K. Lithium tolerance and discontinuation as pathways to refractoriness. In: Birch NJ, Padgham C, Hughes MS, eds Lithium in Medicine and Biology. Lancashire, UK: Marius Press, 1993. p. 71–84. Post RM, Speer AM. A brief history of anticonvulsant use in affective disorders. In: Trimble MR, Schmitz B, eds Seizures, Affective Disorders and Anticonvulsant Drugs. Surrey, UK: Clarius Press, 2002a. p. 53–81. Post RM, Speer AM, Obrocea GV, Leverich GS. Acute and prophylactic effects of anticonvulsants in bipolar depression. Clin Neurosci Res 2002b; 2: 228–251. Post RM, Denicoff KD, Leverich GS, Altshuler LL, Frye MA, Suppes TM, Rush AJ, Keck PE, McElroy SL, Luckenbaugh DA, Pollio C, Kupka R, Nolen WA. Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH Life Chart Method. J Clin Psychiatry 2003a; 64: 680–690. Post RM, Speer AM, Hough CJ, Xing G. Neurobiology of bipolar illnes: Implications for future study and therapeutics. Ann Clin Psychiatry 2003b; 15: 85–94. Prien RF, Caffey EMJ, Klett CJ. Factors associated with treatment success in lithium carbonate prophylaxis. Report of the Veterans Administration and National Institute of Mental Health collaborative study group. Arch Gen Psychiatry 1974; 31: 189–192. Sachs GS, Thase ME, Otto MW, Bauer M, Miklowitz D, Wisniewski SR, Lavori P, Lebowitz B, Rudorfer M, Frank E, Nierenberg AA, Fava M, Bowden C, Ketter T, Marangell L, Calabrese J, Kupfer D, Rosenbaum JF. Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry 2003; 53: 1028–1042.
c09.fm Page 167 Wednesday, October 19, 2005 9:15 AM
Complex Combination Therapy
167
Sarantidis D, Waters B. Predictors of lithium prophylaxis effectiveness. Prog Neuropsychopharmacol 1981; 5: 507–510. Seeger TF, Seymour PA, Schmidt AW, Zorn SH, Schulz DW, Lebel LA, McLean S, Guanowsky V, Howard HR, Lowe JA, III,. Ziprasidone (CP-88,059): A new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 1995; 275: 101–113. Solomon DA, Keller MB, Leon AC, Mueller TI, Lavori PW, Shea MT, Coryell W, Warshaw M, Turvey C, Maser JD, Endicott J. Multiple recurrences of major depressive disorder. Am J Psychiatry 2000; 157: 229–233. Sonne SC, Brady KT. Substance abuse and bipolar comorbidity. Psychiatr Clin North Am 1999; 22: 609–27, ix. Stancer HC, Persad E. Treatment of intractable rapid-cycling manic-depressive disorder with levothyroxine. Clinical observations. Arch Gen Psychiatry 1982; 39: 311–312. Strakowski SM, Del Bello MP, Adler CM, Keck PE, Jr. Atypical antipsychotics in the treatment of bipolar disorder. Expert Opin Pharmacother 2003; 4: 751–760. Suppes T, Baldessarini RJ, Faedda GL, Tohen M. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch Gen Psychiatry 1991; 48: 1082–1088. Suppes T, Leverich GS, Keck PE, Nolen WA, Denicoff KD, Altshuler LL, McElroy SL, Rush AJ, Kupka R, Frye MA, Bickel M, Post RM. The Stanley Foundation Bipolar Treatment Outcome Network. II. Demographics and illness characteristics of the first 261 patients. J Affect Disord 2001; 67: 45–59. Swann AC, Bowden CL, Calabrese JR, Dilsaver SC, Morris DD. Differential effect of number of previous episodes of affective disorder on response to lithium or divalproex in acute mania. Am J Psychiatry 1999; 156: 1264–1266. Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, Mitchell PB, Centorrino F, Risser R, Baker RW, Evans AR, Beymer K, Dube S, Tollefson GD, Breier A. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003; 60: 1079–1088. Tondo L, Baldessarini RJ, Floris G, Rudas N. Effectiveness of restarting lithium treatment after its discontinuation in bipolar I and bipolar II disorders. Am J Psychiatry 1997; 154: 548–550. Tramontina S, Schmitz M, Polanczyk G, Rohde LA. Juvenile bipolar disorder in Brazil. clinical and treatment findings. Biol Psychiatry 2003; 53: 1043–1049. Viguera AC. Course of bipolar disorder in pregnancy. Bipolar Disord 2003; 5: 17–18. Weiss SR, Clark M, Rosen JB, Smith MA, Post RM. Contingent tolerance to the anticonvulsant effects of carbamazepine: Relationship to loss of endogenous adaptive mechanisms. Brain Res Brain Res Rev 1995; 20: 305–325. Zarate CA, Jr, Payne JL, Singh J, Quiroz JA, Luckenbaugh DA, Denicoff KD, Charney DS, Manji HK. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry 2004; 56: 54–60.
c19.fm Page 367 Wednesday, October 19, 2005 9:59 AM
c10.fm Page 169 Wednesday, October 19, 2005 9:16 AM
CHAPTER
10 The Primacy of Mania Athanasios Koukopoulos Centro Lucio Bini, Rome, Italy
Excitement is not a mere somatic accessory but is the fundamental affection of the psyche. (Heinroth, 1818)
THE HISTORICAL CONTEXT For more than two thousand years, mania was considered the most important psychic illness – even more so than melancholia; it was the main form of madness. Like mania in Greek, follia in Latin meant mania and madness, as it does in many modern European languages (Follia, Folie, Folly). The title of the first edition of Pinel’s Handbook published in 1801 was Traité médicophilosophique sur l’alienation mentale ou la manie. Pinel considered mania the most typical and frequent mental illness. Heinroth (1818), the founder of modern clinical psychiatry, regarded excitement as the fundamental affection of the psyche. The majority of the psychic disorders described in his treatise of 1818 was of excitatory nature. Many forms of exaltation, mania and a remarkable series of mixed mood disorders (animi morbi complicati) constitute the main focus of his book. In 1845, Wilhelm Griesinger introduced the term and concept of cycle, that is, the alternation of mania and melancholia. He paid great attention to mixed states, and particularly to melancholia with destructive tendencies and melancholia with persistent excitement of the will. He had the brilliant insight that excitatory phenomena often underlie depressive states: By using the expression ‘psychic depressive states’ we did not mean to imply that the basic nature of these states is inactivity and weakness and suppression [depression] of the psychic or cerebral processes that underlie them. We have much more reason to assume that very intense states of irritation of the brain and excitation of the psychic processes are very often the cause of such states; Bipolar Psychopharmacotherapy: Caring for the Patient Edited by Hagop S. Akiskal and Mauricio Tohen # 2006 John Wiley & Sons, Ltd ISBN: 0-470-85607-6
c10.fm Page 170 Wednesday, October 19, 2005 9:16 AM
170
Bipolar Psychopharmacotherapy
but the end result of these [psychic and cerebral] states as far as mood is concerned is a state of depression or psychic pain. (Griesinger, 1861) This is the core issue in the understanding of agitated depression (Koukopoulos and Koukopoulos, 1999), which, to this day, is not recognized as a mixed state to this date by neither by the DSM-IV TR (2000) ICD-10 (1992). Griesinger (1845) also had the intuition to compare mania to epilepsy: In other cases, the manic attacks recur every 1, 2 or 3 years; a form of true psychic epilepsy which shares with the common recurrent epilepsy the same poor prognosis. Both mania and epileptic seizures are, indeed, states of intense excitement, and the efficacy of modern antiepileptics against both disorders depends upon their anti-excitatory effect; despite this, many authors have tried to demonstrate the antidepressant properties of antiepileptics in order to explain their prophylactic action in affective disorders. Kraepelin is the last representative of this long tradition that created modern psychiatry. His broad criteria for mania, and his mixed states, which are basically conditions of excitement (depressive mania, excited depression, mania with poverty of thought, manic stupor, depression with flight of ideas and inhibited mania), denote the importance he attached to excitatory phenomena. Moreover, his fundamental states, which correspond to the four affective temperaments, are predominantly of excited and excitable nature. Among his manic-depressive patients he estimated the incidence of the following premorbid temperaments (dispositions): 12.1% depressive, 9.0% hypomanic, 12.4% irritable and 3–4% cyclothymic (Kraepelin, 1913). After Kraepelin, the clinical importance of mania diminished and that of schizophrenia expanded, due to the influence of such influential Germanophone psychiatrists as Bleuler (1911), Jaspers (1923) and Schneider (1959). Mixed states lost their clinical importance. With their new cross-sectional criteria, many psychotic manias and mixed states were diagnosed as schizophrenia. Mania, indeed, as a syndrome, is basically a psychotic condition. The criteria of Kahlbaum (1863; reviewed in Baethge, Salvatore and Baldessarini, 2003) and Kraepelin (1913), based on course and outcome, were abandoned in favor of symptom clusters present in the current episode. The motto, ‘once a schizophrenic always a schizophrenic,’ dominated the field for decades. This influence was even greater in the United States, where many psychotic manias were misdiagnosed as schizophrenic and paranoid reactions (American Psychiatric Association, 1952, 1968). The influence of psychoanalysis was also significant since mania was difficult to interpret in psychodynamic terms and impossible to treat with psychotherapy. The practice of excluding family members of the patient from the diagnostic process, especially in the United States, contributed
c10.fm Page 171 Wednesday, October 19, 2005 9:16 AM
The Primacy of Mania
171
significantly to the underdiagnosis of bipolar conditions by allowing hypomanic/ manic symptoms to go undetected. The introduction of chlorpromazine by the Parisian Psychiatrists Delay, Deniker and Harl (1952) could have changed this trend, but at that time the emphasis on schizophrenia was so strong that the antimanic effect of chlorpromazine was overshadowed by its anti-schizophrenic effect. This is curious, because the first patients treated by chlorpromazine at the St Anne Hospital in Paris were manic! The efficacy of neuroleptics in both schizophrenia and psychotic mania reinforced and protracted this diagnostic error. The introduction of effective antidepressants, shortly after chlorpromazine, focused psychiatrists’ attention on depression, resulting in even further neglect of mania. The largely accepted distinction between unipolar and bipolar forms of affective disorders (Angst, 1966; Perris, 1966) caused a diagnostic shift in favor of unipolar depression, termed recurrent major depressive disorder (MDD) by the DSM-III (1980). This shift was unjustified and hard to explain. Bipolar disorder was then limited to the core bipolar I phenotype with clear-cut mania and, furthermore, this disorder, for the most part, was diagnosed as schizophrenia because of its psychotic features. The more common bipolar patients with recurrent depression and hypomania, though formally recognized since at least DSM-III-R (1987), have been considered ‘atypical.’ Their recognition as genuine bipolar disorder (type II) by the DSM-IV (1994) is unfortunately lagging in practice, and many such patients are worldwide misdiagnosed as MDD (see Akiskal et al., 2000). A historic shift was brought about by the use of lithium as an antimanic and prophylactic agent in affective disorders (Baldessarini, 1970; Stoll et al., 1993). The evident antimanic effect of lithium, and the longitudinal observations in clinical practice and research trials, shed new light on the bipolar nature of many depressions and led to the rediscovery of bipolarity as described by Falret (1854), Baillarger (1854) and Kraepelin (1913). This diagnostic shift is reflected in the DSM-III (1980) by the narrowing of the definition of schizophrenia and expanding the category of major affective disorders. An important contribution to the new appreciation of bipolarity and cyclicity was the 1990 publication of Manic-Depressive Illness by Goodwin and Jamison (1990). As Schou states in his foreword, ‘the book is called Manic-Depressive Illness, but readers, especially those from Europe, should be informed that the emphasis is on bipolar disorder.’ In the present chapter, the author often uses the term ‘manic-depressive’ because it corresponds to Kraepelin’s unitarian concept of manic-depressive illness, which comprises what today are regarded by many as the recurrent unipolar and bipolar courses of the illness. It should be noted that there is nowadays a mistaken conflation of the terms ‘bipolar’ and ‘manic-depressive’ as synonymous. This misunderstanding arises out of the term ‘manic-depressive’, which in itself denotes two opposite poles, but as a clinical entity also comprises recurrent unipolar depression and, of course, the mixed states where the two poles come together.
c10.fm Page 172 Wednesday, October 19, 2005 9:16 AM
172
Bipolar Psychopharmacotherapy
The work of Akiskal (1983) expanded this concept to what today is termed the bipolar spectrum. The aim of this expansion was to emphasize the fact that lessthan-manic excitements were prevalent in so-called unipolar depressions. The emphasis in the field, however, has remained primarily on depression (Ghaemi et al., 2003). This is understandable because it is more frequent than mania. Depressed individuals, moreover, have good insight into their depressive feelings and want to be understood and helped; their depressive feelings are close to normal human emotions and moods. Empathy and sympathy are easily evoked. Mania, on the contrary, is far from normal human experience. Manic patients are often aggressive, create enormous apprehension around them and are difficult to handle and treat. They have little, if any, insight into their condition and resist treatment. Furthermore, hypomanic patients deny that their behavior is abnormal and refuse treatment. A major cause of the shift of attention from mania to depression was the expansion of outpatient psychiatric practice in the second half of the 20th century, which tended to treat the milder forms of affective disorders, especially non-psychotic depression. By itself, this need not necessarily have brought about an underestimation of hypomania, but the promotion of antidepressants by the pharmaceutical industry may have played an important role. The asylum psychiatry of the 19th century brought to the forefront syndromes of excitatory nature, while the practice of prescribing antidepressant treatments on an outpatient basis in the second half of the 20th century focused the field’s attention on depressive and anxiety syndromes. Ironically, this emphasis on depression and the excessive use of antidepressant agents (Ghaemi et al., 2003) without concern for the triggering of mania or hypomania increased the number of cycling cases (Kukopulos et al., 1980, 1983) and consequently attracted new interest in bipolarity. In addition, the use and abuse of stimulating substances and caffeinated beverages appears to have had a similar effect to antidepressants on cyclothymic, hyperthymic and irritable temperaments, as well as on other forms of latent bipolarity. It is also likely that lifestyle changes, including artificial light and going to bed later, sleeping fewer hours, experiencing more sleepless nights, and a more intense and hectic lifestyle with an enormous increase of environmental stimuli contributed to a genuine increase in bipolar cases and a younger age at onset. The neglect of mania and bipolarity for so many decades also led to cyclicity being neglected, both in clinical practice and research. There were also other, more general, reasons for this neglect. Wehr (1989), for example, attributes importance to ‘a cultural shift away from a cyclical to a linear perception of time (Gould, 1987), so that psychiatrists and patients may be more likely to perceive affective recurrences as a succession of separate events than as a seasonal cycle of events’. Under such circumstances, it is natural that the intrinsic link between mania and depression would be entirely overlooked. Falret’s concept (1854) of a cercle (a cycle comprising a manic and a depressive phase and a lucid interval, all three intrinsically connected) was lost.
c10.fm Page 173 Wednesday, October 19, 2005 9:16 AM
The Primacy of Mania
173
Psychotropic drugs do, however, act upon the underlying process of the manicdepressive cercle: antidepressants trigger mania and hypomania, antimanic drugs may deepen depression and intervals may be shortened or lengthened under the action of treatments (Kukopulos et al., 1975). This chapter aims to present clinical facts and considerations that suggest not only that there exists an intrinsic link between mania and depression but also that the excitatory process of mania or hypomania is primary and depression secondary in the manic-depressive cycle. Metaphorically speaking, mania is the fire and depression its ash.
OBSERVATIONS FROM PHARMACOTHERAPY LITHIUM The first observations that gave rise to the idea of the primacy of mania came from the course of manic-depressive recurrences during continuous lithium treatment. Cade (1949) discovered the antimanic action of lithium and Schou et al. (1954) demonstrated it in a controlled trial. As an antimanic agent, lithium attracted little attention. One of the reasons for this neglect was the relatively narrow diagnostic range of its usefulness, that is, mania! (Schou, 1963). While testing the prophylactic action of lithium against manic recurrences, Hartigan (1961) and Baastrup (1964) observed a prophylactic action against depressive recurrences, as well Johnson (1984a). Schou fully understood the importance of these clinical observations, and performed with Baastrup the groundbreaking studies that established the prophylactic action of lithium against all the manifestations of manic-depressive illness (Baastrup and Schou, 1967; Baastrup et al., 1970). The prevention of depression by an antimanic agent came as a surprise. This surprise would occur again with antiepileptics and antipsychotics. The likely explanation was that lithium prevented depression through an antidepressant action as it prevented manic attacks through its proven antimanic action. In The History of Lithium Therapy, N.F. Johnson (1984a) writes: Perhaps lithium was also effective as an antidepressant? After all, since mania and depression occurred together in the same patient it was not implausible to suppose that even though the two states were symptomatically different there might be some common features in the control mechanisms underlying each. If lithium produced at least part of its therapeutic effect by acting on such mechanisms then it was possible that depression occurring in association with manic episodes might also be lithium-responsive. A double-blind trial was started but soon abandoned; the results were equivocal and failed to lend any clear support to an antidepressive property for lithium salts.
c10.fm Page 174 Wednesday, October 19, 2005 9:16 AM
174
Bipolar Psychopharmacotherapy
The precedent set by ECT, a treatment effective against both depression and mania, rendered this explanation more plausible. An antidepressant effect of lithium, however, was never demonstrated. Actually, many patients who start lithium during their depressions feel so much more depressed that not only do they discontinue it, but they may also refuse to take it ever again. We have reported that lithium at rather high serum concentrations (close to 1.0 mEq/L) may prolong the duration of a depressive episode (Kukopulos et al., 1975). Lithium augmentation in resistant depression is still reported, but we maintain that the successfully treated cases of depression with lithium are of mixed nature; lithium is not an augmentation in these cases, but the proper treatment against the excitement buried in some resistant depressions. The proven efficacy of lithium in preventing suicide (Tondo, Hennen and Baldessarini, 2001) should be attributed not only to the prevention of depressive relapses but also to a specific action on impulsiveness and agitation, which should be considered mixed components of depression. Similar considerations may explain why the depressive phase of bipolar disorder may respond to lithium (Goodwin et al., 2003). The term mood stabilizer, coined by Kerry (Kerry and Owen, 1970), was first applied to lithium salts when it became clear that these compounds not only were effective in manic excitement, but also tended to avert both manic and depressive recurrences in bipolar patients.
RESPONSE TO LITHIUM PROPHYLAXIS The first clinical observations that gave us the idea of the cardinal role of mania in the manic-depressive cycle were the responses to lithium prophylaxis. When lithium did not act upon and suppress the manic phase, the depression took place as though lithium had not been given. When lithium attenuated and shortened the mania, depression was also attenuated. When mania was completely prevented, the depression did not occur. These observations were published in 1973 (Kukopulos and Reginaldi, 1973) with the hypothesis that lithium prevents depression by suppressing mania. Neil Johnson (1984b), in The Psychopharmacology of Lithium, supported the idea of the primacy of mania on the basis of his stimulus-processing model.
CYCLE SEQUENCE AND LITHIUM RESPONSE In the following years, my colleagues and I (Kukopulos et al., 1980) observed that patients who start the cycle with mania have a better response to prophylactic lithium than those who start with depression which is followed by mania/hypomania (Figure 10.1). This observation was confirmed in the following years by Grof et al. (1987), Haag et al. (1987), Maj, Pirozzi and Starace (1989), Faedda et al. (1991) and again by our group (Koukopoulos et al., 1995).
c10.fm Page 175 Wednesday, October 19, 2005 9:16 AM
The Primacy of Mania
175
Figure 10.1: Cycles
That lithium exerts a greater prophylactic effect in patients with the mania/hypomania–depression sequence is a significant observation. The most likely hypothesis is that lithium easily suppresses a manic process that develops gradually, thus preventing the subsequent depression that otherwise would have followed the mania. The onset of mania after a free interval is generally very gradual and lasts quite some time, from a few weeks to a few months. Slight changes in mood, sleep and behavior last for a long time before mania reaches, in a crescendo, its full intensity. It seems natural that prophylactic lithium, administered during the prodromal period, manages to suppress the underlying process in most cases. This process at its very beginning must be mild. The efficacy of lithium in mild excitatory processes is evidenced even by its effects on excited temperaments: hyperthymics complain of being less hyperthymic under lithium. Even in normal individuals, Judd and colleagues (1977) found that lithium caused lethargy, dysphoria and a loss of interest in interacting with others and the environment. On the other hand, lithium is much less effective on full-blown mania. Lithium as monotherapy is rarely applied in the treatment of acute mania. Mania following a depression emerges more rapidly, frequently as an abrupt switch from one state to the other, and is often activated by the antidepressant treatment administered during the depression (Kukopulos et al., 1980; Reginaldi et al., 1981). The course of rapid cyclers is typical in this regard. Continuous cycling cases with either rapid cycles or long cycles are well known to be treatment-resistant. It should be noted that the transition from depression to mania or hypomania occurs at every cycle in continuous circular cases. As an alternative explanation, Grof et al. (1987) proposed that there are likely different subtypes of bipolar disorder with different sequences of polarity, which respond differently to lithium.1 1
See Chapter 2 for further discussion of this topic – Eds.
c10.fm Page 176 Wednesday, October 19, 2005 9:16 AM
176
Bipolar Psychopharmacotherapy
LITHIUM DISCONTINUATION Further evidence of the importance of the antimanic action in the prophylactic treatments came from the data of lithium discontinuation. The data of Suppes et al. (1991) show that during the first months following discontinuation, the vast majority of recurrences are manias while depression takes place later following the natural course of the illness. Our data confirm this observation (Koukopoulos et al., 1995). In other studies, the relapses were all manic and occurred from a few days to a few weeks after lithium discontinuation (Lapierre, Gagnon and Kokkinidis, 1980; Mander and Loudon, 1988). This clearly indicates that mania is a rebound phenomenon that emerges when the antimanic activity of lithium ceases abruptly. This rebound phenomenon is even clear in the gradual reduction of lithium dose, as is well described by Jamison (1995): Lowering my lithium level had allowed not only a clarity of thinking, but also a vividness and intensity of experience, back into my life; these elements had once formed the core of my normal temperament . . . I did very slowly cut back on the amount of lithium I was taking. The effect was dramatic. It was as though I had taken bandages off my eyes after many years of partial blindness . . . I felt more energetic and alive. Most significant, I could once again read without effort. In summary, the sequence of recurrences following lithium discontinuation clearly demonstrates that the recurrences are rebound phenomena: if the rebound takes the form of mania, it suggests that the therapeutic action expended had been an antimanic one. This also seems to be the case in the discontinuation of antiepileptics and antipsychotics; no systematic studies have, however, thus far been published on the matter. It is also common clinical experience that the discontinuation of depot neuroleptics, given as prophylaxis in bipolar I patients, results in a manic attack.
ANTIDEPRESSANT DISCONTINUATION While cases of mania following discontinuation of antidepressants have been reported (Goldstein et al., 1999), such cases are so rare that it is difficult to attempt an explanation. We could, however, advance the hypothesis that the excitatory process in these cases was in process, though without as yet manifesting itself clinically. The underlying neuronal processes must precede the appearance of clinical symptoms. The suspension of the antidepressant was probably insufficient to stop the excitatory process already underway. Others have resorted to pharmacologic interpretations focusing on anticholinergic rebound (Dilsaver and Greden, 1984).
c10.fm Page 177 Wednesday, October 19, 2005 9:16 AM
The Primacy of Mania
177
ANTIEPILEPTICS The historic development of the use of antiepileptics in affective disorders is similar to that of lithium. The antimanic effect was discovered first, and only subsequently was a prophylactic effect against both mania and depression revealed. At that point, an attempt was made to establish an antidepressant effect, but this was generally unsuccessful; the antimanic effect, however, was clear. Takezaki and Hanaoka (1971) reported that carbamazepine had an antimanic effect in nine of ten endogenous manic-depressive psychotics; they also found that it had a prophylactic effect in one of their cases. Okuma’s group (1973, 1975, 1979) reported a similar experience with the antimanic effect of carbamazepine in a larger number of cases, and their open trial revealed an antimanic effect in 55% of 90 cases and a prophylactic effect in 67% of 51 manic-depressive patients. Post et al. (2000) reported that 19 controlled studies support the efficacy of carbamazepine in acute mania; 16 of 17 partially controlled studies support its prophylactic efficacy for both manic and depressive recurrences. ‘Carbamazepine’s acute antidepressant properties are less well delineated than its antimanic properties, but the data are highly suggestive that in some treatment-refractory depressed patients, it has both acute and prophylactic efficacy’ (Post et al., 1996a,b). Again, we interpret this to mean effectiveness in the excited features of a depressive mixed state. Lambert and coworkers (1966) noticed both antimanic and antidepressant effects of valpromide, an amidation product of valproate, but subsequent studies (Emrich, Dose and von Zerssen, 1985) have confirmed its antimanic efficacy only. The percentage of responsive patients in trials of bipolar depression has been fewer than 40%, ‘suggesting that any benefits are infrequent and modest’ (Bowden, 1995). In 1996 the FDA approved valproate for the treatment of acute mania. However, in an attempt to demonstrate prophylaxis against bipolar disorder, valproate failed, though it appeared efficacious against secondary depressive measures (Bowden et al., 2003). Despite attempts by researchers to establish an antidepressant effect for pharmacological agents that appear to be mood stabilizing, such an effect has been difficult to establish. Nevertheless, the general belief persists that, in some cases, they do have an antidepressant effect. For example, although many psychiatrists were quick to assume that lamotrigine possesses antidepressant properties, the evidence for such an action is actually rather weak. The difference in improvement between patients treated with lamotrigine and those receiving placebo reported by Calabrese and colleagues (1999) (CGI response 51% and 26% respectively) could be attributed at least in part to the improvement of symptoms of agitation, anxiety and sleep disturbance, which may represent an anti-excitatory, rather than antidepressant, action. In fact, the FDA recently approved lamotrigine for maintenance treatment of bipolar I disorder (Bowden et al., 2003; Calabrese et al., 2003) and
c10.fm Page 178 Wednesday, October 19, 2005 9:16 AM
178
Bipolar Psychopharmacotherapy
further stated that, ‘the effectiveness of Lamictal in the acute treatment of mood disorders has not been established’. Lamotrigine appears to be more effective in rapid cyclers (Calabrese et al., 2003), but in this case the rapid succession of states of depression and excitement confounds any putative direct effect on the depressive episodes with an indirect effect resulting from a reduction in mania or hypomania – that is, the attenuation of the depression as a secondary consequence of the attenuation of the excitement, consequent upon an anti-excitatory action of lamotrigine. Another confounding factor is the abundance, among rapid cyclers, of mixed depressions (Koukopoulos et al., 2003) which respond to the anti-excitatory effect of lamotrigine.2
ATYPICAL ANTIPSYCHOTICS The clinical use of atypical antipsychotics (clozapine, risperidone, olanzapine, quetiapine, ziprasidone and aripiprazole) in treating affective disorders continues to expand (Ghaemi, 2000). The pattern of discovery of their efficacy in different phases of bipolar illness, however, is the same as with lithium and with the antiepileptics. Efficacy in mania was first demonstrated, and this was followed by the use of atypical antipsychotics as prophylactic agents in bipolar disorder. Antidepressant effects have been attributed to atypical antipsychotics (especially olanzapine; Tohen et al., 2003), and the term ‘atypical antidepressant’ has been proposed (Parker and Malhi, 2001). Ghaemi et al. (2000) report that, ‘accumulating evidence suggests that olanzapine, and atypical antipsychotics in general, possess mild to moderate adjunctive antidepressant properties.’ Olanzapine is indeed very effective in agitated depressions, both psychotic and non-psychotic, but as stated earlier, these syndromes should be considered mixed states, which improve with anti-excitatory agents.
TYPICAL NEUROLEPTICS One should include among the ‘mood stabilizers’ also the typical neuroleptics. At least in Italy, they have been used widely and successfully, especially in their depot preparations, in the prevention of manic attacks. They also prevent depressive episodes. Their great limitations are sedation, sexual inhibition, reduced vitality and the risk of tardive dyskinesia. Despite these limitations, they are probably the most widely used treatment for bipolar I patients in the Italian national health care system, though as in the rest of Europe, a shift to atypicals is occurring.
2
New data reported by Muzina and Calabrese in this book indicate significant antidepressive prophylaxis and promising antidepressant action – Eds.
c10.fm Page 179 Wednesday, October 19, 2005 9:16 AM
The Primacy of Mania
179
Robertson and Trimble (1982) in their review on the use of major tranquillizers as antidepressants found 34 double-blind trials comparing neuroleptics with tricyclics or placebo. The authors comment: ‘Results suggest that some neuroleptics have antidepressant properties, although most studies have been conducted on mixed anxiety-depressive states.’ The only way to avoid misleading results is to investigate retarded, anxious and agitated depression separately.
RECREATIONAL STIMULANT DRUGS The ‘highs’ created by recreational stimulant drugs are often followed by states of mood very similar to depression. Depressive symptoms are, moreover, considered a major component of stimulant withdrawal (Kosten, Markou and Koob, 1998). For example, MDMA (Ecstasy) is a recreational drug that stimulates the release and inhibits the reuptake of serotonin (5-HT). The acute boost in monoamine activity can generate intense feelings of elation and pleasure, as well as hyperactivity. The on-drug experience is generally followed by rebound depression and lethargy, with 80–90% of weekend Ecstasy users reporting ‘midweek blues’ (Parrott, 2001, 2002).
OTHER SOURCES OF EVIDENCE WEHR’S STUDY Further evidence of the primary importance of mania came from a study by Wehr et al. (1998) on the treatment of a rapid-cycling patient by extended bed rest and darkness. The prevention of hypomania was expected, but unexpectedly the depression was prevented as well. ‘Fostering sleep seemed to prevent not only hypomania . . . but also the depression . . . this result appears to be consistent with the hypothesis of Koukopoulos and colleagues (1980, 1983)’.
ANECDOTAL REPORTS Another source of evidence comes directly from bipolar patients and their relatives. They clearly know that their highs are inevitably followed by depression. These impressionistic convictions should not be taken too lightly by psychiatry. They have a direct and continuous experience of the evolution of the disorder. The literature on this point is vast. Jamison (1995) wrote in An Unquiet Mind, ‘it was difficult to give up the high flights of mind and mood, even though the depressions that inevitably followed nearly cost me my life’. Cioran (1992) states that, ‘although I long for luminous ecstasies, I wouldn’t ask for any, because I know they are followed by great depressions.’
c10.fm Page 180 Wednesday, October 19, 2005 9:16 AM
180
Bipolar Psychopharmacotherapy
THERAPEUTIC IMPLICATIONS Hecker, in his paper on cyclothymia writes, ‘I consider the principal task of therapy the greatest possible suppression of the excitation’ (Koukopoulos, 2003). We should note that in this statement he is referring to the treatment of cyclothymia and bipolar II, and not mania. It is astonishing that Heinroth, Griesinger and Hecker could have such insights into the nature of bipolar disorder, while in modern psychiatry, despite the tools of neurophysiology and psychopharmacology, such ideas are no longer widely recognized. It was the discovery of the antimanic action of lithium, of antiepileptics and of modern atypical antipsychotics that led to a more appropriate understanding and treatment of bipolar disorders; indeed, the expanding use of antipsychotics and antiepileptics suggest that, albeit unwittingly, modern psychiatry is gradually moving toward acceptance of Hecker’s principle. In clinical practice it is an everyday experience to observe the triggering of mania by antidepressants and, alas, even to witness the administration of antidepressants to clearly excited patients. We have also frequently observed patients whose cyclicity increased considerably over years of repeated or continuous antidepressant treatments. These patients eventually became rapid cyclers (Kukopulos et al., 1983). The rule should be to prevent the emergence of excitation of any kind, and, if excitation has already risen, to suppress it as soon as possible. While this may be relatively easy to achieve during the interepisodic free interval, or at the beginning of a period of excitement, it may be extremely difficult during a depression, because any intervention with an intended antidepressive action may trigger excitement. When a bipolar patient on prophylactic mood stabilizing treatment presents with a depression, the safest approach is to first diminish the dose of the mood stabilizer. This often results in a rapid relief of the depression. This effect is analogous to the excitation that follows the withdrawal of mood stabilizers. Whatever the chosen treatment, however, every effort should be undertaken to prevent a subsequent excitement. If antidepressants are administered, they should be tapered to discontinuation as soon as improvement is manifest and, concomitantly, mood stabilizers increased. Altshuler et al. (2003) found that ‘the risk of depressive relapse in bipolar patients were significantly associated with discontinuing antidepressants soon after remission and the risk of manic relapse was not significantly associated with continuing use of antidepressants.’ Since many patients discontinued antidepressants because of a manic relapse, it is natural that they later relapsed into depression. In our view, the relapse was not associated to the antidepressant discontinuation, but to the occurrence of a manic/ hypomanic attack which inevitably was followed by depression. In difficult cases, ECT is certainly very effective and, furthermore, causes less switching than antidepressants.
c10.fm Page 181 Wednesday, October 19, 2005 9:16 AM
The Primacy of Mania
181
The mild hypomania of many bipolar II and cyclothymic patients and the hyperthymia of many ‘unipolar’ depressives are serious and difficult problems to solve. Patients have difficulty giving up these periods of exuberance and their advantages. It is also a problem for the treating physician to suppress such periods of exuberance during which the person could have a pleasant life and achieve important goals. The line between harmful and fruitful hypomania – dark and sunny hypomania, Akiskal would say (Akiskal, Hantouche and Allilaire, 2003) – is not always clear and, in any case, treatment decisions are difficult considering that in these patients the exuberance will be followed by depression. It is troubling that, despite the continually expanding pharmacological options for the treatment and prevention of depression, clinical outcome of the patients is not improving. Suicide rates are not diminishing (van Praag, 2002), chronic disability due to depression is increasing (Holden, 2000) and in clinical practice it seems clear that bipolarity and cyclicity are on the rise (Kukopulos et al., 1983). And yet, these modern psychopharmacological treatments have proven to be efficacious. There may be other unknown reasons for this high rate of treatment failure, but an important cause may be an inappropriate strategy in the application of psychopharmacological agents. We believe that a more appropriate therapeutic strategy should aim to prevent excitement in all its forms. As far as suicide is concerned, the lack of recognition and adequate treatment of agitated depression as a mixed state (Koukopoulos and Koukopoulos, 1999) may be a significant factor in many attempted or completed suicides.
DISCUSSION The idea that mania has primacy over depression in the manic-depressive cycle sits uncomfortably in the context of the present nosological views. From a purely practical standpoint, depression is, indeed, the more important of the two affective states, and the more difficult to treat. Depression is more frequent than mania and lasts longer. It could be, however, that undetected hypomania is as frequent as depression. Treatment-resistant depressions occur more frequently than do resistant manias; chronic depressions are more common than chronic manias; many more cases of disability arise from depression than from mania; and many more suicides occur during depression than mania. Judd et al. (2002) and Post (2003) reported that the duration of depression outweighs the duration of mania/hypomania by 3 to 4 times. In view of such observations, the idea that depression is secondary to excitatory processes may seem illogical. In this chapter we are referring to mania as the prototype of nervous excitement. Other forms of excitement such as hypomania, mixed states and hyperthymic, cyclothymic and irritable temperaments are of the same nature as mania and probably play the same role in the manic-depressive cycle, in a broad sense. The modern
c10.fm Page 182 Wednesday, October 19, 2005 9:16 AM
182
Bipolar Psychopharmacotherapy
concept of the bipolar spectrum (Akiskal, 1983, 2002; Akiskal and Pinto, 1999) corresponds to Kraepelin’s conception of the entity of manic-depressive insanity with the exception of unipolar depression: Manic-Depressive insanity, as it is to be described in this section, includes on the one hand the whole domain of so-called periodic and circular insanity, on the other hand simple mania, the greater part of the morbid states termed melancholia and also a not inconsiderable number of cases of amentia (confusional or delirious insanity). Lastly, we include here certain slight and slightest colourings of mood, some of them periodic, some of them continuously morbid, which on the one hand are to be regarded as the rudiment of more severe disorders, on the other hand pass over without sharp boundary into the domain of personal predisposition. In the course of the years I have become more and more convinced that all the above-mentioned states only represent manifestations of a single morbid process. (Kraepelin, 1913) In a forthcoming paper we shall present clinical data regarding the direct link between these forms of excitement and depressive states. In this chapter, however, discussion is limited to the interpretation of the effects of pharmacological treatments on the course of the illness, and to the significance of such effects as far as the link between manic and depressive processes is concerned.
PHARMACOLOGICAL ACTION All the pharmacological agents used in the prophylaxis of affective disorders have a proven antimanic and prophylactic effect against both mania and depression, while there is little unequivocal support for the view that they also exert any direct antidepressant action. Griesinger’s insight that excitatory phenomena may result in depressive suffering has not yet been appreciated by modern psychiatry. We submit that much of the confusion regarding whether or not lithium, antiepileptics and atypical antipsychotics possess antidepressant properties arises out of their efficacy in cases of mixed depressive states, which are not distinguished from pure depressive disorders by our modern nosology. The vast market potential represented by depressive states has influenced the funding policies of pharmaceutical companies (drug trials, conferences, CME courses, etc.) and this may have influenced the nosologic trends of the last forty years. However, the evolution of pharmacotherapy, as far as prevention of affective disorders is concerned, has proceeded incessantly, though very slowly and with many contrasting views, in one direction: antidepressants worsen the course of the disorder by triggering mania/hypomania and accelerating the course of recurrences (Wehr and Goodwin, 1979; Koukopoulos 1980); anti-excitatory agents, including lithium, antiepileptics and antipsychotics are useful in preventing recurrences.
c10.fm Page 183 Wednesday, October 19, 2005 9:16 AM
The Primacy of Mania
183
NEURONAL ANALOGY OF THE MANIC-DEPRESSIVE CYCLE AND THE PARADIGM OF EPILEPSY The idea of the primacy of excitatory over depressive processes evokes the elementary and fundamental function of the neuron: a stimulus triggers an excitation followed by a refractory period during which the neuron is unresponsive to stimuli. Mania would correspond to the excitatory phase and depression to the refractory one. As far as stimulus is concerned, we should mention all the stimulating conditions that trigger mania: stimulant substances such as narcotics, anorectics, corticosteroids and antidepressants; sleep deprivation; lithium discontinuation; summer heat and light; and psychic stressors, such as mourning and other major life events. John Brown (1795) stated, ‘There is no life without excitement and no excitement without stimulus.’ Hypomania and mania are an excess of life. Depression is, in every respect, a diminution of life. It is conceivable that excessive excitement brings about an exhaustion of nervous activity and results in what we call a ‘depression.’ Kraepelin writes at the end of the chapter on manic states: ‘Very frequently after the disappearance of manic excitement a more or less marked condition of weakness and despondency appears, which is generally regarded as exhaustion after the severe illness; however, it is obviously only the transition to depression, typical of our illness’ (Kraepelin, 1913). There is no doubt that this exhaustion/depression is typical of bipolar disorder. As Cioran (1992) puts it, ‘Sadness accompanies all those events in which life expends itself.’ This relationship is described by Aretaeus and Boerhaave (1735): ‘Once the attack of mania is over they become slowed down, docile, taciturn and sad, and when they recall the illness they have been through they feel anguish for their adversity.’ While comparison of the manic-depressive cycle to the neuronal phenomenon of excitation followed by a refractory period is suggestive of a parallelism with the manic-depressive sequence, there are nevertheless obvious dissimilarities. While the neuronal reaction to stimuli is an all-or-none phenomenon, the manic-depressive cycle consists of phases of heightened excitability (mania) and phases of reduced excitability (depression). Nevertheless, the analogy may be useful in illustrating the rationale for the notion that depression is an inevitable consequence of a preceding period of excitation. As far as mood stabilization is concerned, we maintain that a single agent cannot suppress the excitation of mania and at the same time be able to correct the reduced excitability of the depression. ECT may appear as an exception to this thesis. ECT, however, cannot be considered a single agent; convulsion is a complex phenomenon, consisting of at least two distinct phases: the excitatory phase which produces the muscular contraction and the inhibitory phase which puts an end to the excitation and the muscular contraction. Different neurobiological mechanisms underlie these two phases. Nothing similar is conceivable for pharmacological agents.
c10.fm Page 184 Wednesday, October 19, 2005 9:16 AM
184
Bipolar Psychopharmacotherapy
The paradigm of epilepsy is indeed meaningful. After the intense excitation of convulsive seizures, a period of deep inhibition of the nervous system follows. Antiepileptic drugs prevent both phases. It should be noted that such seizureprovoking factors as sleep deprivation, stress, caffeine, cocaine and alcohol also trigger mania. The histories of epilepsy and manic-depressive illness are not casually interwoven. Maintaining that there is an intrinsic link between mania and depression, it follows that an action upon one phase should be reflected in an effect upon the other. The thrust of the arguments presented in this chapter is that the prevention/suppression of mania prevents the depression. This begs the question as to why the treatment of depression does not prevent mania. The answer is simple: it is obvious that if excitation does not occur, a refractory phase cannot follow. The cycle would thus be broken. The aim of treating the refractory phase (depression), however, is to increase nervous excitability, and not only does this not prevent a subsequent mania, but it can lead to an overshoot, triggering mania, and accelerating cyclicity – as is the case with essentially all antidepressant treatments.
OBJECTIONS TO THE PRIMACY OF MANIA There are certainly important objections to the idea of the primacy of mania, and these ought to be discussed. The first is historical and the others clinical. In the second century, Aretaeus of Cappadocia (Aretaeus and Boerhaave, 1735) remarked: ‘It seems to me that melancholia is the beginning and a part of mania.’ This idea reigned until modern times. In the sixth century, Alexander of Tralles (Puschmann 1878) writes, ‘...[mania is] nothing else but the mounting of melancholia towards aggressive excitation.’ Thomas Willis writes (1672) in his De Anima Brutorum, ‘Often these two (melancholia and mania) like smoke and flame mutually exclude and replace each other.’ Regarding this historically rooted idea, Esquirol (1838) comments: several great scholars, Alexander of Tralles and even Boerhaave, thought that melancholia (lypémanie) was nothing but the first stage of mania; this is true in some cases. There are indeed some individuals who, before becoming manic, are sad, morose, restless or anxious, distrustful and suspicious; some of them have a partial delusion with excitation; there are some who feel ill, they complain about headaches, aching limbs, the premonition of a severe disease that threatens them, and even the fear of becoming mad; they are anxious, tormented, they demand and receive many remedies. In these two cases the melancholic or hypochondriac symptoms are the prodromes of mania; this is the incubation period: these symptoms cannot deceive the expert; they are the signs of a manic attack ready to blow. (pp. 141–142) and
c10.fm Page 185 Wednesday, October 19, 2005 9:16 AM
The Primacy of Mania
185
A few hours, a few days, a few months prior to the explosion of mania, there are individuals who are hypochondriac, deeply melancholic while there are others who fall into a deep stupor . . . (p. 146) We agree with Esquirol. We have seen many patients with this course, which is probably the basis for the ancient belief. This particular course of illness also illustrates that excitatory processes may express themselves on the psychic level, as dysphoric and depressed mood. This fundamental clinical fact is also evident in the third stage of mania described by Carlson and Goodwin (1973). The first clinical objection to the concept espoused in this chapter stems from the fact that approximately 25% of bipolar cases start with depression followed by hypomania or mania (Kukopulos et al., 1980). Eighty percent of patients with this cycle sequence are bipolar II. Such patients have an excitable and labile temperament. The depression in such patients is not really the beginning of the cycle and does not come out of the blue; periods of temperamental instability, stress (including emotional excitation due to life events, both positive and negative), use of stimulants, or irregular sleep patterns, usually precede the depression. Akiskal et al. (1995) formulates the complex relationship between temperament and morbid episodes as follows: ‘Bipolar II represents the most fascinating interface between affective episodes and temperamental instability.’ The second clinical objection to the primacy of mania stems from the existence of two forms of depression: unipolar depression, in the course of which there are no evident manias/hypomanias, and depression occurring in association with states of anxiety. It could well be that these depressions are different from bipolar depressions and originate from a different process in which there is no link to excitatory phenomena. The following alternative view could be taken into consideration. Many unipolar depressions occur in people with hyperthymic temperaments and can thus be considered as belonging to the bipolar spectrum. This entity has been labeled by Cassano et al. (1992) as unipolar with hyperthymic temperament (U H-T) and by Akiskal and Pinto (1999) as bipolar IV. In many other cases, the depression is preceded by stressful life events that cause distress, nervous tension, anxiety, sleep disturbance and other neurovegetative disturbances, and the person is often involved in a flurry of tiring activities. These stressful periods must have a causal connection to the subsequent depression. It is known, for instance, that depression follows the life event several weeks or months later and this period of time is very stressful. We propose that these periods be termed hypomanic equivalents because of the nervous tension, emotional turmoil, hyperactivity and reduction in sleep that often accompany them. In predisposed people, they can bring about the same nervous exhaustion/ depression as true mania or hypomania. The basic difference between these cases and bipolar patients may be the predisposition to cyclicity of the latter.
c10.fm Page 186 Wednesday, October 19, 2005 9:16 AM
186
Bipolar Psychopharmacotherapy
In many other cases, the depression follows a period of intense anxiety often accompanied by panic attacks. Anxiety, and especially a panic attack, is a phenomenon of intense nervous arousal. In this case, too, nervous exhaustion could be viewed as the cause of the depression. This type of depression could be called anxiety-associated depression. The phenomenon of nervous “exhaustion/depression” following different types of prolonged neuronal excitation evokes the more severe phenomenon of excitotoxicity following prolonged excitation and resulting in neural damage and death.
DEPRESSION AS A CONSEQUENCE OF PROLONGED NERVOUS AROUSAL According to the above-proposed hypothesis, depression would follow, and be a consequence of, states of prolonged nervous arousal, such as mania, hypomania, hypomanic equivalents and anxiety, that eventually create a state of nervous exhaustion. This hypothesis would indicate a parallelism between bipolar and unipolar depressions and would explain the efficacy of mood stabilizers in the prophylaxis of unipolar as well as of bipolar depression. The continuous presence of a mood stabilizer in the organism prevents or attenuates this nervous arousal and, by doing so, prevents the genesis of the depression. It is also clear that appropriate changes in lifestyle and sleep pattern, and the avoidance of stimulants and stressful life situations, when possible, are of crucial importance.
IMPLICATIONS FOR EVOLUTIONARY THEORY The primacy of mania would also offer a simple explanation to the evolutionary puzzle of depression. Several authors (Watson and Andrews, 2002; Nesse, 2000; Thierry et al., 1984) have recently focused their attention on the adaptive advantages of depression. According to the theory presented herein, it would not be the depression that presents adaptive advantages but the periods of excitement. Mania, or at least hypomania, offers selective advantages, providing a high level of energy, hyperactivity and aggressiveness, hypersexuality, as well as creativity of thought. High activity level is an asset throughout nature. The excitement would bring about the depression which, in itself, would not carry adaptive advantages but only disadvantages. If depression is a consequence of mania, its evident adaptive disadvantages must be less important than the advantages conferred by mania, so that the balance of selective advantage lies with mania. It was mania, therefore, and not depression, that was selected for. Even the severe disadvantages of mania are often compensated for by the advantages of the temperamental hyperthymia of bipolar I patients.
c10.fm Page 187 Wednesday, October 19, 2005 9:16 AM
The Primacy of Mania
187
ACKNOWLEDGEMENTS The author wishes to thank Matthew J. Albert, Gabriele Sani, Neil F. Johnson, Alexia E. Koukopoulos, Leonardo Tondo, Andreas Erfurth, Daniela Reginaldi, Luca Pani and Denis Greenan for their invaluable help in the preparation of this manuscript.
REFERENCES Akiskal, H. S. (1983) The bipolar spectrum: New concepts in classification and diagnosis, in Grinspoon, L. (ed.), Psychiatry Update: The American Psychiatric Association Annual Review, Vol. 2. Washington, DC, American Psychiatric Press, pp. 271–92. Akiskal, H. S. (2002) The bipolar spectrum—the shaping of a new paradigm. Curr Psychiatry Rep. 4, 1–3. Akiskal, H. S. and Pinto, O. (1999) The evolving bipolar spectrum. Prototypes I, II, III, and IV. Psychiatr Clin North Am. 22, 517–34, vii. Akiskal, H. S., Hantouche, E. G. and Allilaire, J. F. (2003) Bipolar II with and without cyclothymic temperament: “dark” and “sunny” expressions of soft bipolarity. J Affect Disord. 73, 49–57. Akiskal, H. S., Maser, J. D., Zeller, P. J., Endicott, J., Coryell, W., Keller, M., Warshaw, M., Clayton, P. and Goodwin, F. (1995) Switching from ‘unipolar’ to bipolar II. An 11-year prospective study of clinical and temperamental predictors in 559 patients. Arch Gen Psychiatry. 52, 114–23. Akiskal, H. S., Bourgeois, M. L., Angst, J., Post, R., Moller, H. J., Hirschfeld, R. M. A. (2000) Re-evaluating the prevalence of and diagnostic composition within the broad clinical spectrum of bipolar disorders. J Affect Disord. 59, Suppl. 1, 5s–30s. Altshuler, L., Suppes, T., Black, D., Nolen, W. A., Keck, P. E., Jr, Frye, M. A., McElroy, S., Kupka, R., Grunze, H., Walden, J., Leverich, G., Denicoff, K., Luckenbaugh, D. and Post, R. (2003) Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at 1-year follow-up. Am J Psychiatry. 160, 1252–62. Angst, J. (1966) [On the etiology and nosology of endogenous depressive psychoses. A genetic, sociologic and clinical study]. Monogr Gesamtgeb Neurol Psychiatr. 112, 1–118. Aretaeus and Boerhaave, H. (1735) De Causis et signis acutorum, et diuturnorum: libri quatuor. De curatione acutorum et diuturnorum morborum libri quatuor, Janssonios Vander Aa, Lugduni Batavorum. Association Psychiatric Association. (1952) Diagnostic and statistical manual [for] mental disorders, American Psychiatric Association Mental Hospital Service, Washington. Association Psychiatric Association. (1968) Diagnostic and statistical manual of mental disorders, American Psychiatric Association, Washington. Association Psychiatric Association. (1980) Diagnostic and statistical manual of mental disorders, American Psychiatric Association, Washington, DC. Association Psychiatric Association. (2000) Diagnostic and statistical manual of mental disorders: DSM-IV-TR, American Psychiatric Association, Washington, DC. Baastrup, P. C. (1964) The use of lithium in manic-depressive pyschosis. Compr Psychiatry. 5, 396–408. Baastrup, P. C. and Schou, M. (1967) Lithium as a prophylactic agents. Its effect against recurrent depressions and manic-depressive psychosis. Arch Gen Psychiatry. 16, 162–72.
c10.fm Page 188 Wednesday, October 19, 2005 9:16 AM
188
Bipolar Psychopharmacotherapy
Baastrup, P. C., Poulsen, J. C., Schou, M., Thomsen, K. and Amdisen, A. (1970) Prophylactic lithium: Double blind discontinuation in manic-depressive and recurrent-depressive disorders. Lancet. 2, 326–30. Baethge, C., Salvatore, P., Baldessarini, R. J. (2003) “On cyclic insanity” by Karl Ludwig Kahlbaum, MD: a translation and commentary. Harv Rev Psychiatry. 11, 78–90. Baillarger, J. (1854) De la folie à double forme. Ann Med Psychol (Paris). 6, 367–91. Baldessarini, R. J. (1970) Frequency of diagnoses of schizophrenia versus affective disorders from 1944 to 1968. Am J Psychiatry. 127, 759–63. Bleuler, E. (1911) Dementia praecox oder die Gruppe der Schizophrenien. Leipzig-Wien, Franz Deuticke. Bowden, C. L. (1995) In The American Psychiatric Press textbook of psychopharmacology, Schatzberg, A. F., Nemeroff, C. B. (eds). American Psychiatric Press, Washington, DC, pp. xix, 896 pp. Bowden, C. L., Calabrese, J. R., Sachs, G., Yatham, L. N., Asghar, S. A., Hompland, M., Montgomery, P., Earl, N., Smoot, T. M., DeVeaugh-Geiss, J., Lamictal 606 Study Group (2003) A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry. 60, 392–400. Brown, J. (1795) The Elements of Medicine. London: J. Johnson. Cade, J. F. J. (1949) Lithium salts in the treatment of psychotic excitement. Med J Aust. 36, 349–52. Calabrese, J. R., Bowden, C. L., Sachs, G. S., Ascher, J. A., Monaghan, E. and Rudd, G. D. (1999) A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry. 60, 79–88. Calabrese, J. R., Bowden, C. L., Sachs, G., Yatham, L. N., Behnke, K., Mehtonen, O. P., Montgomery, P., Ascher, J., Paska, W., Earl, N., DeVeaugh-Geiss, J., Lamictal 605 Study Group (2003) A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry. 64, 1013–24. Carlson, G. A. and Goodwin, F. K. (1973) The stages of mania. A longitudinal analysis of the manic episode. Arch Gen Psychiatry. 28, 221–8. Cassano, G. B., Akiskal, H. S., Savino, M., Musetti, L. and Perugi, G. (1992) Proposed subtypes of bipolar II and related disorders: With hypomanic episodes (or cyclothymia) and with hyperthymic temperament. J Affect Disord. 26, 127–40. Cioran, E. M. (1992) On the heights of despair, University of Chicago Press, Chicago. Delay, J., Deniker, P., Harl, J. M. (1952) Utilisation en thérapeutique psychiatrique d’une phénothiazine d’action centrale élective (4560 R). Ann Med Psychol (Paris). 110, 112–117. Dilsaver, S. C., Greden, J. F. (1984) Antidepressant withdrawal-induced activation (hypomania and mania): Mechanism and theoretical significance. Brain Res. 319, 29–48. Emrich, H. M., Dose, M. and von Zerssen, D. (1985) The use of sodium valproate, carbamazepine and oxcarbazepine in patients with affective disorders. J Affect Disord. 8, 243–50. Esquirol, E. (1838) Des maladies mentales considérées sous les rapports médicale, hygiénique et médico-légal, J.-B. Baillière, Paris. Faedda, G. L., Baldessarini, R. J., Tohen, M., Strakowski, S. M. and Waternaux, C. (1991) Episode sequence in bipolar disorder and response to lithium treatment. Am J Psychiatry. 148, 1237–39.
c10.fm Page 189 Wednesday, October 19, 2005 9:16 AM
The Primacy of Mania
189
Falret, J. P. (1854) Leçons cliniques de médecine mentale faites à l’Hospice de la Salpêtrière: 1. ptie. Symptomatologie générale des maladies mentales, J.-B. Baillière, Paris. Ghaemi, S. N. (2000) New treatments for bipolar disorder: The role of atypical neuroleptic agents. J Clin Psychiatry. 61, Suppl 14, 33–42. Ghaemi, S. N., Cherry, E. L., Katzow, J. A. and Goodwin, F. K. (2000) Does olanzapine have antidepressant properties? A retrospective preliminary study. Bipolar Disord. 2, 196–99. Ghaemi, S. N., Hsu, D. J., Soldani, F., Goodwin, F. K. (2003) Antidepressants in bipolar disorder: The case for caution. Bipolar Disord. 5, 421–33. Goldstein, T. R., Frye, M. A., Denicoff, K. D., Smith-Jackson, E., Leverich, G. S., Bryan, A. L., Ali, S. O. and Post, R. M. (1999) Antidepressant discontinuation-related mania: Critical prospective observation and theoretical implications in bipolar disorder. J Clin Psychiatry. 60, 563–67; quiz 568–69. Goodwin, F. K. and Jamison, K. R. (1990) Manic-depressive illness, Oxford University Press, New York. Goodwin, F. K., Fireman, B., Simon, G. E., Hunkeler, E. M., Lee, J., Revicki, D. (2003) Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA. 290, 1467–73. Gould, S. J. (1987) Time’s Cycle and Time’s Arrow: Myth and Metaphor in the Discovery of Geological Time, Harvard University Press, Cambridge, MA. Griesinger, W. (1845) Pathologie und Therapie der psychischen Krankheiten, Adolf Krabbe Verlag, Struttgart. Griesinger, W. (1861) Pathologie und Therapie der psychischen Krankheiten, Adolf Krabbe Verlag, Struttgart. Grof, E., Haag, M., Grof, P. and Haag, H. (1987) Lithium response and the sequence of episode polarities: Preliminary report on a Hamilton sample. Prog Neuropsychopharmacol Biol Psychiatry. 11, 199–203. Haag, H., Heidorn, A., Haag, M. and Greil, W. (1987) Sequence of affective polarity and lithium response: preliminary report on Munich sample. Prog Neuropsychopharmacol Biol Psychiatry. 11, 205–208. Hartigan, G. P. (1961) Experiences of treatment with lithium salts. J Ment Sci. Suppl. 49. Heinroth, J. C. A. (1818) Lehrbuch der Stroerungen des Seelenlebens, Vogel, Leipzig. Holden, C. (2000) Mental health. Global survey examines impact of depression. Science. 288, 39–40. Jamison, K. R. (1995) An unquiet mind. A. A. Knopf, New York. Jaspers, K. (1923) Allgemeine psychopathologie, 3rd edn. Springer, Berlin. Johnson, F. N. (1984a) The history of lithium therapy, Macmillan, London. Johnson, F. N. (1984b) The psychopharmacology of lithium, Oxford University Press, New York. Judd, L. L., Hubbard, B., Janowsky, D. S., Huey, L. Y. and Attewell, P. A. (1977) The effect of lithium carbonate on affect, mood, and personality of normal subjects. Arch Gen Psychiatry. 34, 346–51. Judd, L. L., Akiskal, H. S., Schettler, P. J., Endicott, J., Maser, J., Solomon, D. A., Leon, A. C., Rice, J. A. and Keller, M. B. (2002) The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 59, 530–37. Kahlbaum, K. L. (1863) Die Gruppierung der psychischen Krankheiten und die Eintheilung der Seelenstoerungen. Kafemann, Danzig.
c10.fm Page 190 Wednesday, October 19, 2005 9:16 AM
190
Bipolar Psychopharmacotherapy
Kerry, R. J. and Owen, G. (1970) Lithium carbonate as a mood and total body water stabilizer. Arch Gen Psychiatry. 22, 301–303. Kosten, T. R., Markou, A. and Koob, G. F. (1998) Depression and stimulant dependence: neurobiology and pharmacotherapy. J Nerv Ment Dis. 186, 737–45. Koukopoulos, A. (2003) Ewald Hecker’s description of cyclothymia as a cyclical mood disorder: Its relevance to the modern concept of bipolar II. J Affect Disord. 73, 199–205. Koukopoulos, A. and Koukopoulos, A. E. (1999) Agitated depression as a mixed state and the problem of melancholia. Psychiatr Clin North Am. 22, 547–64. Koukopoulos A, Girardi P, Proietti R, Gaston A. (1989) [Diagnostic and therapeutic considerations on agitated depression understood as a mixed affective state]. Minerva Psichiatr. 30, 283–86. Koukopoulos, A., Reginaldi, D., Minnai, G., Serra, G., Pani, L. and Johnson, F. N. (1995) In Depression and mania: from neurobiology to treatment, Gessa, G., Fratta, W., Pani, L. and Serra, G. (eds). Raven Press, New York, pp. 127–47. Koukopoulos, A., Sani, G., Koukopoulos, A. E., Minnai, G. P., Girardi, P., Pani, L., Albert, M. J. and Reginaldi, D. (2003) Duration and stability of the rapid-cycling course: a long-term personal follow-up of 109 patients. J Affect Disord. 73, 75–85. Kraepelin, E. (1913) Psychiatrie, JA Barth, Leipzig. Kukopulos, A. and Reginaldi, D. (1973) Does lithium prevent depressions by suppressing manias? Int Pharmacopsychiatry. 8, 152–58. Kukopulos, A., Reginaldi, D., Girardi, P. and Tondo, L. (1975) Course of manic-depressive recurrences under lithium. Compr Psychiatry. 16, 517–24. Kukopulos, A., Reginaldi, D., Laddomada, P., Floris, G., Serra, G. and Tondo, L. (1980) Course of the manic-depressive cycle and changes caused by treatment. Pharmakopsychiatr Neuropsychopharmakol. 13, 156–67. Kukopulos, A., Caliari, B., Tundo, A., Minnai, G., Floris, G., Reginaldi, D. and Tondo, L. (1983) Rapid cyclers, temperament, and antidepressants. Compr Psychiatry. 24, 249–58. Lambert, P. A., Carraz, G., Borselli, S. and Carbel, S. (1966) [Neuropsychotropic action of a new anti-epileptic agent: depamide]. Ann Med Psychol (Paris) 124, 707–10. Lapierre, Y. D., Gagnon, A. and Kokkinidis, L. (1980) Rapid recurrence of mania following lithium withdrawal. Biol Psychiatry. 15, 859–64. Maj, M., Pirozzi, R. and Starace, F. (1989) Previous pattern of course of the illness as a predictor of response to lithium prophylaxis in bipolar patients. J Affect Disord. 17, 237–41. Mander, A. J. and Loudon, J. B. (1988) Rapid recurrence of mania following abrupt discontinuation of lithium. Lancet. 2, 15–7. Nesse, R. M. (2000) Is depression an adaptation? Arch Gen Psychiatry. 57, 14–20. Okuma, T., Kishimoto, A. and Inoue, K. (1975) Anti-manic and prophylactic effects of carbamazepine (Tegretol) on manic-depressive psychosis. Seishin-igaku. 17, 617–630. Okuma, T., Kishimoto, A., Inoue, K., Matsumoto, H. and Ogura, A. (1973) Anti-manic and prophylactic effects of carbamazepine (Tegretol) on manic depressive psychosis. A preliminary report. Folia Psychiatr Neurol Jpn. 27, 283–97. Okuma, T., Inanaga, K., Otsuki, S., Sarai, K., Takahashi, R., Hazama, H., Mori, A. and Watanabe, M. (1979) Comparison of the antimanic efficacy of carbamazepine and chlorpromazine: a double-blind controlled study. Psychopharmacology (Berl). 66, 211–17. Parker, G. and Malhi, G. (2001) Are atypical antipsychotic drugs also atypical antidepressants? Aust N Z J Psychiatry. 35, 631–38. Parrott, A. C. (2001) Human psychopharmacology of Ecstasy (MDMA): A review of 15 years of empirical research. Hum Psychopharmacol. 16, 557–577.
c10.fm Page 191 Wednesday, October 19, 2005 9:16 AM
The Primacy of Mania
191
Parrott, A. C. (2002) Recreational Ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity. Pharmacol Biochem Behav. 71, 837–44. Perris, C. (1966) A study of bipolar (manic-depressive) and unipolar recurrent depressive psychoses. Acta Psychiatr Scand Suppl. 194, 9–189. Pinel, P. (1801) Traité médico-philosophique sur l’aliénation mentale, ou La manie, Richard Caille et Ravier, Paris. Post, R. M., Ketter, T. A., Denicoff, K., Pazzaglia, P. J., Leverich, G. S., Marangell, L. B., Callahan, A. M., George, M. S. and Frye, M. A. (1996a) The place of anticonvulsant therapy in bipolar illness. Psychopharmacology (Berl). 128, 115–29. Post, R. M., Ketter, T. A., Pazzaglia, P. J., Denicoff, K., George, M. S., Callahan, A., Leverich, G. and Frye, M. (1996b) Rational polypharmacy in the bipolar affective disorders. Epilepsy Res Suppl. 11, 153–80. Post, R. M., Weiss, S. R. B., Clark, M., Chuang, D., Hough, C. and Li, H. (2000) In Bipolar medications: Mechanisms of action, Manji, H. K., Bowden, C. L. and Belmaker, R. H. (eds). American Psychiatric Press, Washington, DC, pp. 219–48. Post, R. M., Baldassano, C. F., Perlis, R. H. and Ginsbery, D. L. (2003) Treatment of bipolar depression. CNS Spect. 8 (12), pp. 1–10. Puschmann, T. (1878) Alexander von Tralles, Wilhelm Braumüller, Wien. Reginaldi, D., Tondo, L., Floris, G., Pignatelli, A. and Kukopulos, A. (1981) Poor prophylactic lithium response due to antidepressants. Int Pharmacopsychiatry. 16, 124–8. Robertson, M. M. and Trimble, M. R. (1982) Major tranquillisers used as antidepressants. A review. J Affect Disord. 4, 173–93. Schneider, K. (1959) Clinical Psychopathology. New York, Grune and Stratton. Schou, M. (1963) Normothymotics, “Mood-Normalizers”: Are lithium and imipramine drugs specific for affective disorders? Brit J Psychiat. 109, 803–809. Schou, M., Juel-Nielsen, N., Stromgren, E. and Voldby, H. (1954) The treatment of manic psychoses by the administration of lithium salts. NJ Neurol Neurosurg Psychiatry. 17, 250–260. Stoll, A. L., Tohen, M., Baldessarini, R. J., Goodwin, D. C., Stein, S., Katz, S., Geenens, D., Swinson, R. P., Goethe, J. W. and McGlashan, T. (1993) Shifts in diagnostic frequencies of schizophrenia and major affective disorders at six North American psychiatric hospitals, 1972–1988. Am J Psychiatry. 150, 1668–73. Suppes, T., Baldessarini, R. J., Faedda, G. L. and Tohen, M. (1991) Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch Gen Psychiatry. 48, 1082–88. Takezaki, H. and Hanaoka, M. (1971) The use of carbamazepine (Tegretol) in the control of manic-depressive psychosis and other manic-depressive states. Seshin-igsku. 13, 173–183. Thierry, B., Steru, L., Chermat, R. and Simon, P. (1984) Searching-waiting strategy: A candidate for an evolutionary model of depression? Behav Neural Biol. 41, 180–89. Tohen, M., Vieta, E., Calabrese, J., Ketter, T. A., Sachs, G., Bowden, C., Mitchell, P. B., Centorrino, F., Risser, R., Baker, R. W., Evans, A. R., Beymer, K., Dube, S., Tollefson, G. D., Breier, A. (2003) Efficacy of Olanzapine and Olanzapine/fluoxetine in combination in the treatment of bipolar I depression. Arch Gen Psych. 60, 1079–1088. Tondo, L., Hennen, J. and Baldessarini, R. J. (2001) Lower suicide risk with long-term lithium treatment in major affective illness: A meta-analysis. Acta Psychiatr Scand. 104, 163–72. van Praag, H. M. (2002) Why has the antidepressant era not shown a significant drop in suicide rates? Crisis. 23, 77–82.
c10.fm Page 192 Wednesday, October 19, 2005 9:16 AM
192
Bipolar Psychopharmacotherapy
Watson, P. J. and Andrews, P. W. (2002) Toward a revised evolutionary adaptationist analysis of depression: The social navigation hypothesis. J Affect Disord. 72, 1–14. Wehr, T. A. (1989) In Seasonal Affective Disorders and Phototherapy, Rosenthal, N. E. and Blehar, M. C. (eds) The Guilford Press, New York, London. Wehr, T. A. and Goodwin, F. K. (1979) Rapid cycling in manic-depressives induced by tricyclic antidepressants. Arch Gen Psychiatry. 36, 555–9. Wehr, T. A., Turner, E. H., Shimada, J. M., Lowe, C. H., Barker, C. and Leibenluft, E. (1998) Treatment of rapidly cycling bipolar patient by using extended bed rest and darkness to stabilize the timing and duration of sleep. Biol Psychiatry. 43, 822–8. Willis, T. (1672) De anima brutorum, e Theatro Sheldoniano, impensis Ric. Davis, Oxonii.
c11.fm Page 193 Wednesday, October 19, 2005 9:16 AM
CHAPTER
11 Diagnostic and Clinical Management Approaches to Bipolar Depression, Bipolar II and Their Comorbidities Giulio Perugi1,2, S. Nassir Ghaemi3 and Hagop Akiskal4 1
2
Institute of Behavioral Sciences “G De Lisio”, Carrara-Pisa, Italy Department of Psychiatry, Neurobiology, Pharmacology and Biotechnology, Section of Psychiatry, University of Pisa, Pisa, Italy 3 Bipolar Disorder Research Program, Emory University, Department of Psychiatry, Atlanta, MA, USA 4 International Mood Center, Department of Psychiatry at the University of California at San Diego, La Jolla, USA
INTRODUCTION The correct diagnosis of bipolar depression has major implications for clinical practice. It has emerged as a major challenge in the treatment of bipolar disorder. Hence the need for a chapter to focus on it. During the last two decades, neuropsychopharmacology has developed new relatively selective antidepressants, anticonvulsants with mood stabilizing properties and atypical antipsychotics with broad spectrum clinical effectiveness across diagnoses. Even if classical euphoric, dysphoric (mixed) and psychotic mania may be successfully treated respectively with lithium, anticonvulsants and atypical antipsychotics, the treatment of bipolar depression remains a clinical dilemma. Although the acute efficacy of various classes of antidepressants (SSRIs, SNRIs, Trycyclics, etc.) in bipolar depression is not in doubt (Pope and Hudson, 1982; Bottlender et al., 1998), there is growing concern about the possibility that these drugs might worsen the course of bipolar illness, favoring the “switch” processes and rapid cycling (Kukopulos et al., 1980; Akiskal and Mallya, 1987; Wehr and Goodwin, 1987; Ghaemi et al., 2003). Moreover, it is uncertain how best to manage agitated depression and other mixed depressive states. Finally, bipolar II depression with its multiple comorbidities is among the most misdiagnosed and mistreated conditions in psychiatry. Bipolar Psychopharmacotherapy: Caring for the Patient Edited by Hagop S. Akiskal and Mauricio Tohen # 2006 John Wiley & Sons, Ltd ISBN: 0-470-85607-6
c11.fm Page 194 Wednesday, October 19, 2005 9:16 AM
194
Bipolar Psychopharmacotherapy
BIPOLAR DEPRESSION Misdiagnosis and inadequate treatment of bipolar depression are two of the main reasons of “pseudorefractoriness” to antidepressant drugs. The nosological approach proposed by the current international diagnostic manuals and the huge availability of a large number of safe and well-tolerated antidepressants have contributed toward an over-diagnosis of unipolar depression (Akiskal and Pinto, 1999). Both DSM-IV and ICD-10 propose criteria that are inclusive for major depression and overly restrictive for bipolar disorder. As a consequence, many patients wait a long time to receive a correct diagnosis. In a research study conducted by the Depressive and Manic-Depressive Illness National Association (Lish, Dime-Meenan and Whybrow, 1994) on a large sample of bipolar subjects, 48% were diagnosed as bipolar only after being visited by three or more psychiatrists, 57% were diagnosed otherwise, more commonly as unipolar major depression (44%), or schizophrenia (34%). A correct diagnosis was formulated only after a mean of about 8 years of other than mood stabilizer treatment. Similarly, in a research study of 48 bipolar I inpatients, 40% of them had been previously diagnosed as unipolar (Ghaemi etal., 1996) and, again, the correct diagnosis was made with a delay of about 8 years. The situation seems to be even worse in the less severe cases; in a follow-up study on 54 bipolar outpatients, including a bipolar II subgroup, the mean timeframe from the first psychiatric observation to the correct diagnosis was about 12 years (Ghaemi, Boiman and Goodwin, 2000). This is critical because suicide in bipolar illness occurs within the first decade of the illness (Guze and Robins, 1970). Lack of insight during mania is one of the most important misleading factors (Amador, Flaum and Andreasen, 1994; Michalakeas et al., 1994; Ghaemi, Stoll and Pope, 1995) in the diagnostic and therapeutic process. As insight is less impaired during depression, diagnostic evaluation based only on patient interview may lead to an underestimation of mania. For this reason, interviewing relatives may mitigate this memory bias (Akiskal et al., 2000). In fact, in a study on prodromal symptoms of mania and depression (Keitner, Solomon and Ryan, 1996), relatives reported manic symptoms twice more frequently than patients (47% vs 22%), while both relatives and patients reported similar percentages of depressive symptoms. Although gathering information from relatives or previous physicians is essential for an accurate diagnostic procedure, cross-sectional or retrospective evaluation by itself can contribute to the underdiagnosis of bipolar disorder (Sprock, 1988). Both clinical and cultural variables seem to contribute to the under-recognition of bipolar disorders in general, and bipolar depression in particular. Depressive symptomatology causes more subjective distress than mania; for this reason patients seek help mostly during depressive episodes and almost never during hypomanic episodes. Moreover, current clinical practice seems to be guided by a “depressocentric” approach (Ghaemi, Boiman and Goodwin, 2000). In the last 50 years, in fact, researchers’, clinicians’ and the public’s interest
c11.fm Page 195 Wednesday, October 19, 2005 9:16 AM
Bipolar Depression
195
has been mainly focused on diagnosis and treatment of depression, while less attention has been devoted to the recognition and treatment of mania and hypomania. This attitude, at least partially, might be favored by the availability of efficacious and safe antidepressants (Baldessarini, 1994); however, among the cultural pressures that contribute to an overdiagnosis of depression and to an underestimation of (hypo)mania is the general “depressophobic” attitude in modern western society. Optimism, narcissism, dynamism, craze for activity, high energy and extroversion are considered “healthy” and positive characteristics; conversely, pessimism, selfconsciousness, slowness, irresoluteness and introversion are viewed negatively and easily attributed to a psychopathological condition. What could be considered particularly pathological in hypomania is a “dark” side characterized by irritable mood lability, impulsivity and increased consumption of drugs, and social instability which are frequently present, but often attributed to an erratic personality problem (Akiskal and Benazzi, 2003).
BIPOLAR II AND RELATED “COMORBID” DISORDERS ISSUES IN DIAGNOSING HYPOMANIA While both type I and type II bipolar conditions are often misdiagnosed, the inability to recognize past hypomania appears to be a special problem in the underestimation of bipolar depression. Although bipolar II may represent the most common bipolar phenotype (Simpson et al., 1993), it is often unrecognized, poorly researched and typically mismanaged. Hypomania is difficult to diagnose with current operational diagnostic criteria. In DSM-IV, in fact, hypomania is defined as a less severe form of mania without providing specific criteria. Mania is essentially a condition of psychomotor excitement, etc. The differential diagnosis of mania, due to its severity and impairment of functioning, has to do with schizophrenia or, with mixed states, severe depression. Hypomania, on the other hand, due to its less extreme manifestations and to its relatively unimpaired (and sometimes enhanced) functionality, has to be distinguished from “normality” and personality disorders. In the DSM-IV criteria, differences between manic and hypomanic episodes are not adequately specified. To further complicate matters, hypomania can sometimes be adaptive (Jamison et al., 1990) and by DSM-IV definition not associated with state-dependent life disruptions. Unfortunately, the statement in that latter that “in contrast to manic episode, hypomania is not severe enough to cause marked impairment in social or occupational functioning” is not only vague, but is responsible for a low diagnostic concordance (Gershon and Guroff, 1984), with the result that hypomania is often misinterpreted as “happiness,” and mania as hypomania. This often leads to bipolar I disorder frequently being diagnosed, if at
c11.fm Page 196 Wednesday, October 19, 2005 9:16 AM
196
Bipolar Psychopharmacotherapy
all, as bipolar II disorder, while bipolar II disorder tends to be completely missed. Moreover, the four-day threshold of DSM-IV for the duration of the episode is unjustified and unnecessarily narrow. An extensive literature based on clinical and community samples validates the definition of hypomania at a duration threshold of two, rather than four, days (reviewed in Akiskal et al., 2000), reporting a modal duration of 1–3 days (Wicki and Angst, 1991).
ANTIDEPRESSANT-ASSOCIATED HYPOMANIA/MANIA Another important question for clinical practice pertains to hypomania that first manifests upon pharmacological treatment with antidepressants; both DSM-IV and ICD-10 have denied bipolar status to these patients. This is an unfortunate decision because an extensive literature strongly supports the inclusion of such patients within the rubric of bipolar disorders (Bunney et al., 1972; Akiskal, Khani and Scott-Strauss, 1979; Akiskal et al., 1983; Sultzer and Cummings, 1989; Altschuler etal., 1995; Benazzi, 1997b; Post etal., 1997). In prospective observations, nearly all adult patients with antidepressant-associated hypomanic episodes progress months or years later to bipolar states with spontaneous hypomania or mania (Akiskal et al., 1983); this also appears to be true for adolescent depressives (Strober and Carlson, 1982). Moreover, patients developing mood switches with antidepressants, especially at the beginning of the treatment, often present a family history of bipolar disorders and manifest a vulnerability to rapid cycling (Kilzieh and Akiskal, 1999). Hence, depressive episodes followed by pharmacological hypomania seem to represent a subtype of bipolar II pattern, which some authors describe as bipolar disorder, type III (Akiskal and Benazzi, 2003), conceptualized as a genetically “less penetrant” form of bipolar disorder requiring exogenous input from antidepressants. The same is probably generally true for phototherapy, sleep deprivation and electroconvulsive therapy. Interestingly, antidepressant-associated hypomania is not limited to major depressions. It can occur in dysthymic patients (Rosenthal et al., 1981; Rihmer, 1990), as well as social-phobic, obsessive-compulsive and other anxiety states (Himmelhoch, 1998; Perugi et al., 1999). In brief, the depressive phase of bipolar II patients can, in a significant minority of patients, be replaced by subthreshold depressive, socially anxious or obsessive inhibitions (Himmelhoch, 1998). The same is true for switches in borderline personality disorder (Akiskal et al., 1985; Levy and Brown, 1985).
THE EVALUATION OF HYPOMANIA Independently from diagnostic criteria, bipolar II diagnosis also depends on the patient’s ability to recall hypomanic episodes, and on the patient’s awareness that
c11.fm Page 197 Wednesday, October 19, 2005 9:16 AM
Bipolar Depression
197
they represent part of the affective illness. In fact, in most cases, patients do not consider hypomania as an expression of the illness, but rather as a period of wellbeing. Therefore, in addition to the clinician’s skill in interviewing patients and in the interpretation of the illness manifestations, the correct diagnosis is often achieved only because of the contribution of relatives and other collateral observers. A correct diagnosis can be formulated only after an in-depth evaluation focused on hypomanic symptoms and related behavioral consequences, such as unusual hyperactivity, impulsiveness and uninhibited or inappropriate demeanor (Benazzi and Akiskal, 2003). Dunner and Tay (1993) found that clinicians specifically trained to recognize bipolar II outperformed such structured instruments as the SAD or the SCID in the diagnosis of bipolar II disorder. Although this point goes against the grain in the literature on structured interviewing, it is consistent in suggesting that the proper identification of bipolar II requires a more sophisticated clinical approach in interviewing and diagnosis. In line with earlier findings (Akiskal et al., 1977), current data indicate that intense activation in psychomotor, social and professional spheres may better define clinical hypomania than elated mood (Benazzi and Akiskal, 2003).
THE PREVALENCE OF BIPOLAR II The French Clinical Epidemiology of Depression (EPIDEP) database (Hantouche et al., 1998), deriving from a national sample of a variety of hospital and outpatient settings in France, has provided the most compelling data on the high prevalence of bipolar II among major depressive patients. At index interview 22% of nearly 500 major depressive patients could be diagnosed as DSM-IV bipolar II; a month later, upon re-interview, 40% of patients were diagnosed within the bipolar II spectrum on the basis of more in-depth evaluation and collateral information from significant others, as well as observed hypomania by the clinician. A great deal of research has been conducted on the clinical prevalence of bipolar II among patients presenting with major depressive disorder to various clinical settings worldwide. What emerges is that from 30 to 70% of all major depressions conform to the features of bipolar II or its variants (reviewed in Akiskal et al., 2000; and amplified in Akiskal and Benazzi, 2003). It is noteworthy that the data are not limited to academic centers specializing in mood disorders (Akiskal and Mallya, 1987; Cassano et al., 1992), but include at least two large outpatient psychiatric private practice settings (Kukopulos et al., 1980; Benazzi, 1997a) and one family practice clinic (Manning et al., 1997). The diagnosis of bipolar II depression is crucial not only because of its therapeutic implications but also for prognostic reasons. These patients are at high risk for relapse and for multiple episodes (Coryell et al., 1995; Vieta et al., 1997), and
c11.fm Page 198 Wednesday, October 19, 2005 9:16 AM
198
Bipolar Psychopharmacotherapy
show a higher rate of suicide attempts and completed suicides than bipolar I or unipolar patients (Rihmer and Pestality, 1999). Bipolar II depressions typically have an early onset, tend to be chronic, with atypical features, and are interspersed with mild hypomanias and infrequent euthymic periods (Coryell et al., 1987; Benazzi, 1999). Although depressive symptomatology is usually mild to moderate in severity, bipolar II patients function more poorly than expected. This appears to be related to a high frequency of coexisting “non-affective” psychopathology such as panic attacks, phobias, alcohol and drug abuse, eating disorders and personality disorders (Perugi et al., 1998, 1999).
COMORBIDITY Bipolar II spectrum includes, in fact, a wide range of psychopathological manifestations and numerous behavioral disorders that suggest a bipolar diathesis which must be explored thoroughly (Perugi and Akiskal, 2002). A history of “hyperactivity” during childhood is more frequent in bipolar patients than in unipolar ones (Winokur etal., 1993), as well as a history of stimulants and alcohol abuse (Regier etal., 1990; Winokur etal., 1998; Sonne and Brady, 1999). Many cyclic, periodic or recurrent phenomena, such as seasonality, high depressive episode recurrence, recurrent irritability, recurrent neurasthenia or periodical sleep disturbances, can also be interpreted along the lines of bipolar II (Akiskal and Pinto, 1999). Furthermore, the episodic course of obsessive-compulsive disorder is often associated with bipolar II disorder (Perugi etal., 1999) and therefore a careful characterization of concurrent affective manifestations is needed. Recently, it has been suggested that some impulsive behaviors, such as explosive personality disorders, pathological gambling and some paraphilias, may belong to the bipolar spectrum (McElroy etal., 1996). Comorbidity among bipolar II, anxiety and impulse control disorders represent a complex picture, susceptible to different pathogenetic interpretations. The pathological process underlying bipolar II disorder does extend beyond euphoric and depressive dimensions, including dysphorically aroused affective states, such as anxiety, panic, irritability and impulsivity (Perugi and Akiskal, 2002). The so-called alcohol- or substance-induced mood disorders may have much in common with bipolar II spectrum disorders, in particular when mood swings outlast detoxification (Maremanni et al., 2004). Finally, many patients within the Bipolar II spectrum, especially when recurrence is high and the inter-episodic period is not free of affective manifestations, may meet criteria for personality disorders. This is particularly true for cyclothymic bipolar II patients, who are often misclassified as borderline personality disorder because of their extreme mood instability and reactivity (Akiskal et al., 1985; Perugi et al., 2003; Perugi and Akiskal, in press). Actually, mood lability of a cyclothymic nature should be considered the core characteristic of the bipolar II spectrum, and it has been prospectively validated as
c11.fm Page 199 Wednesday, October 19, 2005 9:16 AM
Bipolar Depression
199
Table 11.1: Psychiatric comorbidity in bipolar disorder • • • • • • • •
Psychosis Alcohol and Stimulant Abuse ADHD Dramatic cluster PD (e.g. borderline) Bulimia Social phobia Panic attacks Obsessive-compulsive phenomena
a sensitive and specific predictor of bipolar II outcome in major depressives (Akiskal et al., 1995). The enlargement of classical bipolar II disorders to include a spectrum of conditions subsumed by a cyclothymic-anxious-sensitive disposition, with mood reactivity and interpersonal sensitivity, and ranging from mood, anxiety and impulse control disorders, will greatly enhance both clinical practice and research endeavors. In fact, viewing these constructs as related entities with a common affective temperamental diathesis will make these patients more accessible to pharmacological and psychological approaches geared to their common temperamental attributes. The common “comorbidities” of bipolar spectrum conditions are summarized in Table 11.1. Even if the comorbid conditions listed are viewed by many as distinct from bipolar disorders, the rigorous treatment of the bipolar disorder itself will often have a salutary effect on the outcome of these conditions. There are those who consider too much attention to mood lability – the presence of “mood swings” – as nonspecific and likely to lead to overdiagnosis of bipolar disorder. However, while a good deal of evidence suggests underdiagnosis of bipolar disorder, as noted earlier, no published data have provided evidence of overdiagnosis of bipolar disorder. Further, our perspective is not meant to imply that anyone with mood lability automatically has bipolar disorder, but rather that anyone with mood lability may have bipolar disorder and that the bipolar diagnosis needs to be carefully assessed in such patients. More on this will be said later in this chapter.
DEPRESSIVE MIXED STATES KRAEPELIN’S CONCEPTUAL FRAMEWORK Mixed States (MS) are characterized by the mixture of depressive and manic symptoms and, since Kraepelin (1921), have represented the main unifying element in manic-depressive illness, showing that mania and depression are different expressions of the same illness. Kraepelin observed that mixed states only rarely derive from the co-presence of full-blown manic and depressive pictures; more
c11.fm Page 200 Wednesday, October 19, 2005 9:16 AM
200
Bipolar Psychopharmacotherapy
often, some depressive features are present during mania, or hypomanic features appear within depression. In Kraepelin’s systematization, at least six types of mixed states were recognized; among which, anxious or depressive mania and agitated or excited depression are the most common in contemporary psychiatric practice. Although this broad classification is accepted by prominent European psychiatrists (e.g. Berner et al., 1992), DSM-IV identifies MS as the condition in which full-blown major depression and mania are simultaneously present. The American manual does not consider cases in which expansive and depressive elements are combined without fully satisfying the criteria for one or the other type of episode (Perugi et al., 1997). Therefore, despite their clinical relevance, the depressive forms of mixed state are not included in the current official classificatory systems and, until recently, they were largely neglected in the current literature (Akiskal and Benazzi, 2003).
BIPOLAR I MIXED STATES Mixed depressive states are common in bipolar inpatients, and are associated with psychotic symptoms, a high risk of suicide and the tendency to develop a chronic course (Perugi etal., 2001). At a cross-sectional examination, perplexity, impulsivity and accelerated thinking are common (Koukopoulos et al., 1995; Koukopoulos and Koukopoulos, 1999). Unfortunately, these symptoms are not considered as possible markers of mixed states by the current classificatory systems, and the diagnosis of “unipolar” major depression is formulated. From an operational point of view, this classificatory restriction is misleading for therapeutic choices, as antidepressants would then be preferred over mood stabilizers. In order to better characterize depression with mixed features, we compared familial, demographic, clinical and course characteristics of 32 patients with depressive mixed state and those of 36 patients with major bipolar depression (Perugi et al., 2001). The two groups had close similarities in clinical and socio-demographic characteristics, including age, gender distribution, marital status, schooling, residence, age at onset, age of first treatment, age of first hospitalization, percentage of chronicity of the index episode, lifetime suicide attempts and premorbid temperamental dispositions. First-degree family history for bipolar illness and other mental disorders was also similar, except that for major depression, which was significantly more common among the relatives of depressive mixed states. These findings were in part foreshadowed in a previous Pisa study on mixed states from the female unit at our Institute (Dell’Osso et al., 1991), where an excess of depressive familial background had been observed in the entire sample (that had not been divided into depressive and manic mixed state). Patients with depressive mixed states can be distinguished from nonmixed bipolar depressives by the fact that they present fewer episodes of longer duration,
c11.fm Page 201 Wednesday, October 19, 2005 9:16 AM
Bipolar Depression
201
and frequently begin their illness with a mixed episode (Perugi et al., 2001). In agreement with previous clinical observations (Akiskal and Mallya, 1987; Koukopoulos et al., 1995), the symptomatological profile of depressive mixed state is characterized by agitated, mostly psychotic, depression with irritable mood, pressured speech and flight of ideas. For instance, Akiskal and Mallya (1987) reported that 25 patients referred for treatment-resistant depression displayed subacute or chronic mixed states, apparently induced by tricyclic antidepressants; these patients were characterized by dysphoria, severe agitation, refractory anxiety, unendurable sexual excitement, intractable insomnia, suicidal obsessions and impulses and “histrionic” demeanor; they improved with antidepressant discontinuation and initiation of lithium or neuroleptics. Koukopoulos et al. (1995) observed that 45 patients with bipolar disorder, suffering from a “mixed depressive syndrome” who met DSM-III-R criteria for major depression, but not for mania, deteriorated when treated with antidepressants, experiencing increased agitation, insomnia and, in some cases, suicidal impulses; these same patients responded to low-dose neuroleptics, lithium, anticonvulsants and ECT. Koukopoulos and Koukopoulos (1999) have subsequently written a scholarly review on the clinical rationale for the validity of the concept of agitated depression as a mixed state. In light of the foregoing observations, we submit that depressive mixed states might underlie the suicidality attributed to antidepressants (Akiskal et al., 2005; Akiskal and Benazzi, 2005). In children, in particular, this issue of antidepressant induced suicidality may reflect undiagnosed bipolar disorder, since data suggest that about 50% of all depressed preadolescent children, without any evidence of mania or hypomania, will develop manic or hypomanic episodes in 10-year follow-up (Geller et al., 2001).
BIPOLAR II MIXED STATES The literature reviewed pertains largely to mixed states and agitated depression observed among hospitalized and/or psychotic patients. A high prevalence of hypomanic features has been reported (Benazzi, 2000; Benazzi and Akiskal, 2001) in depressed bipolar II and unipolar outpatients as well. Among 70 outpatients with major depression, the prevalence of full syndromal hypomania was low (2.8%), but three or more concurrent hypomanic symptoms were reported in 28.5% of the sample. About half (48.7%) of bipolar II patients had three or more concurrent hypomanic symptoms during major depression. Irritable mood, talkativeness and distractibility were significantly more common in bipolar II than in unipolar patients; racing thoughts were highly prevalent in both unipolar and bipolar II. Among the (hypo)manic symptoms reported in depressive mixed states (termed “DMX” by Benazzi and Akiskal, 2001), flight of ideas, racing thoughts and distractibility belong to the same dimension of psychic excitement. Increased mental activity (day dreaming, mental ruminations) has been reported as one of
c11.fm Page 202 Wednesday, October 19, 2005 9:16 AM
202
Bipolar Psychopharmacotherapy
the fundamental features of bipolar II “depression” (Akiskal et al., 1995; Perugi etal., 1998). Other hypomanic symptoms such as grandiosity are relatively uncommon in depression and to be utilized for the selection of patients with DMX, whereas irritability and restlessness might be somewhat nonspecific. However, depressions with sexual arousal are almost always bipolar mixed states (Akiskal and Mallya, 1998; Akiskal and Benazzi, 2004). According to Akiskal and Benazzi (2001), unipolar depressives with DMX might be classified into the bipolar spectrum, and must be considered ‘pseudo-unipolar’. Two longitudinal studies indicated that intra-episodic hypomanic symptoms during a depressive episode predict a diagnostic switch from unipolar depression to bipolar disorder (Akiskal et al., 2004; Sato et al., 2004). The bipolar nature of depressive mixed states, even among “unipolar” DMX, is validated by family history of bipolar disorder (Akiskal and Benazzi, 2003). Moreover, the suicidal trends in agitated depressions are significantly related to bipolar family history (Akiskal et al., 2004, in press). These considerations may in turn be related to the suicidality risk of bipolar disorder, overt or cryptic (Rihmer and Pestality, 1999). Clinical observations suggest that unipolar DMX may not adequately respond to antidepressants, and that the use of antidepressants for unipolar depressives with intra-episodic hypomanic symptoms may be operative in treatment resistance or lead to cycling (Akiskal and Mallya, 1987; Koukopoulos et al., 1995). Welldesigned controlled trials with antidepressants versus mood stabilizers and/or other anti-manic agents should be conducted comparing unipolar depressives with and without intra-episode excitatory symptoms.
PHARMACOTHERAPY Such studies are of great importance for public health because the majority (over 90%) of bipolar patients seen in clinical practice today belong to the bipolar II spectrum (Akiskal and Mallya, 1987; Cassano et al., 1992; Benazzi and Akiskal, 2001). Yet, drug treatment of bipolar depression is surprisingly understudied, especially in comparison to mania and unipolar depression. The lack of adequate research in this area is even more astonishing considering that depressive episodes and symptoms prevail in most bipolar patients seen in clinical practice (Judd et al., 2002, 2003) and are associated with high degree of suffering and disability and with a significant risk of suicide and high mortality for different causes. Agents such as lithium, valproate and carbamazepine have been studied much more thoroughly in mania than in bipolar depression. Similarly, only a few controlled studies focused on the efficacy of antidepressants in monotherapy. The relative risk of (hypo)manic switches or of rapid cycle induction further complicates the treatment of bipolar depression. In fact, while some guidelines advise limiting the use of antidepressants, others suggest the possibility of utilizing antidepressants
c11.fm Page 203 Wednesday, October 19, 2005 9:16 AM
Bipolar Depression
203
in combination with mood stabilizers. Finally, amongst new anticonvulsants and atypical antipsychotics, lamotrigine and olanzapine, respectively, have shown antidepressant properties in bipolar patients opening new opportunities in the treatment of this phase of manic-depressive illness.
TREATMENT OF THE ACUTE PHASE Only a limited number of controlled studies in the treatment of acute bipolar depression have been conducted. In a recent review of the literature, Thase and Sachs (2000) claimed that not a single antidepressant medication, nor even a particular class of antidepressant, has been demonstrated to be effective in at least two adequately powered, placebo-controlled clinical trials. This may not be entirely accurate. Among antidepressants that have been studied in the 1970s and 1980s, particular attention was devoted to tranylcypromine, an irreversible MAOI that was efficacious in two controlled studies versus placebo (Himmelhoch, Fuchs and Symons, 1982; Himmelhoch et al., 1991). While these studies demonstrate that MAOIs are better than placebo, they do not answer the clinical question whether addition of MAOI to a mood stabilizer like lithium is better than lithium alone. Amongst tricyclic antidepressants, the most studied was imipramine; which, in one study, proved to be more efficacious than placebo (57% vs 38% of responders). The drug has also been compared to several active compounds, such as fluoxetine (Cohn et al., 1989), moclobemide (Baumhackl et al., 1989), maprotiline (Kessell and Holt, 1975) and tranylcypromine (Himmelhoch et al., 1991). Response rates were similar for imipramine, moclobemide and maprotiline, but tranylcypromine was more efficacious than imipramine. While the fluoxetine study reports greater efficacy than imipramine, this result is confounded by the fact that lithium was nonrandomly given to more patients in the fluoxetine arm than the imipramine or placebo arms, making the study more of a comparison of fluoxetine plus lithium versus imipramine alone. Randomized studies on SSRIs are limited to a comparison between fluoxetine, imipramine and placebo (Cohn et al., 1989) and to two recent double blind placebocontrolled studies (Young et al., 2000; Nemeroff et al., 2001), evaluating the adjunctive efficacy of paroxetine to lithium and valproate. In the first study, fluoxetine was more efficacious than placebo (86% vs 38%); as mentioned earlier, however, a higher percentage of patients treated with the active drug were also taking lithium, compared to the percentage of patients who received placebo (17/30 vs 10/29). In the other two studies (Young etal., 2000; Nemeroff etal., 2001), paroxetine showed an additive antidepressant efficacy only in patients with a low serum level of lithium. While one of the studies (Young et al., 2000) has been criticized for small sample size, the other (Nemeroff et al., 2001) was adequately powered to demonstrate even a moderate effect size benefit with paroxetine. Patients treated with paroxetine had a low rate of switching, similar to that observed with
c11.fm Page 204 Wednesday, October 19, 2005 9:16 AM
204
Bipolar Psychopharmacotherapy
placebo. In combination with data derived from other studies on SSRIs ( Kupfer etal., 2001), venlafaxine (Vieta et al., 2002) and bupropion (Sachs, Lafer and Stoll, 1994) seem to indicate that new antidepressants are as efficacious as tricyclics, but perhaps with a lower risk of inducing (hypo)manic switches (Peet, 1994). A recent meta-analysis (Gijsman et al., 2004) claimed evidence of benefit with antidepressants in bipolar disorder compared to placebo, and no risk of mania with them. This paper had a number of flaws. First, the entire meta-analysis of placebo-controlled studies came down to five reports, a relatively small number for meta-analytic techniques. Second, only one study (Nemeroff et al., 2001) was designed with equal concurrent lithium use in all arms. The other studies either had no mood stabilizers (n = 3 studies) or imbalanced lithium usage (n = 1 study, Cohn et al., 1989). Thus, to the clinical question of whether antidepressants are more effective than lithium alone, only one study (Nemeroff et al., 2001) was designed to answer the question, and it found no benefit with antidepressants, given therapeutic lithium levels. It also found some evidence of increased risk of acute mania with imipramine, though not paroxetine. Thus, we would suggest that the meta-analysis might demonstrate that antidepressants are more effective than “nothing” (placebo), but it does not demonstrate that antidepressant plus mood stabilizer is more effective than mood stabilizer alone. Further those limited studies were not powered to assess risk of acute mania, and indeed the best designed studies suggest a likely risk with TCAs. Lithium efficacy in the treatment of bipolar depression has been evaluated in eight placebo-controlled, cross-over studies (for a review see Yatham, Calabrese and Kusumakar, 2003). Amongst these, seven of the studies showed a response rate of about 76%, while all eight reported a response to lithium of 59% and to placebo of 48% respectively. In this latter case, the high placebo response, more than the lack of lithium efficacy, was the main result. Three clinical double-blind trials, comparing lithium with imipramine (Fieve, Platman and Plutchik, 1968; Watanabe, Ishino and Otsuki, 1975; Worral etal., 1979), reported a similar efficacy, even though lithium showed a higher response stability than imipramine. In both Young et al. (2000) and Nemeroff et al. (2001), the controlled and randomized trials confirmed the efficacy of lithium in the treatment of acute bipolar depression. In the first (Nemeroff et al., 2001), paroxetine, imipramine and placebo were combined with lithium. Patients with a plasma level >0.8 mEq/L of lithium did not benefit from adjunctive antidepressants; the combination with paroxetine, on the contrary, offered an advantage when lithium plasma level was lower than 8 mEq/L. Young et al. found that add-on of a second mood stabilizer (lithium or valproate) or of paroxetine to a current therapy with lithium or valproate was evaluated in bipolar patients with depressive recurrence. Differences between the combination of mood stabilizers and the combination of paroxetine plus mood stabilizers did not emerge based on depression rating scores. While this study was small (n = 30), lack of statistical power is not a major criticism one can advance
c11.fm Page 205 Wednesday, October 19, 2005 9:16 AM
Bipolar Depression
205
because the effect size was tiny: the depressive scores in both groups tracked each other closely such that, with the same results, even much larger samples would not demonstrate statistical significance. All these findings indicate efficacy of lithium in the treatment of acute bipolar depression, especially at high serum levels.
ANTICONVULSANTS IN THE TREATMENT OF BIPOLAR DISORDER Valproate and Carbamazepine The antidepressant properties of valproate were initially reported in open observations (Calabrese and Delucchi, 1990). Nevertheless, valproate has not been adequately studied in bipolar depression. One randomized study with a limited sample (n = 45) (Sachs and Collins, 2001) did not show statistically significant differences between valproate and placebo, but, valproate was more effective than placebo (45% vs 27% responders), raising the problem of inadequate statistical power. A second randomized study, not yet published, found valproate more effective than placebo in acute bipolar depression (Davis, Bartolucci and Petly, 2005). Another study suggests that valproate might be more likely to work in bipolar depressives previously naïve to antidepressants (Winsberg et al., 2001). On the whole these limited studies suggest possible benefit with valproate in acute bipolar depression, contrary to common clinical assumptions. Carbamazepine has been studied only in three small controlled trials on resistant bipolar depression (Post et al., 1986). Of these patients, 68% responded to carbamazepine, while only 50% relapsed when the latter was switched to placebo.
Lamotrigine As far as new anticonvulsants are concerned, three controlled trials exploring the efficacy of lamotrigine in bipolar depression have been conducted. Frye et al. (2000) compared lamotrigine, gabapentin and placebo in resistant and rapid cycling bipolar I and II patients. Unlike gabapentin, lamotrigine proved significantly more efficacious against depressive features than placebo. Calabrese et al. (1999), in a seven-weeks double-blind study on 195 bipolar I depressive patients, compared lamotrigine at 50 or 200 mg/day with placebo, observing a significant improvement in Montgomery–Asberg Depression Rating Scale scores, in both groups. According to CGI scores, 48% and 56% of the patients taking respectively 50 mg/day and 200 mg/day of lamotrigine reported a clinical remission, versus 29% of the patients taking placebo (Calabrese et al., 1999). Subsequently, in another double-blind study (Bowden et al., 2003), lamotrigine (n = 103) has been compared to placebo (n = 103) in bipolar I and II patients. Lamotrigine was efficacious in bipolar I, but not in bipolar II; however, in the interpretation of
c11.fm Page 206 Wednesday, October 19, 2005 9:16 AM
206
Bipolar Psychopharmacotherapy
these data it must be taken into account that placebo was associated with a 50% of responders. This high response to placebo complicated the interpretation of the results and made it difficult to ascertain the actual efficacy of lamotrigine. An industry-sponsored unpublished negative study did not find benefit with lamotrigine compared to placebo (GSK, data on file). Thus some positive and some negative data exist with lamotrigine for acute bipolar depression, with the possibility that acute efficacy may be limited by the need for a slow titration of this agent. In these studies, lamotrigine did not seem to induce either (hypo)manic switches or rapid cycling with high frequency, although occasional cases appeared to happen. Finally, in two open observations, lamotrigine proved efficacious in depressive schizoaffective disorder (Erfurth, Walden and Grunze, 1998) and in controlling mood instability in borderline personality disorder (Pinto and Akiskal, 1998). Both groups of patients can be considered to be resistant bipolar variants.
Gabapentin Randomized clinical trials of gabapentin are lacking. The Frye et al. study (2000) compared it with lamotrigine and placebo, and points out gabapentin’s poor efficacy in depressive symptomatology in resistant rapid cycling patients. In a double-blind placebo-controlled study on a small sample of resistant bipolar patients (n = 18), Guille (1999) did not find statistically significant differences between the two groups regarding manic symptoms; however, depressive features improved with gabapentin. According to clinical observations by our group (Perugi et al., 1999), conducted in a naturalistic setting, gabapentin augmentation proved promising in resistant-mixed bipolar patients (47% of responders) at dosages ranging from 600 to 2000 mg/day. In particular, gabapentin was effective in reducing depressive symptoms. Subsequently, we have explored predictors of response to gabapentin in a sample of 43 resistant bipolar I – DSM III R – patients (Perugi et al., 2002). Gabapentin was given in combination with other mood stabilizers, benzodiazepines, antidepressants or antipsychotics, at dosages ranging from 600 to 2400 mg/day, for a period of 8 weeks. As far as positive response predictors are concerned, logistic regression analysis showed a positive correlation when comorbid alcohol abuse, social phobia and panic disorder were present. Obviously, these data need to be confirmed in randomized trials.
Topiramate Topiramate has been also proposed in the treatment of bipolar depression (see Soares (2000) for a review). There is only one randomized study of it, which was not blinded, with topiramate appearing to be similar in efficacy to bupropion in acute bipolar depression, when added to ongoing lithium treatment (McIntyre etal., 2002).
c11.fm Page 207 Wednesday, October 19, 2005 9:16 AM
Bipolar Depression
207
While this study was small, the likelihood of lack of statistical power explaining the results is lessened by the magnitude of effects observed: both topiramate and bupropion tracked each other quite closely in improvement of depressive symptoms. Observational studies suggest greater efficacy in mania than in depression (Erfurth and Kuhn, 2000), although randomized studies of mania have been negative (Janssen Pharmaceutica, data on file). Nonetheless, it is often used clinically in an augmenting mode, to help reduce weight (McElroy et al., 2003).
Olanzapine and Quetiapine Finally, amongst new atypical antipsychotics, olanzapine has also been studied in the treatment of depressive bipolar patients. Olanzapine has more randomized data, all based on industry-sponsored studies, than other antipsychotics in acute bipolar depression. In a small sample of 28 patients with refractory nonpsychotic unipolar depression, olanzapine-fluoxetine combination (OFC) was more effective than placebo, while olanzapine alone was not (Shelton et al., 2001). In two other studies of unipolar psychotic depression (n = 229 total, Rothschild et al., 2004), similar results were found: olanzapine alone was similar to placebo in both trials, but OFC was effective in one trial, though not in the other. In by far the largest study of bipolar depression ever conducted (n = 833), OFC alone was again clearly more effective than placebo, while olanzapine alone was also statistically significantly better than placebo. In very large studies, however, statistical significance can be obtained for small effect sizes (clinically trivial differences). In this study, the difference between olanzapine and placebo was a mean of about 3 points on the Montgomery Asberg Depression Rating Scale (MADRS) and most of those points involved sleep and appetite items, not core mood items. In fact, this minimal effect of olanzapine alone was the same in this study as in the previous smaller studies, the only difference being sample size. Thus, these data altogether support no meaningful clinical benefit with olanzapine alone for depressive symptoms, but likely evidence of benefit with OFC. However, since no direct comparisons have been made to fluoxetine alone, it is unclear if the OFC benefit has to do with the combination in particular, or to the use of fluoxetine. In any case, the combination appears to have an acute mania switch risk similar to placebo (about 5%), which may justify its use as opposed to fluoxetine alone. In contrast, a recent study (Calabrese et al., 2004) of quetiapine versus placebo in acute bipolar depression was more straightforwardly positive, with a large effect size for quetiapine alone, including core mood symptoms. This study is being followed up with another clinical trial for possible replication. Since the current DSM-IV criteria for depression likely include many individuals with mixed states (Akiskal and Benazzi, 2003) as discussed earlier, it is possible that some of the efficacy seen with atypical antipsychotics in depression trials may represent improvement in mixed states.
c11.fm Page 208 Wednesday, October 19, 2005 9:16 AM
208
Bipolar Psychopharmacotherapy
LONG-TERM PREVENTION OF DEPRESSIVE RECURRENCES Many placebo-controlled studies examined the long-term prophylactic efficacy of lithium against bipolar depression recurrences. A pooled analysis of 10 studies conducted in 1970 and 1980 (Goodwin and Jamison, 1990) showed recurrence rates of 34% and 81% respectively for patients who were taking lithium or placebo. Manic recurrences took place in 56% of patients in the placebo group versus 23% of patients treated with lithium; as far as depressive recurrences were concerned, the respective percentages were 37% and 21%. These data suggested a prophylactic efficacy of lithium against depressive, but particularly against manic episodes. These conclusions are concordant with data drawn from the main controlled studies on large samples. Amongst them, two studies (Prien, Kupfer and Mansky, 1994; Bowden et al., 2003) compared lithium and placebo in the prevention of recurrences after the remission of a manic episode. In both of them, lithium was more efficacious than placebo in the prevention of manic episodes, but no differences emerged with respect to depressive recurrences. However, since episode polarity tends to stay consistent in many patients with bipolar disorder, this natural course factor may confound these results. Since these studies began with mania as the index episode, the ability to detect benefit for prevention of depressive episodes may have been lessened due to the decreased frequency of depressive episodes in follow up. To account for this issue, other studies (Prien, Klett and Caffey, 1974; Bowden et al., 1994; Yatham et al., 2002; Bowden et al., 2003) examined course after an index depressive episode. One (Prien, Klett and Caffey, 1974) states that lithium was efficacious in delaying manic recurrences, but no differences emerged between lithium and placebo as far as total recurrences were concerned (either manic or depressive). Two of three other recent studies (Yatham et al., 2002; Bowden et al., 2003) also found that lithium was more active than placebo for manic than for depressive recurrences, while the third found no benefit with lithium compared to placebo (Bowden et al., 1994). While this may be the case, it is important to point out that lithium was a comparator agent in all of these studies (designed to assess efficacy of lamotrigine or olanzapine). Thus, none of these studies were designed to assess lithium responders, unlike the other agents which were all preselected to include only responders (to lamotrigine or olanzapine) in the study. Thus, the fact that lithium was still as or more effective than those agents for mania prevention speaks to the robustness of lithium’s benefit for mania prophylaxis, while less benefit for depressive prophylaxis may reflect the selection of a sample more likely to respond to the other agents. It is worthwhile to note that four randomized studies prospectively assessed lithium’s efficacy for prevention of depressive episodes, compared to imipramine, in patients with index depressive episodes, and in all of those studies lithium was more effective than placebo, and in no case was imipramine more effective than
c11.fm Page 209 Wednesday, October 19, 2005 9:16 AM
Bipolar Depression
209
lithium (Ghaemi et al., 2001). Thus, lithium likely has notable benefits in prevention of depressive episodes in bipolar disorder, with the possibility that it is even more effective in prevention of manic episodes. Few data are available on the prophylactic antidepressant efficacy of carbamazepine and valproate. In fact, although carbamazepine has been used for more than 20 years in the prophylactic treatment of bipolar disorder, only one placebocontrolled study has evaluated its long-term efficacy, showing a positive outcome in 60% of the patients who were taking carbamazepine versus 22% of the patients in the placebo group (Okuma et al., 1981). Several controlled studies (Placidi et al., 1986; Lusznat, Murphy and Nunn, 1988; Coxhead, Silverstone and Cookson, 1992; Simhandl, Denk and Than, 1993; Greil et al., 1997) compared carbamazepine with lithium, stressing the trend of a major efficacy of lithium in classical bipolar pictures and of carbamazepine in mixed and rapid cycling pictures. With respect to valproate, Bowden etal. (2000) reported data drawn from a lithium and placebo-controlled study on 372 bipolar patients, whose manic symptomatology had been remitted for at least 3 months. Valproate and placebo did not differ in the length of time before the first recurrence, which was the primary outcome of the study; however, valproate proved much more efficacious than placebo in reducing the total number of recurrences, especially depressive ones. Further, this study did not employ an “enriched” design, i.e. initially selecting patients to be valproate responders in open treatment. This enriched design has since become standard in studies of newer agents like lamotrigine and olanzapine. When these data were analyzed limited to those who had responded to valproate previously to entering the study, the benefit of valproate was notably greater than placebo. An earlier double-blind lithium-controlled study showed an overlapping activity of both the drugs in the prevention of depressive recurrences, but in the valproate group the dropout rate was smaller than in the lithium group (10% vs 25%) (Lambert and Venand, 1992). As far as new anticonvulsants are concerned, the most interesting data concern lamotrigine. Initially, Calabrese et al. (2000) reported results drawn from a placebo-controlled study on 182 rapid cycling bipolar I and II patients. No differences emerged between placebo and lamotrigine in the main outcome measure, i.e. the time length before the addition of another drug. However, the retention rate was higher in the lamotrigine than in the placebo group. Moreover, a higher number of patients taking lamotrigine (41%) than placebo (26%) remained stable during the entire duration of the study (6 months). Thus, in rapid-cycling bipolar disorder, lamotrigine was not effective overall, though it might have had modest benefit in some patients. Subsequently, lamotrigine was compared with lithium and placebo in bipolar I patients with a recent (hypo)manic episode (Bowden etal., 2003). Using an enriched design, an open observation lasted 8–16 weeks, during which previous drugs were withdrawn and lamotrigine treatment was initiated; patients who responded to lamotrigine were randomly assigned for a period of 18 months to
c11.fm Page 210 Wednesday, October 19, 2005 9:16 AM
210
Bipolar Psychopharmacotherapy
three different double-blind treatment groups: lamotrigine (100–400mg/day), lithium (0.8–1.1 mEq/L) or placebo. Out of 349 baseline patients, 175 became stabilized and were thereafter randomized: 59 to lamotrigine, 46 to lithium and 70 to placebo. In the primary outcome measure both lamotrigine and lithium were more efficacious than placebo in preventing recurrences of both depression and mania and in lengthening the remission period. In secondary analyses, lamotrigine was more efficacious than lithium in lengthening remission before depressive recurrences, while lithium worked better against manic, hypomanic or mixed recurrences. A similar study was conducted on bipolar depressive patients in remission (Yatham et al., 2002). After patients were stabilized openly with lamotrigine, they were randomly given: 50, 200, 400 mg/day lamotrigine, lithium or placebo. Again, both lamotrigine and lithium were more efficacious than placebo in lengthening remission periods for both depressive and manic recurrences. One limitation of these data is the high dropout rate, nearing 80% at 12–18 months, which appears to be a major problem in randomized prevention trials in bipolar disorder. With the limitations of the enriched design, these data support the efficacy of lamotrigine in the prevention of bipolar depression. Recently, five randomized studies on olanzapine in the prophylaxis of bipolar disorder have been conducted. (Only one was placebo-controlled, the other four comparing olanzapine directly to valproate (two studies), lithium or as add-on to valproate or lithium respectively). In the valproate studies (Tohen et al., 2003; Zajecka et al., 2002), olanzapine appeared to be slightly more effective. However, without a placebo arm, one cannot be certain whether these data demonstrate equal efficacy or equal inefficacy, especially since 85% of patients dropped out before the one year follow-up was complete. In the unpublished lithium study (Eli Lilly and Co., data on file), olanzapine appeared similarly effective to lithium overall, with better efficacy in prevention of mania. While this study had a lower overall dropout rate (about 60%), though still a high one, the benefit over lithium should not be overstated. Again, all these patients in this study, as in the others mentioned, were initially selected to be olanzapine responders for acute mania; to establish benefit over lithium, a similar study would perhaps have to be conducted with only lithium responders included. In other words, the generalizability of this study is only limited to olanzapine responders. The same issue holds for the add-on study (Tohen et al., 2004), in which responders to olanzapine plus mood stabilizer (valproate or lithium) for acute mania were randomized to stay on the combination or discontinue olanzapine (mood stabilizer alone). In the primary outcome, which was time to a new mood episode in those who had acutely responded to olanzapine (response defined as >50% improvement in manic symptom ratings), there was no benefit to continuing olanzapine versus stopping it. In a secondary outcome, which was time to symptomatic worsening (not relapse into full mood episodes) in those who remitted with olanzapine acutely (remission defined as Young Mania Rating Scale, YMRS, less than 7), olanzapine continuation was better than placebo.
c11.fm Page 211 Wednesday, October 19, 2005 9:16 AM
Bipolar Depression
211
However, this result is only generalizable to those who achieve full remission with olanzapine acutely, and further, it suggests possible symptomatic benefit but not necessarily prevention of relapse into mood episodes. Further, the addition of olanzapine proved more efficacious than monotherapy with mood stabilizers in preventing manic recurrences (35% vs 15%), but not in depressive recurrences. Finally, a single unpublished industry-sponsored study has directly compared olanzapine to placebo for prophylaxis of mood episodes in bipolar disorder (Eli Lilly and Co., data on file). Again, all patients were initially selected if they responded to olanzapine for acute mania. Those patients were then randomized to continue olanzapine or stop it (rapid taper to placebo). Olanzapine was better than placebo in prevention of mood episodes for up to 1 year, with these data leading to FDA indication for this agent in the prophylaxis of mood episodes in bipolar disorder. However, it is notable that 80% of placebo patients relapsed within 2 months of starting the study, with little further relapse in that group from that point onward. The olanzapine continuation group relapsed at a rate of less than 50% in contrast. In other words, the entire difference between the groups has to do with the first two months of follow-up, which represents the continuation phase of treatment after response for acute mania, not the maintenance phase (generally defined as 6 months or longer). The rapid placebo relapse could reflect a withdrawal phenomenon, which has been demonstrated with similarly designed early studies of lithium. Hence, one might conclude that this study suggests that if patients respond to olanzapine acutely, and then the medication is stopped, they will relapse within 2 months. But whether this report proves long-term efficacy at 6 months, one year or longer would seem to be uncertain. In summary, olanzapine may be similar to valproate or lithium in the prophylactic treatment of mood episodes in those who are olanzapine responders for acute mania. However, these data should be viewed with caution, especially as relates to lithium, since they represent very few studies, no replication with lithium in particular. The presence of unreported negative data cannot be excluded and the contrast with scores of studies by multiple investigators with lithium is notable. Further, olanzapine may enhance the prophylactic activity of mood stabilizers against manic episodes in those with complete remission with olanzapine for acute mania, although its efficacy against depressive recurrences will need further study. Likewise, maintenance phase prevention of recurrence of new mood episodes with olanzapine monotherapy will benefit from new investigations. It is often not sufficiently recognized that antidepressants have been proven ineffective in the prevention of depressive episodes in bipolar disorder. In a recent systematic review of the randomized literature, Ghaemi et al. (2001) identified only seven long-term double-blind randomized studies on the utilization of antidepressants in the treatment of bipolar disorder (especially type I): 5 with TCAs, 1 with bupropion and 1 with fluoxetine. All of them demonstrated that antidepressants were not more efficacious than lithium alone (Prien, Klett and Caffey 1979;
c11.fm Page 212 Wednesday, October 19, 2005 9:16 AM
212
Bipolar Psychopharmacotherapy
Quitkin, Kane and Rifkin, 1981; Kane, Quitkin and Rifkin, 1982; Prien et al., 1994). Moreover, one study supplied evidence suggesting a worsening of the long-term course of the disorder with antidepressant use, especially by increasing the frequency of manic recurrences (Quitkin, Kane and Rifkin, 1981). With respect to the influence of antidepressants on the course of bipolar II disorder, Amsterdam et al. (1998) reported post hoc analyses of clinical studies on unipolar, pointing out that the percentage of manic switches with fluoxetine were low in frequency in patients with bipolar II disorder (5%). However, what was insufficiently emphasized in that report was that the switch rate with bipolar II disorder was still higher than in unipolar depression (0.5%). Thus, the authors concluded that SSRIs may be used in the treatment of bipolar depression with a limited (hypo)manic switch risk; the higher switch risk with bipolar II disorder is concerning to us. In the interpretation of these data, it must be taken into account that a comparison group treated with mood stabilizers was lacking; moreover, manic features were not investigated with adequate instruments. Finally, after one year of follow-up, the baseline sample was reduced from 80 to 10 subjects; therefore the ability to draw conclusions about one year outcome was very limited. With all these limitations, manic switches with fluoxetine were still more frequent in bipolar II disorder than in unipolar depression.
(HYPO)MANIC SWITCHES Antidepressants can worsen bipolar illness in two ways. Acutely, they can cause hypomanic or manic switch, defined as change in polarity from depression immediately to mania or hypomania within 2 months of starting an antidepressant. In long-term use, they can cause rapid-cycling or cycle acceleration, defined as two or more mood episodes during a period of chronic antidepressant treatment lasting 6 months or longer compared to a similar time frame without antidepressant use. In this section, we will initially focus on the risk of acute antidepressant-induced (hypo)manic switch. The rates of (hypo)manic switches among bipolar depressives treated with antidepressants reported in the literature ranges from 10% to 70% (Möller and Grunze, 2000; Thase and Sachs, 2000). The extreme variability of these estimates is due to the differences in sampling procedures, treatment setting and symptomatologic evaluation. Some data derive from randomized controlled trials, others from naturalistic studies; in some research, patients are treated with antidepressants in monotherapy, in others, these drugs are combined with mood stabilizers. A recent meta-analysis (Gijsman et al., 2004) limited to randomized placebocontrolled trials concluded, based on five included studies, that there was no evidence that antidepressants were associated with acute mania. However, only one of those studies utilized lithium in all patients (Nemeroff et al., 2001). In two early studies from the 1980s in which no mood stabilizer was used (Himmelhoch et al. 1982,
c11.fm Page 213 Wednesday, October 19, 2005 9:16 AM
Bipolar Depression
213
Mendelwicz and Youdim, 1983), not a single patient developed mania during the study period (usually up to 2 months), which raises the possibility that manic symptoms were not carefully or systematically assessed (measurement bias). In another study (Cohn et al., 1989), no acute mania was observed with fluoxetine compared to a few cases with placebo and imipramine, but again lithium was used preferentially in the fluoxetine arm of that study, biasing the results. Another study (Tohen et al., 2003) included was the olanzapine fluoxetine combination study, in which similar switch rates were observed with olanzapine fluoxetine combination as with olanzapine plus placebo (about 5% each). All in all, three (Himmelhoch et al. 1982, Mendelwicz and Youdim, 1983, Cohn et al., 1989) of these five studies are so flawed they should not be included in an analysis using high quality data. The other two studies (Nemeroff et al., 2001, Tohen et al., 2003) suggest that switch rates with antidepressants may be low when combined with olanzapine or lithium, though one cannot rule out any antidepressant-induced switch due to the low statistical power to detect switch rates in these studies, even when combined in a meta-analysis. It is also notable that switch rates with the TCA arm in the lithium study were elevated, with low statistical power (thus making statistical significance less relevant). Although it would seem reasonable to limit one’s assessment of the risk of antidepressant-induced mania to randomized placebo-controlled trials, one limitation of this approach is that such trials are not primarily designed to assess this issue (they are mainly designed to assess efficacy). Thus, they are not powered to identify such serious though relatively infrequent (if present 20% of the time or less) side effects. Furthermore, side effects are frequently underestimated in clinical trials because of numerous exclusion criteria that screen out those with risk factors for serious side effects. In the case of antidepressant-induced mania, some potential risk factors, such as substance abuse (Goldberg and Whiteside, 2002), are common exclusion criteria, which could be leading to a serious underestimation of this risk in randomized studies. This is a common issue with side effects, as demonstrated in the past with the problem of sexual dysfunction with SSRIs and more recently with the controversial issue of suicidality and SSRIs. In both those situations, the randomized clinical trial data underestimated or explained away either common (sexual dysfunction) or serious (suicidality) side effects. This is why large-scale observational experience is a legitimate means of exploring such side effects, and one should not feel limited to randomized data in this context. With this background, some conclusions seem reasonable. For instance, TCAs seem to be associated with a higher rate of (hypo)manic switch in comparison with other classes of antidepressants. MAOIs have not been reported to induce fewer “switches” than tricyclics, although several studies reported a greater efficacy in patients with bipolar I depression (for the literature review see Goodwin and Jamison, 1990); interestingly, the hypomanic switches on MAOIs tend to be more euphoric compared with the greater dysphoria encountered with the TCAs. SSRIs
c11.fm Page 214 Wednesday, October 19, 2005 9:16 AM
214
Bipolar Psychopharmacotherapy
may result in a lower number of “switches” than tricyclics; however, usually this conclusion derives from a pooled analysis (Peet, 1994), wherein a rate of 4% with SSRIs, versus 12% with tricyclics and 4% with placebo is reported. The data included in the pooled analysis were based on selected randomized trials of unipolar patients and, therefore, are limited to the few bipolar II patients included in these samples (before DSM-IV in 1994, since criteria for bipolar II disorder were not part of the nosology, such patients were not identified for exclusion from unipolar clinical trials). Moreover, the information on (hypo)manic switches was not explored with specific instruments, but was culled from an evaluation of the adverse events. We know from the experience with SSRI-related sexual dysfunction that this approach can seriously underestimate side effects due to measurement bias. It is likely that egosyntonic hypomania, very frequent with SSRIs in clinical practice, is recorded as full remission instead of adverse reaction. The results of other clinical studies in unipolar patients treated with fluoxetine and venlafaxine are subjected to the same biases (Amsterdam, 1998; Amsterdam and Garcia-Espana, 2000). In contrast with these findings, the contemporary literature is extremely rich in case reports and series reporting (hypo)manic switch with SSRI not only in patients with major depression but also in patients treated for dysthymia, anxiety, eating and impulse control disorders (for review see Perugi and Akiskal, 2002). Only a few studies have explored systematically the prevalence of antidepressantinduced “switches” and the influence of a concomitant treatment with mood stabilizers. Bottlender et al. (1998) reported a 25% rate in bipolar I patients; in the group who presented (hypo)manic switches, tricyclics were more frequently utilized (79.5%) than in the non-switching group of patients (51.3%); conversely, mood stabilizers were used less in switching patients (59% vs 82.4%). These findings seem to confirm previous observations indicating a higher rate of (hypo)manic switches with tricyclics than with SSRIs (Weissman, Leaf and Tischler, 1988; Anthony, Folstein and Ronamoski, 1985). Henry, Sorbara and Lacotte (2001) observed, in a 6-week prospective nonrandomized study, switch in 12 (27%) out of 44 patients, 7 (16%) with hypomania and 5 (11%) with mania. Switches were less frequent in patients treated with lithium than in the rest of the sample (15% vs 44%). Switch rates were as high with SSRIs as with TCAs (both above 20%). The number of previous episodes was not associated with an increased risk of switching, although it was positively correlated with the total score of the scales for hypomania. These well-conducted observational studies suggest that antidepressant-induced (hypo)mania is only partially prevented by concomitant treatments with mood stabilizers, and further that switch rates with SSRIs appear to be notably higher in real-world patients (about 20%) than suggested by randomized studies. Unfortunately, randomized studies on bipolar depression comparing SSRIs with other antidepressants are very few, as well as studies reporting a systematic
c11.fm Page 215 Wednesday, October 19, 2005 9:16 AM
Bipolar Depression
215
evaluation of risk of switching with SSRIs (Cohn et al., 1989; Sachs, Lafer and Stoll, 1994; Young et al., 2000; Nemeroff et al., 2001). A trial reported somewhat less switching on fluoxetine in comparison with imipramine in bipolar depression (Cohn et al., 1989), but lithium was preferentially used in the fluoxetine group. The two studies comparing adjunctive paroxetine, imipramine and placebo in patients treated with lithium (Nemeroff et al., 2001) or with lithium and valproate (Young et al., 2000) have shown a low risk of switching with paroxetine. And finally, Sachs, Lafer and Stoll (1994) reported a low rate of switches with bupropion (1/9 trials) in comparison with nortriptyline (5/10 trials) in a randomized clinical trial, which was statistically significant even though the sample size was small. Recently, Post et al. (2001, 2003) reported data on hypomanic switches in patients with bipolar depression included in a double-blind randomized trial comparing adjunctive bupropion, sertraline and venlafaxine to mood stabilizers. Of the patients included in the acute phase of the treatment (10 weeks), 14% presented manic (6%) or hypomanic (8%) switch. Among the patients who entered in the long-term maintenance phase (1 year), the rate of switching increased to 33% (20% hypomanic, 13% manic). No statistical difference was reported among the three antidepressants utilized; however, because of the absence of placebo control, it was very difficult to reach (arrive at) a firm conclusion on the differences between the rate of spontaneous switches and those induced by antidepressant treatments. Although controlled trials are essential, naturalistic observation can provide some useful indications. In several studies on rapid-cycling bipolar patients, antidepressants were considered the cause of the increased frequency of cycles in a percentage of cases ranging from 25 to 35% (Koukopoulos et al., 1980; Wehr et al., 1988; Altshuler et al., 1995; Ghaemi, Boiman and Goodwin, 2000). Even for the induction of rapid-cycling, it is not clear whether the combination with mood stabilizers might provide some protection. On clinical grounds, this is a reasonable strategy.
ANTIDEPRESSANT-INDUCED CYCLE ACCELERATION OR RAPID-CYCLING As noted in the previous section, a long-term potential risk of antidepressants is induction of cycle acceleration or rapid-cycling. Cycle acceleration, we suggest, is not simply hypomanic switches that happen later in the course of treatment, but rather a worsening of the course of illness, often with longer and more frequent depressive episodes. Because of its long-term complex nature, it is difficult to assess cycle acceleration definitively in the randomized setting. In fact, perhaps there is only one study that has attempted to do so (Wehr et al., 1988): in that report, 51 patients were identified with rapid-cycling bipolar disorder. Of that group 17 were observed by history to appear to have tricyclic antidepressant-induced
c11.fm Page 216 Wednesday, October 19, 2005 9:16 AM
216
Bipolar Psychopharmacotherapy
rapid cycling. Those 17 patients were then double-blind randomized to come off TCAs at some point in follow up and were switched to placebo for a random period of time. Out of 17 patients, 10 (or 20% of the original sample) appeared to have clear TCA-related cycle acceleration in this double-blind placebo-controlled on–off paradigm. No other study approaches a placebo-controlled paradigm. Unfortunately, this trial was part of a larger assessment of these patients, and the actual data underlying these results are sparsely presented in the original report. Nonetheless, with its limitations, this is the only placebo-controlled assessment of this topic, and it supports an association between antidepressant use and cycle acceleration. Observational evidence can be cited both for and against this association, as is the case with observational evidence for many topics. One reason observational data can provide conflicting results is due to the presence of confounding factors: other factors which may explain the results but are not recognized or controlled in the statistical analysis. In the absence of randomization (which automatically removes confounding factors), statistical methods like multivariate regression models can help reduce such confounding bias. Unfortunately, almost none of the observational studies on this topic have attempted any method to reduce relevant confounding factors. For instance, a frequently cited report by Coryell et al. (2003) suggested that antidepressants are not associated with rapid cycling because when the index polarity was included in a regression model, depressive index polarity was statistically associated with rapid cycling, the effect of antidepressants no longer being notable. However, the investigators did not include any of a number of other potential confounding factors in their regression model, such as age, gender, substance abuse, past psychosis, number of depressive or manic episodes in the past, or age of onset. These factors might be related to later rapid cycling, and thus the actual effect of antidepressants, independent of these factors, remains unclear. It is worth noting that in our clinical experience, as documented in repeated recent observational studies from our group and other centers (Ghaemi Boimann and Goodwin, 2000; Ghaemi et al., 2004; Yildiz and Sachs, 2003; Cicero et al., 2003), we estimate that about one-third of patients with bipolar disorder appear to experience antidepressant-associated rapid-cycling. Except for the data discussed above, we have not seen any other studies of any kind which have systematically assessed cycle acceleration comparing periods of antidepressant use and no antidepressant use which report no prevalence of antidepressant-induced cycle acceleration. Many frequently cited studies on this topic in fact do not assess long-term cycle acceleration with antidepressants (Moller et al., 2001, Altshuler etal., 2003). While this observation needs to be more carefully assessed statistically due to potential confounding factors, it seems clinically important that such a large number of patients appear to worsen in association with some of our treatments. Again, given that the only available randomized data support this association, caution would appear to be in order. It must finally be considered that the clinical
c11.fm Page 217 Wednesday, October 19, 2005 9:16 AM
Bipolar Depression
217
substrate may have something to do with both switching and cycle acceleration (possibly greater in the depression–(hypo)mania-interval than in the reverse patterns; see Benazzi and Akiskal, 2005).
RECURRENCES AFTER THE INTERRUPTION OF ANTIDEPRESSANT MEDICATIONS Our review of the literature on antidepressant treatment of bipolar depression may be summarized as follows. Antidepressants may be acutely effective for the current major depressive episodes, but long-term continuation is ineffective at best and harmful at worst. If one accepts these conclusions, then use of antidepressants would be short term, with discontinuation after recovery from the acute major depressive episode (perhaps within 2–6 months). This indeed was the suggestion of the most recent revision of the American Psychiatric Association treatment guidelines for bipolar disorder (American Psychiatric Association, 2002), severely criticized by some in Europe (Moller et al., 2001). However, it could potentially be possible that using antidepressants could lead to cycle acceleration, while stopping them could lead to depressive relapse. The two possibilities are not contradictory. If depressive relapse frequently followed antidepressant discontinuation, though, clinicians would be in a major dilemma. A recent much-cited study claims just that result. Those authors (Altshuler et al., 2001) initially compared the risk of depressive recurrence in 25 bipolar patients, who stopped antidepressants they were using in combination with mood stabilizers, versus 19 patients who did not interrupt. The interruption of antidepressants was associated with a high risk of depressive recurrence, while the continuation of these drugs for the entire period of the study was not associated with a high risk of (hypo)manic switch. More recently, in a prospective 1-year follow-up study on 84 bipolar patients treated with sertraline, venlafaxine and bupropion (Altshuler et al., 2003), 71% of those who stopped antidepressant medications presented a recurrence in comparison to 41% of those who continued; 18% of the patients showed a manic relapse, but only 6% were using antidepressants at the time of the switch. This would suggest that antidepressants were not uniquely effective in their cohort, and when effective, was largely limited to a “bipolar-friendly” antidepressant such as bupropion (Haykal and Akiskal, 1990; Sachs, Lafer and Stoll, 1994). Further, and most importantly, these were all observational studies which made no attempt to statistically correct for confounding factors, such as varying prevalence of rapid-cycling in the two arms, reasons for discontinuation versus continuation of antidepressants by patients or clinicians, number of depressive or manic episodes, past antidepressant-induced mania, age of onset of illness, past substance abuse, and past psychosis. In correspondence, the investigators reported that no patients with rapid cycling were in the study,
c11.fm Page 218 Wednesday, October 19, 2005 9:16 AM
218
Bipolar Psychopharmacotherapy
a point not mentioned in the paper, which would be quite unusual given the typical prevalence of rapid-cycling illness. Nonetheless, the other confounding factors were not assessed, making any direct assessments of the effect of antidepressants highly liable to confounding bias. There are two randomized studies of the same topic which find the opposite results to the above nonrandomized reports. In the first (Prien et al. 1984), patients initially stabilized on lithium plus imipramine openly for acute bipolar depression were double-blind randomized to continuation of the combination or discontinuation of imipramine. Both groups had almost identical relapse rates at 1-year follow-up. In the second study (Ghaemi et al., 2004), patients initially stabilized on mood stabilizers (mostly lithium) plus antidepressants (mostly SSRIs) for acute bipolar depression were openly randomized to continue both agents or discontinue antidepressant. Again, in an interim analysis of 33 patients, both groups had identical relapse rates and very similar overall mood morbidity at one year follow-up. In fact, the only difference was worsened mood morbidity (mostly depressive) in the nonrapid-cycling subgroup randomized to continue antidepressant. These latter data are preliminary and need to be reassessed when this ongoing study ends. Overall, however, the randomized data do not support increased risk of depressive relapse with antidepressant discontinuation in bipolar disorder. The clinical dilemma is how to identify patients who, with long-term use of antidepressants, develop an increasing frequency of episodes and rapid-cycling and those who, when antidepressant medications are discontinued, tend to produce depressive recurrences. Those patients with a history of past switching on antidepressants are likely to do it again, so it is a good idea to avoid antidepressants in such patients. In practice it is generally best to utilize mood stabilizers as the preferred choice of treatment and reserving antidepressants for nonresponders.
CONSIDERATIONS FOR CLINICAL SUBTYPES AND THEIR COMORBIDITY Clinical trials for the treatment of acute bipolar depression have failed to demonstrate better efficacy of antidepressants compared to lithium and other mood stabilizers. Moreover during antidepressant treatment, switches into mania or hypomania are frequently reported, in both bipolar I and II disorders (Goldberg, Rabin and Whiteside, 2001; Henry Sorbara and Lacotte, 2001). Therefore, antidepressants, and especially tricyclics, should not be considered as first treatment choice for bipolar depression, and mood stabilizers should be the preferred choice. In particular lithium and lamotrigine appear to have acute antidepressant properties in bipolar patients. Other mood stabilizers, like valproate, may also be acutely effective in some bipolar patients. Only in the most severe or resistant forms might antidepressants be added, and then always in combination with mood stabilizers; high dosages of antidepressants and their presumably synergistic combination should
c11.fm Page 219 Wednesday, October 19, 2005 9:16 AM
Bipolar Depression
219
be avoided. Their long-term use, even with mood stabilizers, is justified in rare cases only. Even in those studies frequently cited to support long-term antidepressant use (Altshuler et al., 2003), only about 15% of patients with bipolar depression appear to benefit from long-term antidepressant use. In many patients it is advisable to combine two or even three mood stabilizers or mood-stabilizing adjuncts (lithium plus valproate, lithium plus olanzapine, lamotrigine plus quetiapine) before adding an antidepressant. With this approach, the acute depressive symptoms of most patients can be treated and one can then usually continue the mood-stabilizing combination for the long -term, as opposed to long-term risk of mood destabilization with antidepressants. When patients are not acutely suicidal, such approaches emphasizing mood stabilizers can be taken. Earlier use of antidepressants may be needed in very severely suicidal patients, or hospitalized patients, in whom more rapid recovery is desired; yet even then, care should be taken to plan to discontinue antidepressants in most patients after the acute major depressive episode resolves. Clinical experience suggests that some patients indeed may need long-term antidepressant treatment, but that group is a minority (15–20% of the bipolar population, Ghaemi and Goodwin, 2001), and even then, in our experience, many of those patients develop an oscillating course of mood swings that may be mild but is generally not consistently euthymic. Although the recent APA treatment guidelines agree on this approach, antidepressants remain the most frequently prescribed drugs in bipolar disorder in practice. In a sample of bipolar I depressed outpatients we followed up in the last 3 years (Perugi etal., unpublished data), 4 out of the 5 most frequently co-prescribed drugs for bipolar disorder had been antidepressants (citalopram, paroxetine, sertraline and venlafaxine), with valproate as the fifth drug. Their naturalistic use in bipolar depression in the practice setting is surprisingly under-evaluated. Some claim that this frequent use of antidepressants by practitioners may highlight important benefits that are not captured by the scientific literature. In fact, a recent meta-analysis (Gijsman etal., 2004) argues that the placebo-controlled randomized evidence supports the idea that antidepressants should be used almost without hesitation in bipolar depression. We have discussed the limitations of that meta-analysis on its own terms, but we would also add that that review was limited to studies of acute bipolar depression. Even if one grants short-term utility, long-term benefits have been disproven with these agents, and long-term risks are hard to ignore. It seems difficult for us to explain, based on standard models of scientific assessment, why clinicians and some researchers, not to mention many patients, are so infatuated with using these drugs in the long term. Psychotic symptoms are common in bipolar depression (Marneros, Deister and Rohde, 1990) and therefore, especially when symptoms are incongruous, antipsychotics may be helpful (Kaskey, Nasr and Meltzer, 1980). In the treatment of psychotic features, atypical antipsychotics are as efficacious as the typicals and are less likely to induce depression. Olanzapine has been studied most in
c11.fm Page 220 Wednesday, October 19, 2005 9:16 AM
220
Bipolar Psychopharmacotherapy
antidepressant-resistant depression, with some efficacy especially if combined with fluoxetine; this latter combination seems to strengthen the efficacy of both of the drugs. At the moment the prophylactic activity of olanzapine against depressive recurrences has not been proven. One recent study also supports the efficacy of quetiapine in acute bipolar depression. In long-term treatment, olanzapine and other atypical antipsychotics should not be very likely to induce depressive recurrences. The treatment of bipolar II patients is often complicated by the presence of comorbidity. In many cases, the concomitant anxiety, impulse control or eating disorders represent the major complaints and require specific treatment. Most of the controlled trials on bipolar disorder exclude patients with comorbid drug abuse, anxiety and impulse control disorders and vice versa; as a consequence, the empirical basis for treating patients with complex comorbidity are almost exclusively derived from open clinical experience (Table 11.2). This is a deplorable situation because the most common patients treated in everyday clinical practice are bipolar II with complex comorbidity. The “pure” bipolar disorder is a platonic concept that is not even encountered in a trial population! Anxious bipolar patients (i.e. those with high anxiety ratings) are less likely to respond to lithium (Young et al., 1993). Controlled data suggest valproate may be more effective than lithium in mania associated with depressive features, even when the depressive features are mild (Swann et al., 1997). Since anxiety symptoms are often seen in mixed states and may even be related to depression in mania, future investigations should evaluate anxious features as possible predictors of response to valproate (and other antimanic agents) in mania. Actually, valproate has been used successfully in the treatment of panic disorder (Lum et al., 1990). In addition, in an open-label study, Calabrese and Delucchi (1990) reported that rapid-cycling bipolar disorder patients with comorbid panic attacks experienced reduction in their panic symptoms with valproate treatment. Benzodiazepines – such as clonazepam – are relatively safe and well tolerated when used in combination with mood stabilizers. However, long-term benzodiazepine use may be problematic due to the development of tolerance, physical dependence and withdrawal Table 11.2: Sequence of pharmacotherapy for bipolar comorbidity • • • •
Panic attacks – stabilize bipolar first1 OCD – (over) stabilize bipolar first2 Adult ADHD – (over) stabilize bipolar first3 Alcohol/Stimulant abuse – detoxify first4
Note: 1 VPA and/or GBT may suffice 2 Consider risperidone (augmentation of SRI) 3 Consider dexedrine if mood stabilizers inadequate 4 VPA, CBZ, GBT may treat both conditions
c11.fm Page 221 Wednesday, October 19, 2005 9:16 AM
Bipolar Depression
221
phenomena. Gabapentin – which has been shown to be effective in panic disorder (Pande et al., 1997) and social phobia – seems to be helpful when anxiety disorders or alcohol abuse are comorbid (Perugi and Akiskal, 2002). Antidepressants, which are often used in the treatment of anxiety disorders, may worsen the course of the mood disorder by precipitating (hypo)mania, mixed states or rapid-cycling. Antidepressant-induced (hypo)manic symptoms have been reported to occur in the course of the treatment of virtually all anxiety disorders, including obsessive-compulsive, panic disorder/agoraphobia and social phobia (Sholomskas, 1990; Himmelloch et al., 1991; Steiner, 1991). In bipolar disorder, prophylactic treatment with mood stabilizers may prevent antidepressant-induced switching (Jann, Bitar and Rao, 1982; Kane, Quitkin and Rifkin, 1982), but effective management of depressive mixed states may require discontinuation of antidepressant drugs. However, discontinuation of antidepressants may create problems; these include recurrence of depressive or anxious symptoms and, although rarely, precipitation of (hypo)mania (Landry, 1997). When treating comorbid bipolar and anxiety disorders, it is imperative to begin treatment with a mood stabilizer first. In the treatment of comorbid bipolar disorder and panic disorder/agoraphobia, it appears reasonable to utilize as first choice mood stabilizers which have been shown to possess some anti-panic efficacy, such as valproate. In patients with persistent and disabling anxiety, combination with short-term (<2 months) clonazepam or small dosages of SSRI or tricyclics (i.e. paroxetine or trimipramine) can be considered. Paroxetine may be considered an optimal choice because it is effective in all anxiety disorders as well as major depression, and additionally has proven efficacious in bipolar II depression in combination with mood stabilizers (Young et al., 2000). Less information is available for comorbid bipolar disorder and social phobia. A small positive study (Pande et al., 1997) on gabapentin in social phobia suggests the possible efficacy of this drug for both mood and anxiety disorders. The combination of mood stabilizers – such as lithium, valproate and carbamazepine with SSRIs, RIMAs or MAOIs – might reduce the number of switches in these patients. However, there is virtually no information on long-term outcome of patients treated with drug combinations for comorbid bipolar disorder and social anxiety. Patients with bipolar and comorbid obsessive-compulsive disorder are among the most difficult to treat. While no mood stabilizer has been shown to exert any antiobsessive-compulsive activity, highly effective anti-obsessive pharmacological treatments (e.g. high doses of clomipramine or SSRIs) are likely to trigger (hypo)manic switches and to increase mixed states in bipolar spectrum patients. A combination of different mood stabilizers (e.g. lithium plus antiepileptics) is often necessary – preferably coupled with those antidepressants less likely to induce rapid-cycling (e.g. MAOIs). However, many of these patients present residual obsessive compulsive symptomatology and very severe manic or mixed
c11.fm Page 222 Wednesday, October 19, 2005 9:16 AM
222
Bipolar Psychopharmacotherapy
episodes (aggressive, hostile mood) that may require hospitalization. In som